Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy

Abstract

The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles and new diagnostic kits and methods. The invention further relates to treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from Mage expressing tumours.

Description

FIELD OF THE INVENTION

The present invention relates to gene expression profiles; microarrays comprising nucleic acid sequences for identifying said profiles, for example, by analysing patient derived samples; new diagnostic kits and methods for identification of same. The invention further relates to treatment of specific populations of patients, for example cancer patients, characterised as a responder by their gene expression profile, such as patients suffering from Mage expressing tumours. The invention further includes methods of inducing a responder's profile in a patient initially or originally designated as a non-responder.

BACKGROUND

Melanomas are tumors originating from melanocyte cells in the epidermis. Patients with malignant melanoma in distant metastasis (stage IV according to the American Joint Commission on Cancer (AJCC) classification) have a median survival time of one year, with a long-term survival rate of only 5%. Even the standard chemotherapy for stage IV melanoma has therapeutic response rates of only 8-25%, but with no effect on overall survival. Patients with regional metastases (stage III) have a median survival of two to three years with very low chance of long-term survival, even after an adequate surgical control of the primary and regional metastases (Balch et al., 1992). Most Patients with stage I to III melanoma have their tumour removed surgically, but these patients maintain a substantial risk of relapse. Thus there remains a need to prevent melanoma progression, and to have improved treatment regimes for metastatic melanoma and adjuvant treatments for patients having had a primary tumour removed.

There are two types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The names simply describe the type of cell found in the tumours. NSCLC includes squamous-cell carcinoma, adenocarcinoma, and large-cell carcinoma and accounts for around 80% of lung cancers. NSCLC is hard to cure and treatments available tend to have the aim of prolonging life, as far as possible, and relieving symptoms of disease. NSCLC is the most common type of lung cancer and is associated with poor outcomes (Gatzmeier et al., 1994). Of all NSCLC patients, only about 25% have loco-regional disease at the time of diagnosis and are still amenable to surgical excision (stages IB, IIA or IIB according to the AJCC classification). However, more than 50% of these patients will relapse within the two years following the complete surgical resection. There is therefore a need to provide better treatment for these patients.

Traditional chemotherapy is based on administering toxic substances to the patient and relying, in part, on the aggressive uptake of the toxic agent by the tumour/cancer cells. These toxic substances adversely affect the patient's immune system, leaving the individual physically weakened and susceptible to infection.

It is known that not all patients with cancer respond to current cancer treatments. It is thought that only 30% or less of persons suffering from a cancer will respond to any given treatment. The cancers that do not respond to treatment are described as resistant. In many instances there have not been reliable methods for establishing if the patients will respond to treatment. However, administering treatment to patients who are both responders and non-responders because they cannot be differentiated is an inefficient use of resources and, even worse, can be damaging to the patient because, as discussed already, many cancer treatments have significant side effects, such as severe immunosuppression, emesis and/or alopecia. It is thought that in a number of cases patients receive treatment, when it is not necessary or when it will not be effective.

Cells including cancer/tumour cells express many hundreds even thousands of genes.

A large amount of work has been done in recent times to assist in the diagnosis and prognosis of cancer patients, for example to identify those patients who do not require further treatment because they have no risk of metastasis, recurrence or progression of the disease.

WO 2006/124836 identifies certain gene expression signatures over several oncogenic pathways, thereby defining the prognosis of the patient and sensitivity to therapeutic agents that target these pathways. The specific oncogenes are; Myc, Ras, E2, S3, Src and beta-catenin.

US 2006/0265138 discloses a method of generating a genetic profile, generally for identifying the primary tumour so that appropriate treatment can be given.

US 2006/0240441 and US 2006/0252057 describe methods of diagnosing lung cancer based on the differential expression of certain genes.

US 2006/0234259 relates to the identification and use of certain gene expression profiles of relevance to prostate cancer.

WO 2006/103442 describes gene expression profiles expressed in a subset of estrogen receptor (ER) positive tumours, which act, as a predictive signature for response to certain hormone therapies such as tamoxifen and also certain chemotherapies.

WO 2006/093507 describes a gene profile useful for characterising a patient with colorectal cancer as having a good prognosis or a bad prognosis, wherein patients with a good prognosis are suitable for chemotherapy.

WO 2006/092610 describes a method for monitoring melanoma progression based on differential expression of certain genes and novel markers for the disease, in particular TSBY1, CYBA and MT2A.

WO 2005/049829 describes an isolated set of marker genes that may be employed to predict the sensitivity of certain cancers to a chemotherapeutic agent, which is an erbB receptor kinase inhibitor, such as gefitinib.

Generally, these cases relate to markers for one or more cancers based on biological markers for the identification and/or progression of the cancer. In some instances these pathways are modulated by so-called oncogenes. Diagnosis employing the above techniques allows those patients who are likely to relapse and/or suffer metastasis to be identified and targeted for further therapy. In other instances a specific marker relevant to resistance to a specific treatment is identified.

A new generation of cancer treatments based on antigens, peptides, DNA and the like is currently under investigation by a number of groups. The strategy behind many of these therapies, often referred to as cancer immunotherapy, is to stimulate the patient's immune system into fighting the cancer. These therapies are likely to be advantageous because the side effects, of taking such treatments, are expected to be minimal in comparison to the side effects currently encountered by patients undergoing cancer treatment. An antigen used in a cancer immunotherapy may be referred to as an ASCI, that is antigen-specific cancer immunotherapeutic.

In the early 1980s, Van Pel and Boon published the discovery of cytolytic T cells directed against an antigen presented on tumour cells. This led to the characterization of the first tumour-specific, shared antigen: Melanoma AGE-1 (MAGE-1, subsequently renamed MAGE-A1). It was followed by the identification of a large number of genes sharing the same expression pattern: they are expressed in a wide range of tumour types such as, melanoma, lung, bladder, breast, head and neck cancers. They are not expressed in normal cells, except testis. However, this expression in the testis does not normally lead to antigen expression, as these germ line cells do not express MHC class I molecules. From their peculiar expression profile, the name of Cancer Testis (CT) genes was proposed for these genes.

MAGE antigens are antigens encoded by the family of Melanoma-associated antigen genes (MAGE). MAGE genes are predominately expressed on melanoma cells (including malignant melanoma) and some other cancers including NSCLC (non small cell lung cancer), head and neck squamous cell carcinoma, bladder transitional cell carcinoma and oesophagus carcinoma, but are not detectable on normal tissues except in the testis and the placenta (Gaugler et al Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes J Exp Med. 1994 Mar. 1; 179(3):921-930); Weynants et al Expression of mage genes by non-small-cell lung carcinomas Int. J. Cancer. 1994 Mar. 15; 56(6):826-829, Patard et al Int J. Cancer 64: 60, 1995). MAGE-A3 is expressed in 69% of melanomas (Gaugler, 1994), and can also be detected in 44% of NSCLC (Yoshimatsu 1988), 48% of head and neck squamous cell carcinoma, 34% of bladder transitional cell carcinoma, 57% of oesophageal carcinoma, 32% of colon cancers and 24% of breast cancers (Van Pel, et al Genes coding for tumor antigens recognized by cytolytic T lymphocytes Immunological Reviews 145, 229-250, 1995, 1995.); Inoue 1995; Fujie 1997; Nishimura 1997). Cancers expressing MAGE proteins are known as Mage associated tumours.

SUMMARY

In one aspect the invention provides a method for detection of a gene signature, indicative of a responder or non-responder to immunotherapy, such as cancer immunotherapy, in a biological sample. Thus the invention provides a method of screening patients to establish if they are suitable for treatment, for example with a cancer immunotherapy.

In one aspect the invention provides a diagnostic kit comprising one or more nucleotide probes capable of hybridising to the mRNA or cDNA of one or more immune activation genes relevant to the profile.

In one aspect the invention provides one or more probes for identifying said one or more immune activation genes relevant to the profile.

In one aspect the invention provides a microarray of said probes suitable for the detection of said gene(s)/profile.

In another aspect the invention provides use of a microarray, including known microarrays, for the identification of said immune gene(s)/profile.

In one aspect the invention provides use of PCR (or other known techniques) for identification of differential expression (such as upregulation) of one or more of said genes.

In one aspect the invention provides a method of treating a patient with an appropriate immunotherapy after screening to identify the patient as a responder to said treatment.

In another aspect the invention provides a method of increasing the efficacy of an immunotherapy in a patient population comprising the step of first screening the population for the differential expression of one or more immune genes/said profile, and a second step of characterising the patient as a responder or non-responder.

In a further aspect the invention provides a method of generating a list of differentially expressed immune genes (ie a profile of immune genes) indicative of a responder or non-responder to immunotherapy.

BRIEF DESCRIPTION OF THE FIGURES, SEQUENCES & TABLES

FIG. 1 is a diagrammatic representation of hierarchical clustering using Spotfire analysis linking the clinical outcome of 31 patients found to be responders (defined herein to include responder, mixed responder and stable disease) or non-responders, to Mage immunotherapy in the MAGE008 clinical trial, with the gene profile identified by microarray analysis and employing the 148 top probe sets.

FIG. 2 is a diagrammatic representation of the same analysis as FIG. 1, wherein the hierarchical clustering was performed using the BaldiBH analysis using 100 probes sets.

FIG. 3 is a diagrammatic representation of the same analysis as FIG. 1, wherein the hierarchical clustering was performed using Arrayminer Classmaker gene list.

FIG. 4 is a Venn diagram representing the comparison of gene lists used in FIG. 1, FIG. 2 and FIG. 3.

FIG. 5 is a visual representation of the expression profile of various genes (36 probe sets) for 30 different patients (patients are along the X-axis and the various probe sets extend along the Y-axis).

FIG. 5 a is a visual representation of the expression of 2 genes for 30 different patients (patients along the X-axis).

FIG. 6 shows the Principal Component Analysis using PRF1, GZMB, GNLY, CD8A, PRKCQ, FOXP3, IFNG, CCL5, GPR171 and TRBV19 genes.

FIG. 7 is a visual representation of the expression profile of various genes (41 probe sets) for 33 different patients (patient identification numbers are along the X-axis) from the MAGE008 clinical trial using the adjuvant AS15.

FIG. 8 is a diagrammatic representation of hierarchical clustering for patients in the AS15 arm of the MAGE008 clinical trial.

FIG. 9 is a visual representation of the expression profile of various genes (41 probe sets) for 33 different patients (patient identification numbers are along the X-axis) from the MAGE008 clinical trial using the adjuvant AS02b.

FIG. 10 is a diagrammatic representation of hierarchical clustering for patients in the AS02b arm of the MAGE008 clinical trial.

In the heat maps herein upregulated genes are represented in red which in greyscale tends to be presented by darker shades. Lighter shades in greyscale tend to present green on the heat map (genes which are not upregulated).

• • Seq ID No 1 Chromosome 6 open reading frame 190
  • Seq ID No 2 Hematopoietic cell-specific Lyn substrate 1
  • Seq ID No 3 Interleukin 2 receptor, gamma (severe combined immunodeficiency)
  • Seq ID No 4 CD52 antigen (CAMPATH-1 antigen) /// CD52 antigen (CAMPATH-1 antigen)
  • Seq ID No 5 CD2 antigen (p50), sheep red blood cell receptor /// CD2 antigen (p50), sheep red blood cell receptor
  • Seq ID No 6 Ubiquitin D
  • Seq ID No 7 Signal transducer and activator of transcription 4
  • Seq ID No 8 Granzyme K (granzyme 3; tryptase 11) /// granzyme K (granzyne 3; tryptase II)
  • Seq ID No 9 CD3G antigen, gamma polypeptide (TiT3 complex)
  • Seq ID No 10 G protein-coupled receptor 171
  • Seq ID No 11 Protein kinase C, beta 1
  • Seq ID No 12 Major histocompatibility complex, class II, DR alpha /// major histocompatibility complex, class II, DR alpha
  • Seq ID No 13 Major histocompatibility complex, class II, DQ beta /// Major histocompatibility complex, class II, DQ beta 1
  • Seq ID No 14 Alcohol dehydrogenase IB (class I), beta polypeptide
  • Seq ID No 15 T cell receptor alpha constant /// T cell receptor alpha constant
  • Seq ID No 16 CD69 antigen (p60, early T-cell activation antigen)
  • Seq ID No 17 Protein kinase C, theta
  • Seq ID No 18 T cell receptor beta variable 19 /// T cell receptor beta constant 1
  • Seq ID No 19 T cell receptor alpha locus /// T cell receptor delta variable 2 μl T cell receptor alpha variable 20 /// T cell receptor alpha joining 17 /// T cell receptor alpha constant
  • Seq ID No 20 T cell receptor gamma constant 2
  • Seq ID No 21 T cell receptor beta variable 21-1 /// T cell receptor beta variable 19 /// T cell receptor beta variable 5-4 μl T cell receptor beta variable 3-1 /// T cell receptor beta constant 1
  • Seq ID No 22 T cell receptor alpha locus
  • Seq ID No 23 T cell receptor beta variable 19 /// T cell receptor beta variable 19 /// T cell receptor beta constant 1 /// T cell receptor beta constant 1
  • Seq ID No 24 CD3D antigen, delta polypeptide (TiT3 complex)
  • Seq ID No 25 T cell receptor gamma constant 2 /// T cell receptor gamma variable 9 /// similar to T-cell receptor gamma chain C region PT-gamma-1/2 /// similar to T-cell receptor gamma chain V region PT-gamma-1/2 precursor /// TCR gamma alternate reading frame protein
  • Seq ID No 26 Pyrin and HIN domain family, member 1
  • Seq ID No 27 T cell receptor associated transmembrane adaptor 1
  • Seq ID No 28 SLAM family member 7
  • Seq ID No 29 Chromosome 4 open reading frame 7
  • Seq ID No 30 Major histocompatibility complex, class II, DQ alpha 1
  • Seq ID No 31 Transcribed locus
  • Seq ID No 32 Amphiphysin (Stiff-Man syndrome with breast cancer 128 kDa auto antigen)
  • Seq ID No 33 Dendritic cell-associated lectin-1Each sequences above is given in Table 1A below.
  • Seq ID No 34 Nucleotide sequence encoding fusion protein of Lipoprotein D fragment, Mage3 fragment, and histidine tail
  • Seq ID No 35 Amino acid sequence of the fusion protein of Lipoprotein D fragment, Mage3 fragment and histidine tails
  • Seq ID No.s 36 to 43 (found in the description) are peptide sequences relevant to MAGE A3.
  • Seq ID No.s 44 to 48 are examples of oliogionucleotide sequences containing a CpG motif.
  • Seq ID No.s 49 to 84 (listed in Table 1B) are probes sets suitable for hybridising to the genes listed in Table 1.
  • Seq ID No.s 85 to 97 (listed in Table 3A) are sequences for the genes listed in Table 3.

Tables 1 to 4, 11 and 12 provide lists of genes that are differentially regulated according to the present invention.

Table 1A provides the nucleotide sequence listing for each of the genes listed in Table 1.

Table 1B provides the probe set identifier number (a unique reference number for the probe) of probes (and sequence thereof) wherein each probe is suitable for identifying particular genes listed in Table 1.

Table 3A links the genes (and sequences thereof) of Table 3 and probes suitable for identifying said genes.

Table 5 provides a list of genes, primers and probes suitable for use in PCR analysis.

Table 6 is a list of gene included in the TaqMan® (Q-PCR) Immune Profiling Array.

Table 7 provides a list of genes according to one aspect of the invention.

Table 7A provides the geomean ratio between responders and non-responder groups for the genes listed in Table 7.

Table 8 provides a correlation matrix for 30 genes.

Table 9 provides a list of genes according to one aspect of the invention.

Table 9A logistical regression results for certain genes listed in Table 9

Table 10 shows the percentage of correct classification using a logistical regression model for the genes listed in Table 9.

Table 11 provides a list of genes according to one aspect of the invention.

Tables 11A & 11B show the level of gene expression (based on the results of 41 probe sets) for various patients.

Tables 12 and 13 show gene lists that form further aspects of the invention.

Table 14 provides a correlation between the gene expression levels given in Tables 11A & 11B with the clinical outcome for said patients.

Annexes A to C are computer code for assisting with stastical analysis of samples.

The MAGE-1 gene belongs to a family of 12 closely related genes, MACE 1, MAGE 2, MAGE 3, MAGE 4, MAGE 5, MAGE 6, MAGE 7, MAGE 8, MAGE 9, MAGE 10, MAGE 11, MAGE 12, located on chromosome X and sharing with each other 64 to 85% homology in their coding sequence (De Plaen, 1994). These are sometimes known as MAGE A1, MAGE A2, MAGE A3, MAGE A4, MAGE A5, MAGE A6, MAGE A7, MAGE A8, MAGE A9, MAGE A 10, MAGE A11, MAGE A12 (The MAGE A family).

Two other groups of proteins are also part of the MAGE family although more distantly related. These are the MAGE B and MAGE C group. The MAGE B family includes MAGE B1 (also known as MAGE Xp1, and DAM 10), MAGE B2 (also known as MAGE Xp2 and DAM 6) MAGE B3 and MAGE B4—the Mage C family currently includes MAGE C1 and MAGE C2.

In general terms, a MAGE A protein can be defined as containing a core sequence signature located towards the C-terminal end of the protein (for example with respect to MAGE A1 a 309 amino acid protein, the core signature corresponds to amino acid 195-279).

It does not simply follow that if the tumour expresses, for example, Mage that the patient will respond to immunotherapy based on a Mage antigen.

STATEMENT OF INVENTION

Analysis performed on cancers/tumours from patients prior to receiving immunotherapy, such as Mage immunotherapy, identified that certain genes were differentially expressed in patients that responded well to the treatment, in comparison to those patients who did not respond to the immunotherapy. The present inventors have discovered a gene signature/profile that is predictive of the likely response of the patient to an appropriate immunotherapy. More specifically the present inventors have discovered a gene signature that is predictive of improved survival after treatment with Mage antigen specific immunotherapy.

Thus the invention provides a gene profile, from a patient derived sample, which is indicative of an increased likelihood that the patient will be a responder (or alternatively a non-responder) to an immunotherapy, for example a cancer immunotherapy, such as Mage immunotherapy, wherein the profile comprises differential expression of at least one immune activation gene. The invention provides a gene profile, from a patient derived sample, which is indicative of an increased likelihood that the patient will be a responder to an immunotherapy, for example a cancer immunotherapy, such as Mage immunotherapy, wherein the profile comprises upregulation of at least one immune activation gene.

The present invention provides a predictive profile in contrast to a diagnostic or prognostic profile.

Whilst not wishing to be bound by theory it is hypothesised that the gene signature identified is in fact indicative of an immune/inflammatory, such as a T cell infiltration/activation response in the patients who are designated as responders, for example, the signature may represent a T-cell activation marker. The presence of this response is thought to assist the patient's body to fight the disease, such as cancer, after administration of the immunotherapy thereby rendering a patient more responsive to said immunotherapy.

Thus the signature of the present invention does not focus on markers/genes specifically associated with the diagnosis and/or prognosis of the relevant disease, for example cancer such as oncogenes, but rather is predictive of whether the patient will respond to an appropriate immunotherapy, such as cancer immunotherpay.

The gene profile identified herein for cancer and methods for identifying the same are thought to be indicative of the microenvironment of the tumor. The correct microenvironment of the tumor seems to be key to whether the patient responds to appropriate cancer immunotherapy. Immunotherapy in the context of the invention means therapy based on stimulating an immune response, generally to an antigen, wherein the response results in the treatment, amelioration and/or retardation of the progression of a disease associated therewith. Treatment in this context would not usually include prophylactic treatment.

Cancer immunotherapy in the context of this specification means immunotherapy for the treatment of cancer. In one aspect the immunotherapy is based on a cancer testis antigen, such as Mage (discussed in more detail below).

This invention may be used for identifying cancer patients that are likely to respond to appropriate immunotherapy, for example patients with melanoma, breast, bladder, lung, NSCLC, head and neck cancer, squamous cell carcinoma, colon carcinoma and oesophageal carcinoma, such as in patients with MAGE-expressing cancers. In an embodiment, the invention may be used in an adjuvant (post-operative, for example disease-free) setting in such cancers, particularly lung and melanoma. The invention also finds utility in the treatment of cancers in the metastatic setting.

Thus in a first aspect the invention provides a signature indicative of a patient, such as a cancer patient, designated a responder or non-responder to treatment with an appropriate immunotherapy, the signature comprising differential expression of one or more genes selected from immune activation/immune response/inflammatory response genes, for example, the group of genes indicative of T cell infiltration/activation, such as a gene listed (or a gene list comprising or consisting) those listed in Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 such as Table 1 or 2. Differential expression in the context of the present invention means the gene is upregulated or downregulated in comparison to its normal expression. Statistical methods for calculating gene differentiation are discussed below.

Immune activation gene is intended to mean a gene that facilitates, increases or stimulates an appropriate immune response. Immune response gene and immune activation gene are used interchangeably herein.

An important technique for the analysis of the genes expressed by cells, such as cancer/tumour cells, is DNA microarray (also known as gene chip technology), where hundreds or more probe sequences (such as 55,000 probe sets) are attached to a glass surface. The probe sequences are generally all 25 mers or 60 mers and are sequences from known genes. These probes are generally arranged in a set of 11 individual probes (a probe set) and are fixed in a predefined pattern on the glass surface. Once exposed to an appropriate biological sample these probes hybridise to the relevant RNA or DNA of a particular gene. After washing, the chip is “read” by an appropriate method and a quantity such as colour intensity recorded. The differential expression of a particular gene is proportional to the measure/intensity recorded. This technology is discussed in more detail below.

Once a target gene profile has been identified there are several analytical methods to measure whether the gene(s) is/are differentially expressed. These analytical techniques include real-time polymerase chain reaction, also called quantitative real time polymerase chain reaction (QRT-PCR or Q-PCR), which is used to simultaneously quantify and amplify a specific part of a given DNA molecule present in the sample.

The procedure follows the general pattern of polymerase chain reaction, but the DNA is quantified after each round of amplification (the “real-time” aspect). Two common methods of quantification are the use of fluorescent dyes that intercalate with double-strand DNA, and modified DNA oligonucleotide probes that fluoresce when hybridized with a complementary DNA.

The basic idea behind real-time polymerase chain reaction is that the more abundant a particular cDNA (and thus mRNA) is in a sample, the earlier it will be detected during repeated cycles of amplification. Various systems exist which allow the amplification of DNA to be followed and they often involve the use of a fluorescent dye which is incorporated into newly synthesised DNA molecules during real-time amplification. Real-time polymerase chain reaction machines, which control the thermocycling process, can then detect the abundance of fluorescent DNA and thus the amplification progress of a given sample. Typically, amplification of a given cDNA over time follows a curve, with an initial flat-phase, followed by an exponential phase. Finally, as the experiment reagents are used up, DNA synthesis slows and the exponential curve flattens into a plateau.

Alternatively the mRNA or protein product of the target gene(s) may be measured by Northern Blot analysis, Western Blot and/or immunohistochemistry.

In one aspect the analysis to identify the profile/signature is performed on a patient sample wherein a cancer testis antigen is expressed.

If a gene is always upregulated or always down regulated in patients that are deemed to be responders (or alternatively non-responders) then this single gene can be used to establish if the patient is a responder or a non-responder once a threshold is established and provided the separation of the two groups is adequate.

When a single gene is analysed, for example, by Q-PCR then the gene expression can be normalised by reference to a gene that remains constant, for example genes with the symbol H3F3A, GΔPDH, TFRC, GUSB or PGK1. The normalisation can be performed by substracting the value obtained for the constant gene from the value obtained for the gene under consideration. A threshold may be established by plotting a measure of the expression of the relevant gene for each patient. Generally the responders and the non-responders will be clustered about a different axis/focal point. A threshold can be established in the gap between the clusters by classical statistical methods or simply plotting a “best fit line” to establish the middle ground between the two groups. Values, for example, above the pre-defined threshold can be designated as responders and values, for example below the pre-designated threshold can be designated as non-responders.

In one aspect the invention provides a gene profile for identifying a responder comprising one or more of said genes wherein 50, 60, 70, 75, 80, 85, 90, 95, 99 or 100% of the genes are upregulated.

The genes listed in Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 such as Table 1, 2 and/or 3 are generally upregulated in responders.

The robustness of the predictive method of the invention can be further improved for larger sample sizes by employing 2, 3, 4, 5, 6, etc genes from Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 such as Table 1 or 2.

Furthermore, once at least two differential expressed genes are included in the signature then statistical clustering methods can be used to differentiate the responders and non-responders. Methods for statistical clustering and software for the same are discussed below.

One parameter used in quantifying the differential expression of genes is the fold change, which is a metric for comparing a gene's mRNA-expression level between two distinct experimental conditions. Its arithmetic definition differs between investigators. However, the higher the fold change the more likely that the differential expression of the relevant genes will be adequately separated, rendering it easier to decide which category (responder or non-responder) the patient falls into.

The fold change may, for example be at least 10, at least 15, at least 20 or 30.

Another parameter also used to quantify differential expression is the “p” value. It is thought that the lower the p value the more differentially expressed the gene is likely to be, which renders it a good candidate for use in profiles of the invention. P values may for example include 0.1 or less, such as 0.05 or less, in particular 0.01 or less. P values as used herein include corrected “P” values and/or also uncorrected “P” values.

The invention provides a method for the detection of a gene signature in a biological sample, the method comprising the analysis of the expression of at least 5 genes as set forth in Table 1. Alternatively one or more genes may be selected from Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 such as Table 1 or 2.

Thus in one aspect the invention provides a method of identifying whether a cancer patient will be a responder or non-responder to immunotherapy, the method comprising:

• • 1. analysing a sample comprising mRNA or fragments thereof expressed by genes of cancerous cells or DNA or fragments thereof from cancerous cells, for differential expression of one or more genes indicative of T-cell infiltration/activation, for example selected from the group comprising or consisting of genes listed in Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 such as Table 1 or 2, and
  • 2. characterising a patient as a responder or a non-responder based on the results of step 1.

Responder in the context of the present invention includes persons where the cancer/tumor(s) is irradiated, reduced or improved (mixed responder or partial responder) or simply stabilised such that the disease is not progressing. In responders where the cancer is stabilised then the period of stabilisation is such that the quality of life and/or patients life expectancy is increased (for example stable disease for more than 6 months) in comparison to a patient that does not receive treatment.

Partial clinical response in respect of cancer is wherein all of the tumors/cancers respond to treatment to some extent, for example where said cancer is reduced by 30, 40, 50, 60% or more. Mixed clinical responder in respect of cancer is defined as wherein some of the tumors/cancers respond to treatment and others remain unchanged or progress.

Standard definitions are available for responders, partial responders and mixed responders to cancer treatment. These standard definitions apply herein unless from the context it is clear that they do not apply.

As used herein, methods to predict a favorable clinical response or to identify subjects more likely to respond to therapy, is not meant to imply a 100% predictive ability, but to indicate that subjects with certain characteristics are more likely to experience a favorable clinical response to a specified therapy than subjects who lack such characteristics. However, as will be apparent to one skilled in the art, some individuals identified as more likely to experience a favorable clinical response may nonetheless fail to demonstrate measurable clinical response to the treatment. Similarly, some individuals predicted as non-responders may nonetheless exhibit a favorable clinical response to the treatment.

As used herein, a ‘favorable response’ (or ‘favorable clinical response’) to, for example, an anticancer treatment refers to a biological or physical response that is recognized by those skilled in the art as indicating a decreased rate of tumor growth, compared to tumor growth that would occur with an alternate treatment or the absence of any treatment. “Favorable clinical response” as used herein is not synonymous with a cure, but includes Partial Response, Mixed Response or Stable Disease. A favorable clinical response to therapy may include a lessening of symptoms experienced by the subject, an increase in the expected or achieved survival time, a decreased rate of tumor growth, cessation of tumor growth (stable disease), regression in the number or mass of metastatic lesions, and/or regression of the overall tumor mass (each as compared to that which would occur in the absence of therapy, or in response to an alternate therapy).

Patients in need of treatment for, for example, a Mage-expressing tumor, whose tumor cells have a gene signature described herein as a “Responder” signature are more likely to have a favorable clinical response, compared to patients whose tumor cells show a gene signature described herein as a “Non-Responder” signature, when treated with Mage specific immunotherapy.

Non-responder in the context of this invention includes persons whose symptoms ie cancers/tumors are not improved or stabilised.

Optionally the characterisation of the patient as a responder or non-responder can be performed by reference to a “standard” or a training set. The standard may be the profile of a person/patient who is known to be a responder or non-responder or alternatively may be a numerical value. Such pre-determined standards may be provided in any suitable form, such as a printed list or diagram, computer software program, or other media.

Training set in the context of the present specification is intended to refer to a group of samples for which the clinical results can be correlated with the gene profile and can be employed for training an appropriate stastical model/programme to identify responders and/or non-responser for new samples. Tables 11A, 11B and 14 contain the training set information relevant to the 41 probe set model described in Example 4.

In one aspect a mathematical model/algorithm/statical method is employed to characterise the patient as responder or non-responder.

In one aspect the invention provides a profile based one or more immune activation genes, such as 5 or more such genes.

In one aspect the invention provides a profile based on the genes in Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 such as Table 1 or 2.

In one aspect the invention provides a profile based on 489 probes (listed in Table 4A) and/or approximately 480 genes as listed in Table 4.

According to one aspect the present invention provides a gene signature indicative of improved survival of patients with Mage expressing cancers following treatment with Mage specific immunotherapy. This gene signature, of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31, genes from the genes disclosed in Table 1, is characterised by differential expression compared to the gene signature of MAGE-expressing tumour patients who do not respond to Mage antigen specific cancer immunotherapy. Improved survival in likely to be a corollary of a response to the immunotherapy administered, if the patient is in fact a responder.

Tables with Gene Lists

In one aspect the invention relates to one or more genes listed in Table 1

	TABLE 1
	Gene Title	Seq Id No
1.1	chromosome 6 open reading frame 190	1
1.2	hematopoietic cell-specific Lyn substrate 1	2
1.3	interleukin 2 receptor, gamma (severe combined	3
	immunodeficiency)
1.4	CD52 antigen (CAMPATH-1 antigen) /// CD52 antigen	4
	(CAMPATH-1 antigen)
1.5	CD2 antigen (p50), sheep red blood cell receptor /// CD2 antigen	5
	(p50), sheep red blood cell receptor
1.6	ubiquitin D	6
1.7	signal transducer and activator of transcription 4	7
1.8	granzyme K (granzyme 3; tryptase II)///granzyme K (granzyme 3;	8
	tryptase II)
1.9	CD3G antigen, gamma polypeptide (TiT3 complex)	9
1.10	G protein-coupled receptor 171	10
1.11	Protein kinase C, beta 1	11
1.12	major histocompatibility complex, class II, DR alpha /// major	12
	histocompatibility complex, class II, DR alpha
1.13	Major histocompatibility complex, class II, DQ beta 1 /// Major	13
	histocompatibility complex, class II, DQ beta 1
1.14	alcohol dehydrogenase IB (class I), beta polypeptide	14
1.15	T cell receptor alpha constant /// T cell receptor alpha constant	15
1.16	CD69 antigen (p60, early T-cell activation antigen)	16
1.17	protein kinase C, theta	17
1.18	T cell receptor beta variable 19 /// T cell receptor beta constant 1	18
1.19	T cell receptor alpha locus /// T cell receptor delta variable 2 /// T	19
	cell receptor alpha variable 20 /// T cell receptor alpha joining 17 ///
	T cell receptor alpha constant
1.20	T cell receptor gamma constant 2	20
1.21	T cell receptor beta variable 21-1 /// T cell receptor beta variable 19	21
	/// T cell receptor beta variable 5-4 /// T cell receptor beta variable
	3-1 /// T cell receptor beta constant 1
1.22	T cell receptor alpha locus	22
1.23	T cell receptor beta variable 19 /// T cell receptor beta variable 19 ///	23
	T cell receptor beta constant 1 /// T cell receptor beta constant 1
1.24	CD3D antigen, delta polypeptide (TiT3 complex)	24
1.25	T cell receptor gamma constant 2 /// T cell receptor gamma variable	25
	9 /// similar to T-cell receptor gamma chain C region PT-gamma-1/2
	/// similar to T-cell receptor gamma chain V region PT-gamma-1/2
	precursor /// TCR gamma alternate reading frame protein
1.26	pyrin and HIN domain family, member 1	26
1.27	T cell receptor associated transmembrane adaptor 1	27
1.28	SLAM family member 7	28
1.29	chromosome 4 open reading frame 7	29
1.30	Major histocompatibility complex, class II, DQ alpha 1	30
1.31	Transcribed locus	31
1.32	Amphiphysin (Stiff-Man syndrome with breast cancer 128 kDa	32
	autoantigen)
1.33	dendritic cell-associated lectin-1	33

Table 1A at the end of this specification gives the full nucleotide sequence for each of the above genes.

In one aspect the invention provides a profile based on differential expression of 1 or more of 62 genes, identified in the literature, that relate to immune infiltration and activation.

In one aspect the invention provides a profile based on the genes listed in Table 2.

	TABLE 2
	Gene Symbol	Gene Title	Seq Id No
2.1	HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1	30
2.2	TRBV3-1	T cell receptor beta variable 3-1	21
2.3	IL2RG	interleukin 2 receptor, gamma (severe combined	3
		immunodeficiency
2.4	CD2	CD2 antigen (p50), sheep red blood cell receptor	5
2.5	GPR171	G protein-coupled receptor 171	10
2.6	ADH1B	alcohol dehydrogenase IB (class I), beta polypeptide	14
2.7	CD69	CD69 antigen (p60, early T-cell activation antigen)	16
2.8	TRBV19	T cell receptor beta variable 19	18
2.9	TRAT1	T cell receptor associated transmembrane adaptor 1	27
2.10	C4orf7	chromosome 4 open reading frame 7	29
2.11	PRKCB1	protein kinase C, beta 1	11
2.12	CD3D	CD3D antigen, delta polypeptide (TiT3 complex)	24
2.13	UBD	ubiquitin D	6

In one aspect the invention provides the list of genes in Table 3.

	TABLE 3
	Gene Symbol	Gene Title
3.1	CD52	CD52 molecule /// CD52 molecule
3.2	UBD	gamma-aminobutyric acid (GABA) B receptor, 1 /// ubiquitin D
3.3	STAT4	signal transducer and activator of transcription 4
3.4	GZMK	granzyme K (granzyme 3; tryptase II) /// granzyme K (granzyme
		3; tryptase II)
3.5	GPR171	G protein-coupled receptor 171
3.6	PRKCQ	protein kinase C, theta
3.7	TRA@ /// TRDV2 ///	T cell receptor alpha locus /// T cell receptor delta variable 2 /// T
	TRAV20 /// TRAC	cell receptor alpha variable 20 /// T cell receptor alpha constant
3.8	TRGC2 /// TRGV2 ///	T cell receptor gamma constant 2 /// T cell receptor gamma
	TRGV9 /// TARP ///	variable 2 /// T cell receptor gamma variable 9 /// TCR gamma
	LOC642083	alternate reading frame protein /// hypothetical protein
		LOC642083
3.9	TRBV21-1 ///	T cell receptor beta variable 21-1 /// T cell receptor beta variable
	TRBV19 /// TRBV5-4	19 /// T cell receptor beta variable 5-4 /// T cell receptor beta
	/// TRBV3-1 ///	variable 3-1 /// T cell receptor beta constant 1 /// similar to T-cell
	TRBC1	receptor beta chain V region CTL-L17 precursor
3.10	TRBV19 /// TRBC1	T cell receptor beta variable 19 /// T cell receptor beta variable 19
		/// T cell receptor beta constant 1 /// T cell receptor beta constant 1
3.11	CD3D	CD3d molecule, delta (CD3-TCR complex)
3.12	TRAT1	T cell receptor associated transmembrane adaptor 1

In one aspect the invention provides a profile based on one or more genes of Table 4

	TABLE 4
	Gene Symbol	Gene Title
4.1	FLJ20647	NA
4.2	NAV1	neuron navigator 1
4.3	GPR171	G protein-coupled receptor 171
4.4	CCL14	chemokine (C-C motif) ligand 14
4.5	C1S	complement component 1, s subcomponent
4.6	CXCL2	chemokine (C—X—C motif) ligand 2
4.7	TRBV3-1	T cell receptor beta variable 3-1
4.8	TRDV2	T cell receptor delta variable 2
4.9	RUFY3	RUN and FYVE domain containing 3
4.10	DOCK8	dedicator of cytokinesis 8
4.11	GCH1	GTP cyclohydrolase 1 (dopa-responsive dystonia)
4.12	CENTD3	centaurin, delta 3
4.13	ACSL5	acyl-CoA synthetase long-chain family member 5
4.14	AMICA1	adhesion molecule, interacts with CXADR antigen 1
4.15	IL2RG	interleukin 2 receptor, gamma (severe combined
		immunodeficiency)
4.16	TNFAIP3	tumor necrosis factor, alpha-induced protein 3
4.17	PSCDBP	pleckstrin homology, Sec7 and coiled-coil domains, binding
		protein
4.18	ESR1	estrogen receptor 1
4.19	TRBC1	T cell receptor beta constant 1
4.20	CD52	CD52 antigen (CAMPATH-1 antigen)
4.21	LOC442535	NA
4.22	TRBV19	T cell receptor beta variable 19
4.23	IL7R	interleukin 7 receptor
4.24	TRAC	T cell receptor alpha constant
4.25	NCF2	neutrophil cytosolic factor 2 (65 kDa, chronic granulomatous
		disease, autosomal 2)
4.26	LOC92689	NA
4.27	GZMK	c(“granzyme K (granzyme 3”, “tryptase II)”)
4.28	NA	NA (gene identified by probe 235831_at)
4.29	RAB34	RAB34, member RAS oncogene family
4.30	DPT	dermatopontin
4.31	PVT1	Pvt1 oncogene homolog, MYC activator (mouse)
4.32	TRGC2	T cell receptor gamma constant 2
4.33	GIMAP5	GTPase, IMAP family member 5
4.34	CD52	CD52 antigen (CAMPATH-1 antigen)
4.35	CD3D	CD3d antigen, delta polypeptide (TiT3 complex)
4.36	TMEM132C	transmembrane protein 132C
4.37	NFKBIA	nuclear factor of kappa light polypeptide gene enhancer in B-
		cells inhibitor, alpha
4.38	TRA@	T cell receptor alpha locus
4.39	TRAT1	T cell receptor associated transmembrane adaptor 1
4.40	LOC442535 (NA)	NA (duplicate)
4.41	RAB34	RAB34, member RAS oncogene family
4.42	CD69	CD69 antigen (p60, early T-cell activation antigen)
4.43	DOCK8	dedicator of cytokinesis 8
4.44	GIMAP5 (NA)	GTPase, IMAP family member 5 (NA-duplicate)
4.45	IRF8	interferon regulatory factor 8
4.46	KLRB1	killer cell lectin-like receptor subfamily B, member 1
4.47	NA	NA
4.48	ITGA3	integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3
		receptor)
4.49	MAP3K8	mitogen-activated protein kinase kinase kinase 8
4.50	C1orf162	chromosome 1 open reading frame 162
4.51	UBD	ubiquitin D
4.52	TRGV9	T cell receptor gamma variable 9
4.53	NAV1 (NA)	neuron navigator 1 (NA-duplicate)
4.54	ARHGAP9	Rho GTPase activating protein 9
4.55	TIFA	NA
4.56	DPT	dermatopontin
4.57	NA	NA (gene identified by probe 1569942_at)
4.58	GIMAP4	GTPase, IMAP family member 4
4.59	HCLS1	hematopoietic cell-specific Lyn substrate 1
4.60	PRKCH	protein kinase C, eta
4.61	STAT4	signal transducer and activator of transcription 4
4.62	HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1
4.63	ADRB2	adrenergic, beta-2-, receptor, surface
4.64	NA	NA
4.65	CTSW	cathepsin W (lymphopain)
4.66	MYH11	myosin, heavy polypeptide 11, smooth muscle
4.67	GIMAP6	GTPase, IMAP family member 6
4.68	HLA-DQB1	major histocompatibility complex, class II, DQ beta 1
4.69	CD8A	CD8 antigen, alpha polypeptide (p32)
4.70	TNFAIP3	tumor necrosis factor, alpha-induced protein 3
4.71	CP	ceruloplasmin (ferroxidase)
4.72	SMOC2	SPARC related modular calcium binding 2
4.73	C20orf24	chromosome 20 open reading frame 24
4.74	C16orf54	chromosome 16 open reading frame 54
4.75	CD2	CD2 antigen (p50), sheep red blood cell receptor
4.76	SLIT3	slit homolog 3 (Drosophila)
4.77	BAALC	brain and acute leukemia, cytoplasmic
4.78	TRIB3	tribbles homolog 3 (Drosophila)
4.79	LOC440160	NA
4.80	C6orf190	chromosome 6 open reading frame 190
4.81	TAGAP	T-cell activation GTPase activating protein
4.82	FAM92A1	family with sequence similarity 92, member A1
4.83	PSTPIP2	proline-serine-threonine phosphatase interacting protein 2
4.84	PTPRC	protein tyrosine phosphatase, receptor type, C
4.85	HLA-DRA	major histocompatibility complex, class II, DR alpha
4.86	EFCAB2	EF-hand calcium binding domain 2
4.87	TNFAIP8	tumor necrosis factor, alpha-induced protein 8
4.88	SLIC1	NA
4.89	CD1C	CD1c antigen
4.90	TRAF3IP3	TRAF3 interacting protein 3
4.91	HLA-DQA1 (NA)	MHC, class II, DQ α-1 (NA-duplicate)
4.92	NAV1 (NA)	neuron navigator 1 (NA-duplicate)
4.93	HLA-DQB1 (NA)	MHC, class II, DQ beta 1 (NA-duplicate)
4.94	PTPRC (NA)	protein tyrosine phosphatase, receptor type, C (NA-duplicate)
4.95	IGJ	immunoglobulin J polypeptide, linker protein for
		immunoglobulin alpha and mu polypeptides
4.96	PLEK	pleckstrin
4.97	TRA@ (NA)	T cell receptor alpha locus (NA-duplicate)
4.98	TMEM44	transmembrane protein 44
4.99	TRA@	T cell receptor alpha locus
4.100	EBI2	Epstein-Barr virus induced gene 2 (lymphocyte-specific G
		protein-coupled receptor)
4.101	SAMSN1	SAM domain, SH3 domain and nuclear localisation signals, 1
4.102	KIAA1794	KIAA1794
4.103	ALDH2	aldehyde dehydrogenase 2 family (mitochondrial)
4.104	CDC42SE2	CDC42 small effector 2
4.105	GFRA1	GDNF family receptor alpha 1
4.106	ITK	IL2-inducible T-cell kinase
4.107	HLA-DRA	major histocompatibility complex, class II, DR alpha
4.108	GIMAP7	GTPase, IMAP family member 7
4.109	FLJ20273	NA
4.110	PTPN6	protein tyrosine phosphatase, non-receptor type 6
4.111	PTGER3	prostaglandin E receptor 3 (subtype EP3)
4.112	RAI2	retinoic acid induced 2
4.113	LGALS2	lectin, galactoside-binding, soluble, 2 (galectin 2)
4.114	HMOX1	heme oxygenase (decycling) 1
4.115	NA	NA (gene identified by probe 227995_at)
4.116	ZNFN1A1	zinc finger protein, subfamily 1A, 1 (Ikaros)
4.117	CSF2RB	colony stimulating factor 2 receptor, beta, low-affinity
		(granulocyte-macrophage)
4.118	PCSK5	proprotein convertase subtilisin/kexin type 5
4.119	CCDC69	coiled-coil domain containing 69
4.120	CDC42SE2	CDC42 small effector 2
4.121	GZMA	granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated
		serine esterase 3)
4.122	C3	complement component 3
4.123	TNFAIP8 (NA)	tumor necrosis factor, alpha-induced protein 8 (NA-duplicate)
4.124	C15orf48	chromosome 15 open reading frame 48
4.125	RARRES3	retinoic acid receptor responder (tazarotene induced) 3
4.126	LOC283537	NA
4.127	CXCL12	chemokine (C—X—C motif) ligand 12 (stromal cell-derived factor
		1)
4.128	NAV1 (NA)	neuron navigator 1 (NA-duplicate)
4.129	NA	NA (gene identified by probe set 231882_at)
4.130	SOD2	superoxide dismutase 2, mitochondrial
4.131	CTSS	cathepsin S
4.132	CTBP2	C-terminal binding protein 2
4.133	BCL11B	B-cell CLL/lymphoma 11B (zinc finger protein)
4.134	CCL22	chemokine (C-C motif) ligand 22
4.135	ACSL5	acyl-CoA synthetase long-chain family member 5
4.136	DOC1	NA
4.137	SLC31A2	solute carrier family 31 (copper transporters), member 2
4.138	POPDC3	popeye domain containing 3
4.139	DOC1 (NA)	NA (duplicate)
4.140	SQRDL	sulfide quinone reductase-like (yeast)
4.141	RASGEF1B	RasGEF domain family, member 1B
4.142	FGL2	fibrinogen-like 2
4.143	C10orf128	chromosome 10 open reading frame 128
4.144	IL10RA	interleukin 10 receptor, alpha
4.145	EGFL6	EGF-like-domain, multiple 6
4.146	IL18	interleukin 18 (interferon-gamma-inducing factor)
4.147	ARHGAP30	Rho GTPase activating protein 30
4.148	PALMD	palmdelphin
4.149	RASSF5	Ras association (RalGDS/AF-6) domain family 5
4.150	GATA3	GATA binding protein 3
4.151	DKFZP564O0823	NA
4.152	BCL11B	B-cell CLL/lymphoma 11B (zinc finger protein)
4.153	TXNIP	thioredoxin interacting protein
4.154	DTX4	deltex 4 homolog (Drosophila)
4.155	DARC	Duffy blood group, chemokine receptor
4.156	RNASE6	ribonuclease, RNase A family, k6
4.157	CD86	CD86 antigen (CD28 antigen ligand 2, B7-2 antigen)
4.158	ZFP36	zinc finger protein 36, C3H type, homolog (mouse)
4.159	BASP1	brain abundant, membrane attached signal protein 1
4.160	CKAP1	cytoskeleton associated protein 1
4.161	HCP5	HLA complex P5
4.162	GRB14	growth factor receptor-bound protein 14
4.163	GJA7	gap junction protein, alpha 7, 45 kDa (connexin 45)
4.164	FLJ14054	NA
4.165	VNN1	vanin 1
4.166	ADCY7	adenylate cyclase 7
4.167	MS4A6A	membrane-spanning 4-domains, subfamily A, member 6A
4.168	CPA3	carboxypeptidase A3 (mast cell)
4.169	PIM1	pim-1 oncogene
4.170	CCL19	chemokine (C-C motif) ligand 19
4.171	SYK	spleen tyrosine kinase
4.172	NAV1 (NA)	neuron navigator 1 (NA-duplicate)
4.173	SIT1	signaling threshold regulating transmembrane adaptor 1
4.174	NA	NA (gene identified by probe set 228812_at)
4.175	NAP1L2	nucleosome assembly protein 1-like 2
4.176	CCL13	chemokine (C-C motif) ligand 13
4.177	SLA	Src-like-adaptor
4.178	NOD3	NA
4.179	PRKCH	protein kinase C, eta
4.180	TRD@	T cell receptor delta locus
4.181	BAALC	brain and acute leukemia, cytoplasmic
4.182	RP1-93H18.5	NA
4.183	FLJ20701	NA
4.184	SH3TC2	SH3 domain and tetratricopeptide repeats 2
4.185	CCR2	chemokine (C-C motif) receptor 2
4.186	CCL5	chemokine (C-C motif) ligand 5
4.187	HLA-DPA1	major histocompatibility complex, class II, DP alpha 1
4.188	MS4A6A (NA)	membrane spanning 4-domains, subfamilyA, member6A (NA-
		duplicate)
4.189	PECAM1	platelet/endothelial cell adhesion molecule (CD31 antigen)
4.190	AMIGO2	adhesion molecule with Ig-like domain 2
4.191	CCDC69	coiled-coil domain containing 69
4.192	CLEC7A	C-type lectin domain family 7, member A
4.193	P2RY14	purinergic receptor P2Y, G-protein coupled, 14
4.194	PIK3AP1	phosphoinositide-3-kinase adaptor protein 1
4.195	ADH1B	alcohol dehydrogenase IB (class I), beta polypeptide
4.196	TOP1MT	topoisomerase (DNA) I, mitochondrial
4.197	CD276	CD276 antigen
4.198	HLA-DQB1	major histocompatibility complex, class II, DQ beta I
4.199	JAM2	junctional adhesion molecule 2
4.200	C1S	complement component 1, s subeomponent
4.201	MS4A6A	membrane-spanning 4-domains, subfamily A, member 6A
4.202	TGFBR3	transforming growth factor, beta receptor III (betaglycan, 300 kDa)
4.203	ITGAL	c(“integrin, alpha L (antigen CD11A (p180), lymphocyte function-
		associated antigen 1”, “alpha polypeptide)”)
4.204	IL1R1	interleukin 1 receptor, type I
4.205	MS4A6A	membrane-spanning 4-domains, subfamily A, member 6A
4.206	HLA-DRB1	major histocompatibility complex, class II, DR beta 1
4.207	GIMAP2	GTPase, IMAP family member 2
4.208	ZC3H12D	zinc finger CCCH-type containing 12D
4.209	PCDH9	protocadherin 9
4.210	SLAMF7	SLAM family member 7
4.211	MGC7036	NA
4.212	RGS18	regulator of G-protein signalling 18
4.213	HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1
4.214	CD53	CD53 antigen
4.215	MPEG1	NA
4.216	SSBP4	single stranded DNA binding protein 4
4.217	NA	NA (gene identified by probe set 231262_at)
4.218	CDH19	cadherin 19, type 2
4.219	CTBP2	C-terminal binding protein 2
4.220	NAV1 (NA)	neuron navigator 1 (NA-duplicate)
4.221	FAM107B	family with sequence similarity 107, member B
4.222	IGKC	immunoglobulin kappa constant
4.223	ITGAM	integrin, alpha M (complement component 3 receptor 3 subunit)
4.224	CKAP1	cytoskeleton associated protein 1
4.225	HLA-DRB1	major histocompatibility complex, class II, DR beta 1
4.226	CDH19	cadherin 19, type 2
4.227	MGC16291	NA
4.228	DDEF2	development and differentiation enhancing factor 2
4.229	TNFAIP2	tumor necrosis factor, alpha-induced protein 2
4.230	CXCL14	chemokine (C—X—C motif) ligand 14
4.231	CD209	CD209 antigen
4.232	COL9A3	collagen, type IX, alpha 3
4.233	ANKRD22	ankyrin repeat domain 22
4.234	NCKAP1L	NCK-associated protein 1-like
4.235	CMKOR1	chemokine orphan receptor 1
4.236	HLA-DRB5	major histocompatibility complex, class II, DR beta 5
4.237	LCP1	lymphocyte cytosolic protein 1 (L-plastin)
4.238	ADH1B	alcohol dehydrogenase IB (class I), beta polypeptide
4.239	CXXC5	CXXC finger 5
4.240	GJA7	gap junction protein, alpha 7, 45 kDa (connexin 45)
4.241	FGD2	FYVE, RhoGEF and PH domain containing 2
4.242	MAN1A1	mannosidase, alpha, class 1A, member 1
4.243	C6orf115	chromosome 6 open reading frame 115
4.244	RP1-93H18.5 (NA)	NA (duplicate)
4.245	CXCL9	chemokine (C—X—C motif) ligand 9
4.246	FAM107B (NA)	family with sequence similarity 107, member B (NA-duplicate)
4.247	NPR3	natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic
		peptide receptor C)
4.248	FYB	FYN binding protein (FYB-120/130)
4.249	VCAM1	vascular cell adhesion molecule 1
4.250	FLI1	Friend leukemia virus integration 1
4.251	CXXC5	CXXC finger 5
4.252	TRAM2	translocation associated membrane protein 2
4.253	IGKC (NA)	immunoglobulin kappa constant (NA-duplicate)
4.254	SHC4	SHC (Src homology 2 domain containing) family, member 4
4.255	SLC9A9	solute carrier family 9 (sodium/hydrogen exchanger), member 9
4.256	PTPRC	protein tyrosine phosphatase, receptor type, C
4.257	PTGER4	prostaglandin E receptor 4 (subtype EP4)
4.258	LILRB1	leukocyte immunoglobulin-like receptor, subfamily B (with TM
		and ITIM domains), member 1
4.259	PRDM1	PR domain containing 1, with ZNF domain
4.260	RP1-93H18.5 (NA)	NA (duplicate)
4.261	ARHGAP15	Rho GTPase activating protein 15
4.262	SLC5A3	solute carrier family 5 (inositol transporters), member 3
4.263	DOCK9	dedicator of cytokinesis 9
4.264	GPSM1	G-protein signalling modulator 1 (AGS3-like, C. elegans)
4.265	CCL5	chemokine (C-C motif) ligand 5
4.266	GLIPR1	GLI pathogenesis-related 1 (glioma)
4.267	APOL3	apolipoprotein L, 3
4.268	HLA-DMB	major histocompatibility complex, class II, DM beta
4.269	SYNPO2	synaptopodin 2
4.270	NA	NA (gene identified by probe set 221651_x_at)
4.271	NA	NA (gene identified by probe set 231929_at)
4.272	RP1-93H18.5	NA
4.273	CASP1	caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta,
		convertase)
4.274	PRKCQ	protein kinase C, theta
4.275	IL1R2	interleukin 1 receptor, type II
4.276	CARD15	caspase recruitment domain family, member 15
4.277	ARHGDIB	Rho GDP dissociation inhibitor (GDI) beta
4.278	HLA-DRB4	major histocompatibility complex, class II, DR beta 4
4.279	SART2	squamous cell carcinoma antigen recognized by T cells 2
4.280	LSP1	lymphocyte-specific protein 1
4.281	AMPD3	adenosine monophosphate deaminase (isoform E)
4.282	SEMA4F	sema domain, immunoglobulin domain (Ig), transmembrane
		domain (TM) and short cytoplasmic domain, (semaphorin) 4F
4.283	ISOC1	isochorismatase domain containing 1
4.284	CCL5 (NA)	chemokine (C-C motif) ligand 5 (NA-duplicate)
4.285	HPS3	Hermansky-Pudlak syndrome 3
4.286	HLA-DPA1 (NA)	MHC, class II, DP alpha 1 (NA-duplicate)
4.287	HLA-DQB1 (NA)	MHC, class II, DQ beta 1 (NA-duplicate)
4.288	HOXB7	homeobox B7
4.289	FGL2 (NA)	fibrinogen-like 2 (NA-duplicate)
4.290	ZNFN1A1	zinc finger protein, subfamily 1A, 1 (Ikaros)
4.291	ARHGAP9	Rho GTPase activating protein 9
4.292	GATA2	GATA binding protein 2
4.293	AP2B1	adaptor-related protein complex 2, beta 1 subunit
4.294	CTSC	cathepsin C
4.295	PLK2	polo-like kinase 2 (Drosophila)
4.296	CD4	CD4 antigen (p55)
4.297	GGTA1	glycoprotein, alpha-galactosyltransferase 1
4.298	GADD45B	growth arrest and DNA-damage-inducible, beta
4.299	GADD45B (NA)	growth arrest and DNA-damage-inducible, beta (NA-duplicate)
4.300	FLJ10847	NA
4.301	KIF21B	kinesin family member 21B
4.302	CCND2	cyclin D2
4.303	PRG1	proteoglycan 1, secretory granule
4.304	SLC40A1	solute carrier family 40 (iron-regulated transporter), member 1
4.305	HLA-DPA1 (NA)	MHC, class II, DP alpha 1 (NA-duplicate)
4.306	SOD2 (NA)	superoxide dismutase 2, mitochondrial (NA-duplicate)
4.307	CRIP1	cysteine-rich protein 1 (intestinal)
4.308	LOC283070	NA
4.309	SIGLEC1	sialic acid binding Ig-like lectin 1, sialoadhesin
4.310	ZNF11B	zinc finger protein 11B
4.311	CXCR4	chemokine (C—X—C motif) receptor 4
4.312	HLA-DMA	major histocompatibility complex, class II, DM alpha
4.313	MRC1	mannose receptor, C type 1
4.314	CASP1 (NA)	caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta,
		convertase) (NA-duplicate)
4.315	LMO2	LIM domain only 2 (rhombotin-like 1)
4.315a	DENND2D	DENN/MADD domain containing 2D
4.316	CCL18	chemokine (C-C motif) ligand 18 (pulmonary and activation-
		regulated)
4.317	P2RY13	purinergic receptor P2Y, G-protein coupled, 13
4.318	CCL18 (NA)	chemokine (C-C motif) ligand 18 (pulmonary and activation-
		regulated) (NA-duplicate)
4.319	ANGPTL1	angiopoietin-like 1
4.320	NA	NA (gene identified by probe set 230391_at)
4.321	ITGAL (NA)	c(“integrin, alpha L (antigen CD11A (p180), lymphocyte function-
		associated antigen 1”, “alpha polypeptide)”) (NA-duplicate)
4.322	C8orf51	chromosome 8 open reading frame 51
4.323	GIMAP8	GTPase, IMAP family member 8
4.324	NA	NA (gene identified by probe set 227780_s_at)
4.325	JAK2	Janus kinase 2 (a protein tyrosine kinase)
4.326	TNFSF10	tumor necrosis factor (ligand) superfamily, member 10
4.327	C1R	complement component 1, r subcomponent
4.328	ACPL2	acid phosphatase-like 2
4.329	TNFRSF19	tumor necrosis factor receptor superfamily, member 19
4.330	PCSK5 (NA)	proprotein convertase subtilisin/kexin type 5 (NA-duplicate)
4.331	LRP12	low density lipoprotein-related protein 12
4.332	NA	NA (gene identified by probe set 1557116_at)
4.333	PECAM1 (NA)	platelet/endothelial cam (CD31 antigen) (NA-duplicate)
4.334	PRKCB1	protein kinase C, beta 1
4.335	IPO11	importin 11
4.336	DLGAP1	discs, large (Drosophila) homolog-associated protein 1
4.337	PRKAR2B	protein kinase, cAMP-dependent, regulatory, type II, beta
4.338	MAP3K8	mitogen-activated protein kinase kinase kinase 8
4.339	EVI2B	ecotropic viral integration site 2B
4.340	GBP1	guanylate binding protein 1, interferon-inducible, 67 kDa
4.341	CXCL10	chemokine (C—X—C motif) ligand 10
4.342	CAMK2N1	calcium/calmodulin-dependent protein kinase II inhibitor 1
4.343	MED12L	mediator of RNA polymerase II transcription, subunit 12 homolog
		(yeast)-like
4.344	ID2	inhibitor of DNA binding 2, dominant negative helix-loop-helix
		protein
4.345	CTBP2	C-terminal binding protein 2
4.346	IGLJ3	immunoglobulin lambda joining 3
4.347	GBP4	guanylate binding protein 4
4.348	LOC439949	NA
4.349	FBXO16	F-box protein 16
4.350	PRF1	perforin 1 (pore forming protein)
4.351	TRAM2	translocation associated membrane protein 2
4.352	LYN	v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
4.353	CENTD1	centaurin, delta 1
4.354	CASP1 (NA)	caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta,
		convertase) (NA-duplicate)
4.355	FLJ20273	NA
4.356	TFEC	transcription factor EC
4.357	PPP1R16B	protein phosphatase 1, regulatory (inhibitor) subunit 16B
4.358	CD48	CD48 antigen (B-cell membrane protein)
4.359	HLA-DPB1	major histocompatibility complex, class II, DP beta 1
4.360	SHC4 (NA)	SHC family, member 4 (NA-duplicate)
4.361	GTPBP5	GTP binding protein 5 (putative)
4.362	GBP5	guanylate binding protein 5
4.363	MAP1B	microtubule-associated protein 1B
4.364	EXTL3	exostoses (multiple)-like 3
4.365	CORO1A	coronin, actin binding protein, 1A
4.366	PDGFRL	platelet-derived growth factor receptor-like
4.367	RP9	retinitis pigmentosa 9 (autosomal dominant)
4.368	RHOU	ras homolog gene family, member U
4.369	MTAC2D1	membrane targeting (tandem) C2 domain containing 1
4.370	CCL8	chemokine (C-C motif) ligand 8
4.371	CECR1	cat eye syndrome chromosome region, candidate 1
4.372	IGKC (NA)	immunoglobulin kappa constant (NA-duplicate)
4.373	SLC40A1	solute carrier family 40 (iron-regulated transporter), member 1
4.374	ADCY6	adenylate cyclase 6
4.375	CP	ceruloplasmin (ferroxidase)
4.376	EDG1	endothelial differentiation, sphingolipid G-protein-coupled
		receptor, 1
4.377	RGS3	regulator of G-protein signalling 3
4.378	CD28 (NA)	CD28 antigen (Tp44) (NA-duplicate)
4.379	NA	NA (gene identified by probe set 228339_at)
4.380	ABHD5	abhydrolase domain containing 5
4.381	MS4A7	membrane-spanning 4-domains, subfamily A, member 7
4.382	PRKCH	protein kinase C, eta
4.383	GBP1 (NA)	guanylate binding protein 1, i-inducible, 67 kDa (NA-duplicate)
4.384	LOC286071	NA
4.385	BLNK	B-cell linker
4.386	NA	NA (gene identified by probe set 242546_at)
4.387	PCDHGC3	protocadherin gamma subfamily C, 3
4.388	CCL13 (NA)	chemokine (C-C motif) ligand 13 (NA-duplicate)
4.389	JAK2 (NA)	Janus kinase 2 (a protein tyrosine kinase) (NA-duplicate)
4.390	CAMSAP1L1	calmodulin regulated spectrin-associated protein 1-like 1
4.391	NPY1R	neuropeptide Y receptor Y1
4.392	CD274	CD274 antigen
4.393	PGM5	phosphoglucomutase 5
4.394	PLCG2	phospholipase C, gamma 2 (phosphatidylinositol-specific)
4.395	TNFSF10	tumor necrosis factor (ligand) superfamily, member 10
4.396	SOD2 (NA)	superoxide dismutase 2, mitochondrial (NA-duplicate)
4.397	BTG2	BTG family, member 2
4.398	LAMP3	lysosomal-associated membrane protein 3
4.399	IGLC1	immunoglobulin lambda constant 1 (Mcg marker)
4.400	SIPA1L1	signal-induced proliferation-associated 1 like 1
4.401	AIF1	allograft inflammatory factor 1
4.402	IGLC2	immunoglobulin lambda constant 2 (Kern-Oz-marker)
4.403	B2M	beta-2-microglobulin
4.404	CLEC7A	C-type lectin domain family 7, member A
4.405	MGC17330	NA
4.406	IGF1R	insulin-like growth factor 1 receptor
4.407	HIVEP1	human immunodeficiency virus type I enhancer binding protein 1
4.408	FKBP14	FK506 binding protein 14, 22 kDa
4.409	LAPTM5	lysosomal associated multispanning membrane protein 5
4.410	ABI3BP	ABI gene family, member 3 (NESH) binding protein
4.411	HLA-E	major histocompatibility complex, class I, E
4.412	ARL4C	ADP-ribosylation factor-like 4C
4.413	ASS	argininosuccinate synthetase
4.414	CASP1 (NA)	caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta,
		convertase) (NA-duplicate)
4.415	ITGB3	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
4.416	SYK	spleen tyrosine kinase
4.417	RAC2	ras-related C3 botulinum toxin substrate 2 (rho family, small GTP
		binding protein Rac2)
4.418	NA	NA (gene identified by probe set 1557222_at)
4.419	CD3G	CD3g antigen, gamma polypeptide (TiT3 complex)
4.420	IGF1	insulin-like growth factor 1 (somatomedin C)
4.421	NA	NA (gene identified by probe set 228858_at)
4.422	CYB5A	cytochrome b5 type A (microsomal)
4.423	TTC25	tetratricopeptide repeat domain 25
4.424	SLAMF6	SLAM family member 6
4.425	ARHGAP21	Rho GTPase activating protein 21
4.426	FLOT1	flotillin 1
4.427	AIF1 (NA)	allograft inflammatory factor 1 (NA-duplicate)
4.428	IBRDC2	IBR domain containing 2
4.429	KIAA1794	KIAA1794
4.430	OLFML1	olfactomedin-like 1
4.431	GMFG	glia maturation factor, gamma
4.432	TNFRSF1B	tumor necrosis factor receptor superfamily, member 1B
4.433	NA	NA (gene identified by probe set 217629_at)
4.434	DEF6	differentially expressed in FDCP 6 homolog (mouse)
4.435	HLA-E (NA)	major histocompatibility complex, class I, E (NA-duplicate)
4.436	MAP4K4	mitogen-activated protein kinase kinase kinase kinase 4
4.437	CMKOR1	chemokine orphan receptor 1
4.438	NA	NA (gene identified by probe set 1563461_at)
4.439	CHKA	choline kinase alpha
4.440	NA	NA (gene identified by probe set 226865_at)
4.441	HS3ST3B1	heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1
4.442	CXorf9	chromosome X open reading frame 9
4.443	EVI2A	ecotropic viral integration site 2A
4.444	GBP1 (NA)	guanylate binding protein 1, i-inducible, 67 kDa (NA-duplicate)
4.445	NFAM1	NFAT activating protein with ITAM motif 1
4.446	NA	NA (gene identified by probe set 242874_at)
4.447	ATP5J	ATP synthase, H+ transporting, mitochondrial F0 complex,
		subunit F6
4.448	NAV1 (NA)	neuron navigator 1 (NA-duplicate)
4.449	IGLC2 (NA)	immunoglobulin λ constant 2 (Kern-Oz-marker) (NA-duplicate)
4.450	CYLD	cylindromatosis (turban tumor syndrome)
4.451	GIMAP6	GTPase, IMAP family member 6
4.452	MFAP4	microfibrillar-associated protein 4
4.453	TUBB2B	tubulin, beta 2B
4.454	NELL2	NEL-like 2 (chicken)
4.455	NA	NA
4.456	IL1RN	interleukin 1 receptor antagonist
4.457	KIAA1211 (NA)	NA (duplicate)
4.458	SYK	spleen tyrosine kinase
4.459	ADAMDEC1	ADAM-like, decysin 1
4.460	AOC3	amine oxidase, copper containing 3 (vascular adhesion protein 1)
4.461	SAMHD1	SAM domain and HD domain 1
4.462	CXCL14 (NA)	chemokine (C—X—C motif) ligand 14 (NA-duplicate)
4.463	SLC22A3	solute carrier family 22 (extraneuronal monoamine transporter),
		member 3
4.464	IL1R1 (NA)	interleukin 1 receptor, type I (NA-duplicate)
4.465	IGLV3-25	immunoglobulin lambda variable 3-25
4.466	NA	NA (gene identified by probe set 1556185_a_at)
4.467	RAB11FIP1	RAB11 family interacting protein 1 (class I)
4.468	PER2	period homolog 2 (Drosophila)
4.469	TTL	tubulin tyrosine ligase
4.470	SIAHBP1	NA
4.471	LAPTM5	lysosomal associated multispanning membrane protein 5
4.472	FLJ22536	NA
4.473	RP6-213H19.1	NA
4.474	NA	NA (gene identified by probe set 235804_at)
4.475	NCF4	neutrophil cytosolic factor 4, 40 kDa
4.476	EPSTI1	epithelial stromal interaction 1 (breast)
4.477	LOC441212	NA
4.478	ANK3	ankyrin 3, node of Ranvier (ankyrin G)
4.479	PCDH9	protocadherin 9
4.480	C21orf86	chromosome 21 open reading frame 86
4.481	DHRS9	dehydrogenase/reductase (SDR family) member 9
4.482	ARHGAP25	Rho GTPase activating protein 25
4.483	TRAF4	TNF receptor-associated factor 4
4.484	LST1	leukcocyte specific transcript 1
4.485	PALMD	palmdelphin
4.486	TAP1	transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
4.487	MSX2	msh homeobox homolog 2 (Drosophila)
4.488	SIRPG	signal-regulatory protein gamma
NA = not applicable

In the tables listed herein the given gene may be listed more than once, for example as a specific gene or as a gene cluster. Table 4 above is generated from the probe sets listed in Table 4A below. There are often multiple probe sets for each gene and thus where more than one probe set has been used to identify a particular gene then the gene appears more than once in Table 4. An attempt has been made to remove the duplication by scoring through genes that appear more than once in Table 4.

In one aspect the invention provides across the various embodiments herein one or more genes selected from Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 including combinations thereof. In a further aspect the invention provides all the genes of Table 1, 2, 3, 4, 7, 9, 11, 12 or 13 or indeed combinations thereof.

In a further aspect the invention provides at least 10% of the genes listed in Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13, for example at least 40%, 50%, 60% or 70% such as 80%, 90% or 100% thereof.

One or more genes includes 1-5, 6-10, 11-15, 16-20, 21-25, 26-30, 31-35, 36-40, 41-45, 46-50, 51-55, 56-60, 61-65, 66-70, 71-75, 76-80, 81-85, 86-90, 91-95, 96-100, 101-105, 106-110, 111-115, 116-120, 121-125, 126-130, 131-135, 136-140, 141-145, 146-150, 151-155, 156-160, 161-165, 166-170, 171-175, 176-180, 181-185, 186-190, 191-195, 196-200, 201-205, 206-210, 211-215, 216-220, 221-225, 226-230, 231-235, 236-240, 241-245, 246-250, 251-255, 256-260, 261-265, 266-270, 271-275, 276-280, 281-285, 286-290, 291-295, 296-300, 301-305, 306-310, 311-315, 316-320, 321-325, 326-330, 331-335, 336-340, 341-345, 346-350, 351-355, 356-360, 361-365, 366-370, 371-375, 376-380, 381-385, 386-390, 391-395, 396-400, 401-405, 406-410, 411-415, 416-420, 421-425, 426-430, 431-435, 436-440, 441-445, 446-450, 451-455, 456-460, 461-465, 466-470, 471-475, 476-480, as appropriate and combinations thereof.

In one or more aspects the invention provides an embodiment as described in any one of paragraphs 1 to 430 below.

1) Thus the invention may employ one or more genes from Table 4.

2) In another aspect the invention employs one or more genes according to paragraph 1, wherein the gene has the symbol FLJ20647, optionally in combination with one or more genes labeled as 4.2 to 4.488 identified in Table 4.

3) In another aspect the invention employs one or more genes according to paragraph 1 or 2, wherein the gene has the NAV1, optionally in combination with one or more genes labeled as 4.3 to 4.488 identified in Table 4.

4) In another aspect the invention employs one or more genes according to any one of paragraphs 1-3, wherein the gene has the symbol GPR171, optionally in combination with one or more genes labeled as 4.4 to 4.488 identified in Table 4.

5) In another aspect the invention employs one or more genes according to any one of paragraphs 1-4, wherein the gene has the symbol CCL14, optionally in combination with one or more genes labeled as 4.5 to 4.488 identified in Table 4.

6) In another aspect the invention employs one or more genes according to any one of paragraphs 1-5, wherein the gene has the symbol C1S, optionally in combination with one or more genes labeled as 4.6 to 4.488 identified in Table 4.

7) In another aspect the invention employs one or more genes according to any one of paragraphs 1-6, wherein the gene has the symbol CXCL2, optionally in combination with one or more genes labeled as 4.7 to 4.488 identified in Table 4.

8) In another aspect the invention employs one or more genes according to any one of paragraphs 1-7, wherein the gene has the symbol TRBV3-1, optionally in combination with one or more genes labeled as 4.8 to 4.488 identified in Table 4.

9) In another aspect the invention employs one or more genes according to any one of paragraphs 1-8, wherein the gene has the symbol TRDV2, optionally in combination with one or more genes labeled as 4.9 to 4.488 identified in Table 4.

10) In another aspect the invention employs one or more genes according to any one of paragraphs 1-9, wherein the gene has the symbol RUFY3, optionally in combination with one or more genes labeled as 4.10 to 4.488 identified in Table 4.

11) In another aspect the invention employs one or more genes according to any one of paragraphs 1-10, wherein the gene has the symbol DOCK8, optionally in combination with one or more genes labeled as 4.11 to 4.488 identified in Table 4.

12) In another aspect the invention employs one or more genes according to any one of paragraphs 1-11, wherein the gene has the symbol GCH1, optionally in combination with one or more genes labeled as 4.12 to 4.488 identified in Table 4.

13) In another aspect the invention employs one or more genes according to any one of paragraphs 1-12, wherein the gene has the symbol CENTD3, optionally in combination with one or more genes labeled as 4.13 to 4.488 identified in Table 4.

14) In another aspect the invention employs one or more genes according to any one of paragraphs 1-13, wherein the gene has the symbol ACSL5, optionally in combination with one or more genes labeled as 4.14 to 4.488 identified in Table 4.

15) In another aspect the invention employs one or more genes according to any one of paragraphs 1-14, wherein the gene has the symbol AMICA1, optionally in combination with one or more genes labeled as 4.15 to 4.488 identified in Table 4.

16) In another aspect the invention employs one or more genes according to any one of paragraphs 1-15, wherein the gene has the symbol IL2RG, optionally in combination with one or more genes labeled as 4.16 to 4.488 identified in Table 4.

17) In another aspect the invention employs one or more genes according to any one of paragraphs 1-16, wherein the gene has the symbol TNFAIP3, optionally in combination with one or more genes labeled as 4.17 to 4.488 identified in Table 4.

18) In another aspect the invention employs one or more genes according to any one of paragraphs 1-17, wherein the gene has the symbol PSCDBP, optionally in combination with one or more genes labeled as 4.18 to 4.488 identified in Table 4.

19) In another aspect the invention employs one or more genes according to any one of paragraphs 1-18, wherein the gene has the symbol ESR1, optionally in combination with one or more genes labeled as 4.19 to 4.488 identified in Table 4.

20) In another aspect the invention employs one or more genes according to any one of paragraphs 1-19, wherein the gene has the symbol TRBC1, optionally in combination with one or more genes labeled as 4.20 to 4.488 identified in Table 4.

21) In another aspect the invention employs one or more genes according to any one of paragraphs 1-20, wherein the gene has the symbol CD52, optionally in combination with one or more genes labeled as 4.21 to 4.488 identified in Table 4.

22) In another aspect the invention employs one or more genes according to any one of paragraphs 1-21, wherein the gene has the symbol LOC442535, optionally in combination with one or more genes labeled as 4.22 to 4.488 identified in Table 4.

23) In another aspect the invention employs one or more genes according to any one of paragraphs 1-22, wherein the gene has the symbol TRBV19, optionally in combination with one or more genes labeled as 4.23 to 4.488 identified in Table 4.

24) In another aspect the invention employs one or more genes according to any one of paragraphs 1-23, wherein the gene has the symbol IL7R, optionally in combination with one or more genes labeled as 4.24 to 4.488 identified in Table 4.

25) In another aspect the invention employs one or more genes according to any one of paragraphs 1-24, wherein the gene has the symbol TRAC, optionally in combination with one or more genes labeled as 4.25 to 4.488 identified in Table 4.

26) In another aspect the invention employs one or more genes according to any one of paragraphs 1-25, wherein the gene has the symbol NCF2, optionally in combination with one or more genes labeled as 4.26 to 4.488 identified in Table 4.

27) In another aspect the invention employs one or more genes according to any one of paragraphs 1-26, wherein the gene has the symbol LOC92689, optionally in combination with one or more genes labeled as 4.27 to 4.488 identified in Table 4.

28) In another aspect the invention employs one or more genes according to any one of paragraphs 1-27, wherein the gene has the symbol GZMK, optionally in combination with one or more genes labeled as 4.28 to 4.488 identified in Table 4.

29) In another aspect the invention employs one or more genes according to any one of paragraphs 1-28, wherein the gene is the one identified by probe set 235831, optionally in combination with one or more genes labeled as 4.29 to 4.488 identified in Table 4.

30) In another aspect the invention employs one or more genes according to any one of paragraphs 1-29, wherein the gene has the symbol RAB34, optionally in combination with one or more genes labeled as 4.30 to 4.488 identified in Table 4.

31) In another aspect the invention employs one or more genes according to any one of paragraphs 1-30, wherein the gene has the symbol DPT, optionally in combination with one or more genes labeled as 4.31 to 4.488 identified in Table 4.

32) In another aspect the invention employs one or more genes according to any one of paragraphs 1-31, wherein the gene has the symbol PVT1, optionally in combination with one or more genes labeled as 4.32 to 4.488 identified in Table 4.

33) In another aspect the invention employs one or more genes according to any one of paragraphs 1-32, wherein the gene has the symbol TRGC2, optionally in combination with one or more genes labeled as 4.33 to 4.488 identified in Table 4.

34) In another aspect the invention employs one or more genes according to any one of paragraphs 1-33, wherein the gene has the symbol GIMAP5, optionally in combination with one or more genes labeled as 4.34 to 4.488 identified in Table 4.

35) In another aspect the invention employs one or more genes according to any one of paragraphs 1-34, wherein the gene has the symbol CD52, optionally in combination with one or more genes labeled as 4.35 to 4.488 identified in Table 4.

36) In another aspect the invention employs one or more genes according to any one of paragraphs 1-35, wherein the gene has the symbol CD3D, optionally in combination with one or more genes labeled as 4.36 to 4.488 identified in Table 4.

37) In another aspect the invention employs one or more genes according to any one of paragraphs 1-36, wherein the gene has the symbol TMEM132C, optionally in combination with one or more genes labeled as 4.37 to 4.488 identified in Table 4.

38) In another aspect the invention employs one or more genes according to any one of paragraphs 1-37, wherein the gene has the symbol NFKBIA, optionally in combination with one or more genes labeled as 4.38 to 4.488 identified in Table 4.

39) In another aspect the invention employs one or more genes according to any one of paragraphs 1-38, wherein the gene has the symbol TRA@, optionally in combination with one or more genes labeled as 4.39 to 4.488 identified in Table 4.

40) In another aspect the invention employs one or more genes according to any one of paragraphs 1-39, wherein the gene has the symbol TRAT1, optionally in combination with one or more genes labeled as 4.41 to 4.488 identified in Table 4.

41) In another aspect the invention employs one or more genes according to any one of paragraphs 1-40, wherein the gene has the symbol RAB34, optionally in combination with one or more genes labeled as 4.42 to 4.488 identified in Table 4.

42) In another aspect the invention employs one or more genes according to any one of paragraphs 1-41, wherein the gene has the symbol CD69, optionally in combination with one or more genes labeled as 4.43 to 4.488 identified in Table 4.

43) In another aspect the invention employs one or more genes according to any one of paragraphs 1-42, wherein the gene has the symbol DOCK8 optionally in combination with one or more genes labeled as 4.44 to 4.488 identified in Table 4.

44) In another aspect the invention employs one or more genes according to any one of paragraphs 1-43, wherein the gene has the symbol IRF8 optionally in combination with one or more genes labeled as 4.46 to 4.488 identified in Table 4.

45) In another aspect the invention employs one or more genes according to any one of paragraphs 144, wherein the gene has the symbol KLRB1 optionally in combination with one or more genes labeled as 4.47 to 4.488 identified in Table 4.

46) In another aspect the invention employs one or more genes according to any one of paragraphs 1-45, wherein the gene is identifiable by probe set number 236280_at, optionally in combination with one or more genes labeled as 4.48 to 4.488 identified in Table 4.

47) In another aspect the invention employs one or more genes according to any one of paragraphs 1-46, wherein the gene has the symbol ITGA3, optionally in combination with one or more genes labeled as 4.49 to 4.488 identified in Table 4.

48) In another aspect the invention employs one or more genes according to any one of paragraphs 1-47, wherein the gene has the symbol MAP3K8, optionally in combination with one or more genes labeled as 4.50 to 4.488 identified in Table 4.

49) In another aspect the invention employs one or more genes according to any one of paragraphs 1-48, wherein the gene has the symbol Clorf162, optionally in combination with one or more genes labeled as 4.51 to 4.488 identified in Table 4.

50) In another aspect the invention employs one or more genes according to any one of paragraphs 1-49, wherein the gene has the symbol UBD, optionally in combination with one or more genes labeled as 4.52 to 4.488 identified in Table 4.

51) In another aspect the invention employs one or more genes according to any one of paragraphs 1-50, wherein the gene has the symbol TRGV9, optionally in combination with one or more genes labeled as 4.54 to 4.488 identified in Table 4.

52) In another aspect the invention employs one or more genes according to any one of paragraphs 1-51, wherein the gene has the symbol NAV1, optionally in combination with one or more genes labeled as 4.54 to 4.488 identified in Table 4.

53) In another aspect the invention employs one or more genes according to any one of paragraphs 1-51, wherein the gene has the symbol ARHGAP9, optionally in combination with one or more genes labeled as 4.55 to 4.488 identified in Table 4.

54) In another aspect the invention employs one or more genes according to any one of paragraphs 1-53, wherein the gene has the symbol TIFA, optionally in combination with one or more genes labeled as 4.56 to 4.488 identified in Table 4.

55) In another aspect the invention employs one or more genes according to any one of paragraphs 1-54, wherein the gene is identified by probe number 1569942 at, optionally in combination with one or more genes labeled as 4.58 to 4.488 identified in Table 4.

56) In another aspect the invention employs one or more genes according to any one of paragraphs 1-55, wherein the gene has the symbol GIMAP4, optionally in combination with one or more genes labeled as 4.59 to 4.488 identified in Table 4.

57) In another aspect the invention employs one or more genes according to any one of paragraphs 1-56, wherein the gene has the symbol HCLS1, optionally in combination with one or more genes labeled as 4.60 to 4.488 identified in Table 4.

58) In another aspect the invention employs one or more genes according to any one of paragraphs 1-57, wherein the gene has the symbol PRKCH, optionally in combination with one or more genes labeled as 4.61 to 4.488 identified in Table 4.

59) In another aspect the invention employs one or more genes according to any one of paragraphs 1-58, wherein the gene has the symbol STAT4, optionally in combination with one or more genes labeled as 4.62 to 4.488 identified in Table 4.

60) In another aspect the invention employs one or more genes according to any one of paragraphs 1-59, wherein the gene has the symbol HLA-DQA1, optionally in combination with one or more genes labeled as 4.63 to 4.488 identified in Table 4.

61) In another aspect the invention employs one or more genes according to any one of paragraphs 1-60, wherein the gene has the symbol ADRB2, optionally in combination with one or more genes labeled as 4.64 to 4.488 identified in Table 4.

62) In another aspect the invention employs one or more genes according to any one of paragraphs 1-61, wherein the gene is identifiable by probe set number 239237_at, optionally in combination with one or more genes labeled as 4.65 to 4.488 identified in Table 4.

63) In another aspect the invention employs one or more genes according to any one of paragraphs 1-62, wherein the gene has the symbol CTSW, optionally in combination with one or more genes labeled as 4.66 to 4.488 identified in Table 4.

64) In another aspect the invention employs one or more genes according to any one of paragraphs 1-63, wherein the gene has the symbol MYH11, optionally in combination with one or more genes labeled as 4.67 to 4.488 identified in Table 4.

65) In another aspect the invention employs one or more genes according to any one of paragraphs 1-64, wherein the gene has the symbol GIMAP6, optionally in combination with one or more genes labeled as 4.68 to 4.488 identified in Table 4.

66) In another aspect the invention employs one or more genes according to any one of paragraphs 1-65, wherein the gene has the symbol HLA-DQB1, optionally in combination with one or more genes labeled as 4.69 to 4.488 identified in Table 4.

67) In another aspect the invention employs one or more genes according to any one of paragraphs 1-66, wherein the gene has the symbol CD8A, optionally in combination with one or more genes labeled as 4.70 to 4.488 identified in Table 4.

68) In another aspect the invention employs one or more genes according to any one of paragraphs 1-67, wherein the gene has the symbol TNFAIP3, optionally in combination with one or more genes labeled as 4.71 to 4.488 identified in Table 4.

69) In another aspect the invention employs one or more genes according to any one of paragraphs 1-68, wherein the gene has the symbol CP, optionally in combination with one or more genes labeled as 4.72 to 4.488 identified in Table 4.

70) In another aspect the invention employs one or more genes according to any one of paragraphs 1-69, wherein the gene has the symbol SMOC2, optionally in combination with one or more genes labeled as 4.73 to 4.488 identified in Table 4.

71) In another aspect the invention employs one or more genes according to any one of paragraphs 1-70, wherein the gene has the symbol C20orf24, optionally in combination with one or more genes labeled as 4.74 to 4.488 identified in Table 4.

72) In another aspect the invention employs one or more genes according to any one of paragraphs 1-71, wherein the gene has the symbol C16orf54, optionally in combination with one or more genes labeled as 4.75 to 4.488 identified in Table 4.

73) In another aspect the invention employs one or more genes according to any one of paragraphs 1-72, wherein the gene has the symbol CD2, optionally in combination with one or more genes labeled as 4.76 to 4.488 identified in Table 4.

74) In another aspect the invention employs one or more genes according to any one of paragraphs 1-73, wherein the gene has the symbol SLIT3, optionally in combination with one or more genes labeled as 4.77 to 4.488 identified in Table 4.

75) In another aspect the invention employs one or more genes according to any one of paragraphs 1-74, wherein the gene has the symbol BAALC, optionally in combination with one or more genes labeled as 4.78 to 4.488 identified in Table 4.

76) In another aspect the invention employs one or more genes according to any one of paragraphs 1-75, wherein the gene has the symbol TRIB3, optionally in combination with one or more genes labeled as 4.79 to 4.488 identified in Table 4.

77) In another aspect the invention employs one or more genes according to any one of paragraphs 1-76, wherein the gene has the symbol LOC440160, optionally in combination with one or more genes labeled as 4.80 to 4.488 identified in Table 4.

78) In another aspect the invention employs one or more genes according to any one of paragraphs 1-77, wherein the gene has the symbol C6orf190, optionally in combination with one or more genes labeled as 4.81 to 4.488 identified in Table 4.

79) In another aspect the invention employs one or more genes according to any one of paragraphs 1-78, wherein the gene has the symbol TAGAP, optionally in combination with one or more genes labeled as 4.82 to 4.488 identified in Table 4.

80) In another aspect the invention employs one or more genes according to any one of paragraphs 1-79, wherein the gene has the symbol FAM92A1, optionally in combination with one or more genes labeled as 4.83 to 4.488 identified in Table 4.

81) In another aspect the invention employs one or more genes according to any one of paragraphs 1-80, wherein the gene has the symbol PSTPIP2, optionally in combination with one or more genes labeled as 4.84 to 4.488 identified in Table 4.

82) In another aspect the invention employs one or more genes according to any one of paragraphs 1-81, wherein the gene has the symbol PTPRC, optionally in combination with one or more genes labeled as 4.85 to 4.488 identified in Table 4.

83) In another aspect the invention employs one or more genes according to any one of paragraphs 1-82, wherein the gene has the symbol HLA-DRA, optionally in combination with one or more genes labeled as 4.86 to 4.488 identified in Table 4.

84) In another aspect the invention employs one or more genes according to any one of paragraphs 1-83, wherein the gene has the symbol EFCAB2, optionally in combination with one or more genes labeled as 4.87 to 4.488 identified in Table 4.

85) In another aspect the invention employs one or more genes according to any one of paragraphs 1-84, wherein the gene has the symbol TNFAIP8, optionally in combination with one or more genes labeled as 4.88 to 4.488 identified in Table 4.

86) In another aspect the invention employs one or more genes according to any one of paragraphs 1-85, wherein the gene has the symbol SLIC1, optionally in combination with one or more genes labeled as 4.89 to 4.488 identified in Table 4.

87) In another aspect the invention employs one or more genes according to any one of paragraphs 1-86, wherein the gene has the symbol CD1C, optionally in combination with one or more genes labeled as 4.90 to 4.488 identified in Table 4.

88) In another aspect the invention employs one or more genes according to any one of paragraphs 1-87, wherein the gene has the symbol TRAF31P3, optionally in combination with one or more genes labeled as 4.91 to 4.488 identified in Table 4.

89) In another aspect the invention employs one or more genes according to any one of paragraphs 1-88, wherein the gene has the symbol IGJ, optionally in combination with one or more genes labeled as 4.96 to 4.488 identified in Table 4.

90) In another aspect the invention employs one or more genes according to any one of paragraphs 1-89, wherein the gene has the symbol PLEK, optionally in combination with one or more genes labeled as 4.98 to 4.488 identified in Table 4.

91) In another aspect the invention employs one or more genes according to any one of paragraphs 1-90, wherein the gene has the symbol TMEM44, optionally in combination with one or more genes labeled as 4.100 to 4.488 identified in Table 4.

92) In another aspect the invention employs one or more genes according to any one of paragraphs 1-91, wherein the gene has the symbol EBI2, optionally in combination with one or more genes labeled as 4.101 to 4.488 identified in Table 4.

93) In another aspect the invention employs one or more genes according to any one of paragraphs 1-92, wherein the gene has the symbol SAMSN1, optionally in combination with one or more genes labeled as 4.102 to 4.488 identified in Table 4.

94) In another aspect the invention employs one or more genes according to any one of paragraphs 1-93, wherein the gene has the symbol KIAA1794, optionally in combination with one or more genes labeled as 4.103 to 4.488 identified in Table 4.

95) In another aspect the invention employs one or more genes according to any one of paragraphs 1-94, wherein the gene has the symbol ALDH2, optionally in combination with one or more genes labeled as 4.104 to 4.488 identified in Table 4.

96) In another aspect the invention employs one or more genes according to any one of paragraphs 1-95, wherein the gene has the symbol CDC42SE2, optionally in combination with one or more genes labeled as 4.105 to 4.488 identified in Table 4.

97) In another aspect the invention employs one or more genes according to any one of paragraphs 1-96, wherein the gene has the symbol GFRA1, optionally in combination with one or more genes labeled as 4.106 to 4.488 identified in Table 4.

98) In another aspect the invention employs one or more genes according to any one of paragraphs 1-97, wherein the gene has the symbol ITK, optionally in combination with one or more genes labeled as 4.107 to 4.488 identified in Table 4.

99) In another aspect the invention employs one or more genes according to any one of paragraphs 1-98, wherein the gene has the symbol GIMAP7, optionally in combination with one or more genes labeled as 4.109 to 4.488 identified in Table 4.

100) In another aspect the invention employs one or more genes according to any one of paragraphs 1-99, wherein the gene has the symbol FLJ20273, optionally in combination with one or more genes labeled as 4.110 to 4.488 identified in Table 4.

101) In another aspect the invention employs one or more genes according to any one of paragraphs 1-100, wherein the gene has the symbol PTPN6, optionally in combination with one or more genes labeled as 4.111 to 4.488 identified in Table 4.

102) In another aspect the invention employs one or more genes according to any one of paragraphs 1-101, wherein the gene has the symbol PTGER3, optionally in combination with one or more genes labeled as 4.112 to 4.488 identified in Table 4.

103) In another aspect the invention employs one or more genes according to any one of paragraphs 1-102, wherein the gene has the symbol RAI2, optionally in combination with one or more genes labeled as 4.113 to 4.488 identified in Table 4.

104) In another aspect the invention employs one or more genes according to any one of paragraphs 1-103, wherein the gene has the symbol LGALS2, optionally in combination with one or more genes labeled as 4.114 to 4.488 identified in Table 4.

105) In another aspect the invention employs one or more genes according to any one of paragraphs 1-104, wherein the gene has the symbol HMOX1, optionally in combination with one or more genes labeled as 4.115 to 4.488 identified in Table 4.

106) In another aspect the invention employs one or more genes according to any one of paragraphs 1-105, wherein the gene is identifiable by probe set number 227995 at, optionally in combination with one or more genes labeled as 4.116 to 4.488 identified in Table 4.

107) In another aspect the invention employs one or more genes according to any one of paragraphs 1-106, wherein the gene has the symbol ZNFN1A1, optionally in combination with one or more genes labeled as 4.117 to 4.488 identified in Table 4.

108) In another aspect the invention employs one or more genes according to any one of paragraphs 1-107, wherein the gene has the symbol CSF2RB, optionally in combination with one or more genes labeled as 4.118 to 4.488 identified in Table 4.

109) In another aspect the invention employs one or more genes according to any one of paragraphs 1-108, wherein the gene has the symbol PCSK5, optionally in combination with one or more genes labeled as 4.119 to 4.488 identified in Table 4.

110) In another aspect the invention employs one or more genes according to any one of paragraphs 1-109, wherein the gene has the symbol CCDC69, optionally in combination with one or more genes labeled as 4.120 to 4.488 identified in Table 4.

111) In another aspect the invention employs one or more genes according to any one of paragraphs 1-110, wherein the gene has the symbol CDC42SE2, optionally in combination with one or more genes labeled as 4.121 to 4.488 identified in Table 4.

112) In another aspect the invention employs one or more genes according to any one of paragraphs 1-111, wherein the gene has the symbol GZMA, optionally in combination with one or more genes labeled as 4.122 to 4.488 identified in Table 4.

113) In another aspect the invention employs one or more genes according to any one of paragraphs 1-112, wherein the gene has the symbol C3, optionally in combination with one or more genes labeled as 4.123 to 4.488 identified in Table 4.

114) In another aspect the invention employs one or more genes according to any one of paragraphs 1-113, wherein the gene has the symbol C15orf48, optionally in combination with one or more genes labeled as 4.125 to 4.488 identified in Table 4.

115) In another aspect the invention employs one or more genes according to any one of paragraphs 1-114, wherein the gene has the symbol RARRES3, optionally in combination with one or more genes labeled as 4.126 to 4.488 identified in Table 4.

116) In another aspect the invention employs one or more genes according to any one of paragraphs 1-115, wherein the gene has the symbol LOC283537, optionally in combination with one or more genes labeled as 4.127 to 4.488 identified in Table 4.

117) In another aspect the invention employs one or more genes according to any one of paragraphs 1-116, wherein the gene has the symbol CXCL12, optionally in combination with one or more genes labeled as 4.129 to 4.488 identified in Table 4.

118) In another aspect the invention employs one or more genes according to any one of paragraphs 1-117, wherein the gene is identifiable by probe set number 231882_at, optionally in combination with one or more genes labeled as 4.130 to 4.488 identified in Table 4.

119) In another aspect the invention employs one or more genes according to any one of paragraphs 1-118, wherein the gene has the symbol SOD2, optionally in combination with one or more genes labeled as 4.131 to 4.488 identified in Table 4.

120) In another aspect the invention employs one or more genes according to any one of paragraphs 1-119, wherein the gene has the symbol CTSS, optionally in combination with one or more genes labeled as 4.132 to 4.488 identified in Table 4.

121) In another aspect the invention employs one or more genes according to any one of paragraphs 1-120, wherein the gene has the symbol CTBP2, optionally in combination with one or more genes labeled as 4.133 to 4.488 identified in Table 4.

122) In another aspect the invention employs one or more genes according to any one of paragraphs 1-121, wherein the gene has the symbol BCL11B, optionally in combination with one or more genes labeled as 4.134 to 4.488 identified in Table 4.

123) In another aspect the invention employs one or more genes according to any one of paragraphs 1-122, wherein the gene has the symbol CCL22, optionally in combination with one or more genes labeled as 4.135 to 4.488 identified in Table 4.

124) In another aspect the invention employs one or more genes according to any one of paragraphs 1-123, wherein the gene has the symbol ACSL5, optionally in combination with one or more genes labeled as 4.136 to 4.488 identified in Table 4.

125) In another aspect the invention employs one or more genes according to any one of paragraphs 1-124, wherein the gene has the symbol DOC1, optionally in combination with one or more genes labeled as 4.137 to 4.488 identified in Table 4.

126) In another aspect the invention employs one or more genes according to any one of paragraphs 1-125, wherein the gene has the symbol SLC31A2, optionally in combination with one or more genes labeled as 4.138 to 4.488 identified in Table 4.

127) In another aspect the invention employs one or more genes according to any one of paragraphs 1-126, wherein the gene has the symbol POPDC3, optionally in combination with one or more genes labeled as 4.139 to 4.488 identified in Table 4.

128) In another aspect the invention employs one or more genes according to any one of paragraphs 1-127, wherein the gene has the symbol SQRDL, optionally in combination with one or more genes labeled as 4.141 to 4.488 identified in Table 4.

129) In another aspect the invention employs one or more genes according to any one of paragraphs 1-128, wherein the gene has the symbol RASGEF1B, optionally in combination with one or more genes labeled as 4.142 to 4.488 identified in Table 4.

130) In another aspect the invention employs one or more genes according to any one of paragraphs 1-129, wherein the gene has the symbol FGL2, optionally in combination with one or more genes labeled as 4.143 to 4.488 identified in Table 4.

131) In another aspect the invention employs one or more genes according to any one of paragraphs 1-130, wherein the gene has the symbol C10orf128, optionally in combination with one or more genes labeled as 4.144 to 4.488 identified in Table 4.

132) In another aspect the invention employs one or more genes according to any one of paragraphs 1-131, wherein the gene has the symbol IL10RA, optionally in combination with one or more genes labeled as 4.145 to 4.488 identified in Table 4.

133) In another aspect the invention employs one or more genes according to any one of paragraphs 1-132, wherein the gene has the symbol EGFL6, optionally in combination with one or more genes labeled as 4.146 to 4.488 identified in Table 4.

134) In another aspect the invention employs one or more genes according to any one of paragraphs 1-133, wherein the gene has the symbol IL18, optionally in combination with one or more genes labeled as 4.147 to 4.488 identified in Table 4.

135) In another aspect the invention employs one or more genes according to any one of paragraphs 1-134, wherein the gene has the symbol ARHGAP30, optionally in combination with one or more genes labeled as 4.148 to 4.488 identified in Table 4.

136) In another aspect the invention employs one or more genes according to any one of paragraphs 1-135, wherein the gene has the symbol PALMD, optionally in combination with one or more genes labeled as 4.149 to 4.488 identified in Table 4.

137) In another aspect the invention employs one or more genes according to any one of paragraphs 1-136, wherein the gene has the symbol RASSF5, optionally in combination with one or more genes labeled as 4.150 to 4.488 identified in Table 4.

138) In another aspect the invention employs one or more genes according to any one of paragraphs 1-137, wherein the gene has the symbol GATA3, optionally in combination with one or more genes labeled as 4.151 to 4.488 identified in Table 4.

139) In another aspect the invention employs one or more genes according to any one of paragraphs 1-138, wherein the gene has the symbol DKFZP564O0823, optionally in combination with one or more genes labeled as 4.152 to 4.488 identified in Table 4.

140) In another aspect the invention employs one or more genes according to any one of paragraphs 1-139, wherein the gene has the symbol TXNIP, optionally in combination with one or more genes labeled as 4.154 to 4.488 identified in Table 4.

141) In another aspect the invention employs one or more genes according to any one of paragraphs 1-140, wherein the gene has the symbol DTX4, optionally in combination with one or more genes labeled as 4.155 to 4.488 identified in Table 4.

142) In another aspect the invention employs one or more genes according to any one of paragraphs 1-141, wherein the gene has the symbol DARC, optionally in combination with one or more genes labeled as 4.156 to 4.488 identified in Table 4.

143) In another aspect the invention employs one or more genes according to any one of paragraphs 1-142, wherein the gene has the symbol RNASE6, optionally in combination with one or more genes labeled as 4.157 to 4.488 identified in Table 4.

144) In another aspect the invention employs one or more genes according to any one of paragraphs 1-143, wherein the gene has the symbol CD86, optionally in combination with one or more genes labeled as 4.158 to 4.488 identified in Table 4.

145) In another aspect the invention employs one or more genes according to any one of paragraphs 1-144, wherein the gene has the symbol ZFP36, optionally in combination with one or more genes labeled as 4.159 to 4.488 identified in Table 4.

146) In another aspect the invention employs one or more genes according to any one of paragraphs 1-145, wherein the gene has the symbol BASP1, optionally in combination with one or more genes labeled as 4.160 to 4.488 identified in Table 4.

147) In another aspect the invention employs one or more genes according to any one of paragraphs 1-146, wherein the gene has the symbol CKAP1, optionally in combination with one or more genes labeled as 4.161 to 4.488 identified in Table 4.

148) In another aspect the invention employs one or more genes according to any one of paragraphs 1-147, wherein the gene has the symbol HCP5, optionally in combination with one or more genes labeled as 4.162 to 4.488 identified in Table 4.

149) In another aspect the invention employs one or more genes according to any one of paragraphs 1-148, wherein the gene has the symbol GRB14, optionally in combination with one or more genes labeled as 4.163 to 4.488 identified in Table 4.

150) In another aspect the invention employs one or more genes according to any one of paragraphs 1-149, wherein the gene has the symbol GJA7, optionally in combination with one or more genes labeled as 4.164 to 4.488 identified in Table 4.

151) In another aspect the invention employs one or more genes according to any one of paragraphs 1-150, wherein the gene has the symbol FLJ14054, optionally in combination with one or more genes labeled as 4.165 to 4.488 identified in Table 4.

152) In another aspect the invention employs one or more genes according to any one of paragraphs 1-151, wherein the gene has the symbol VNN1, optionally in combination with one or more genes labeled as 4.166 to 4.488 identified in Table 4.

153) In another aspect the invention employs one or more genes according to any one of paragraphs 1-152, wherein the gene has the symbol ADCY7, optionally in combination with one or more genes labeled as 4.167 to 4.488 identified in Table 4.

154) In another aspect the invention employs one or more genes according to any one of paragraphs 1-153, wherein the gene has the symbol MS4A6A, optionally in combination with one or more genes labeled as 4.168 to 4.488 identified in Table 4.

155) In another aspect the invention employs one or more genes according to any one of paragraphs 1-154, wherein the gene has the symbol CPA3, optionally in combination with one or more genes labeled as 4.169 to 4.488 identified in Table 4.

156) In another aspect the invention employs one or more genes according to any one of paragraphs 1-155, wherein the gene has the symbol PIM1, optionally in combination with one or more genes labeled as 4.170 to 4.488 identified in Table 4.

157) In another aspect the invention employs one or more genes according to any one of paragraphs 1-156, wherein the gene has the symbol CCL19, optionally in combination with one or more genes labeled as 4.171 to 4.488 identified in Table 4.

158) In another aspect the invention employs one or more genes according to any one of paragraphs 1-157, wherein the gene has the symbol SYK, optionally in combination with one or more genes labeled as 4.172 to 4.488 identified in Table 4.

159) In another aspect the invention employs one or more genes according to any one of paragraphs 1-158, wherein the gene has the symbol SIT1, optionally in combination with one or more genes labeled as 4.174 to 4.488 identified in Table 4.

160) In another aspect the invention employs one or more genes according to any one of paragraphs 1-159, wherein the gene is identifiable by probe set number 228812_at, optionally in combination with one or more genes labeled as 4.175 to 4.488 identified in Table 4.

161) In another aspect the invention employs one or more genes according to any one of paragraphs 1-160, wherein the gene has the symbol NAP1L2, optionally in combination with one or more genes labeled as 4.176 to 4.488 identified in Table 4.

162) In another aspect the invention employs one or more genes according to any one of paragraphs 1-161, wherein the gene has the symbol CCL13, optionally in combination with one or more genes labeled as 4.177 to 4.488 identified in Table 4.

163) In another aspect the invention employs one or more genes according to any one of paragraphs 1-162, wherein the gene has the symbol SLA, optionally in combination with one or more genes labeled as 4.178 to 4.488 identified in Table 4.

164) In another aspect the invention employs one or more genes according to any one of paragraphs 1-163, wherein the gene has the symbol NOD3, optionally in combination with one or more genes labeled as 4.179 to 4.488 identified in Table 4.

165) In another aspect the invention employs one or more genes according to any one of paragraphs 1-164, wherein the gene has the symbol PRKCH, optionally in combination with one or more genes labeled as 4.180 to 4.488 identified in Table 4.

166) In another aspect the invention employs one or more genes according to any one of paragraphs 1-165, wherein the gene has the symbol TRD@, optionally in combination with one or more genes labeled as 4.181 to 4.488 identified in Table 4.

167) In another aspect the invention employs one or more genes according to any one of paragraphs 1-166, wherein the gene has the symbol BAALC, optionally in combination with one or more genes labeled as 4.182 to 4.488 identified in Table 4.

168) In another aspect the invention employs one or more genes according to any one of paragraphs 1-167, wherein the gene has the symbol RP1-93H18.5, optionally in combination with one or more genes labeled as 4.183 to 4.488 identified in Table 4.

169) In another aspect the invention employs one or more genes according to any one of paragraphs 1-168, wherein the gene has the symbol FLJ20701, optionally in combination with one or more genes labeled as 4.184 to 4.488 identified in Table 4.

170) In another aspect the invention employs one or more genes according to any one of paragraphs 1-169, wherein the gene has the symbol SH3TC2, optionally in combination with one or more genes labeled as 4.185 to 4.488 identified in Table 4.

171) In another aspect the invention employs one or more genes according to any one of paragraphs 1-170, wherein the gene has the symbol CCR2, optionally in combination with one or more genes labeled as 4.186 to 4.488 identified in Table 4.

172) In another aspect the invention employs one or more genes according to any one of paragraphs 1-171, wherein the gene has the symbol CCL5, optionally in combination with one or more genes labeled as 4.187 to 4.488 identified in Table 4.

173) In another aspect the invention employs one or more genes according to any one of paragraphs 1-172, wherein the gene has the symbol HLA-DPA1, optionally in combination with one or more genes labeled as 4.189 to 4.488 identified in Table 4.

174) In another aspect the invention employs one or more genes according to any one of paragraphs 1-173, wherein the gene has the symbol PECAM1, optionally in combination with one or more genes labeled as 4.190 to 4.488 identified in Table 4.

175) In another aspect the invention employs one or more genes according to any one of paragraphs 1-174, wherein the gene has the symbol AMIGO2, optionally in combination with one or more genes labeled as 4.192 to 4.488 identified in Table 4.

176) In another aspect the invention employs one or more genes according to any one of paragraphs 1-175, wherein the gene has the symbol CLEC7A, optionally in combination with one or more genes labeled as 4.193 to 4.488 identified in Table 4.

177) In another aspect the invention employs one or more genes according to any one of paragraphs 1-176, wherein the gene has the symbol P2RY14, optionally in combination with one or more genes labeled as 4.194 to 4.488 identified in Table 4.

178) In another aspect the invention employs one or more genes according to any one of paragraphs 1-177, wherein the gene has the symbol PIK3AP1, optionally in combination with one or more genes labeled as 4.195 to 4.488 identified in Table 4.

179) In another aspect the invention employs one or more genes according to any one of paragraphs 1-178, wherein the gene has the symbol ADH1B, optionally in combination with one or more genes labeled as 4.196 to 4.488 identified in Table 4.

180) In another aspect the invention employs one or more genes according to any one of paragraphs 1-179, wherein the gene has the symbol TOP1MT, optionally in combination with one or more genes labeled as 4.197 to 4.488 identified in Table 4.

181) In another aspect the invention employs one or more genes according to any one of paragraphs 1-180, wherein the gene has the symbol CD276, optionally in combination with one or more genes labeled as 4.199 to 4.488 identified in Table 4.

182) In another aspect the invention employs one or more genes according to any one of paragraphs 1-181, wherein the gene has the symbol JAM2, optionally in combination with one or more genes labeled as 4.200 to 4.488 identified in Table 4.

183) In another aspect the invention employs one or more genes according to any one of paragraphs 1-182, wherein the gene has the symbol C1S, optionally in combination with one or more genes labeled as 4.202 to 4.488 identified in Table 4.

184) In another aspect the invention employs one or more genes according to any one of paragraphs 1-183, wherein the gene has the symbol TGFBR3, optionally in combination with one or more genes labeled as 4.203 to 4.488 identified in Table 4.

185) In another aspect the invention employs one or more genes according to any one of paragraphs 1-184, wherein the gene has the symbol ITGAL, optionally in combination with one or more genes labeled as 4.204 to 4.488 identified in Table 4.

186) In another aspect the invention employs one or more genes according to any one of paragraphs 1-185, wherein the gene has the symbol IL1R1, optionally in combination with one or more genes labeled as 4.206 to 4.488 identified in Table 4.

187) In another aspect the invention employs one or more genes according to any one of paragraphs 1-186, wherein the gene has the symbol HLA-DRB1, optionally in combination with one or more genes labeled as 4.207 to 4.488 identified in Table 4.

188) In another aspect the invention employs one or more genes according to any one of paragraphs 1-187, wherein the gene has the symbol GIMAP2, optionally in combination with one or more genes labeled as 4.208 to 4.488 identified in Table 4.

189) In another aspect the invention employs one or more genes according to any one of paragraphs 1-188, wherein the gene has the symbol ZC3H12D, optionally in combination with one or more genes labeled as 4.209 to 4.488 identified in Table 4.

190) In another aspect the invention employs one or more genes according to any one of paragraphs 1-189, wherein the gene has the symbol PCDH9, optionally in combination with one or more genes labeled as 4.210 to 4.488 identified in Table 4.

191) In another aspect the invention employs one or more genes according to any one of paragraphs 1-190, wherein the gene has the symbol SLAMF7, optionally in combination with one or more genes labeled as 4.211 to 4.488 identified in Table 4.

192) In another aspect the invention employs one or more genes according to any one of paragraphs 1-191, wherein the gene has the symbol MGC7036, optionally in combination with one or more genes labeled as 4.212 to 4.488 identified in Table 4.

193) In another aspect the invention employs one or more genes according to any one of paragraphs 1-192, wherein the gene has the symbol RGS18, optionally in combination with one or more genes labeled as 4.214 to 4.488 identified in Table 4.

194) In another aspect the invention employs one or more genes according to any one of paragraphs 1-193, wherein the gene has the symbol CD53, optionally in combination with one or more genes labeled as 4.215 to 4.488 identified in Table 4.

195) In another aspect the invention employs one or more genes according to any one of paragraphs 1-194, wherein the gene has the symbol MPEG1, optionally in combination with one or more genes labeled as 4.216 to 4.488 identified in Table 4.

196) In another aspect the invention employs one or more genes according to any one of paragraphs 1-195, wherein the gene has the symbol SSBP4, optionally in combination with one or more genes labeled as 4.217 to 4.488 identified in Table 4.

197) In another aspect the invention employs one or more genes according to any one of paragraphs 1-196, wherein the gene is identifiable by probe set number 231262_at, optionally in combination with one or more genes labeled as 4.218 to 4.488 identified in Table 4.

198) In another aspect the invention employs one or more genes according to any one of paragraphs 1-197, wherein the gene has the symbol CDH19, optionally in combination with one or more genes labeled as 4.219 to 4.488 identified in Table 4.

199) In another aspect the invention employs one or more genes according to any one of paragraphs 1-198, wherein the gene has the symbol CTBP2, optionally in combination with one or more genes labeled as 4.221 to 4.488 identified in Table 4.

200) In another aspect the invention employs one or more genes according to any one of paragraphs 1-199, wherein the gene has the symbol FAM107B, optionally in combination with one or more genes labeled as 4.222 to 4.488 identified in Table 4.

201) in another aspect the invention employs one or more genes according to any one of paragraphs 1-200, wherein the gene has the symbol IGKC, optionally in combination with one or more genes labeled as 4.223 to 4.488 identified in Table 4.

202) In another aspect the invention employs one or more genes according to any one of paragraphs 1-201, wherein the gene has the symbol ITGAM, optionally in combination with one or more genes labeled as 4.224 to 4.488 identified in Table 4.

203) In another aspect the invention employs one or more genes according to any one of paragraphs 1-202, wherein the gene has the symbol CKAP1, optionally in combination with one or more genes labeled as 4.227 to 4.488 identified in Table 4.

204) In another aspect the invention employs one or more genes according to any one of paragraphs 1-203, wherein the gene has the symbol MGC16291, optionally in combination with one or more genes labeled as 4.228 to 4.488 identified in Table 4.

205) In another aspect the invention employs one or more genes according to any one of paragraphs 1-204, wherein the gene has the symbol DDEF2, optionally in combination with one or more genes labeled as 4.229 to 4.488 identified in Table 4.

206) In another aspect the invention employs one or more genes according to any one of paragraphs 1-205, wherein the gene has the symbol TNFAIP2, optionally in combination with one or more genes labeled as 4.230 to 4.488 identified in Table 4.

207) In another aspect the invention employs one or more genes according to any one of paragraphs 1-206, wherein the gene has the symbol CXCL14, optionally in combination with one or more genes labeled as 4.231 to 4.488 identified in Table 4.

208) In another aspect the invention employs one or more genes according to any one of paragraphs 1-207, wherein the gene has the symbol CD209, optionally in combination with one or more genes labeled as 4.232 to 4.488 identified in Table 4.

209) In another aspect the invention employs one or more genes according to any one of paragraphs 1-208, wherein the gene has the symbol COL9A3, optionally in combination with one or more genes labeled as 4.233 to 4.488 identified in Table 4.

210) In another aspect the invention employs one or more genes according to any one of paragraphs 1-209, wherein the gene has the symbol ANKRD22, optionally in combination with one or more genes labeled as 4.234 to 4.488 identified in Table 4.

211) In another aspect the invention employs one or more genes according to any one of paragraphs 1-210, wherein the gene has the symbol NCKAP1L, optionally in combination with one or more genes labeled as 4.235 to 4.488 identified in Table 4.

212) In another aspect the invention employs one or more genes according to any one of paragraphs 1-211, wherein the gene has the symbol CMKOR1, optionally in combination with one or more genes labeled as 4.236 to 4.488 identified in Table 4.

213) In another aspect the invention employs one or more genes according to any one of paragraphs 1-212, wherein the gene has the symbol HLA-DRB5, optionally in combination with one or more genes labeled as 4.237 to 4.488 identified in Table 4.

214) In another aspect the invention employs one or more genes according to any one of paragraphs 1-213, wherein the gene has the symbol LCP1, optionally in combination with one or more genes labeled as 4.239 to 4.488 identified in Table 4.

215) In another aspect the invention employs one or more genes according to any one of paragraphs 1-214, wherein the gene has the symbol CXXC5, optionally in combination with one or more genes labeled as 4.240 to 4.488 identified in Table 4.

216) In another aspect the invention employs one or more genes according to any one of paragraphs 1-215, wherein the gene has the symbol GJA7, optionally in combination with one or more genes labeled as 4.241 to 4.488 identified in Table 4.

217) In another aspect the invention employs one or more genes according to any one of paragraphs 1-216, wherein the gene has the symbol FGD2, optionally in combination with one or more genes labeled as 4.242 to 4.488 identified in Table 4.

218) In another aspect the invention employs one or more genes according to any one of paragraphs 1-217, wherein the gene has the symbol MAN1A1, optionally in combination with one or more genes labeled as 4.243 to 4.488 identified in Table 4.

219) In another aspect the invention employs one or more genes according to any one of paragraphs 1-218, wherein the gene has the symbol C6orf115, optionally in combination with one or more genes labeled as 4.245 to 4.488 identified in Table 4.

220) In another aspect the invention employs one or more genes according to any one of paragraphs 1-219, wherein the gene has the symbol CXCL9, optionally in combination with one or more genes labeled as 4.247 to 4.488 identified in Table 4.

221) In another aspect the invention employs one or more genes according to any one of paragraphs 1-220, wherein the gene has the symbol NPR3, optionally in combination with one or more genes labeled as 4.248 to 4.488 identified in Table 4.

222) In another aspect the invention employs one or more genes according to any one of paragraphs 1-221, wherein the gene has the symbol FYB, optionally in combination with one or more genes labeled as 4.249 to 4.488 identified in Table 4.

223) In another aspect the invention employs one or more genes according to any one of paragraphs 1-222, wherein the gene has the symbol VCAM1, optionally in combination with one or more genes labeled as 4.250 to 4.488 identified in Table 4.

224) In another aspect the invention employs one or more genes according to any one of paragraphs 1-223, wherein the gene has the symbol FLI1, optionally in combination with one or more genes labeled as 4.251 to 4.488 identified in Table 4.

225) In another aspect the invention employs one or more genes according to any one of paragraphs 1-224, wherein the gene has the symbol CXXC5, optionally in combination with one or more genes labeled as 4.252 to 4.488 identified in Table 4.

226) In another aspect the invention employs one or more genes according to any one of paragraphs 1-225, wherein the gene has the symbol TRAM2, optionally in combination with one or more genes labeled as 4.254 to 4.488 identified in Table 4.

227) In another aspect the invention employs one or more genes according to any one of paragraphs 1-226, wherein the gene has the symbol SHC4, optionally in combination with one or more genes labeled as 4.255 to 4.488 identified in Table 4.

228) In another aspect the invention employs one or more genes according to any one of paragraphs 1-227, wherein the gene has the symbol SLC9A9, optionally in combination with one or more genes labeled as 4.256 to 4.488 identified in Table 4.

229) In another aspect the invention employs one or more genes according to any one of paragraphs 1-228, wherein the gene has the symbol PTPRC, optionally in combination with one or more genes labeled as 4.257 to 4.488 identified in Table 4.

230) In another aspect the invention employs one or more genes according to any one of paragraphs 1-229, wherein the gene has the symbol PTGER4, optionally in combination with one or more genes labeled as 4.258 to 4.488 identified in Table 4.

231) In another aspect the invention employs one or more genes according to any one of paragraphs 1-230, wherein the gene has the symbol LILRB1, optionally in combination with one or more genes labeled as 4.259 to 4.488 identified in Table 4.

232) In another aspect the invention employs one or more genes according to any one of paragraphs 1-231, wherein the gene has the symbol PRDM1, optionally in combination with one or more genes labeled as 4.261 to 4.488 identified in Table 4.

233) In another aspect the invention employs one or more genes according to any one of paragraphs 1-232, wherein the gene has the symbol ARHGAP15, optionally in combination with one or more genes labeled as 4.262 to 4.488 identified in Table 4.

234) In another aspect the invention employs one or more genes according to any one of paragraphs 1-233, wherein the gene has the symbol SLC5A3, optionally in combination with one or more genes labeled as 4.263 to 4.488 identified in Table 4.

235) In another aspect the invention employs one or more genes according to any one of paragraphs 1-234, wherein the gene has the symbol DOCK9, optionally in combination with one or more genes labeled as 4.264 to 4.488 identified in Table 4.

236) In another aspect the invention employs one or more genes according to any one of paragraphs 1-235, wherein the gene has the symbol GPSM1, optionally in combination with one or more genes labeled as 4.265 to 4.488 identified in Table 4.

237) In another aspect the invention employs one or more genes according to any one of paragraphs 1-236, wherein the gene has the symbol CCL5, optionally in combination with one or more genes labeled as 4.266 to 4.488 identified in Table 4.

238) In another aspect the invention employs one or more genes according to any one of paragraphs 1-237, wherein the gene has the symbol GLIPR1, optionally in combination with one or more genes labeled as 4.267 to 4.488 identified in Table 4.

239) In another aspect the invention employs one or more genes according to any one of paragraphs 1-238, wherein the gene has the symbol APOL3, optionally in combination with one or more genes labeled as 4.268 to 4.488 identified in Table 4.

240) In another aspect the invention employs one or more genes according to any one of paragraphs 1-239, wherein the gene has the symbol HLA-DMB, optionally in combination with one or more genes labeled as 4.269 to 4.488 identified in Table 4.

241) In another aspect the invention employs one or more genes according to any one of paragraphs 1-240, wherein the gene has the symbol SYNPO2, optionally in combination with one or more genes labeled as 4.270 to 4.488 identified in Table 4.

242) In another aspect the invention employs one or more genes according to any one of paragraphs 1-241, wherein the gene is identifiable by probe set number 221651_x_at, optionally in combination with one or more genes labeled as 4.271 to 4.488 identified in Table 4.

243) In another aspect the invention employs one or more genes according to any one of paragraphs 1-242, wherein the gene is identifiable by probe set number 231929_at, optionally in combination with one or more genes labeled as 4.273 to 4.488 identified in Table 4.

244) In another aspect the invention employs one or more genes according to any one of paragraphs 1-243, wherein the gene has the symbol CASP1, optionally in combination with one or more genes labeled as 4.274 to 4.488 identified in Table 4.

245) In another aspect the invention employs one or more genes according to any one of paragraphs 1-244, wherein the gene has the symbol PRKCQ, optionally in combination with one or more genes labeled as 4.275 to 4.488 identified in Table 4.

246) In another aspect the invention employs one or more genes according to any one of paragraphs 1-245, wherein the gene has the symbol IL1R2, optionally in combination with one or more genes labeled as 4.276 to 4.488 identified in Table 4.

247) In another aspect the invention employs one or more genes according to any one of paragraphs 1-246, wherein the gene has the symbol CARD15, optionally in combination with one or more genes labeled as 4.277 to 4.488 identified in Table 4.

248) In another aspect the invention employs one or more genes according to any one of paragraphs 1-247, wherein the gene has the symbol ARHGDIB, optionally in combination with one or more genes labeled as 4.278 to 4.488 identified in Table 4.

249) In another aspect the invention employs one or more genes according to any one of paragraphs 1-248, wherein the gene has the symbol HLA-DRB4, optionally in combination with one or more genes labeled as 4.279 to 4.488 identified in Table 4.

250) In another aspect the invention employs one or more genes according to any one of paragraphs 1-249, wherein the gene has the symbol SART2, optionally in combination with one or more genes labeled as 4.280 to 4.488 identified in Table 4.

251) In another aspect the invention employs one or more genes according to any one of paragraphs 1-250, wherein the gene has the symbol LSP1, optionally in combination with one or more genes labeled as 4.281 to 4.488 identified in Table 4.

252) In another aspect the invention employs one or more genes according to any one of paragraphs 1-251, wherein the gene has the symbol AMPD3, optionally in combination with one or more genes labeled as 4.282 to 4.488 identified in Table 4.

253) In another aspect the invention employs one or more genes according to any one of paragraphs 1-252, wherein the gene has the symbol SEMA4F, optionally in combination with one or more genes labeled as 4.283 to 4.488 identified in Table 4.

254) In another aspect the invention employs one or more genes according to any one of paragraphs 1-253, wherein the gene has the symbol ISOC1, optionally in combination with one or more genes labeled as 4.285 to 4.488 identified in Table 4.

255) In another aspect the invention employs one or more genes according to any one of paragraphs 1-254, wherein the gene has the symbol HPS3, optionally in combination with one or more genes labeled as 4.288 to 4.488 identified in Table 4.

256) In another aspect the invention employs one or more genes according to any one of paragraphs 1-255, wherein the gene has the symbol HOXB7, optionally in combination with one or more genes labeled as 4.290 to 4.488 identified in Table 4.

257) In another aspect the invention employs one or more genes according to any one of paragraphs 1-256, wherein the gene has the symbol ZNFN1A1, optionally in combination with one or more genes labeled as 4.291 to 4.488 identified in Table 4.

258) In another aspect the invention employs one or more genes according to any one of paragraphs 1-257, wherein the gene has the symbol ARHGAP9, optionally in combination with one or more genes labeled as 4.292 to 4.488 identified in Table 4.

259) In another aspect the invention employs one or more genes according to any one of paragraphs 1-258, wherein the gene has the symbol GATA2, optionally in combination with one or more genes labeled as 4.293 to 4.488 identified in Table 4.

260) In another aspect the invention employs one or more genes according to any one of paragraphs 1-259, wherein the gene has the symbol AP2B1, optionally in combination with one or more genes labeled as 4.294 to 4.488 identified in Table 4.

261) In another aspect the invention employs one or more genes according to any one of paragraphs 1-260, wherein the gene has the symbol CTSC, optionally in combination with one or more genes labeled as 4.295 to 4.488 identified in Table 4.

262) In another aspect the invention employs one or more genes according to any one of paragraphs 1-261, wherein the gene has the symbol PLK2, optionally in combination with one or more genes labeled as 4.296 to 4.488 identified in Table 4.

263) In another aspect the invention employs one or more genes according to any one of paragraphs 1-262, wherein the gene has the symbol CD4, optionally in combination with one or more genes labeled as 4.297 to 4.488 identified in Table 4.

264) In another aspect the invention employs one or more genes according to any one of paragraphs 1-263, wherein the gene has the symbol GGTA1, optionally in combination with one or more genes labeled as 4.298 to 4.488 identified in Table 4.

265) In another aspect the invention employs one or more genes according to any one of paragraphs 1-264, wherein the gene has the symbol GADD45B, optionally in combination with one or more genes labeled as 4.300 to 4.488 identified in Table 4.

266) In another aspect the invention employs one or more genes according to any one of paragraphs 1-265, wherein the gene has the symbol FLJ10847, optionally in combination with one or more genes labeled as 4.301 to 4.488 identified in Table 4.

267) In another aspect the invention employs one or more genes according to any one of paragraphs 1-266, wherein the gene has the symbol KIF21B, optionally in combination with one or more genes labeled as 4.302 to 4.488 identified in Table 4.

268) In another aspect the invention employs one or more genes according to any one of paragraphs 1-267, wherein the gene has the symbol CCND2, optionally in combination with one or more genes labeled as 4.303 to 4.488 identified in Table 4.

269) In another aspect the invention employs one or more genes according to any one of paragraphs 1-268, wherein the gene has the symbol PRG1, optionally in combination with one or more genes labeled as 4.304 to 4.488 identified in Table 4.

270) In another aspect the invention employs one or more genes according to any one of paragraphs 1-269, wherein the gene has the symbol SLC40A1, optionally in combination with one or more genes labeled as 4.307 to 4.488 identified in Table 4.

271) In another aspect the invention employs one or more genes according to any one of paragraphs 1-270, wherein the gene has the symbol CRIP1, optionally in combination with one or more genes labeled as 4.308 to 4.488 identified in Table 4.

272) In another aspect the invention employs one or more genes according to any one of paragraphs 1-271, wherein the gene has the symbol LOC283070, optionally in combination with one or more genes labeled as 4.309 to 4.488 identified in Table 4.

273) In another aspect the invention employs one or more genes according to any one of paragraphs 1-272, wherein the gene has the symbol SIGLEC1, optionally in combination with one or more genes labeled as 4.310 to 4.488 identified in Table 4.

274) In another aspect the invention employs one or more genes according to any one of paragraphs 1-273, wherein the gene has the symbol ZNF11B, optionally in combination with one or more genes labeled as 4.311 to 4.488 identified in Table 4.

275) In another aspect the invention employs one or more genes according to any one of paragraphs 1-274, wherein the gene has the symbol CXCR4, optionally in combination with one or more genes labeled as 4.312 to 4.488 identified in Table 4.

276) In another aspect the invention employs one or more genes according to any one of paragraphs 1-275, wherein the gene has the symbol HLA-DMA, optionally in combination with one or more genes labeled as 4.313 to 4.488 identified in Table 4

277) In another aspect the invention employs one or more genes according to any one of paragraphs 1-276, wherein the gene has the symbol MRC1, optionally in combination with one or more genes labeled as 4.315 to 4.488 identified in Table 4.

278) In another aspect the invention employs one or more genes according to any one of paragraphs 1-277, wherein the gene has the symbol LMO2, optionally in combination with one or more genes labeled as 4.315a to 4.488 identified in Table 4.

279) In another aspect the invention employs one or more genes according to any one of paragraphs 1-278, wherein the gene has the symbol DENND2D, optionally in combination with one or more genes labeled as 4.316 to 4.488 identified in Table 4.

280) In another aspect the invention employs one or more genes according to any one of paragraphs 1-279, wherein the gene has the symbol CCL18, optionally in combination with one or more genes labeled as 4.317 to 4.488 identified in Table 4.

281) In another aspect the invention employs one or more genes according to any one of paragraphs 1-280, wherein the gene has the symbol P2RY13, optionally in combination with one or more genes labeled as 4.319 to 4.488 identified in Table 4.

282) In another aspect the invention employs one or more genes according to any one of paragraphs 1-281, wherein the gene has the symbol ANGPTL1, optionally in combination with one or more genes labeled as 4.320 to 4.488 identified in Table 4.

283) In another aspect the invention employs one or more genes according to any one of paragraphs 1-282, wherein the gene is identifiable by probe set number 230391_at, optionally in combination with one or more genes labeled as 4.322 to 4.488 identified in Table 4.

284) In another aspect the invention employs one or more genes according to any one of paragraphs 1-283, wherein the gene has the symbol C8orf51, optionally in combination with one or more genes labeled as 4.323 to 4.488 identified in Table 4.

285) In another aspect the invention employs one or more genes according to any one of paragraphs 1-284, wherein the gene has the symbol GIMAP8, optionally in combination with one or more genes labeled as 4.324 to 4.488 identified in Table 4.

286) In another aspect the invention employs one or more genes according to any one of paragraphs 1-285, wherein the gene is identifiable by probe set number 2277880_at, optionally in combination with one or more genes labeled as 4.325 to 4.488 identified in Table 4.

287) In another aspect the invention employs one or more genes according to any one of paragraphs 1-286, wherein the gene has the symbol JAK2, optionally in combination with one or more genes labeled as 4.326 to 4.488 identified in Table 4.

288) In another aspect the invention employs one or more genes according to any one of paragraphs 1-287, wherein the gene has the symbol TNFSF10, optionally in combination with one or more genes labeled as 4.327 to 4.488 identified in Table 4.

289) In another aspect the invention employs one or more genes according to any one of paragraphs 1-288, wherein the gene has the symbol C1R, optionally in combination with one or more genes labeled as 4.328 to 4.488 identified in Table 4.

290) In another aspect the invention employs one or more genes according to any one of paragraphs 1-289, wherein the gene has the symbol ACPL2, optionally in combination with one or more genes labeled as 4.329 to 4.488 identified in Table 4.

291) In another aspect the invention employs one or more genes according to any one of paragraphs 1-290, wherein the gene has the symbol TNFRSF19, optionally in combination with one or more genes labeled as 4.331 to 4.488 identified in Table 4.

292) In another aspect the invention employs one or more genes according to any one of paragraphs 1-291, wherein the gene has the symbol LRP12, optionally in combination with one or more genes labeled as 4.332 to 4.488 identified in Table 4.

293) In another aspect the invention employs one or more genes according to any one of paragraphs 1-292, wherein the gene is identifiable by probe set number 1557116_at, optionally in combination with one or more genes labeled as 4.334 to 4.488 identified in Table 4.

294) In another aspect the invention employs one or more genes according to any one of paragraphs 1-293, wherein the gene has the symbol PRKCB1, optionally in combination with one or more genes labeled as 4.335 to 4.488 identified in Table 4.

295) In another aspect the invention employs one or more genes according to any one of paragraphs 1-294, wherein the gene has the symbol IPO11, optionally in combination with one or more genes labeled as 4.336 to 4.488 identified in Table 4.

296) In another aspect the invention employs one or more genes according to any one of paragraphs 1-295, wherein the gene has the symbol DLGAP1, optionally in combination with one or more genes labeled as 4.337 to 4.488 identified in Table 4.

297) In another aspect the invention employs one or more genes according to any one of paragraphs 1-296, wherein the gene has the symbol PRKAR2B, optionally in combination with one or more genes labeled as 4.338 to 4.488 identified in Table 4.

298) In another aspect the invention employs one or more genes according to any one of paragraphs 1-297, wherein the gene has the symbol MAP3K8, optionally in combination with one or more genes labeled as 4.339 to 4.488 identified in Table 4.

299) In another aspect the invention employs one or more genes according to any one of paragraphs 1-298, wherein the gene has the symbol EVI2B, optionally in combination with one or more genes labeled as 4.340 to 4.488 identified in Table 4.

300) In another aspect the invention employs one or more genes according to any one of paragraphs 1-299, wherein the gene has the symbol GBP1, optionally in combination with one or more genes labeled as 4.341 to 4.488 identified in Table 4.

301) In another aspect the invention employs one or more genes according to any one of paragraphs 1-300, wherein the gene has the symbol CXCL10, optionally in combination with one or more genes labeled as 4.342 to 4.488 identified in Table 4.

302) In another aspect the invention employs one or more genes according to any one of paragraphs 1-301, wherein the gene has the symbol CAMK2N1, optionally in combination with one or more genes labeled as 4.343 to 4.488 identified in Table 4

303) In another aspect the invention employs one or more genes according to any one of paragraphs 1-302, wherein the gene has the symbol MED12L, optionally in combination with one or more genes labeled as 4.344 to 4.488 identified in Table 4.

304) In another aspect the invention employs one or more genes according to any one of paragraphs 1-303, wherein the gene has the symbol ID2, optionally in combination with one or more genes labeled as 4.345 to 4.488 identified in Table 4.

305) In another aspect the invention employs one or more genes according to any one of paragraphs 1-304, wherein the gene has the symbol CTBP2, optionally in combination with one or more genes labeled as 4.346 to 4.488 identified in Table 4.

306) In another aspect the invention employs one or more genes according to any one of paragraphs 1-305, wherein the gene has the symbol IGLJ3, optionally in combination with one or more genes labeled as 4.347 to 4.488 identified in Table 4.

307) In another aspect the invention employs one or more genes according to any one of paragraphs 1-306, wherein the gene has the symbol GBP4, optionally in combination with one or more genes labeled as 4.348 to 4.488 identified in Table 4.

308) In another aspect the invention employs one or more genes according to any one of paragraphs 1-307, wherein the gene has the symbol LOC439949, optionally in combination with one or more genes labeled as 4.349 to 4.488 identified in Table 4.

309) In another aspect the invention employs one or more genes according to any one of paragraphs 1-308, wherein the gene has the symbol FBXO16, optionally in combination with one or more genes labeled as 4.350 to 4.488 identified in Table 4.

310) In another aspect the invention employs one or more genes according to any one of paragraphs 1-309, wherein the gene has the symbol PRF1, optionally in combination with one or more genes labeled as 4.351 to 4.488 identified in Table 4.

311) In another aspect the invention employs one or more genes according to any one of paragraphs 1-310, wherein the gene has the symbol TRAM2, optionally in combination with one or more genes labeled as 4.352 to 4.488 identified in Table 4.

312) In another aspect the invention employs one or more genes according to any one of paragraphs 1-311, wherein the gene has the symbol LYN, optionally in combination with one or more genes labeled as 4.353 to 4.488 identified in Table 4.

313) In another aspect the invention employs one or more genes according to any one of paragraphs 1-312, wherein the gene has the symbol CENTD1, optionally in combination with one or more genes labeled as 4.355 to 4.488 identified in Table 4.

314) In another aspect the invention employs one or more genes according to any one of paragraphs 1-313, wherein the gene has the symbol FLJ20273, optionally in combination with one or more genes labeled as 4.356 to 4.488 identified in Table 4.

315) In another aspect the invention employs one or more genes according to any one of paragraphs 1-314, wherein the gene has the symbol TFEC, optionally in combination with one or more genes labeled as 4.357 to 4.488 identified in Table 4.

316) In another aspect the invention employs one or more genes according to any one of paragraphs 1-315, wherein the gene has the symbol PPP1R16B, optionally in combination with one or more genes labeled as 4.358 to 4.488 identified in Table 4.

317) In another aspect the invention employs one or more genes according to any one of paragraphs 1-316, wherein the gene has the symbol CD48, optionally in combination with one or more genes labeled as 4.359 to 4.488 identified in Table 4.

318) In another aspect the invention employs one or more genes according to any one of paragraphs 1-317, wherein the gene has the symbol HLA-DPB1, optionally in combination with one or more genes labeled as 4.361 to 4.488 identified in Table 4.

319) In another aspect the invention employs one or more genes according to any one of paragraphs 1-318, wherein the gene has the symbol GTPBP5, optionally in combination with one or more genes labeled as 4.362 to 4.488 identified in Table 4.

320) In another aspect the invention employs one or more genes according to any one of paragraphs 1-319, wherein the gene has the symbol GBP5, optionally in combination with one or more genes labeled as 4.363 to 4.488 identified in Table 4.

321) In another aspect the invention employs one or more genes according to any one of paragraphs 1-320, wherein the gene has the symbol MAP B, optionally in combination with one or more genes labeled as 4.364 to 4.488 identified in Table 4.

322) In another aspect the invention employs one or more genes according to any one of paragraphs 1-321, wherein the gene has the symbol EXTL3, optionally in combination with one or more genes labeled as 4.365 to 4.488 identified in Table 4.

323) In another aspect the invention employs one or more genes according to any one of paragraphs 1-322, wherein the gene has the symbol CORO1A, optionally in combination with one or more genes labeled as 4.366 to 4.488 identified in Table 4.

324) In another aspect the invention employs one or more genes according to any one of paragraphs 1-323, wherein the gene has the symbol PDGFRL, optionally in combination with one or more genes labeled as 4.367 to 4.488 identified in Table 4.

325) In another aspect the invention employs one or more genes according to any one of paragraphs 1-324, wherein the gene has the symbol RP9, optionally in combination with one or more genes labeled as 4.368 to 4.488 identified in Table 4.

326) In another aspect the invention employs one or more genes according to any one of paragraphs 1-325, wherein the gene has the symbol RHOU, optionally in combination with one or more genes labeled as 4.369 to 4.488 identified in Table 4.

327) In another aspect the invention employs one or more genes according to any one of paragraphs 1-326, wherein the gene has the symbol MTAC2D1, optionally in combination with one or more genes labeled as 4.370 to 4.488 identified in Table 4.

328) In another aspect the invention employs one or more genes according to any one of paragraphs 1-327, wherein the gene has the symbol CCL8, optionally in combination with one or more genes labeled as 4.371 to 4.488 identified in Table 4.

329) In another aspect the invention employs one or more genes according to any one of paragraphs 1-328, wherein the gene has the symbol CECR1, optionally in combination with one or more genes labeled as 4.373 to 4.488 identified in Table 4.

330) In another aspect the invention employs one or more genes according to any one of paragraphs 1-329, wherein the gene has the symbol SLC40A1, optionally in combination with one or more genes labeled as 4.374 to 4.488 identified in Table 4.

331) In another aspect the invention employs one or more genes according to any one of paragraphs 1-330, wherein the gene has the symbol ADCY6, optionally in combination with one or more genes labeled as 4.375 to 4.488 identified in Table 4.

332) In another aspect the invention employs one or more genes according to any one of paragraphs 1-331, wherein the gene has the symbol CP, optionally in combination with one or more genes labeled as 4.376 to 4.488 identified in Table 4.

333) In another aspect the invention employs one or more genes according to any one of paragraphs 1-332, wherein the gene has the symbol EDG1, optionally in combination with one or more genes labeled as 4.377 to 4.488 identified in Table 4.

334) In another aspect the invention employs one or more genes according to any one of paragraphs 1-333, wherein the gene has the symbol RGS3, optionally in combination with one or more genes labeled as 4.379 to 4.488 identified in Table 4.

335) In another aspect the invention employs one or more genes according to any one of paragraphs 1-334, wherein the gene is identifiable by probe set number 228339_at, optionally in combination with one or more genes labeled as 4.380 to 4.488 identified in Table 4.

336) In another aspect the invention employs one or more genes according to any one of paragraphs 1-335, wherein the gene has the symbol ABHD5, optionally in combination with one or more genes labeled as 4.381 to 4.488 identified in Table 4.

337) In another aspect the invention employs one or more genes according to any one of paragraphs 1-336, wherein the gene has the symbol MS4A7, optionally in combination with one or more genes labeled as 4.382 to 4.488 identified in Table 4.

338) In another aspect the invention employs one or more genes according to any one of paragraphs 1-337, wherein the gene has the symbol PRKCH, optionally in combination with one or more genes labeled as 4.384 to 4.488 identified in Table 4.

339) In another aspect the invention employs one or more genes according to any one of paragraphs 1-338, wherein the gene has the symbol LOC286071, optionally in combination with one or more genes labeled as 4.385 to 4.488 identified in Table 4.

340) In another aspect the invention employs one or more genes according to any one of paragraphs 1-339, wherein the gene has the symbol BLNK, optionally in combination with one or more genes labeled as 4.386 to 4.488 identified in Table 4.

341) In another aspect the invention employs one or more genes according to any one of paragraphs 1-340, wherein the gene is identifiable by the probe set number 242546 at, optionally in combination with one or more genes labeled as 4.387 to 4.488 identified in Table 4.

342) In another aspect the invention employs one or more genes according to any one of paragraphs 1-341, wherein the gene has the symbol PCDHGC3, optionally in combination with one or more genes labeled as 4.390 to 4.488 identified in Table 4.

343) In another aspect the invention employs one or more genes according to any one of paragraphs 1-342, wherein the gene has the symbol CAMSAP1L1, optionally in combination with one or more genes labeled as 4.391 to 4.488 identified in Table 4.

344) In another aspect the invention employs one or more genes according to any one of paragraphs 1-343, wherein the gene has the symbol NPY1R, optionally in combination with one or more genes labeled as 4.392 to 4.488 identified in Table 4.

345) In another aspect the invention employs one or more genes according to any one of paragraphs 1-344, wherein the gene has the symbol CD274, optionally in combination with one or more genes labeled as 4.393 to 4.488 identified in Table 4.

346) In another aspect the invention employs one or more genes according to any one of paragraphs 1-345, wherein the gene has the symbol PGM5, optionally in combination with one or more genes labeled as 4.394 to 4.488 identified in Table 4.

347) In another aspect the invention employs one or more genes according to any one of paragraphs 1-346, wherein the gene has the symbol PLCG2, optionally in combination with one or more genes labeled as 4.395 to 4.488 identified in Table 4.

348) In another aspect the invention employs one or more genes according to any one of paragraphs 1-347, wherein the gene has the symbol TNFSF10, optionally in combination with one or more genes labeled as 4.397 to 4.488 identified in Table 4.

349) In another aspect the invention employs one or more genes according to any one of paragraphs 1-348, wherein the gene has the symbol BTG2, optionally in combination with one or more genes labeled as 4.398 to 4.488 identified in Table 4.

350) In another aspect the invention employs one or more genes according to any one of paragraphs 1-349, wherein the gene has the symbol LAMP3, optionally in combination with one or more genes labeled as 4.399 to 4.488 identified in Table 4.

351) In another aspect the invention employs one or more genes according to any one of paragraphs 1-350, wherein the gene has the symbol IGLC1, optionally in combination with one or more genes labeled as 4.400 to 4.488 identified in Table 4.

352) In another aspect the invention employs one or more genes according to any one of paragraphs 1-351, wherein the gene has the symbol SIPA1L1, optionally in combination with one or more genes labeled as 4.401 to 4.488 identified in Table 4.

353) In another aspect the invention employs one or more genes according to any one of paragraphs 1-352 wherein the gene has the symbol AIF1, optionally in combination with one or more genes labeled as 4.402 to 4.488 identified in Table 4.

354) In another aspect the invention employs one or more genes according to any one of paragraphs 1-353, wherein the gene has the symbol IGLC2, optionally in combination with one or more genes labeled as 4.403 to 4.488 identified in Table 4.

355) In another aspect the invention employs one or more genes according to any one of paragraphs 1-354, wherein the gene has the symbol B2M, optionally in combination with one or more genes labeled as 4.404 to 4.488 identified in Table 4.

356) In another aspect the invention employs one or more genes according to any one of paragraphs 1-355, wherein the gene has the symbol CLEC7A, optionally in combination with one or more genes labeled as 4.405 to 4.488 identified in Table 4.

357) In another aspect the invention employs one or more genes according to any one of paragraphs 1-356, wherein the gene has the symbol MGC17330, optionally in combination with one or more genes labeled as 4.406 to 4.488 identified in Table 4.

358) In another aspect the invention employs one or more genes according to any one of paragraphs 1-357, wherein the gene has the symbol IGF1R, optionally in combination with one or more genes labeled as 4.407 to 4.488 identified in Table 4.

359) In another aspect the invention employs one or more genes according to any one of paragraphs 1-358, wherein the gene has the symbol HIVEP1, optionally in combination with one or more genes labeled as 4.408 to 4.488 identified in Table 4.

360) In another aspect the invention employs one or more genes according to any one of paragraphs 1-359, wherein the gene has the symbol FKBP14, optionally in combination with one or more genes labeled as 4.409 to 4.488 identified in Table 4.

361) In another aspect the invention employs one or more genes according to any one of paragraphs 1-360, wherein the gene has the symbol LAPTM5, optionally in combination with one or more genes labeled as 4.410 to 4.488 identified in Table 4.

362) In another aspect the invention employs one or more genes according to any one of paragraphs 1-361, wherein the gene has the symbol AB13BP, optionally in combination with one or more genes labeled as 4.411 to 4.488 identified in Table 4.

363) In another aspect the invention employs one or more genes according to any one of paragraphs 1-362, wherein the gene has the symbol HLA-E, optionally in combination with one or more genes labeled as 4.412 to 4.488 identified in Table 4.

364) In another aspect the invention employs one or more genes according to any one of paragraphs 1-363, wherein the gene has the symbol ARLAC, optionally in combination with one or more genes labeled as 4.413 to 4.488 identified in Table 4.

365) In another aspect the invention employs one or more genes according to any one of paragraphs 1-364, wherein the gene has the symbol ASS, optionally in combination with one or more genes labeled as 4.415 to 4.488 identified in Table 4.

366) In another aspect the invention employs one or more genes according to any one of paragraphs 1-365, wherein the gene has the symbol ITGB3, optionally in combination with one or more genes labeled as 4.417 to 4.488 identified in Table 4.

367) In another aspect the invention employs one or more genes according to any one of paragraphs 1-366, wherein the gene has the symbol SYK, optionally in combination with one or more genes labeled as 4.417 to 4.488 identified in Table 4.

368) In another aspect the invention employs one or more genes according to any one of paragraphs 1-366, wherein the gene has the symbol RAC2, optionally in combination with one or more genes labeled as 4.418 to 4.488 identified in Table 4.

369) In another aspect the invention employs one or more genes according to any one of paragraphs 1-368, wherein the gene is identifiable by probe set number 1557222_at, optionally in combination with one or more genes labeled as 4.419 to 4.488 identified in Table 4.

370) In another aspect the invention employs one or more genes according to any one of paragraphs 1-369, wherein the gene has the symbol CD3G, optionally in combination with one or more genes labeled as 4.420 to 4.488 identified in Table 4.

371) In another aspect the invention employs one or more genes according to any one of paragraphs 1-370, wherein the gene has the symbol IGF1, optionally in combination with one or more genes labeled as 4.421 to 4.488 identified in Table 4.

372) In another aspect the invention employs one or more genes according to any one of paragraphs 1-371, wherein the gene is identifiable by probe set number 228858_at, optionally in combination with one or more genes labeled as 4.422 to 4.488 identified in Table 4.

373) In another aspect the invention employs one or more genes according to any one of paragraphs 1-372, wherein the gene is has the symbol CYB5A, optionally in combination with one or more genes labeled as 4.423 to 4.488 identified in Table 4.

374) In another aspect the invention employs one or more genes according to any one of paragraphs 1-373, wherein the gene is has the symbol TTC25, optionally in combination with one or more genes labeled as 4.424 to 4.488 identified in Table 4.

375) In another aspect the invention employs one or more genes according to any one of paragraphs 1-374, wherein the gene is has the symbol SLAMF6, optionally in combination with one or more genes labeled as 4.425 to 4.488 identified in Table 4.

376) In another aspect the invention employs one or more genes according to any one of paragraphs 1-375, wherein the gene is has the symbol ARHGAP21, optionally in combination with one or more genes labeled as 4.426 to 4.488 identified in Table 4.

377) In another aspect the invention employs one or more genes according to any one of paragraphs 1-376, wherein the gene is has the symbol FLOT1, optionally in combination with one or more genes labeled as 4.428 to 4.488 identified in Table 4.

378) In another aspect the invention employs one or more genes according to any one of paragraphs 1-377, wherein the gene is has the symbol IBRDC2 optionally in combination with one or more genes labeled as 4.429 to 4.488 identified in Table 4.

379) In another aspect the invention employs one or more genes according to any one of paragraphs 1-378, wherein the gene is has the symbol KIAA1794, optionally in combination with one or more genes labeled as 4.430 to 4.488 identified in Table 4.

380) In another aspect the invention employs one or more genes according to any one of paragraphs 1-379, wherein the gene is has the symbol OLFML1, optionally in combination with one or more genes labeled as 4.431 to 4.488 identified in Table 4.

381) In another aspect the invention employs one or more genes according to any one of paragraphs 1-380, wherein the gene is has the symbol GMFG, optionally in combination with one or more genes labeled as 4.432 to 4.488 identified in Table 4.

382) In another aspect the invention employs one or more genes according to any one of paragraphs 1-381, wherein the gene is has the symbol TNFRSF1B, optionally in combination with one or more genes labeled as 4.433 to 4.488 identified in Table 4.

383) In another aspect the invention employs one or more genes according to any one of paragraphs 1-382, wherein the gene is identifiable by probe set number 217629_at, optionally in combination with one or more genes labeled as 4.434 to 4.488 identified in Table 4.

384) In another aspect the invention employs one or more genes according to any one of paragraphs 1-383, wherein the gene is has the symbol DEF6, optionally in combination with one or more genes labeled as 4.436 to 4.488 identified in Table 4.

385) In another aspect the invention employs one or more genes according to any one of paragraphs 1-384, wherein the gene is has the symbol MAP4K4, optionally in combination with one or more genes labeled as 4.437 to 4.488 identified in Table 4.

386) In another aspect the invention employs one or more genes according to any one of paragraphs 1-385, wherein the gene is has the symbol CMKOR1, optionally in combination with one or more genes labeled as 4.438 to 4.488 identified in Table 4.

387) In another aspect the invention employs one or more genes according to any one of paragraphs 1-386, wherein the gene is identifiable by probe set number 1563461_at, optionally in combination with one or more genes labeled as 4.439 to 4.488 identified in Table 4.

388) In another aspect the invention employs one or more genes according to any one of paragraphs 1-387, wherein the gene is has the symbol CHKA, optionally in combination with one or more genes labeled as 4.440 to 4.488 identified in Table 4.

389) In another aspect the invention employs one or more genes according to any one of paragraphs 1-388, wherein the gene is identifiable by probe set number 226865_at, optionally in combination with one or more genes labeled as 4.441 to 4.488 identified in Table 4.

390) In another aspect the invention employs one or more genes according to any one of paragraphs 1-389, wherein the gene has the symbol HS3ST3B1, optionally in combination with one or more genes labeled as 4.442 to 4.488 identified in Table 4.

391) In another aspect the invention employs one or more genes according to any one of paragraphs 1-390, wherein the gene has the symbol CXorf9, optionally in combination with one or more genes labeled as 4.443 to 4.488 identified in Table 4.

392) In another aspect the invention employs one or more genes according to any one of paragraphs 1-391, wherein the gene has the symbol EVI2A, optionally in combination with one or more genes labeled as 4.445 to 4.488 identified in Table 4.

393) In another aspect the invention employs one or more genes according to any one of paragraphs 1-392, wherein the gene has the symbol NFAM1, optionally in combination with one or more genes labeled as 4.446 to 4.488 identified in Table 4.

394) In another aspect the invention employs one or more genes according to any one of paragraphs 1-393, wherein the gene is identifiable by probe set number 242874_at, optionally in combination with one or more genes labeled as 4.447 to 4.488 identified in Table 4.

395) In another aspect the invention employs one or more genes according to any one of paragraphs 1-394, wherein the gene has the symbol ATP5J, optionally in combination with one or more genes labeled as 4.450 to 4.488 identified in Table 4.

396) In another aspect the invention employs one or more genes according to any one of paragraphs 1-395, wherein the gene has the symbol CYLD, optionally in combination with one or more genes labeled as 4.451 to 4.488 identified in Table 4.

397) In another aspect the invention employs one or more genes according to any one of paragraphs 1-396, wherein the gene has the symbol GIMAP6, optionally in combination with one or more genes labeled as 4.452 to 4.488 identified in Table 4.

398) In another aspect the invention employs one or more genes according to any one of paragraphs 1-397, wherein the gene has the symbol MFAP4, optionally in combination with one or more genes labeled as 4.453 to 4.488 identified in Table 4.

399) In another aspect the invention employs one or more genes according to any one of paragraphs 1-398, wherein the gene has the symbol TUBB2B, optionally in combination with one or more genes labeled as 4.454 to 4.488 identified in Table 4.

400) In another aspect the invention employs one or more genes according to any one of paragraphs 1-399, wherein the gene has the symbol NELL2, optionally in combination with one or more genes labeled as 4.455 to 4.488 identified in Table 4.

401) In another aspect the invention employs one or more genes according to any one of paragraphs 1-400, wherein the gene is identifiable by probe set number 236583_at, optionally in combination with one or more genes labeled as 4.456 to 4.488 identified in Table 4.

402) In another aspect the invention employs one or more genes according to any one of paragraphs 1-401, wherein the gene has the symbol IL1RN, optionally in combination with one or more genes labeled as 4.457 to 4.488 identified in Table 4.

403) In another aspect the invention employs one or more genes according to any one of paragraphs 1-402, wherein the gene has the symbol KIAA1211, optionally in combination with one or more genes labeled as 4.459 to 4.488 identified in Table 4.

404) In another aspect the invention employs one or more genes according to any one of paragraphs 1-403, wherein the gene has the symbol ADAMDEC1, optionally in combination with one or more genes labeled as 4.460 to 4.488 identified in Table 4.

405) In another aspect the invention employs one or more genes according to any one of paragraphs 1-404, wherein the gene has the symbol AOC3, optionally in combination with one or more genes labeled as 4.461 to 4.488 identified in Table 4.

406) In another aspect the invention employs one or more genes according to any one of paragraphs 1-405, wherein the gene has the symbol SAMHD1, optionally in combination with one or more genes labeled as 4.463 to 4.488 identified in Table 4.

407) In another aspect the invention employs one or more genes according to any one of paragraphs 1-406, wherein the gene has the symbol SLC22A3, optionally in combination with one or more genes labeled as 4.465 to 4.488 identified in Table 4.

408) In another aspect the invention employs one or more genes according to any one of paragraphs 1-407, wherein the gene has the symbol IGLV3-25, optionally in combination with one or more genes labeled as 4.466 to 4.488 identified in Table 4.

409) In another aspect the invention employs one or more genes according to any one of paragraphs 1-408, wherein the gene is identifiable by probe set number 1556185_a_at, optionally in combination with one or more genes labeled as 4.467 to 4.488 identified in Table 4.

410) In another aspect the invention employs one or more genes according to any one of paragraphs 1-409, wherein the gene has the symbol RAB11FIP1, optionally in combination with one or more genes labeled as 4.468- to 4.488 identified in Table 4.

411) In another aspect the invention employs one or more genes according to any one of paragraphs 1-410, wherein the gene has the symbol PER2, optionally in combination with one or more genes labeled as 4.469 to 4.488 identified in Table 4.

412) In another aspect the invention employs one or more genes according to any one of paragraphs 1-411, wherein the gene has the symbol TTL, optionally in combination with one or more genes labeled as 4.470 to 4.488 identified in Table 4.

413) In another aspect the invention employs one or more genes according to any one of paragraphs 1-412, wherein the gene has the symbol SIAHBP1, optionally in combination with one or more genes labeled as 4.472 to 4.488 identified in Table 4.

414) In another aspect the invention employs one or more genes according to any one of paragraphs 1-413, wherein the gene has the symbol FLJ22536, optionally in combination with one or more genes labeled as 4.473 to 4.488 identified in Table 4.

415) In another aspect the invention employs one or more genes according to any one of paragraphs 1-414, wherein the gene has the symbol RP6-213H19.1, optionally in combination with one or more genes labeled as 4.474 to 4.488 identified in Table 4.

416) In another aspect the invention employs one or more genes according to any one of paragraphs 1-415, wherein the gene is identifiable by probe set number 235804_at, optionally in combination with one or more genes labeled as 4.475 to 4.488 identified in Table 4.

417) In another aspect the invention employs one or more genes according to any one of paragraphs 1-416, wherein the gene has the symbol NCF4, optionally in combination with one or more genes labeled as 4.476 to 4.488 identified in Table 4.

418) In another aspect the invention employs one or more genes according to any one of paragraphs 1-417, wherein the gene has the symbol EPSTI1, optionally in combination with one or more genes labeled as 4.477 to 4.488 identified in Table 4.

419) In another aspect the invention employs one or more genes according to any one of paragraphs 1-418, wherein the gene has the symbol LOC441212, optionally in combination with one or more genes labeled as 4.478 to 4.488 identified in Table 4.

420) In another aspect the invention employs one or more genes according to any one of paragraphs 1-419, wherein the gene has the symbol ANK3, optionally in combination with one or more genes labeled as 4.479 to 4.488 identified in Table 4.

421) In another aspect the invention employs one or more genes according to any one of paragraphs 1-420, wherein the gene has the symbol PCDH9, optionally in combination with one or more genes labeled as 4.480 to 4.488 identified in Table 4.

422) In another aspect the invention employs one or more genes according to any one of paragraphs 1-421, wherein the gene has the symbol C21orf86, optionally in combination with one or more genes labeled as 4.481 to 4.488 identified in Table 4.

423) In another aspect the invention employs one or more genes according to any one of paragraphs 1-422, wherein the gene has the symbol DHRS9, optionally in combination with one or more genes labeled as 4.482 to 4.488 identified in Table 4.

424) In another aspect the invention employs one or more genes according to any one of paragraphs 1-423, wherein the gene has the symbol ARHGAP25, optionally in combination with one or more genes labeled as 4.483 to 4.488 identified in Table 4.

425) In another aspect the invention employs one or more genes according to any one of paragraphs 1-424, wherein the gene has the symbol TRAF4, optionally in combination with one or more genes labeled as 4.484 to 4.488 identified in Table 4.

426) In another aspect the invention employs one or more genes according to any one of paragraphs 1-425, wherein the gene has the symbol LST1, optionally in combination with one or more genes labeled as 4.485 to 4.488 identified in Table 4.

427) In another aspect the invention employs one or more genes according to any one of paragraphs 1-426, wherein the gene has the symbol PALMD, optionally in combination with one or more genes labeled as 4.486 to 4.488 identified in Table 4.

428) In another aspect the invention employs one or more genes according to any one of paragraphs 1-427, wherein the gene has the symbol TAP1, optionally in combination with one or more genes labeled as 4.487 to 4.488 identified in Table 4.

429) In another aspect the invention employs one or more genes according to any one of paragraphs 1-428, wherein the gene has the symbol MSX2, optionally in combination with one or more genes labeled as 4.448 identified in Table 4.

430) In another aspect the invention employs one or more genes according to any one of paragraphs 1-429, wherein the gene has the symbol SIRPG.

In one aspect the invention employs a gene listed in Table 7.

TABLE 7
Gene Symbol
CCL5
FASLG
GNLY
GZMB
PRF1
IFNG
ICOS
TBX21
CD8A
CD3E
CXCL11
CXCL10
CXCR3
CD20
FOXP3
INDO
CD45Ro
CD45R
CD69
TRBV19
TRAT1
TRDV2
STAT4
PRKCQ
GMZK
GPR171
UBD
CD52
CD3D
IL7R
IRF1
TLR7

In one aspect the invention employs one or more genes selected from Table 9.

TABLE 9
Gene Symbol
PRF1
IRF1
GZMB
GNLY
CD8A
PRKCQ
FOXP3
IFNG
CCL5
GPR171
TRBV19
CD3E
TBX21
FASLG
CXCL10
ICOS
CXCR3
CXCL11

In one aspect the invention employs one or more genes selected from Table 11.

TABLE 11
Gene Symbol        Gene Title
CCL5               chemokine (C-C motif) ligand 5
UCHL1              Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
PVT1 /// LOC441378 Pvt1 oncogene homolog, MYC activator (mouse) /// LOC441378
—                  CDNA clone IMAGE: 4796388
CD52               CD52 antigen (CAMPATH-1 antigen) /// CD52 antigen (CAMPATH-1
                   antigen)
UBD                ubiquitin D
STAT4              signal transducer and activator of transcription 4
GZMK               granzyme K (granzyme 3; tryptase II) /// granzyme K (granzyme 3; tryptase
                   II)
IL18RAP            interleukin 18 receptor accessory protein
GPR171             G protein-coupled receptor 171
PSCDBP             pleckstrin homology, Sec7 and coiled-coil domains, binding protein ///
                   pleckstrin homology, Sec7 and coiled-coil domains, binding protein
NCF2               neutrophil cytosolic factor 2 (65 kDa, chronic granulomatous disease,
                   autosomal 2)
PRKCQ              protein kinase C, theta
LST1               leukocyte specific transcript 1
TRA@ /// TRDV2 /// T cell receptor alpha locus /// T cell receptor delta variable 2 /// T cell receptor
TRAV20 /// TRAJ17  alpha variable 20 /// T cell receptor alpha joining 17 /// T cell receptor alpha
/// TRAC           constant
TRGC2              T cell receptor gamma constant 2
TRBV21-1 ///       T cell receptor beta variable 21-1 /// T cell receptor beta variable 19 /// T cell
TRBV19 /// TRBV5-4 receptor beta variable 5-4 /// T cell receptor beta variable 3-1 /// T cell receptor
/// TRBV3-1 ///    beta constant 1
TRBC1
HLA-DQA1 /// HLA-  major histocompatibility complex, class II, DQ alpha 1 /// major
DQA2               histocompatibility complex, class II, DQ alpha 2
TRBV19 /// TRBC1   T cell receptor beta variable 19 /// T cell receptor beta variable 19 /// T cell
                   receptor beta constant 1 /// T cell receptor beta constant 1
CD3D               CD3D antigen, delta polypeptide (TiT3 complex)
GADD45B            Growth arrest and DNA-damage-inducible, beta
ITGB3              integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
TRAT1              T cell receptor associated transmembrane adaptor 1
HLA-DMA            major histocompatibility complex, class II, DM alpha
CENTD3             centaurin, delta 3
SAMSN1             SAM domain, SH3 domain and nuclear localisation signals, 1
CLEC4E             C-type lectin domain family 4, member E
TNFRSF19           tumor necrosis factor receptor superfamily, member 19
NAV1               neuron navigator 1
LOXL4              lysyl oxidase-like 4
TNFRSF19           tumor necrosis factor receptor superfamily, member 19
TAGAP              T-cell activation GTPase activating protein
GIMAP2             GTPase, IMAP family member 2
IGF1R              Insulin-like growth factor 1 receptor
C17orf63           Chromosome 17 open reading frame 63
CD52               CD52 antigen (CAMPATH-1 antigen)

In one aspect the invention employs one or more genes selected from Table 12.

TABLE 12
Gene symbol Gene title
CCL5        chemokine (C-C motif) ligand 5
TRAT1       T cell receptor associated transmembrane adaptor 1
STAT4       signal transducer and activator of transcription 4
PRKCQ       protein kinase C, theta
GPR171      G protein-coupled receptor 171
UBD         ubiquitin D
CD52        CD52 molecule
CD3D        CD3d molecule, delta (CD3-TCR complex)
PRF1        perforin 1 (pore forming protein)
CD8A        CD8a molecule
CXCL10      chemokine (C—X—C motif) ligand 10
CD69        CD69 molecule
TRBV19      T cell receptor beta variable 19
TRDV2       T cell receptor delta variable 2
IL7R        interleukin 7 receptor
GZMK        granzyme K
CD45R       PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-
            TYPE, C (PTPRC)

In one aspect the invention provides one or more genes selected from Table 13.

TABLE 13
Gene
symbol Gene title
FASLG  Fas ligand (TNF superfamily, member 6)
GNLY   granulysin
GZMB   granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated
       serine esterase 1)
IFNG   interferon, gamma
ICOS   inducible T-cell co-stimulator
TBX21  T-box 21
CD3E   CD3e molecule, epsilon (CD3-TCR complex)
CXCL11 chemokine (C—X—C motif) ligand 11
CXCR3  chemokine (C—X—C motif) receptor 3
CD20   CD20 molecule
FOXP3  forkhead box P3
INDO   indoleamine-pyrrole 2,3 dioxygenase
IRF1   interferon regulatory factor 1
TLR7   toll-like receptor 7

PCR is a more sensitive technique than microarray and therefore can detect lower levels of differentially expressed genes.

In particular the following genes are suitable for PCR analysis: IL7R, CD3D, CD3E, CD52, UBD, GPR171, GMZK, PRKCQ, STAT4, TRDV2, TRAT1, TRBV19, CD69, INDO, CD45R, CD45RO, FOXP3, CD20, CCL5, FASLG, GNLY, GZMB, PRF1, IFNG, ICOS, TBX21, CD8A, CD3E, CXCL10, CXCL11, IRF1, TLR7 and CXCR3.

In one aspect the gene(s) employed are selected from the group comprising or consisting of: CCL5, TRAT1, STAT4, PRKCQ, GPR171, UBD, CD52, CD3D, PRF1, CD8A, CXCL10, CD69, TRBV19, TRDV2, IL7R, GZMK and CD45R.

In one aspect the gene(s) employed are selected from the comprising or consisting of: FASLG, GNLY, GZMB, IFNG, ICOS, TBX21, CD3E, CXCL11, CXCR3, CD20, FOXP3, INDO, IRF1 and TLR7.

The gene(s) FOXP3 and/or PRF1 is/are particularly suitable for PCR analysis according to the invention.

Suitable targets for immunohistochemistry include CD3, CD8, CD86, LAMP, CD20, CD45RO, CXCR3, CXL10/11, CD69, granzyme B, IDO, B cells and gene products from one or more genes from the NK family, HLA family, T cell receptor family and/or activated T cell.

In a further aspect of the invention there is provided a gene signature indicative of a non-responder, for example wherein one or more of immune genes such as those listed herein are NOT differentially expressed and/or are down regulated and/or are NOT upregulated.

In one aspect the gene is NOT FOXP3.

According to a further aspect the present invention provides a gene signature indicative of an increased likelihood of a patients responding favourably to appropriate immunotherapy, which in turn is likely to result in an improved survival of patients, for example with Mage expressing cancers following treatment with Mage specific immunotherapy. This gene signature, of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes from the genes disclosed in Table 1, is characterised by differential expression compared to the gene signature of Mage-expressing tumour patients who do not respond to Mage antigen specific cancer immunotherapy.

In one aspect the invention provides a profile based on differential expression of 1 or more of 62 known genes that relate to immune infiltration and activation.

The predictive genes correspond mainly to expression of and often upregulation of genes related to immune infiltration and activation. These genes include HLA class II, Interleukin-2 receptor gamma, T cell receptor genes (TRBV19, TRAT1, TRGC2), granzyme, and CD69.

In one embodiment there is provided a gene signature, present in patients, for example with or who have had MAGE-expressing tumours, who respond to treatment, in which one or more, for example at least 5, suitably 6, 7, 8, 9, 10 of the genes of Table 2 are differentially expressed:

As shown in FIG. 5a below, characterisation of responders and non-responders may be based on the differential expression on only one or two genes, such as TCR, CD3 and/or IL-7. Other genes that are thought to be particularly suitable in methods employing only one or two genes include: IL7R, CD3D, CD3E, CD52, UBD, GPR171, GMZK, PRKCQ, STAT4, TRDV2, TRAT1, TRBV19, CD69, INDO, CD45R, CD45RO, FOXP3, CD20, CCL5, FASLG, GNLY, GZMB, PRF1, IFNG, ICOS, TBX21, CD8A, CD3E, CXCL10, CXCL11, TRF1, TLR7 and CXCR3, which may require the use of appropriately sensitive analytical techniques.

The invention herein extends to use of all permutations of the genes listed herein for identification of said signature/profile.

The invention also extends to embodiments according to the invention described herein, which comprise, consist essentially of, or consists of the components/elements described.

The invention extends to the functional equivalents of genes listed herein, for example as characterised by hierarchical classification of genes such as described by Hongwei Wu et al 2007 (Hierarchical classification of equivalent genes in prokaryotes-Nucliec Acid Research Advance Access).

Whilst not wishing to be bound by theory, it is thought that is not necessarily the gene per se that is characteristic of the signature but rather it is the gene function which is fundamentally important. Thus a functionally equivalent gene to an immune activation gene such as those listed above, for example in Table 1, 2, 3, 4, 7, 9, 11, 12 or 13 may be employed in the signature, see for example, Journal of the National Cancer Institute Vol 98, No. 7 Apr. 5, 2006.

The genes were identified by specific probes and thus a skilled person will understand that the description of the genes above is a description based on current understanding of what hybridises to the probe. However, regardless of the nomenclature used for the genes by repeating the hybridisation to the relevant probe under the prescribed conditions the requisite gene can be identified.

The invention extends to use of the profile(s) according to the invention for predicting or identifying a patient as a responder or non-responder to immunotherapy, such as cancer immunotherapy, for example cancer testis immunotherapy.

Thus the invention includes a method of analyzing a patient derived sample, based on differential expression of the profile/gene(s) according to the invention for the purpose of characterising the patient from which the sample was derived as a responder or non-responder to immunotherapy. In one aspect the invention provides a method of identifying a profile according to the invention comprising the steps:

• • a) analyzing a patient derived sample for differential expression of one or more immune response genes, and
  • b) characterising the patient from which the sample was derived as a responder or non-responder to appropriate immunotherapy, based on the results of step (a), wherein the characterisation step is optionally performed by reference or comparison to a standard.

Suitable standards are described above.

The present invention therefore, generally relates, in one aspect, to a method for the detection of a gene signature in a biological sample, the method comprising the analysis of the expression of one or more genes of Tables 1, 2, 3, 4, 7, 9, 11, 12 or 13, for example at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2021, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes (eg for genes set forth in Table 1). In an embodiment, the analysis comprises the expression of at least 5, suitably 6, 7, 8, 9 or 10 genes set forth in Table 2.

In one aspect the invention provides a method for measuring expression levels of polynucleotides from immune activation genes such as one or more genes listed in Tables 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 in a sample for the purpose of identifying if the patient, from whom the sample was derived, is likely to be a responder or non-responder to immunotherapy such a cancer immunotherapy comprising the steps:

• • isolating the RNA from the sample,
  • optionally amplifying the copies of the cDNA from the sample for said genes, and
  • quantifying the levels of cDNA in the sample.

In one embodiment, the diagnostic method comprises determining whether a subject expresses any of the gene products of the genes set forth in Table 1 or any other embodiment of the invention described herein by, for example, detecting the level of the corresponding mRNA and/or protein level of the gene products of the genes set forth in Table 1 etc. For example, by using techniques such as by Northern blot analysis, reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, immunoprecipitation, Western blot hybridization, or immunohistochemistry. According to the method, cells may be obtained from a subject and the levels of the protein, or mRNA, of the analyzed genes, compared to that of a non-responder patient. Patients who differentially express one or more, for example, 5, 6, 7, 8, 9, 10, 1, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes selected from Table 1 or another embodiment of the invention are those which can be predicted to benefit from immunotherapy, for example cancer immunotherapy, such as Mage antigen specific cancer immunotherapy. For example, a nucleic acid molecule which hybridizes to a given location on a microarray is said to be differentially expressed if the hybridization signal is, for example, higher than the hybridization signal at the same location on an identical array hybridized with a nucleic acid sample obtained from a subject that does not clinically respond to Mage specific immunotherapy.

The results of 30 patients who have been subjected to gene profiling are shown in FIG. 5. This pictorially demonstrates that the gene signature of the present invention is aligned with clinical response to MAGE-antigen specific cancer immunotherapy.

Alternatively the cancer patient may be characterised as a responder or non-responder to immunotherapy from a visual inspection of a tissue section derived from the cancer or tumour. A responder is likely to be a patient with an infiltration of immune response cells into the cancer/tumour microenvironment.

The invention also provides a method of generating a new gene profile not specifically recited herein, based on differential expression of one or more immune response/activation genes, for indicating whether a patient is likely to be a responder or non-responder to appropriate immunotherapy, for example cancer immunotherapy such as Mage immunotherapy comprising the steps:

• • a) analysing at least two patient derived samples for differential expression of one or more of immune activation genes, where the sample group comprises both responders and non-responders to appropriate immunotherapy, and
  • b) correlating same with clinical outcome, after appropriate treatment, of patients from which the samples were derived, and
  • c) identifying one or more genes which are differentially expressed in responders and/O non-responders.

After the new profile has been identified the invention also extends to analysis of a previously uncharacterised sample, designating same as responders or non-responders (as appropriate) and if desired administering a therapeutically effective amount of an appropriate immunotherapy, for example cancer immunotherapy such as Mage immunotherapy to one or more patients designated as responders.

The invention also provides a method of generating a gene profile based on differential expression of one or more gene sequences recited in Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 for indicating whether a patient is likely to be a responder or non-responder to immunotherapy comprising the steps:

• • a) analyzing at least two patient derived samples for differential expression of
    • (i) one or more gene sequences recited in Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 and
    • (ii) optionally one or more gene sequences not recited in Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13,
  • where the sample group comprises both responders and non-responders to appropriate immunotherapy;
  • b) correlating differential expression of said one or more gene sequences with clinical outcome, after appropriate treatment, of patients from which the samples were derived, and
  • c) identifying one or more genes which are differentially expressed in responders and non-responders.

After the profile has been identified the invention also extends to analysis of a previously uncharacterised sample, designating same as responders or non-responders (as appropriate) and if desired administering a therapeutically effective amount of an appropriate immunotherapy, for example cancer immunotherapy such as Mage immunotherapy to one or more patients designated as responders.

The invention provides a diagnostic kit comprising at least one component for performing an analysis on a patient derived sample to identify a profile according to the invention, the results of which may be used to designate a patient from which the sample was derived as a responder or non-responder to immunotherapy.

The kit may comprise materials/reagents for PCR (such as QPCR), microarray analysis, immunohistochemistry or other analytical technique that may be used for accessing differential expression of one or more genes.

The invention also provides a diagnostic kit comprising a set of probes capable of hybridising to the mRNA or cDNA of one or more, such as at least 5 genes as set forth in Table 1 or alternatively Tables 2, 3, 4, 7, 9, 11, 12 and/or 13, for example a diagnostic kit comprising a set of probes capable of hybridising to the mRNA or its cDNA of at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes as set forth in Table 1.

In another embodiment this invention relates to diagnostic kits. For example, diagnostic kits containing such microarrays comprising a microarray substrate and probes that are capable of hybridising to mRNA or cDNA expressed from, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes from, for example Table 1 or any other embodiment of the invention that are capable of demonstrating the gene signature of the invention.

In one aspect the invention provides microarrays adapted for identification of a signature according to the invention.

The invention also extends to substrates and probes suitable for hybridising to an mRNA or cDNA moiety expressed from one or more genes employed in the invention, for example from Table 1, 2, 3, 4, 7, 9, 11, 12 or 13.

Commercially available microarrays contain many more probes than are required to characterise the differential expression of the genes under consideration at any one time, to aid the accuracy of the analysis. Thus one or more probe sets may recognise the same gene.

Thus in one embodiment multiple probes or probe sets are used to identify if an immune activation gene is differentially expressed, such as upregulated.

The diagnostic kit may, for example comprise probes, which are arrayed in a microarray. Specifically, prepared microarrays, for example, containing one or more probe sets described herein can readily be prepared by companies such as Affymetrix, thereby providing a specific test and optionally reagents for identifying the profile, according to the invention.

In an embodiment the microarrays or diagnostic kits will additionally be able to test for the presence or absence of the relevant cancer testis antigen expressing gene such as the Mage gene. Thus in one aspect the invention provides a probe and/or probe set suitable for said hybridisation, under appropriate conditions. The invention also extends to use of probes, for example as described herein or functional equivalents thereof, for the identification of a gene profile according to the present invention.

The invention herein described extends to use of all permutations of the probes listed herein (or functional analogues thereof) for identification of the said signature.

In one aspect the invention provides use of a probe for the identification of differential expression of at least one gene product of an immune activation gene for establishing if a gene profile according to the present invention is present in a patient derived sample.

Table 1B discloses probe sets from which probes of typically 25 mer in length may be designed and which are suitable for identifying the mRNA (or its cDNA) expressed from, for example the genes of Table 1 (or alternatively Table 2, 3, 4, 7, 9, 11, 12 or 13). Such probes and probe sets are an aspect of the invention. Typically each probe set may comprise about or exactly 11 individual sequences of about or exactly 25 nucleotides, which correspond precisely to a run of sequences from the probe set.

Accordingly, in one aspect, this invention relates to oligonucleotide probes and primers capable of recognising the mRNA (or its cDNA) expressed from the genes from Table 1, (or alternatively Table 2, 3, 4, 7, 9, 11, 12 or 13) and diagnostic kits based on these probes and primers. Such kits may include probes or kits for the detection of a Mage gene.

In an aspect the invention provides a profile based on the differential expression of one or more of the genes of Table 3 identifiable by one or more of following 13 probes: 204661_at, 205890_at, 206118_at, 206666_at, 207651_at, 210038_at, 210972_x_at, 211144_x_at, 211796_s_at, 213193_x_at, 213539_at, 217147_s_at, 34210_at.

Further details of these probes and the target genes of the same are given in Table 3A below. Hybridisation will generally be preformed under stringent conditions, such as 3×SSC, 0.1% SDS, at 50° C.

Once the target gene(s)/profile has/have been identified then it is well within the skilled person's ability to design alternative probes that hybridise to the same target. Therefore the invention also extends to probes, which under appropriate conditions measure the same differential expression of the gene(s) of the present invention to provide a signature/profile as described.

The invention also extends to use of the relevant probe in analysis of whether a cancer patient will be a responder or non-responder to treatment with an appropriate immunotherapy.

The invention also extends to use (and processes employing same) of known microarrays for identification of said signature.

A nucleic acid probe may be at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100 or more nucleotides in length and may comprise the full length gene. Probes for use in the invention are those that are able to hybridise specifically to the mRNA (or its cDNA) expressed from the genes listed in Table 1 (or Table 2, 3, 4, 7, 9, 11, 12 or 13) under stringent conditions.

The present invention further relates to a method of screening the effects of a drug on a tissue or cell sample comprising the step of analysing the expression profile of, for example 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes selected from Table 1 or any other embodiment of the invention described herein before and after drug treatment. The invention therefore provides a method for screening for a drug, which would alter the gene profile to that of a patient having improved survival following treatment with, for example, Mage antigen specific cancer immunotherapy (ie. to alter the gene profile to that of a responder), to enable the patient to benefit from, for example, Mage antigen specific cancer immunotherapy.

The present invention further provides a method of patient diagnosis comprising, for example, the step of analysing the expression profile of, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes selected from Table 1 or any other embodiment of the invention described herein and comparing it with a standard to diagnose whether the patient would benefit from Mage specific immunotherapy.

The invention includes a method of patient diagnosis comprising the step of analysing the expression profile of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes selected from Table 1 or other embodiment of the invention from a tumour tissue sample given by a patient and assessing whether 5 or more of said genes are expressed.

Thus in clinical applications, tissue samples from a human patient may be screened for the presence and/or absence of the expression of, for example 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes selected from Table 1 or any other embodiment of the invention described herein.

In the context of the present invention, the sample may be of any biological tissue or fluid derived from a patient potentially in need of treatment. The sample maybe derived from sputum, blood, urine, or from solid tissues such as biopsy from a primary tumour or metastasis, or from sections of previously removed tissues.

Samples could comprise or consist of, for example, needle biopsy cores, surgical resection samples or lymph node tissue. These methods include obtaining a biopsy, which is optionally fractionated by cryostat sectioning to enrich tumour cells to about 80% of the total cell population. In certain embodiments, nucleic acids extracted from these samples may be amplified using techniques well known in the art. The levels of selected markers (eg the gene products of table 1) can be detected and can be compared with statistically valid groups of, for example, Mage positive non responder patients.

For cancer, the biological sample will contain cancer or tumour cells and may, for example, be derived from the cancer or tumour such as a fresh sample (including frozen samples) or a sample that has been preserved in paraffin. Having said this, samples preserved in paraffin can suffer from degradation and the profile observed may be modified. A person working the in field is well able to compensate of these changes observed by recalibrating the parameters of the profile.

Microarrays

A microarray is an array of discrete regions, typically nucleic acids, which are separate from one another and are typically arrayed at a density of between, about 100/cm² to 1000/cm², but can be arrayed at greater densities such as 10000/cm². The principle of a microarray experiment, is that mRNA from a given cell line or tissue is used to generate a labeled sample typically labeled cDNA, termed the ‘target’, which is hybridized in parallel to a large number of, nucleic acid sequences, typically DNA sequences, immobilised on a solid surface in an ordered array. Tens of thousands of transcript species can be detected and quantified simultaneously. Although many different microarray systems have been developed the most commonly used systems today can be divided into two groups, according to the arrayed material: complementary DNA (cDNA) and oligonucleotide microarrays. The arrayed material has generally been termed the probe since it is equivalent to the probe used in a northern blot analysis. Probes for cDNA arrays are usually products of the polymerase chain reaction (PCR) generated from cDNA libraries or clone collections, using either vector-specific or gene-specific primers, and are printed onto glass slides or nylon membranes as spots at defined locations. Spots are typically 10-300 μm in size and are spaced about the same distance apart. Using this technique, arrays consisting of more than 30,000 cDNAs can be fitted onto the surface of a conventional microscope slide. For oligonucleotide arrays, short 20-25mers are synthesized in situ, either by photolithography onto silicon wafers (high-density-oligonucleotide arrays from Affymetrix or by ink-jet technology (developed by Rosetta Inpharmatics, and licensed to Agilent Technologies). Alternatively, presynthesized oligonucleotides can be printed onto glass slides. Methods based on synthetic oligonucleotides offer the advantage that because sequence information alone is sufficient to generate the DNA to be arrayed, no time-consuming handling of cDNA resources is required. Also, probes can be designed to represent the most unique part of a given transcript, making the detection of closely related genes or splice variants possible. Although short oligonucleotides may result in less specific hybridization and reduced sensitivity, the arraying of presynthesized longer oligonucleotides (50-100mers) has recently been developed to counteract these disadvantages. Thus in performing a microarray to ascertain whether a patient presents with a gene signature of the present invention, the following steps are performed: obtain mRNA from the sample and prepare nucleic acids targets, contact the array under conditions, typically as suggested by the manufactures of the microarray (suitably stringent hybridisation conditions such as 3×SSC, 0.1% SDS, at 50° C.) to bind corresponding probes on the array, wash if necessary to remove unbound nucleic acid targets and analyse the results.

It will be appreciated that the mRNA may be enriched for sequences of interest such as those in Table 1 or 2 (or other embodiment of the invention) by methods known in the art, such as primer specific cDNA synthesis. The population may be further amplified, for example, by using PCR technology. The targets or probes are labeled to permit detection of the hybridisation of the target molecule to the microarray. Suitable labels include isotopic or fluorescent labels which can be incorporated into the probe.

In an alternative embodiment, a patient may be diagnosed to ascertain whether his/her tumor expresses the gene signature of the invention utilising a diagnostic kit based on PCR technology, in particular Quantative PCR (For a review see Ginzinger D Experimental haematology 30 (2002) p 503-512 and Giuliette et al Methods, 25 p 386 (2001).

In an alternative aspect the invention provides a method further comprising the steps of analyzing a tumour derived sample to determine which antigen(s) are expressed by the tumour and hence enabling administration of an a therapeutically effective amount of an appropriate antigen specific cancer immunotherapeutic, for example where the tumour is found to be MAGE (such as Mage A3) positive, appropriate treatment may, for example, include administration of Mage A3 antigen specific immunotherapy.

A sample such as tumour tissue of a patient is deemed to present the gene signature of the invention if one or more genes of Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13 are differentially expressed (such as upregulated), for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes from for example Table 1 or other embodiment of the invention are expressed and can be detected by microarray analysis or other appropriate analysis for example as described herein. The tumour tissue preferably shows expression of at least 5 genes selected from Table 1, 2, 3, 4, 7, 9, 11, 12 and/or 13, more preferably 10 genes, particularly 5, 6, 7, 8, 9 or 10 genes from Table 1, 2, 3, 4, 7, 9, 11, 12 or 13.

Immunotherapeutics

In a further aspect the invention provides a method of treating a responder patient with an appropriate immunotherapy, for example cancer immunotherapy such as cancer testis immunotherapy, after identification of the same as a responder thereto.

Thus the invention provides a method of treating a patient comprising the step of administering a therapeutically effective amount of an appropriate immunotherapy (for example cancer immunotherapy, such as Mage cancer immunotherapy), after first characterising the patient as a responder based on differential expression of at least one immune activation gene, for example as shown by appropriate analysis of a sample derived from the patient. In particular wherein the patient is characterised as a responder based on one or more embodiments described herein.

In one aspect the immunotherapy comprises an appropriate adjuvant (immunostimulant), see description below.

In yet a further embodiment of the invention there is provided a method of treating a patient suffering from, for example, a Mage expressing tumour, the method comprising determining whether the patient expresses the gene signature of the invention and then administering, for example, a Mage specific immunotherapeutic. In a further embodiment, the patient is treated with, for example, the Mage specific immunotherapy to prevent or ameliorate recurrence of disease, after first receiving treatment such as resection by surgery of any tumour or other chemotherapeutic or radiotherapy treatment.

A further aspect of the invention is a method of treating a patient suffering from a Mage expressing tumour, the method comprising determining whether the patient's tumour expresses at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2021, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes selected from Table 1 (or other embodiment of the invention) from a tumour tissue sample given by a patient and then administering a Mage specific immunotherapeutic to said patient.

Also provided is a method of treating a patient susceptible to recurrence of Mage expressing tumour having been treated to remove/treat a Mage expressing tumour, the method comprising determining whether the patient's tumour expresses at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes selected from Table 1 (or other embodiment of the invention) from a tumour tissue sample given by a patient and then administering a Mage specific immunotherapeutic.

The invention also provides as method of treatment or use employing:

• • MAGE specific immunotherapeutic comprising a MAGE antigen or peptide thereof,
  • MAGE antigen comprising a MAGE-A3 protein or peptide,
  • MAGE antigen comprising the peptide EVDPIGHLY,
  • MAGE antigen or peptide fused or conjugated to a carrier protein, for example in which the carrier protein is selected from protein D, NS1 or CLytA or fragments thereof, and/or
  • MAGE specific immunotherapeutic further comprises an adjuvant, for example in which the adjuvant comprises one or more or combinations of: 3D-MPL; aluminium salts; CpG containing oligonucleotides; saponin-containing adjuvants such as QS21 or ISCOMs; oil-in-water emulsions; and liposomes.

The invention also extends to use of an immunotherapy such as a cancer immunotherapy, in particular Mage immunotherapy in the manufacture of a medicament for the treatment of a patient such as a cancer patient designated as a responder, thereto.

It was observed that one patient initially characterised as a non-responder was subsequently characterised as responder after radiation therapy. Interestingly the inventors also believe that it may be possible to induce a responders profile in at least some non-responders, for example by subjecting the patient to radiation therapy, or administering an inflammatory stimulant such as interferon (for example imiquimod such as administered topically) or a TLR3 (for example as described in WO 2006/054177), 4, 7, 8 or TLR 9 agonist (for example containing a CpG motif, in particular administering a high dose thereof such as 0.1 to 75 mg per Kg adminstered, for example weekly). See for example Krieg, A. M., Efler, S. M., Wittpoth, M., Al Adhami, M. J. & Davis, H. L. Induction of systemic TH 1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 27, 460-471 (2004).

The high dose of CpG may, for example be inhaled or given subcutaneously.

Whilst not wishing to be bound by theory, it is hypothesised that the radiation therapy stimulated a systemic inflammatory response/immune response, which once triggered rendered the patient (or tumour tissue therein) more responsive to immunotherapy.

Accordingly, the invention further provides a method of inducing a responders profile by stimulating a systemic immune response, for example by administering an immunostimulant. The invention further provides the use of Mage specific immunotherapy in the manufacture of a medicament for the treatment of patients suffering from Mage expressing tumour or patients who have received treatment (e.g. surgery, chemotherapy or radiotherapy) to remove/treat a Mage expressing tumour, said patient expressing the gene signature of the invention.

The immunotherapy may then be administered once the responders profile has been induced. In one aspect the invention provides use of Mage specific immunotherapy in the manufacture of a medicament for the treatment of patients suffering from Mage expressing tumour, said patient characterised by their tumour expressing at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes selected from Table 1, or alternatively other embodiments of the invention.

The invention also provides use of Mage specific immunotherapy in the manufacture of a medicament for the treatment of patients susceptible to recurrence from Mage expressing tumour said patient characterised by their tumour expressing at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2021, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 genes selected from Table 1 or alternatively other embodiments of the invention.

Advantageously, the invention may allow medics to target those populations of patients that will obtain a clinical benefit from receiving an appropriate immunotherapy. It is expected that after screening that at least 60% of patients such as 70, 75, 80, 85% or more of patients deemed/characterised as responders will receive a clinical benefit from the immunotherapy, which is a significant increase over the current levels observed with therapy such as cancer therapy generally.

Advantageously if the cancer immunotherapy is given concomitantly or subsequent to chemotherapy it may assist in raising the patient's immune responses, which may have been depleted by the chemotherapy.

Antigen Specific Cancer Immunotherapeutics (ASCIs) suitable for use in the invention may, for example include those capable of raising a Mage specific immune response. Such immunotherapeutics may be capable of raising an immune response to a Mage gene product, for example a Mage-A antigen such as Mage-A3. The immunotherapeutic will generally contain at least one epitope from a Mage gene product. Such an epitope may be present as a peptide antigen optionally linked covalently to a carrier and optionally in the presence of an adjuvant. Alternatively larger protein fragments may be used. For example, the immunotherapeutic for use in the invention may comprise an antigen that corresponds to or comprises amino acids 195-279 of MAGE-A1. The fragments and peptides for use must however, when suitably presented be capable of raising a Mage specific immune response. Examples of peptides that may be used in the present invention include the MAGE-3.A1 nonapeptide EVDPIGHLY [Seq. ID No 36] (see Marchand et al., International Journal of Cancer 80(2), 219-230), and the following MAGE-A3 peptides:

FLWGPRALV;        [Seq. ID No 37]
MEVDPIGHLY;       [Seq. ID No 38]
VHFLLLKYRA;       [Seq. ID No 39]
LVHFLLLKYR;       [Seq. ID No 40]
LKYRAREPVT;       [Seq. ID No 41]
ACYEFLWGPRALVETS; [Seq. ID No 42]
and
TQHFVQENYLEY;     [Seq. ID No 43]

Alternative ASCIs include cancer testis antigens such as PRAME, LAGE 1, LAGE 2, and others, for example details of which can be obtained from www.cancerimmunity.org/CTdatabase. The cancer immunotherapy may be based, for example on one or more of the antigens discussed below.

In one embodiment of the present invention, the antigen to be used may consist or comprise a MAGE tumour antigen, for example, MAGE 1, MAGE 2, MAGE 3, MAGE 4, MAGE 5, MAGE 6, MAGE 7, MAGE 8, MAGE 9, MAGE 10, MAGE 11 or MAGE 12. The genes encoding these MAGE antigens are located on chromosome X and share with each other 64 to 85% homology in their coding sequence (De Plaen, 1994). These antigens are sometimes known as MAGE A1, MAGE A2, MAGE A3, MAGE A4, MAGE A5, MAGE A6, MAGE A7, MAGE A8, MAGE A9, MAGE A 10, MAGE A11 and/or MAGE A12 (The MAGE A family). In one embodiment, the antigen is MAGE A3.

In one embodiment, an antigen from one of two further MAGE families may be used: the MAGE B and MAGE C group. The MAGE B family includes MAGE B1 (also known as MAGE Xp1, and DAM 10), MAGE B2 (also known as MAGE Xp2 and DAM 6) MAGE B3 and MAGE B4—the Mage C family currently includes MAGE C1 and MAGE C2.

In general terms, a MAGE protein can be defined as containing a core sequence signature located towards the C-terminal end of the protein (for example with respect to MAGE A1 a 309 amino acid protein, the core signature corresponds to amino acid 195-279).

The consensus pattern of the core signature is thus described as follows wherein x represents any amino acid, lower case residues are conserved (conservative variants allowed) and upper case residues are perfectly conserved.

Core Sequence Signature

• • LixvL(2×)I(3×)g(2×)apEExiWexl(2×)m(3-4×)Gxe(3-4×)gxp(2×)llt(3×)VqexYLxYxqVPxsxP(2×)yeFLWGprA(2×)Et(3×)kvConservative substitutions are well known and are generally set up as the default scoring matrices in sequence alignment computer programs. These programs include PAM250 (Dayhoft M. O. et al., (1978), “A model of evolutionary changes in proteins”, In “Atlas of Protein sequence and structure” 5(3) M. O. Dayhoft (ed.), 345-352), National Biomedical Research Foundation, Washington, and Blosum 62 (Steven Henikoft and Joija G. Henikoft (1992), “Amino acid substitution matricies from protein blocks”), Proc. Natl. Acad. Sci. USA 89 (Biochemistry): 10915-10919.

In general terms, substitution within the following groups are conservative substitutions, but substitutions between groups are considered non-conserved. The groups are:

• • i) Aspartate/asparagine/glutamate/glutaminc
  • ii) Serine/threonine
  • iii) Lysine/arginine
  • iv) Phenylalanine/tyrosine/tryptophane
  • v) Leucine/isoleucine/valine/methionine
  • vi) Glycine/alanine

In general and in the context of this invention, a MAGE protein will be approximately 50% or more identical, such as 70, 80, 90, 95 or 99% identical, in this core region with amino acids 195 to 279 of MAGE A1.

MAGE protein derivatives are also known in the art, see: WO 99/40188. Such derivatives are suitable for use in therapeutic vaccine formulations (Immunotherapeutic) which are suitable for the treatment of a range of tumour types.

Several CTL epitopes have been identified on the MAGE-3 protein. One such epitope, MAGE-3.A1, is a nonapeptide sequence located between amino acids 168 and 176 of the MAGE-3 protein which constitutes an epitope specific for CTLs when presented in association with the MHC class I molecule HLA.A1. Recently two additional CTL epitopes have been identified on the peptide sequence of the MAGE-3 protein by their ability to mount a CTL response in a mixed culture of melanoma cells and autologous lymphocytes. These two epitopes have specific binding motifs for the HLA.A2 (Van der Bruggen, 1994) and HLA.B44 (Herman, 1996) alleles respectively.

In a further embodiment of the invention, the tumour antigen may comprise or consist of one of the following antigens, or an immunogenic portion thereof which is able to direct an immune response to the antigen:

SSX-2; SSX-4; SSX-5; NA17; MELAN-A; Tyrosinase; LAGE-1; NY-ESO-1; PRAME; P790; P510; P835; B305D; B854; CASB618 (as described in WO00/53748); CASB7439 (as described in WO01/62778); C1491; C1584; and C1585.

In one embodiment, the antigen may comprise or consist of P501S (also known as prostein). The P501S antigen may be a recombinant protein that combines most of the P501S protein with a bacterial fusion protein comprising the C terminal part of protein LytA of Streptococcus pneumoniae in which the P2 universal T helper peptide of tetanus toxoid has been inserted, ie. a fusion comprising CLytA-P2-CLyta (the “CPC” fusion partner), as described in WO03/104272;

In one embodiment, the antigen may comprise or consist of WT-1 expressed by the Wilm's tumor gene, or its N-terminal fragment WT-1F comprising about or approximately amino acids 1-249; the antigen expressed by the Her-2/neu gene, or a fragment thereof. In one embodiment, the Her-2/neu antigen may be one of the following fusion proteins which are described in WO00/44899.

In a further embodiment, the antigen may comprise or consist of “HER-2/neu ECD-ICD fusion protein,” also referred to as “ECD-ICD” or “ECD-ICD fusion protein,” which refers to a fusion protein (or fragments thereof) comprising the extracellular domain (or fragments thereof) and the intracellular domain (or fragments thereof) of the HER-2/neu protein. In one embodiment, this ECD-ICD fusion protein does not include a substantial portion of the HER-2/neu transmembrane domain, or does not include any of the HER-2/neu transmembrane domain.

In a further embodiment, the antigen may comprise or consist of “HER-2/neu ECD-PD fusion protein,” also referred to as “ECD-PD” or “ECD-PD fusion protein,” or the “HER-2/neu ECD-ΔPD fusion protein,” also referred to as “ECD-ΔPD” or “ECD-ΔPD fusion protein,” which refers to fusion proteins (or fragments thereof) comprising the extracellular domain (or fragments thereof) and phosphorylation domain (or fragments thereof, e.g., ΔPD) of the HER-2/neu protein.

In one embodiment, the ECD-PD and ECD-ΔPD fusion proteins do not include a substantial portion of the HER-2/neu transmembrane domain, or does not include any of the HER-2/neu transmembrane domain.

In one embodiment, the antigen may comprise a Mage or other appropriate protein linked to an immunological fusion or expression enhancer partner. Fusion proteins may include a hybrid protein comprising two or more antigens relevant to a given disease or may be a hybrid of an antigen and an expression enhancer partner.

The antigen and partner may be chemically conjugated, or may be expressed as a recombinant fusion protein. In an embodiment in which the antigen and partner are expressed as a recombinant fusion protein, this may allow increased levels to be produced in an expression system compared to non-fused protein. Thus the fusion partner may assist in providing T helper epitopes (immunological fusion partner), preferably T helper epitopes recognised by humans, and/or assist in expressing the protein (expression enhancer) at higher yields than the native recombinant protein. In one embodiment, the fusion partner may be both an immunological fusion partner and expression enhancing partner.

In one embodiment of the invention, the immunological fusion partner that may be used is derived from protein D, a surface protein of the gram-negative bacterium, Haemophilus influenza B (WO 91/18926) or a derivative thereof. The protein D derivative may comprise the first ⅓ of the protein, or approximately or about the first ⅓ of the protein, in particular it may comprise the first N-terminal 100-110 amino acids or approximately the first N-terminal 100-110 amino acids.

In one embodiment the fusion protein comprises the first 109 residues (or 108 residues therefrom) or amino acids 20 to 127 of protein D.

Other fusion partners that may be used include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically the N terminal 81 amino acids of NS1 may be utilised, although different fragments may be used provided they include T-helper epitopes.

In another embodiment the immunological fusion partner is the protein known as LytA. LytA is derived from Streptococcus pneumoniae which synthesise an N-acetyl-L-alanine amidase, amidase LytA, (coded by the LytA gene (Gene, 43 (1986) page 265-272) an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LytA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E. coli C-LytA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LytA fragment at its amino terminus has been described (Biotechnology: 10, (1992) page 795-798). In one embodiment, the C terminal portion of the molecule may be used. The embodiment may utilise the repeat portion of the LytA molecule found in the C terminal end starting at residue 178. In one embodiment, the LytA portion may incorporate residues 188-305.

In one embodiment of the present invention, the Mage protein may comprise a derivatised free thiol. Such antigens have been described in WO 99/40188. In particular carboxyamidated or carboxymethylated derivatives may be used.

In one embodiment of the present invention, the tumour associated antigen comprises a Mage-A3-protein D molecule. The nucleotide and amino acid sequences for this molecule are shown in seq ID No 35. This antigen and those summarised below are described in more detail in WO 99/40188.

In further embodiments of the present invention, the tumour associated antigen may comprise any of the following fusion proteins:

A fusion protein of Lipoprotein D fragment, MAGE 1 fragment, and histidine tail; fusion protein of NS1-MAGE3, and Histidine tail; fusion protein of CLYTA-MAGE1-Histidine; fusion protein of CLYTA-MAGE3-Histidine.

A further embodiment of the present invention comprises utilising a nucleic acid immunotherapeutic, which comprises a nucleic acid molecule encoding a Mage specific tumour associated antigens as described herein. Such sequences may be inserted into a suitable expression vector and used for DNA/RNA vaccination. Microbial vectors expressing the nucleic acid may also be used as vectored delivered immunotherapeutics. Such vectors include for example, poxvirus, adenovirus, alphavirus and listeria.

Conventional recombinant techniques for obtaining nucleic acid sequences, and production of expression vectors of are described in Maniatis et al., Molecular Cloning—A Laboratory Manual; Cold Spring Harbor, 1982-1989.

For protein based immunotherapeutics the proteins of the present invention are provided either in a liquid form or in a lyophilised form.

It is generally expected that each human dose will comprise 1 to 1000 μg of protein, and preferably 30-300 μg.

The method(s) as described herein may comprise a composition further comprises a vaccine adjuvant, and/or immunostimulatory cytokine or chemokine.

Suitable vaccine adjuvants for use in the present invention are commercially available such as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.); AS-2 (SmithKline Beecham, Philadelphia, Pa.); aluminium salts such as aluminium hydroxide gel (alum) or aluminium phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatised polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quit A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, and chemokines may also be used as adjuvants.

In formulations it may be desirable that the adjuvant composition induces an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (e.g., IFN-γ, TNFα, IL-2 and IL-12) tend to favour the induction of cell mediated immune responses to an administered antigen. According to one embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, Ann. Rev. Immunol. 7:145-173, 1989. Accordingly, suitable adjuvants that may be used to elicit a predominantly Th1-type response include, for example a combination of monophosphoryl lipid A, such as 3-de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminium salt. 3D-MPL or other toll like receptor 4 (TLR4) ligands such as aminoalkyl glucosaminide phosphates as disclosed in WO 98/50399, WO 01/34617 and WO 03/065806 may also be used alone to generate a predominantly Th1-type response.

Other known adjuvants, which may preferentially induce a TH1 type immune response, include TLR9 agonists such as unmethylated CpG containing oligonucleotides. The oligonucleotides are characterised in that the CpG dinucleotide is unmethylated. Such oligonucleotides are well known and are described in, for example WO 96/02555.

Suitable oligionucleotides include:

OLIGO 1:
[Seq ID No 44]
TCC ATG ACG TTC CTG ACG TT (CpG 1826)
OLIGO 2:
[Seq ID No 45]
TCT CCC AGC GTG CGC CAT (CpG 1758)
OLIGO 3:
[Seq ID No 46]
ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG
OLIGO 4
[Seq ID No 47]
TCG TCG TTT TGT CGT TTT GTC GTT (CpG 2006, CpG
7909)
OLIGO 5
[Seq ID No 48]
TCC ATG ACG TTC CTG ATG CT (CpG 1668)

CpG-containing oligonucleotides may also be used alone or in combination with other adjuvants. For example, an enhanced system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of CpG and QS21 as disclosed in WO 00/09159 and WO 00/62800.

The formulation may additionally comprise an oil in water emulsion and/or tocopherol. Another suitable adjuvant is a saponin, for example QS21 (Aquila Biopharmaceuticals Inc., Framingham, Mass.), that may be used alone or in combination with other adjuvants. For example, an enhanced system involves the combination of a monophosphoryl lipid A and saponin derivative, such as the combination of QS21 and 3D-MPL as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other suitable formulations comprise an oil-in-water emulsion and tocopherol. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in, for example, an oil-in-water emulsion is described in WO 95/17210.

In another embodiment, the adjuvants may be formulated in a liposomal composition.

The amount of 3D-MPL used is generally small, but depending on the immunotherapeutic formulation may be in the region of 1-1000 μg per dose, preferably 1-500 μg per dose, and more preferably between 1 to 100 μg per dose.

In an embodiment, the adjuvant system comprises three immunostimulants: a CpG oligonucleotide, 3D-MPL, & QS21 either presented in a liposomal formulation or an oil in water emulsion such as described in WO 95/17210.

The amount of CpG or immunostimulatory oligonucleotides in the adjuvants or immunotherapeutics of the present invention is generally small, but depending on the immunotherapeutic formulation may be in the region of 1-1000 μg per dose, preferably 1-500 μg per dose, and more preferably between 1 to 100 μg per dose.

The amount of saponin for use in the adjuvants of the present invention may be in the region of 1-1000 μg per dose, preferably 1-500 μg per dose, more preferably 1-250 μg per dose, and most preferably between 1 to 100 μg per dose.

Generally, it is expected that each human dose will comprise 0.1-1000 μg of antigen, preferably 0.1-500 μg, preferably 0.1-100 μg, most preferably 0.1 to 50 μg. An optimal amount for a particular immunotherapeutic can be ascertained by standard studies involving observation of appropriate immune responses in vaccinated subjects. Following an initial vaccination, subjects may receive one or several booster immunisation adequately spaced.

Other suitable adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, Calif., United States), ISCOMS (CSL), MF-59 (Chiron), Ribi Detox, RC-529 (GSK, Hamilton, Mont.) and other aminoalkyl glucosaminide 4-phosphates (AGPs).

Accordingly there is provided an immunogenic composition for use in the method of the present invention comprising an antigen as disclosed herein and an adjuvant, wherein the adjuvant comprises one or more of 3D-MPL, QS21, a CpG oligonucleotide, a polyethylene ether or ester or a combination of two or more of these adjuvants. The antigen within the immunogenic composition may be presented in an oil in water or a water in oil emulsion vehicle or in a liposomal formulation.

In one embodiment, the adjuvant may comprise one or more of 3D-MPL, QS21 and an immunostimulatory CpG oligonucleotide. In an embodiment all three immunostimulants are present. In another embodiment 3D-MPL and QS21 are presented in an oil in water emulsion, and in the absence of a CpG oligonucleotide.

A composition for use in the method of the present invention may comprise a pharmaceutical composition comprising tumour associated antigen as described herein, or a fusion protein, in a pharmaceutically acceptable excipient.

EXAMPLES

Example 1

MAGE008 Mage Melanoma Clinical Trial

In this on-going trial, the recMAGE-A3 protein (recombinant mage fusion protein as shown in Seq Id No 35) is combined with two different immunological adjuvants: either AS02B (QS21, MPL) or AS15 (QS21, MPL and CpG7909). The objectives were to discriminate between the adjuvants in terms of safety profile, clinical response and immunological response.

In this experiment two adjuvant compositions are made up of mixtures of two immunostimulants:

• • 1. QS21 (Purified, naturally occurring saponin molecule from the South-American tree Quillaja Saponaria Molina), and
  • 2. MPL (3 de-O-acetylated monophosphoryl lipid A-detoxified derivative of lipid A, derived from S. minnesota LPS).AS02B is an oil-in-water emulsion of QS21 and MPL.

In animal models these adjuvants have been successfully shown to induce both humoral and TH1 types of cellular-mediated immune responses, including CD4 and CD8 T-cells producing IFNα (Moore et al., 1999; Gérard et al., 2001). Moreover, the injection of recombinant protein formulated in this type of adjuvant leads to the induction of a systemic anti-tumor response: indeed, vaccinated animals were shown to be protected against challenges with murine tumor cells genetically engineered to express the tumor antigen, and regressing tumors were shown to be highly infiltrated by CD8, CD4 and NK cells and by macrophages.

The second adjuvant system is AS15: it contains a third immunostimulant, namely CpG7909 (otherwise known as CpG 2006 supra), in addition to MPL and QS21, in a liposome formulation. In animal models (mainly mice), it has been shown that the addition of CpG7909 further improves the induced immune and anti-tumor responses (Krieg and Davis, 2001; Ren et al., 2004). CpG oligodeoxynucleotides (ODNs) directly stimulate dendritic-cell activation through TLR9 triggering. In addition, in mice, the systemic application of CpG7909 greatly increases the infiltration of transferred T-cells into tumors (Meidenbauer et al., 2004).

Study Overview

1. Design

The MAGE008 trial is:

• • open
  • randomized
  • two-arm (AS02B vs. AS15)
  • with 68 patients in total.

As described above, the recMAGE-A3 protein is combined with either AS02B or AS15 adjuvant system.

2. Patients Population

The recMAGE-A3 protein is administered to patients with progressive metastatic melanoma with regional or distant skin and/or lymph-node lesions (unresectable stage III and stage IV M1a). The expression of the MAGE-A3 gene by the tumor was assessed by quantitative PCR. The selected patients did not receive previous treatment for melanoma (recMAGE-A3 is given as first-line treatment) and had no visceral disease.

3. Schedule of Immunization

Method of Treatment Schedules

Adjuvant Setting

The method of treatment schedule for use in disease in an adjuvant (post-operative) setting may comprise administration of an antigen as described herein according to the following schedules: Administration of antigen at three week intervals for the first 5 to 8 vaccinations, followed at 3 month intervals for the next 8, 9 or more vaccinations.

The antigen may be administered at the exact time frame indicated, or the antigen may be given 1, 2, 3 or 4 days before or after the exact interval, as required or as practical. An example of this schedule is shown in the table below:

• Induction: 5 vaccinations at intervals of 3 weeks for example Weeks 0, 3, 6, 9, 12 or Weeks 0, 6, 9, 12
• Maintenance: 9 vaccinations at intervals of 3 monthsAlternatively, the vaccinations may be given initially at 2 week intervals, for example 6 injections at two week intervals followed by appropriate maintenance therapy.

Active Disease

The method of treatment schedule for use in active or unresectable disease, for example in melanoma cancer, comprising: administration of an antigen as described herein at two or three week intervals for the first six months to one year of treatment. A schedule may comprise the following pattern of injections: the antigen may be given at two week intervals for the first 4 to 10 vaccinations, followed by 3 week intervals for the next 4 to 10 vaccinations, then at 6 week intervals for the next 3 to 7 vaccinations. Long term treatment may then continue with vaccinations at 3 month intervals for 3 to 5 vaccinations, followed by 6 month intervals for the next 3 to 5 vaccinations.

The antigen may be administered at the exact time frame indicated, or the antigen may be given 1, 2, 3 or 4 days before or after the exact interval, as required or as practical.

An example of this schedule is shown in the table below:

• Cycle 1: 6 vaccinations at intervals of 2 weeks (Weeks 1, 3, 5, 7, 9, 11)
• Cycle 2: 6 vaccinations at intervals of 3 weeks (Weeks 15, 18, 21, 24, 27, 30)
• Cycle 3: 4 vaccinations at intervals of 6 weeks (Weeks 34, 40, 46, 52)
• Long Term Treatment: 4 vaccinations at intervals of 3 months, for example followed by 4 vaccinations at intervals of 6 monthsFor both of the above treatment regimes additional vaccinations may be given after treatment, as required.

In order to screen potential participants in the above clinical trial we received biopsies of the tumor, prior to any immunization, as frozen tumor samples. From these samples we extracted RNA for the quantitative PCR. The quality of this purified RNA was extremely high and it was suitable for microarray analysis. We therefore analyzed the tumor samples by microarrays. The goal was to identify a set of genes associated with the clinical response so that patients likely to benefit from this antigen-specific cancer immunotherapeutic are properly identified and selected. Gene profiling has been performed only on biopsies from patients who signed the informed consent for microarray analysis.

Materials and Methods

Tumor Specimens

30 tumor specimens (pre-vaccination) were used from the Mage008 Mage-3 melanoma clinical trial. These were fresh frozen preserved in the RNA stabilizing solution RNAlater.

RNA Purification

Tumoral total RNA was purified using the Tripure method—Tripure extraction (Roche Cat. No. 1 667 165). The protocols provided were followed subsequently by the use of an RNeasy Mini kit—clean-up protocol with DNAse treatment (Qiagen Cat. No. 74106). http://www1.qiagen.com/literature/handbooks/PDF/RNAStabilizationAndPurification/FromAnim alAndPlantTissuesBacteriaYeastAndFungi/RNY_Mini/1035969_HB.pdf. www.roche-applied-science.com/PROD_INF/MANUALS/napi_man/pdf/chapter4/page_—152-158.pdf

RNA Quality Control

Quantification of RNA was initially completed using optical density at 260 nm and Quant-IT RiboGreen RNA assay kit (Invitrogen—Molecular probes R11490). http://probes.invitrogen.com/media/pis/mp11490.pdf.

The Quality of the 28s and 18s ribosomal RNA peaks were assessed by use of the Agilent bioanalyser.

RNA Labeling and Amplification for Microarray Analysis

Due to the small biopsy size received during the clinical study an amplification method was used in conjunction with the labeling of the RNA for microarray analysis.

The Nugen 3′ ovation biotin kit (Labelling of 50 ng of RNA—Ovation biotin system Cat; 2300-12, 2300-60) http://www.nugeninc.com/html/03_products2.html

A starting input of 50 ng of total RNA was used.

Microarray Chips

The Affymetrix HU-U133.Plus 2.0 gene chips were utilized as these were the most up to date chips (based on the human genome project) available from the supplier. These chips cover about 47,000 potential gene transcripts.

Microarray Hybridization and Scanning

The hybridized chips were washed and scanned according to the standard Affymetrix protocols:

Affymetrix gene chip expression analysis protocols can be downloaded from http://www.affvmetrix.com/support/technical/manual/expression_manual.affx.

The scanner that has to be used with the Affymetrix microarray workstation is http://www.affymetrix.com/products/instruments/specific/scanner_—3000.affx

Data Normalization

The fluorescent scanned data was then normalized using RMA to allow comparisons between individual chips. The following reference describes this method.

Irizarry R A, Hobbs B, Collin F, Beazer-Barclay Y D, Antonellis K J, Scherf U, Speed T P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003 April; 4(2):249-64.

Data Analysis

Three independent methods were used to generate gene lists to distinguish responder from non-responding patients. The methods are 1. Spotfire, 2. Baldi B H and 3. Arrayminer. The Baldi analysis method is available from the following website. http://www.igb.uci.edu/˜pfbaldi/software_and_servers.htm.

The spotfire software can be purchased from this site http://www.spotfire.com. The arrayminer software is available for purchase at http://www.optimaldesign.com/ArrayMiner/ArrayMiner.htm.

All data analysis was performed with the use of the R statistics software (available at www.r-project.org) and various Bioconductor packages for R (available at www.bioconductor.org). The raw data were pre-processed for background correction, normalisation and probe summarisation by the RMA (Irizarry R A, Hobbs B, Collin F, Beazer-Barclay Y D, Antonellis K J, Scherf U, Speed T P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003 April; 4(2):249-64)

The differential gene expression between any two groups was computed by two different statistical methods, the RankProduct (Breitling, R., Armengaud, P., Amtmann, A., and Herzyk, P. (2004) Rank Products: A simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments, FEBS Letter, 57383-92) and the CyberT (P. Baldi and A. D. Long, “A Bayesian Framework for the Analysis of Microarray Expression Data: Regularized t-Test and Statistical Inferences of Gene Changes”, Bioinformatics, 17, 6, 509-519, (2001)) methods.

In each of them, a correction for multiple testing was done with the method of Benjamini-Hochberg (Y. Benjamini and Y. Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J. Roy. Stat. Soc. B 57 (1995)), and the threshold of 5% was chosen for the false discovery rate; thus, the genes had to have a corrected p-value less or equal to 0.05 to be considered as differentially expressed. Baldi-BH is equivalent to CyberT followed by Benjamini-Hochberg correction.

1. Spotfire Analysis

The results of the analysis of patient samples (from the clinical research program named Mage008) are summarized in the FIG. 1.

As a first step, a supervised comparison was performed in order to find a group of genes able to cluster. Two patients that showed clinical response (patient 67 and 59) fell within the cluster of non-repsonders. Two patients who were non-responders (patient 3 and 39) fell within the cluster designated as responders. The responding patients are also found within cross over cluster (ie the areas of overlap in the figure). However, there are two patients who are non-responders that fall within this area of overlap.

In FIG. 1 RESPONDERS were patients 27 and 38 (full/complete clinical responders), patients 2, 10, 20, 26-1, 26-2, 59 & 67 (mixed responders) and patients 19, 23, 65 and 75 (stable disease). NON-RESPONDERS in FIG. 1 were patients 3, 5, 8, 9, 13, 14, 15, 16, 28, 30, 36, 37, 39, 52, 55, 56, 60 and 66.

2. Baldi BH Analysis

This software is designed for statistical supervised gene classification in microarray experiments. A list of 100 most significant genes were identified that define the two groups. See FIG. 2 below. The clustering is a more effective than with spotfire with the majority of the responders found in the responder cluster. However we still see the same patients non responding (patients 3, 39), and the responding patients (67 and 59) that are located within the wrong clusters.

In FIG. 2 RESPONDERS were patients 27 and 38 (full/complete clinical responders), patients 2, 10, 20, 26-1, 26-2, 59 & 67 (mixed responders) and patients 19, 23, 65 and 75 (stable disease). NON-RESPONDERS in FIG. 2 were patients 3, 5, 8, 9, 13, 14, 15, 16, 28, 30, 36, 37, 39, 52, 55, 56, 60 and 66.

3. Arrayminer Analysis

This software is classifies genes by using a “train and test” method. In this method the software first identifies a discriminant set of markers for the training classes, similar to a classical cross-validation study.

Here due to the analysis there is only the responder or non-responder cluster, with no area of overlap. Here again there is mis-classification of samples, in particular patients 59 and 67 who both responded to treatment but in this analysis were in the cluster of non-responders. Patients 3, 14, 39, 52 and 66 were non-responders but were located in the cluster for responders using this analysis.

In FIG. 3 RESPONDERS were patients 27 and 38 (full/complete clinical responders), patients 10, 20, 26-1, 26-2, 59 & 67 (mixed responders and patients) 19, 23, 65 and 75 (stable disease). NON-RESPONDERS in FIG. 3 were patients 3, 5, 8, 9, 13, 14, 15, 16, 28, 30, 36, 37, 39, 52, 55, 56, 60 and 66.

Combination of the Three Methods

The three methods were used together to find a common set of gene probes that will define the signature with high significance. A venn diagram was created comparing all of the results. See FIG. 4. A list of 36 probesets was found that are common with all three programs. (Table 1B). These 36 probesets were then used for a supervised clustering of the responding and non-responding patients. The genes which are identified by the 36 probes sets form a specific aspect of the invention.

Fold Change Definition

In programs such as Arrayminer, Fold change of gene expression can be calculated. This is shown in Table 1B and is the change in average gene expression between two groups, for example responder vs non-responder. The statistical value attached to the fold change is calculated and is the more significant in genes where the level of expression is less variable between patients in each group, and difference between groups is larger.

Gene Expression Shown on a Heat Map

FIG. 5 is a heat map (a diagrammatic respresentation of the expression level of various genes for a given patient), on which can be seen individual expression of genes represented in the Y-Axes by a coloured box and the patients in the X-axes. The expression values of each gene in all samples are normalized to a mean of zero and a standard deviation of 1, and these normalized values are coded into a gradient of colors.

Affymetrix arrays have 11 probe pairs available to interrogate each gene. Ideally, the signal intensity from all of these 11 probes should be equal as they all interrogate the same gene. However, there are enormous differences between individual probes in a probe set. The pattern of the probe signals in a probe set is called a “probe response pattern”. The Robust Multi-array Average” (RMA) software uses, model-based algorithms to incorporate information from multiple microarrays to calculate the expression of a gene. After proper correction for background, and quantile normalisation of the probe intensities, the probe response pattern is fitted over multiple arrays an additive model in RMA software. These algorithms use the fitted models to detect abnormally behaving probes, which are subsequently excluded for calculating gene expression. Therefore, gene expression from these model-based algorithms can be expected to provide more reproducible results. RMA use a stochastic model to estimate gene expression which is potentially a better way of estimating gene expression. Algorithms are implemented in RMA software.

FIG. 4: The predictive 36 probesets correspond mainly to upregulation of genes related to immune infiltration and activation. These genes include HLA class II, Interleukin-2 receptor gamma, T cell receptor genes (TRBV19, TRAT1, TRGC2), granzyme, and CD69.

Increase in Treatment Efficacy

As described herein, gene profiling has allowed the identification of a subset of patients likely to respond to recMAGE-A3 treatment. This subset corresponds to ˜30% of the patient population. Patients having the gene profile show far higher efficacy levels could be obtained. Indeed, with the early identification of patients susceptible for anti-MAGE-A3 immunization, the efficacy of the treatment will probably increase to levels far higher than other current cancer treatments. This may also lead to a better compliance by the patient. For example, in 100 patients with melanoma, 60 will be found to express MAGE-A3. If these patients all receive recMAGE-A3 injections, 10 out of them will respond; leading to a 15% efficacy rate. However, if gene profile is performed on the 60 MAGE-A3-expressing patients, only the 14 out of them who are predicted to be susceptible to this treatment will receive recMAGE-A3 injections. The other 46 patients will receive another treatment. 10 out of these 14 patients will respond to the treatment, leading to a 71% efficacy rate.

Gene Profile in Other Tumour Types

This gene profiling has also been performed in a NSCLC study. However, as this study is blinded, only preliminary data are available. It is thought that the signature observed in melanoma is also present in NSCLC, stages IB and II. Preliminary data suggests approximately 30% of the patients present a gene profile signature characteristic of immune response and immune cell infiltration and that suggests they will respond to ASCI treatment.

FIG. 5 shows and expression profile for 30 individual patients for a number of genes.

FIG. 5 a shows the expression profiles for 31 patients of two genes.

Example 2

Predicting the Clinical Outcome of Patients Using Machine Learning Approaches

Materials & Methods.

Tumor Specimens, RNA Purification, Quality Control, Labeling and Amplification for Microarray Analysis

Tumor specimens (pre-vaccination) were used from a Mage-3 melanoma clinical trial (MAGE008). These were preserved, RNA prepared, labeled and amplified as in Example 1 above. The quality of the RNA samples was checked prior to hybridization to the genechip. Only data from samples that were deemed to adequately hybridize to the genechip were used in this Example (61 samples in total).

Microarray Chips, Hybridizations and Scanning.

As in the material and methods section of the first example above (referred to herein as Example 1), Affymetrix HG-U133.Plus2.0 genechips were employed, and hybridized and scanned as described therein.

Data Processing & Normalization.

The fluorescent scanned data image was processed and normalized using a R 2.3.1 [1] implementation of GCRMA algorithm [2,3].

Unspecific Filtering of Gene Expression Matrix

Prior to calculation of differential expression gene expression matrix was filtered in an unspecific (i.e. independently of experimental groups) manner. 4 processes were used:

• 1. panp filtering: calls indicating whether a gene is expressed in a given sample (present call, P) or not (absent call, A) were derived for all array measures using the panp method implemented in the panp R package [4]. Only probe sets showing at least one P call throughout experimental samples were kept for subsequent calculations.
• 2. SD filtering: standard deviation (SD) of each probe sets were calculated throughout samples, were only kept probe sets having SDs above the 75th percentile of all SDs.
• 3. IQR filtering: interquartile range (IQR) of each probe sets were calculated throughout samples, were only kept probe sets having IQRs above the 7th quantile of all IQRs.
• 4. SH filtering: SD of each probe sets were calculated throughout samples, the midpoint of the SD shorth (the shortest interval containing all of the data) as calculated using the shorth function of genefilter package [5] under R 2.3.1, were only kept probes sets having SD above the shorth for subsequent calculations.

Calculation of Differential Expression.

The differential expression between the groups of patients showing a clinical benefit after vaccination or not (subsequently called Responder (R) or Non-Responder (NR) groups) was calculated in R 2.3.1 program according to 2 statistical procedures:

• 1. Regular t-test, as implemented in the genefilter package, and
• 2. A modified (regularized, moderated) t-test, to account for poor estimates of gene-specific variance under standard t-test, such as the method of Jain et al [6], implemented the LPE R package [7], or the method of Smyth [8], implemented in the limma R package [9], or the method of Baldi and Long [10], also known as Cyber-T [11].

Correction for multiple testing by controlling the false discovery rate (FDR) at 5% was done under R 2.3.1 with Benjamini-Hochberg method [12] implemented in the multitest package [13].

Gene Profile Normalizations

To make the probe sets having low and high levels of expression comparable and to put an emphasis on differential profiles rather than absolute profiles, data was further normalized at the probe set level. Two gene-level normalizations schemes were used:

• 1. IQR normalization, where each probe set measure is subtracted by its median over samples and divided by its IQR.
• 2. Z-score normalization, where each probe set measure is subtracted by its mean over samples and divided by its SD.

Machine Learning Algorithms

The 14 machine learning algorithms (or predictive rules) interfaced in MLInterfaces package [14] running under R 2.3.1 program were used to train clinical outcome predictive models and to predict the Mage008 patient clinical outcomes, under the reporter lists calculated by the unspecific filtering, differential expression, gene normalization processes. These algorithms were, knn (k-nearest neighbour, kNN, function of class package), nnet (neural network), gbm (generalized boost regression), lvq1 (learning vector quantization 1), naiveBayes (naïve bayes classifier), svm (support vector machine), lda (linear discriminant algorithm), rpart (recursive partitioning), stat.diag.da (diagonal discriminant analysis), randomforest (random forest), bagging, ipredknn (k-nearest neighbour function form ipred package, equivalent to knn form class package), slda (stabilized linear discriminant analysis), pamr (partition around medoids, also known as nearest shrunken centroid classifier). Default parameters were used for all algorithms except for kNN rule where even values of k ranging from 1 to 7 were tested.

Leave-one-out (LOO) scheme of MLinterfaces coded in the xval function was used for cross-validation when appropriate, without re-calculation of reporter list at each cross-validation loop. The misclassification rate was calculated by averaging the number of wrongly predicted samples to the total number of samples of each patient group or class (either R or NR).

Some of the MLIinterfaces interfaced predictive rules (nnet, Ida, naiveBayes) were used outside of the MLInterfaces package as direct calling to make the related classifiers usable on external data sets independently of the data used to train the models.

The MiPP algorithm [15, 16], implemented in the MiPP R library and ran under R 2.3.1, was employed to reduce the number of probe sets involved in the reporter lists. The best reporters out of the submitted list were selected as optimizing the 10-fold cross-validation of linear discriminant analysis predictions of a training set and further reduced to reporters giving an optimized global misclassification error of linear discriminant analysis predictions of a testing set. Global misclassification error or rate was calculated as the ratio of the total number of misclassified patients to the total of set patients.

Results

Patient Sample Stratification for Training and Testing Section Definitions

A 31 sample subpart of the full 61 sample data set was used to train and test the classifying model in a first attempt; the remaining 30 samples were kept for subsequent model evaluations. Several training and testing sections were defined from the 31 sample data set subpart. The training sections were used to calculate the reporter list (i.e. the differentially expressed genes to be used in clinical outcome prediction of patient samples) and to set the machine learning algorithm weights for clinical outcome prediction. The testing sections allowed evaluation of the model performance independently of the patients used to construct the predictive model. Model evaluations were also undertaken on the training sections according to a cross-validation procedure.

Training and testing sections from the 31 sample data set subpart were defined as follows:

• 1. A first training section containing 5 Responders and 5 Non-Responders, leaving 21 patients for the testing section;
• 2. A second training section of 10 Responders and 11 Non-Responders, leaving 10 patients for the testing section;
• 3. A last training section containing all 31 patients (13 Responders and 18 Non-Responders). In this last stratification there is no patient left for a testing section, classifying model would only be evaluated by a cross-validation procedure.

Identification of the Differential Expression Calculation Process Performing Best for Classification.

Gene expression data was pre-processed and normalized according to Material & Methods taking into account the full data set. Differential expressions (DE) between the Responder and Non-Responder groups were calculated for each training/testing section according to various processes.

The DE calculation framework was constructed as follows:

• 1. Unspecific filtering of gene expression matrix: panp filtering, or not, followed by either SD, IQR or SH filtering, or none.
• 2. Calculation of DE: either t-test or a modified (regularized, moderated) t-test, such as the method of Jain et al, implemented the LPE R package, or the method of Smyth, implemented in the limma R package, or the method of Baldi and Long (Cyber-T), followed by multiple testing correction, or not.
• 3. Gene profile normalizations: Either IQR or Z-score normalizations, or none.

The processes minimizing the overall misclassification rates in both training and testing sections in at least two out of the three available training/testing stratification's were selected. The misclassification rate was obtained by comparing the predicted clinical outcome given by a kNN predictive rule to the given clinical outcome.

Seven DE processes were found as minimizing the overall misclassification rate according to the kNN rule:

• • t-test without correction for multiple testing and irrespective of panp filtering;
  • SH filter, t-test without correction for multiple testing and irrespective of panp filtering;
  • SD filter, t-test without correction for multiple testing;
  • SD filter, t-test without correction for multiple testing, Z-score normalization;
  • IQR filter, t-test without correction for multiple testing, IQR normalization.

The minimized overall misclassification rates for these processes were as follows:

• • 0% in the 5 Responders to 5 Non-Responders stratification, as evaluated by leave-one-out cross-validation, all patients were therefore correctly classified.
  • 20% in the 21 patients testing section, given by the direct prediction of these patients from the model defined from the 5 Responders to 5 Non-Responders training set. 80% of patients were correctly predicted.
  • 12% for the 13 Responders to 18 Non-Responders segregation, as assessed by cross-validation, being 88% of patient correctly predicted.

The performances for the other training/testing stratification was not found to be informative (i.e. no DE process converging to a minimized misclassification rate), hence not mentioned.

The last process, IQR filter, t-test without correction for multiple testing, IQR normalization, was preferred since the minimized misclassification rates were obtained with a higher value of k (k=5) than other six processes (k=3). It was anticipated that working with higher values of k would facilitate the transposition of the predictive model in further settings, since high k values generate simpler models supposed to be less biased towards a training set.

This process generated a reporter list of 489 Affymetrix probe sets. The reporter list is given in Table 4A, as Affymetrix probe set identifications along with gene names and symbols.

External Validation: Independent Evaluation of the Best Clinical Outcome Predicting Model.

The best DE calculation and gene expression treatment process (IQR filter, t-test without correction for multiple testing, IQR normalization) was used to build a kNN predictive model (k=5) from 13 Responders/18 Non-responders training section.

The clinical outcome of the independent patients that were previously left away was then directly predicted from this model. Of these 30 independent patients only 15 were informative (i.e. having a characterized clinical outcome). Misclassification rate was calculated on the basis on these 15 informative patients for the model evaluation.

According to this predictive model, misclassification rate was 34%, hence 66% of independent patients had their clinical outcome correctly predicted.

Improvement of Clinical Outcome Predicting Model Through Other Classification Rules.

On the basis of the best DE (and expression normalization) process as selected with a kNN rule, further classification (predictive) rules were tried to eventually increase the predictive model performance. Beside kNN, 13 other rules were assessed. For each selected DE process that performed for the kNN rule, each further rule was trained on the 13 Responders/18 Non-responders section of the data set, its predictive performance evaluated on the training set by cross-validation and on the independent set of 30 patient samples by direct prediction. Further classification rules did not improve the misclassification rate, as assessed by cross-validation on the training set, the lowest remaining unchanged at 12% of samples miss-predicted (88% of patient assigned to their correct clinical outcome).

However, for the above mentioned preferred DE process, the neural network rule did improve the misclassification rate on the independent set of 15 informative patients out of the 30 available, by reducing it from 34%, as given by KNN rule, to 30% (i.e. one additional patient correctly predicted), while keeping it the lowest on the cross-validation evaluation of the training set. Neural network rule then allows the correct prediction of 70% of patient independently of those used to train the model.

Furthermore, in a further evaluation of the predictive modeling performance, when clinical outcomes were available for all 30 external patient samples, i.e. when all the independent patients were informative for misclassification rate calculation, the lowest misclassification error became 26%, which is 74% of patients were correctly classified. This best performance obtained on a wider data set in terms of informative sample number was given by a Ida rule. A naiveBayes rule was also able to give a 28% misclassification rate, correctly prediction the clinical outcome of 72% of patients. However, the misclassification rate using kNN and nnet rules became 35% and 41%, respectively. This performance is based on the use of the gene list and probes of Table 4A.

Implementation of the Preferred Classifiers, Predicting the Clinical Outcome of Further Patient Biopsies.

To make use on further metastatic melanoma samples of the exemplified neural network classifier, yielding 30% of misclassification on the 15 informative sample external set, the following R code can be used in a R session (a stastical programme):

library(nnet)set.seed(1234)predict(nn, data, type=“class”)where

• • data is a data frame containing the 489 reporter (Table 4A) expression data of the samples to classify (GCRMA sample normalized and IQR gene normalized). Samples are organized in columns and reporters in rows;
  • nn is the R object of class nnet shown in Appendix A.the Ida (linear discriminant analysis) classifier would be reproduced by programming the following R code chunk:library (MASS)predict(lda, data, type=“class”)where
  • data is as previously;
  • lda is the R object of class Ida shown in Appendix B.

The naïve Bayes classifier works under the following R coding:

library(e1071)predict(nb, data, type=“class”)where

• • data is as previously;
  • nb is the R object of class naiveBayes shown in Appendix C.

Down-Sizing the 489 Probe Set Reporter List While Maintaining an Identical Classification Performance.

The MiPP algorithm was used to determine if it was possible to reduce the number of reporters involved in the IQR filter, t-test without correction for multiple testing, IQR normalization, based predictive model while keeping the same misclassification rate. Indeed, working under a shorter reporter list would be more convenient for classifier follow-up purposes for instance such as transposition from a microarray based format to a quantitative RT-PCR format.

The 489 probe set microarray data was submitted to the MiPP process: 11 classifying probe sets were selected on the 13 R/18 NR training section as being sufficient to achieve a lowest global misclassification error, and 4 probe sets out of these were further identified as minimal on the 30 informative external sample data set to obtain the lowest global misclassification rate for the independent patients.

The 4 probe set reporter list was then used in leave-one-out cross-validation predictions of the 13 R/18 NR stratification of data as training set and direct prediction the 30 informative patient section as external testing set under all 14 predictive rules. LOO performance was increased for most of the rules (being as high as 3% of misclassification rate for Ida and naiveBayes among other), while misclassification rate stayed 28% on the external data set under svm and gbm rules.

The following table depicts the identity of the genes involved in the 4 probe set model:

Probe	Gene	Gene
Set ID	Symbol	Name
207651_at	GPR171	G protein-coupled receptor 171
205392_s_at	CCL14	chemokine (C-C motif) ligand 14
212233_at	MAP1B	microtubule-associated protein 1B
206204_at	GRB14	growth factor receptor-bound protein 14.

Example 3

Predicting the Clinical Outcome of Patients Using Quantitative Polymerase Chain Reaction (Q-PCR)

Material & Methods

Tumor Specimens and RNA Purification.

30 tumor specimens (pre-vaccination) were used from MAGE-A3 melanoma clinical trial (MAGE008). These were preserved and RNA extracted as in Example 1 above.

cDNA Synthesis and Quantitative PCR Amplification

2 μg of total RNA were retro-transcripted into cDNA using M-MLV reverse transcriptase (Invitrogen) and oligo(dT) or random primers.

The different interesting genes were amplified by quantitative PCR using TaqMan chemistry and 7900 sequence detection system (Applied Biosystems).

Genes were amplified using standard 96 well plates or the TaqMan® Immune Profiling Array (TaqMan Low density arrays—TLDA—Applied Biosystems). TLDA are ready to use 384 well plates pre-coated with primers and probes.

The 7900 apparatus is a fully integrated system for real-time detection of PCR including a 96-well or a TLDA thermal cycler, a laser to induce fluorescence, a charge-coupled device detector, a computer and a real-time sequence detection software.

In standard 96 well plates, cDNA corresponding to 50 ng of total RNA was amplified by polymerase-chain-reaction using the TF,TAQMAN,PCR REAGENT CORE KIT (Applied Biosystems). Primers and probes are listed in Table 5.

For the TaqMan® Immune Profiling Array, cDNA corresponding to only 1 ng of RNA was amplified by polymerase-chain-reaction using the TF,TAQMAN,PCR CORE REAGENT KIT (Applied Biosystems). The genes included in the array are listed in Table 6.

Data Processing and Normalization

All PCR data were normalized against H3F3A (standard 96 Well plates) or the geometric mean of GUSB and PGK1 (TLDA) house keeping genes (also referred to as constant genes). Expression values were afterwards log transformed.

Univariate Statistical Analysis

Analyses of variance (ANOVA1) were performed using the SAS software to significantly select the genes able to differentiate responder from non-responder groups. The first group was composed of 14 responder patients, the second one was composed of 15 non-responder patients. Each gene was analyzed independently from the others.

IL7R, CD3D, CD52, UBD, GPR171, GMZK, PRKCQ, STAT4, TRDV2, TRAT1, TRBV19, CD69, INDO1, CD45R, CD45RO, FoxP3, CD20, CCL5, FASLG, GNLY, GZMB, PRF1, IFNG, ICOS, TBX21, CD8A, CD3E, CXCL10, CXCL11, IRF1, TLR7 and CXCR3 genes were selected for their capacity to differentiate both groups. The p-value was <0.00001 for every gene. For every gene, a significant difference was proven between mean (responder/non-responder). The Geomean ratios between both groups were also calculated for all genes (Table 7A) and range from 3.4 to 21.2.

Correlation Analysis

A correlation matrix (Table8) was calculated between 30 genes showing that all these genes are pretty well correlated.

Logistic Regression Model

An analysis by logistic regression was performed using Proc logistic (SAS Sofware). Logistic regression analysis is often used to investigate the relationship between binary responses and a set of explanatory variables.

The number of predictors is too large and the use of all possible regression is not feasible. So, stepwise selection was employed. This procedure gives a model with a good value (high) for a specified criterion: Score Chi-square. This is analogous to the use of SSE or R² in multiple linear regression.

The model information are:

• • Data: 29 patients and 111 genes.
  • Response variable: clinical status
  • Number of response level: 2 (responder-non responder)
  • Mode: binary logit
  • Optimization technique: Fisher's scoring

The model giving the best value of score Chi-square (Chi-square=16 and pvalue <0.00001) is:

Logit (p)=7.69+5.07 log(PRF1), with p the probability to be responderCoefficient B0 (7.69) & B1 (5.07) are significant (p<0.005)Other criterion can be used to test goodness of fit

Likehood Ratio 23.1429 (chi-square) and <0.001 (p-value)
Wald           6.9250 (chi-sqaure) and <0.001 (p-value)

Like in linear regression, a R² is computed: 0.55.

From the 111 genes, 18 (with only one predictor) are listed in the Table 9. Higher the R2(%) and chi-square score are the better the model/gene.

Using the PRF1 model, it is possible to classify correctly 86.6% of patients.

Table 10 gives the percentage of correct classification calculated using the logistic regression model for some other genes.

Combining more than 1 gene didn't improve the classification performance.

Genex Analysis

The 30 patients were also classified using the PCA (Principal Component Analysis) and neural network analysis from Genex software with the genes PRF1, GZMB, GNLY, CD8A, PRKCQ, FOXP3, IFNG, CCL5, GPR171 and TRBV19.

For the neural network analysis, 5 responder patients (Patient ID No.s 27, 53, 65, 119, 127) and 5 non responder patients (Patient ID No.s 8, 60, 66, 81, 160) were used as training set. The remaining 20 patients were used as testing set.

FIG. 6 shows the Principal Component Analysis using PRF1, GZMB, GNLY, CD8A, PRKCQ, FOXP3, IFNG, CCL5, GPR171 and TRBV19 genes.

It can be seen the responders are clustered on the left-hand side of FIG. 6 and the non-responders are clustered on the right-hand side of the figure. Patients labeled 85, 3 and 154 are miss-classified. Therefore, the percentage of “correct” classification is 85% using the PCA.

The neural network approach confirms a correct classification range of 85%.

Comparison: Microarray to Q-PCR data.

17 genes (Table 12) evaluated by the Q-PCR technology were already present in the microarray gene lists. These genes are therefore able to discriminate responder from non responder patients whatever the technology used to detect them. These genes form a specific aspect of the invention.

TABLE 12
Genes present in microarray and Q-PCR list.
Gene symbol Gene title
CCL5        chemokine (C-C motif) ligand 5
TRAT1       T cell receptor associated transmembrane adaptor 1
STAT4       signal transducer and activator of transcription 4
PRKCQ       protein kinase C, theta
GPR171      G protein-coupled receptor 171
UBD         ubiquitin D
CD52        CD52 molecule
CD3D        CD3d molecule, delta (CD3-TCR complex)
PRF1        perforin 1 (pore forming protein)
CD8A        CD8a molecule
CXCL10      chemokine (C—X—C motif) ligand 10
CD69        CD69 molecule
TRBV19      T cell receptor beta variable 19
TRDV2       T cell receptor delta variable 2
IL7R        interleukin 7 receptor
GZMK        granzyme K
            PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-
            TYPE, C
CD45R       (PTPRC)

Fourteen genes (Table 13) were able to discriminate responder from non-responder patients using Q-PCR technology were not present in the microarray gene lists. This may be due to the increased sensitivity of the Q-PCR technology compared to the microarray.

TABLE 13
Gene used to classify patients using Q-PCR technology, absent
in Microarray gene lists.
Gene
symbol Gene title
FASLG  Fas ligand (TNF superfamily, member 6)
GNLY   granulysin
       granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated
       serine
GZMB   esterase 1)
IFNG   interferon, gamma
ICOS   inducible T-cell co-stimulator
TBX21  T-box 21
CD3E   CD3e molecule, epsilon (CD3-TCR complex)
CXCL11 chemokine (C—X—C motif) ligand 11
CXCR3  chemokine (C—X—C motif) receptor 3
CD20   CD20 molecule
FOXP3  forkhead box P3
INDO   indoleamine-pyrrole 2,3 dioxygenase
IRF1   interferon regulatory factor 1
TLR7   toll-like receptor 7

Some genes absent in the microarray signature but are known to be expressed by immunological cells and thus are also able to predict the clinical outcome of the patients.

The presence of an immune infiltration into the tumoral tissue seems to be the most important biological event to predict the clinical outcome of the patients rather than only a limited list of genes.

For example, PRF1 and CD8A are present in the microarray gene lists and are expressed by CD8 T lymphocytes. CD8 T lymphocytes express also IFNG that is absent in the microarray gene lists. Nevertheless, a good prediction of the clinical response was achieved using this gene by Q-PCR.

The number of miss-classified patients using the q-PCR data remains in the same range than clustering and KNN approaches using microarray data. Therefore different technologies and softwares can be used to classify the patients.

Example 4

Predicting the Clinical Outcome of Patients Using Hierarchical Clustering Approach

Material & Methods

Tumor Specimens and RNA Purification.

67 tumor specimens (pre-vaccination) were used from MAGE-A3 melanoma clinical trial (MAGE008). These were preserved, RNA prepared, quality controlled, labeled and amplified as in Example 1 above. The quality of the RNA samples was checked prior to hybridization to the genechip.

Microarray Chips, Hybridizations and Scanning

As in the material and methods section of the first example above (referred to herein as Example 1), Affymetrix HG-U133.Plus2.0 genechips were employed, and hybridized and scanned as described in Example 1.

Data Processing & Normalization.

The fluorescent scanned data image was processed and normalized using a R 2.3.1 implementation of GCRMA algorithm as described in Example 2.

Selection of the Gene List

41 Probe Sets were selected to discriminate responder from non responder patients using Arrayminer software described in Example 1.

Analysis parameters were:

• • Train and test evaluation
  • Pre-definition of 2 class
    • a. Responder class: PID2, PID65, PID75, PID20, PID10, PID19, PID23, PID26, PID27, PID38, PID67
    • b. Non Responder class: PID14, PID52, PID66, PID37, PID16, PID13, PID55, PID56, PID5, PID60, PID8
      • wherein PID stands for patient identification No (ie the numerical label given to the patient)
  • Maximum number of markers per class: 25
  • Number of markers per couple: 1
  • Allow multi-class markers: Yes
  • Use KNN classification: No—Proprietary voting method was used.

A list of 50 probe sets was obtained. 9 Probe sets were removed due the Absence status in all samples. The intensities of the 41 probe sets for the 22 patients listed above are listed in Tables 11A and 11B.

Prediction of the Clinical Status

The clinical status of the 67 patients was predicted using the hierarchical clustering approach of Spotfire software.

Data were normalized regarding the genes using a Z-score calculation available in Spotfire before performing the Hierarchical clustering.

Calculation options of the hierarchical clustering were:

• • Clustering method: complete linkage
  • Similarity measure: Euclidean distance
  • Ordering function: average value

This clustering was performed for patients included into the AS15 (FIGS. 7 and 8) or the AS02B (FIGS. 9 and 10) arms.

Using the hierarchical clustering approach, about 58% of patients have the responder signature whatever the adjuvant group.

100% and 87.5% of patients with a clinical benefit are well clustered respectively in AS15 and in AS02b groups.

71% and 52% of patients with a progressive disease are well clustered respectively in AS15 and in AS02b groups.

In the clinical benefit cluster, 28% and 55% of patients have a progressive disease respectively in AS15 and in AS02b groups. The percentage of patients with a responder gene profile according to the invention who achieved a clinical benefit to the MAGE-A3 vaccination when the AS15 adjuvant was used was larger than the percentage who achieved a clinical benefit to the MAGE-A3 vaccination when AS02b adjuvant was employed in the formulation.

Example 5

Inducing a Responder's Profile

Initial biopsy (sampled before irradiation) of patient 59 did not have the responder signature while his second biopsy (sampled after irradiation) had the responder signature (data not shown) suggesting that irradiation of lesions may induce the responder signature.

• 1. R Development Core Team (2006). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org)
• 2. Jean (ZHIJIN) Wu and Rafael Irizarry with contributions from James MacDonald Jeff Gentry (2005). germa: Background Adjustment Using Sequence Information. R package version 2.4.1.
• 3. Wu Z, Irizarry R A, Gentleman R, Martinez-Murillo F, Spencer F: A model-based background adjustment for oligonucleotide expression arrays. Journal of the American Statistical Association 2004, 99:909-917.
• 4. Peter Warren (2005). panp: Presence-Absence Calls from Negative Strand Matching Probesets. R package version 1.2.0.
• 5. R. Gentleman, V. Carey and W. Huber (2006). genefilter: genefilter: filter genes. R package version 1.10.1.
• 6. Jain N, Thatte J, Braciale T, Ley K, O'Connell M, Lee J K. Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics. 2003 Oct. 12; 19(15):1945-51.
• 7. Nitin Jain, Michael O'Connell and Jae K. Lee. Includes R source code contributed by HyungJun Cho <hcho(virginia.edu> (2006). LPE: Methods for analyzing microarray data using Local Pooled Error (LPE) method. R package version 1.6.0. http:/www.r-project.org.
• 8. Smyth, G. K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology (2004)₃, No. 1, Article 3.
• 9. Smyth, G. K. (2005). Limma: linear models for microarray data. In: ‘Bioinformatics and Computational Biology Solutions using R and Bioconductor’. R. Gentleman, V. Carey, S. Dudoit, R. Irizarry, W. Huber (eds), Springer, N.Y., pages 397-420.
• 10. Baldi P, Long A D. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics. 2001 June; 17(6):509-19.
• 11. http://visitor.ics.uci.edu/genex/cybert/
• 12. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerfuil approach to multiple testing. J. Roy. Stat. Soc. B., 57, 289-300.
• 13. Katherine S. Pollard, Yongchao Ge and Sandrine Dudoit. multtest: Resampling-based multiple hypothesis testing. R package version 1.10.2.
• 14. Jess Mar, Robert Gentleman and Vince Carey. MLInterfaces: Uniform interfaces to R machine learning procedures for data in Bioconductor containers. R package version 1.4.0.
• 15. Soukup M, Cho H, and Lee J K (2005). Robust classification modeling on microarray data using misclassification penalized posterior, Bioinformatics, 21 (Suppl): i423-i430.
• 16. Soukup M and Lee J K (2004). Developing optimal prediction models for cancer classification using gene expression data, Journal of Bioinformatics and Computational Biology, 1(4) 681-694.

TABLE 1A
Gene sequences for and Seq ID No.s for the genes of Table 1
Seq
ID
No.	Gene name	Full gene sequence
1	chromosome 6 open	>gi|58218985|ref|NM_001010923.1|Homo sapiens chromosome 6 open reading
	reading frame 190	frame 190 (C6orf190), mRNA
		ATACTTACAATTACGAGATTTATATTTGCATTAGTCTCTTTGGCTGGTGGGTAGGGGTGAGAGGCTCTTC
		CTGGATCCCTTATTTTCTACAGGAGAGGAGGAAAACACCTGGGATGCTCCAGTGCTCTTACGCAGATAAT
		GATCATTAACATCAGCCTCTCTGATCAAAGAGCTACTCCACCCCACTCTGGCTGTAGTGTGACATTCCTG
		CCTGCCTGAGGAAGAAATGGTGAGCAGGGGCTGCAATTGCAGACAAGTGTCACCCAGAAGCCACAAGTTT
		CTGTGAGCACCAGGTCTACAAACTACCCAAGGCATAGCAATGGCATTATCACTGGAAGAATTCGTCCACT
		CCCTTGACCTCAGGACCCTACCCAGGGTTCTAGAAATCCAGGCAGGCATCTATCTTGAAGGCTCTATTTA
		TGAAATGTTTGGAAATGAATGCTGTTTTTCAACAGGAGAAGTGATTAAAATTACTGGTCTCAAAGTTAAG
		AAGATCATAGCTGAAATTTGTGAGCAGATTGAAGGTTGTGAGTCTCTACAGCCATTTGAACTGCCTATGA
		ATTTTCCAGGTCTTTTTAAGATTGTGGCTGATAAAACTCCATACCTTACTATGGAAGAAATCACAAGGAC
		CATTCATATTGGACCAAGTAGACTAGGGCATCCTTGCTTCTATCATCAGAAGGATATAAAACTAGAGAAC
		CTCATCATAAAGCAGGGTGAGCAAATCATGCTCAACTCAGTTGAAGAGATTGATGGAGAAATAATGGTGA
		GCTGTGCAGTAGCAAGGAATCATCAAACTCACTCATTTAATTTGCCTTTGTCACAAGAAGGAGAATTCTA
		CGAGTGTGAAGATGAACGTATTTACACTCTAAAGGAGATTGTTGAATGGAAGATTCCTAAGAACAGAACA
		AGAACTGTAAACCTTACAGATTTTTCAAATAAGTGGGACTCAACGAATCCATTTCCTAAAGACTTTTATG
		GTACCCTGATTCTCAAGCCTGTTTATGAAATTCAAGGTGTGATGAAATTTCGAAAAGATATAATCCGCAT
		CCTCCCCAGTCTAGATGTCGAAGTCAAAGACATCACTGATTCTTACGATGCTAACTGGTTTCTTCAGCTG
		TTATCAACAGAAGATCTTTTTGAAATGACTAGTAAAGAGTTCCCCATAGTGACTGAAGTCATAGAAGCAC
		CTGAAGGAAACCACCTGCCCCAAAGCATTTTACAGCCTGGGAAAACCATTGTGATCCACAAAAAGTACCA
		GGCATCAAGAATCTTAGCTTCAGAAATTAGAAGCAATTTTCCTAAAAGACACTTCTTGATCCCCACTAGC
		TATAAAGGCAAGTTCAAGCGGCGACCGAGGGAGTTCCCAACGGCCTATGACCTAGAGATCGCTAAGAGTG
		AAAAGGAGCCTCTTCACGTGGTGGCCACCAAAGCGTTTCATTCCCCTCATGACAAGCTGTCATCCGTATC
		TGTTGGGGACCAGTTTCTGGTGCATCAGTCAGAGACGACTGAAGTCCTCTGTGAGGGAATAAAAAAAGTG
		GTGAATGTTCTGGCCTGTGAAAAAATCCTCAAAAAGTCCTATGAGGCTGCGCTGCTCCCTTTGTACATGG
		AAGGAGGTTTTGTAGAGGTGATTCATGATAAGAAACAGTACCCGATTTCTGAGCTCTGTAAACAGTTCCG
		TTTGCCCTTCAATGTGAAGGTGTCTGTCAGGGATCTTTCCATTGAAGAGGACGTGTTGGCTGCCACACCA
		GGACTGCAGTTGGAGGAGGACATTACAGACTCTTACCTACTCATAAGTGACTTTGCCAACCCCACGGAGT
		GCTGGGAAATTCCTGTGGGCCGCTTGAATATGACTGTTCAGTTAGTTAGTAATTTCTCTAGGGATGCAGA
		ACCATTTCTAGTCAGGACTCTGGTAGAAGAGATCACTGAAGAGCAATATTACATGATGCGGAGATATGAA
		AGCTCAGCCTCACATCCCCCACCTCGCCCTCCGAAACACCCCTCAGTAGAGGAAACAAAGTTAACCCTGC
		TAACCTTAGCAGAAGAAAGGACGGTAGACCTGCCCAAGTCTCCCAAGCGTCATCACGTAGACATAACCAA
		GAAACTTCACCCAAATCAAGCTGGCCTGGATTCAAAAGTACTGATTGGTAGTCAGAATGATTTGGTGGAT
		GAAGAGAAAGAAAGGAGCAACCGTGGGGCCACAGCAATAGCAGAAACATTCAAAAATGAAAAACATCAAA
		AATAACAAGATGTGACAGAAGCCACTTAGGCAGCAAACATAAATGTTGCAGTGAAAAAAGAAGCTAGCCT
		TCTAGCTGAAAAACGAGTATTCCCCAATGGACTCCAGAAGAAACTTGATTCATCGCTGCAAAGGAAAGAA
		CAACCTTAAAACTTTTAACAGATAAAACTTACAGAAACCTATGATATAGAATTCATATAGTCTATTCTGT
		TGTGTCTAAATCTGTAGGCATTGTGTTGTTGTTCTTTAGGACGTATTTATTTAACTTGCACATTTTTTCA
		GATTCTTATTTCTACTACCAACAACTAAGTAATTGGGAAATAATTCTGTATTTCAGTTTCTGAGTAAAAC
		CAGTCTGAAATAGGATAAAAGCCACCAAATATTTTCTTTTTTTTCCAGAATTTGTTTTGCCATTTTTTAG
		TGCTATCATCATTCCTAACAAGACTAACTTACAGAAAAATAATTATATCTGACTGATTTAAAATGTTCAG
		GTTTCTTATCCAAATCCCTTGGAACTATGGAAAGGAGTTTGATTTCACATTCACAGTGTATTTACAAAAT
		ACGCTGTGTCATAAATATGTTTGAATTCCAACAGCCAAAGCCATTGAGAGTCATAGGAGTTTTCCATAAC
		CTTCTCTTCTATGACCCAACAACAAGCTCATGACTGAAATTTCACCAGATTTCTGAGACGATGTCTTAAT
		ATTCTATGTGCTATGTACCAGATAATTCTTTAGATGAATGTTTCTTAGGATTGTAGGAAAATTATCTAGT
		TAATCATAATATTTGATGGAAAGAAAAAGACAATAAAATTGTAATATAATAAATTTGGCTGACAAGAAAC
		CAAAGTGATTCTTAATTAGTATACATCAGAATGATGCTCTTATAGTTGTACCATCTATAAAAATTACTTT
		AAGGGCTCTCACATTTTAATAATTTATCTTATTATGTATTAAGTATACAGGAACAATATTATTTTTCCTT
		TAACAAAATGAAGAGACAGGCTATCTGGTTAATGTTACATAGGAATTTAATAGTAATGCTTGAACTTCAT
		CCATAGATCATACTCTGTACAAAATTTGTTAGCTAACATCCTATCTCATAATTATTTTATGTTTTGTGGA
		GAAATTTGTTGATTTTGTACCAAAGTGTTTCTGAAGACAATAAATTGTGAGTCAACTTTAGAACAAAAAA
		AATTAGAGTTTTTTCAATGTTTATATTCTGATTAAGCTTACTTTACCTTACATTTTTTCTAAGTAACAAT
		GAATCCTGATTTCTAGTGTCCTAAAAATTGCTTAGTGATTTGATTGTGGTAATATCATTTCTTATCTACA
		ATGTCTAAAGTTTTATGGGACAGTTTTTCTTTTATTTATTTTGCCTGTTTGTGCAGATAAGAACAGAAAC
		TTTTCTAAGACCCACATTTGGTTATTGAAGGCCACAGCGAATCTTAACCTAACAGCCTTGACAAACTGCA
		CCATAGGTGTTTTTAGACTCATATAATTTGTTATTTTTCAAACAATAGTGAATAATTAATATTTTTGTTT
		GGAATTTGAGAACAATTAAATTTGTACTTTTAGTAACTACCATTCTTTGATTAGAAAATTAAGAGAATGC
		ATATCTTACTTTGGTTGTAAATTATCAAGGGCTTTCTAATAGAAATCATATATAACATTTCTAAATATAA
		GTCCTTTCACATACTGTGTTTCCAGTTGTCTTGATATTGAAAAGTGTAATAAACTTCATGCTCACCTATT
		GGAGATTTGGGAAGGTTGAAAATAAACTTCCTAATTTTTAAAAAAAAAA
2	hematopoietic cell-	>gi|37059786|ref|NM_005335.3|Homo sapiens hematopoietic cell-specific Lyn
	specific Lyn	substrate 1 (HCLS1), mRNA
	substrate 1	GTGGACGCGAGGAGCCGGGCGCTTAGAACAGAGGCTTGCACAGGTGGAGATGTGGAAGTCTGTAGTGGGC
		CATGATGTGTCTGTTTCCGTGGAGACCCAGGGTGATGATTGGGACACAGATCCTGACTTTGTGAATGACA
		TCTCTGAAAAGGAGCAACGATGGGGAGCCAAGACCATCGAGGGGTCTGGACGCACAGAACACATCAACAT
		CCACCAGCTGAGGAACAAAGTATCAGAGGAGCATGATGTTCTCAGGAAGAAAGAGATGGAGTCAGGGCCC
		AAAGCATCCCATGGCTATGGAGGTCGGTTTGGAGTAGAAAGAGACCGAATGGACAAGAGTGCAGTGGGCC
		ATGAGTATGTTGCCGAGGTGGAGAAGCACTCTTCTCAGACGGATGCTGCCAAAGGCTTTGGGGGCAAGTA
		CGGAGTTGAGAGGGACAGGGCAGACAAGTCAGCAGTCGGCTTTGATTATAAAGGAGAAGTGGAGAAGCAT
		ACATCTCAGAAAGATTACTCTCGTGGCTTTGGTGGCCGGTACGGGGTGGAGAAGGATAAATGGGACAAAG
		CAGCTCTGGGATATGACTACAAGGGAGAGACGGAGAAACACGAGTCCCAGAGAGATTATGCCAAGGGCTT
		TGGTGGCCAGTATGGAATCCAGAAGGACCGAGTGGATAAGAGCGCTGTCGGCTTCAATGAAATGGAGGCC
		CCGACCACAGCTTATAAGAAGACGACGCCCATAGAAGCCGCTTCTAGTGGTGCCCGTGGGCTGAAGGCGA
		AATTTGAGTCCATGGCTGAGGAGAAGAGGAAGCGAGAGGAAGAGGAGAAGGCACAGCAGGTGGCCAGGAG
		GCAACAGGAGCGAAAGGCTGTGACAAAGAGGAGCCCTGAGGCTCCACAGCCAGTGATAGCTATGGAAGAG
		CCAGCAGTACCGGCCCCACTGCCCAAGAAAATCTCCTCAGAGGCCTGGCCTCCAGTTGGGACTCCTCCAT
		CATCAGAGTCTGAGCCTGTGAGAACCAGCAGGGAACACCCAGTGCCCTTGCTGCCCATTAGGCAGACTCT
		CCCGGAGGACAATGAGGAGCCCCCAGCTCTGCCCCCTAGGACTCTGGAAGGCCTCCAGGTGGAGGAAGAG
		CCAGTGTACGAAGCAGAGCCTGAGCCTGAGCCCGAGCCTGAGCCCGAGCCTGAGAATGACTATGAGGACG
		TTGAGGAGATGGACAGGCATGAGCAGGAGGATGAACCAGAGGGGGACTATGAGGAGGTGCTCGAGCCTGA
		AGATTCTTCTTTTTCTTCTGCTCTGGCTGGATCATCAGGCTGCCCGGCTGGGGCTGGGGCTGGGGCTGTG
		GCTCTGGGGATCTCAGCTGTGGCTCTATATGATTACCAAGGAGAGGGAAGTGATGAGCTTTCCTTTGATC
		CGGACGACGTAATCACTGACATTGAGATGGTGGACGAGGGCTGGTGGCGGGGACGTTGCCATGGCCACTT
		TGGACTCTTCCCTGCAAATTATGTCAAGCTTCTGGAGTGACTAGAGCTCACTGTCTACTGCAACTGTGAT
		TTCCCATGTCCAAAGTGGCTCTGCCTCCACCCCCTCCCTATTCCTGATGCAAATGTCTAACCAGATGAGT
		TTCTGGACAGACTTCCCTCTCCTGCTTCATTAAGGGCTTGCGGCAGAGACAGCATGGGGAAGGAGGTCCC
		CTTCCCCAAGAGTCCTCTCTATCCTGGATGAGCTCATGAACATTTCTCTTGTGTTCCTGACTCCTTCCCA
		ATGAACACCTCTCTGCCACCCCAAGCTCTGCTCTCCTCCTCTGTGAGCTCTGGGCTTCCCAGTTTGTTTA
		CCCGGGAAAGTACGTCTAGATTGTGTGGTTTGCCTCATTGTGCTATTTGCCCACTTTCCTTCCCTGAAGA
		AATATCTGTGAACCTTCTTTCTGTTCAGTCCTAAAATTCGAAATAAAGTGAGACTATGGTTCACCTGTAA
		AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
3	interleukin 2	>gi|4557881|ref|NM_000206.1|Homo sapiens interleukin 2 receptor, gamma
	receptor, gamma	(severe combined immunodeficiency) (IL2RG), mRNA
	(severe combined	GAAGAGCAAGCGCCATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCT
	immunodeficiency)	GGGAGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTCTTCCTG
		ACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTTCAGTGTTTTGTGTTCA
		ATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCCCAGCCTACCAACCTCACTCTGCATTA
		TTGGTACAAGAACTCGGATAATGATAAAGTCCAGAAGTGCAGCCACTATCTATTCTCTGAAGAAATCACT
		TCTGGCTGTCAGTTGCAAAAAAAGGAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCAC
		GGGAACCCAGGAGACAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAA
		CCTAACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAACCACTGT
		TTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAATCAGTGGATTATAGAC
		ATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACGTTTCGTGTTCGGAGCCGCTTTAACCC
		ACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGGAGCCACCCAATCCACTGGGGGAGCAATACTTCAAAA
		GAGAATCCTTTCCTGTTTGCATTGGAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCC
		TTCTCTGTGTGTATTTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCT
		TGTTACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGTCTGCAG
		CCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGGGCCCTTGGGGAGGGGC
		CTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCCCCATGTTACACCCTAAAGCCTGAAAC
		CTGAACCCCAATCCTCTGACAGAAGAACCCCAGGGTCCTGTAGCCCTAAGTGGTACTAACTTTCCTTCAT
		TCAACCCACCTGCGTCTCATACTCACCTCACCCCACTGTGGCTGATTTGGAATTTTGTGCCCCCATGTAA
		GCACCCCTTCATTTGGCATTCCCCACTTGAGAATTACCCTTTTGCCCCGAACATGTTTTTCTTCTCCCTC
		AGTCTGGCCCTTCCTTTTCGCAGGATTCTTCCTCCCTCCCTCTTTCCCTCCCTTCCTCTTTCCATCTACC
		CTCCGATTGTTCCTGAACCGATGAGAAATAAAGTTTCTGTTGATAATCATC
4	CD52 antigen	>gi|68342029|ref|NM_001803.2|Homo sapiens CD52 molecule (CD52), mRNA
	(CAMPATH-1	CTCCTGGTTCAAAAGCAGCTAAACCAAAAGAAGCCTCCAGACAGCCCTGAGATCACCTAAAAAGCTGCTA
	antigen)///	CCAAGACAGCCACGAAGATCCTACCAAAATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTG
	CD52 antigen	GTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCAT
	(CAMPATH-1	CCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAG
	antigen)	TTGAGGTGACACGTCTCAGCCTTAGCCCTGTGCCCCCTGAAACAGCTGCCACCATCACTCGCAAGAGAAT
		CCCCTCCATCTTTGGGAGGGGTTGATGCCAGACATCACCAGGTTGTAGAAGTTGACAGGCAGTGCCATGG
		GGGCAACAGCCAAAATAGGGGGGTAATGATGTAGGGGCCAAGCAGTGCCCAGCTGGGGGTCAATAAAGTT
		ACCCTTGTACTTGCAAAAAAAAAAAAAAAAAAA
5	CD2 antigen (p50),	>gi|31542293|ref|NM_001767.2|Homo sapiens CD2 molecule (CD2), mRNA
	sheep red blood	ACCAACCCCTAAGATGAGCTTTCCATGTAAATTTGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCTTCC
	cell receptor///	AAAGGTGCAGTCTCCAAAGAGATTACGAATGCCTTGGAAACCTGGGGTGCCTTGGGTCAGGACATCAACT
	CD2 antigen (p50),	TGGACATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAAAAAACTTCAGACAAGAA
	sheep red blood	AAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAAAAAGATACATATAAGCTATTTAAAAAT
	cell receptor	GGAACTCTGAAAATTAAGCATCTGAAGACCGATGATCAGGATATCTACAAGGTATCAATATATGATACAA
		AAGGAAAAAATGTGTTGGAAAAAATATTTGATTTGAAGATTCAAGAGAGGGTCTCAAAACCAAAGATCTC
		CTGGACTTGTATCAACACAACCCTGACCTGTGAGGTAATGAATGGAACTGACCCCGAATTAAACCTGTAT
		CAAGATGGGAAACATCTAAAACTTTCTCAGAGGGTCATCACACACAAGTGGACCACCAGCCTGAGTGCAA
		AATTCAAGTGCACAGCAGGGAACAAAGTCAGCAAGGAATCCAGTGTCGAGCCTGTCAGCTGTCCAGAGAA
		AGGTCTGGACATCTATCTCATCATTGGCATATGTGGAGGAGGCAGCCTCTTGATGGTCTTTGTGGCACTG
		CTCGTTTTCTATATCACCAAAAGGAAAAAACAGAGGAGTCGGAGAAATGATGAGGAGCTGGAGACAAGAG
		CCCACAGAGTAGCTACTGAAGAAAGGGGCCGGAAGCCCCAACAAATTCCAGCTTCAACCCCTCAGAATCC
		AGCAACTTCCCAACATCCTCCTCCACCACCTGGTCATCGTTCCCAGGCACCTAGTCATCGTCCCCCGCCT
		CCTGGACACCGTGTTCAGCACCAGCCTCAGAAGAGGCCTCCTGCTCCGTCGGGCACACAAGTTCACCAGC
		AGAAAGGCCCGCCCCTCCCCAGACCTCGAGTTCAGCCAAAACCTCCCCATGGGGCAGCAGAAAACTCATT
		GTCCCCTTCCTCTAATTAAAAAAGATAGAAACTGTCTTTTTCAATAAAAAGCACTGTGGATTTCTGCCCT
		CCTGATGTGCATATCCGTACTTCCATGAGGTGTTTTCTGTGTGCAGAACATTGTCACCTCCTGAGGCTGT
		GGGCCACAGCCACCTCTGCATCTTCGAACTCAGCCATGTGGTCAACATCTGGAGTTTTTGGTCTCCTCAG
		AGAGCTCCATCACACCAGTAAGGAGAAGCAATATAAGTGTGATTGCAAGAATGGTAGAGGACCGAGCACA
		GAAATCTTAGAGATTTCTTGTCCCCTCTCAGGTCATGTGTAGATGCGATAAATCAAGTGATTGGTGTGCC
		TGGGTCTCACTACAAGCAGCCTATCTGCTTAAGAGACTCTGGAGTTTCTTATGTGCCCTGGTGGACACTT
		GCCCACCATCCTGTGAGTAAAAGTGAAATAAAAGCTTTGACTAGAAAAAAAAAAAAAAAAAAAAAAAAAA
		AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
6	ubiquitin D	>gi|50355987|ref|NN_006398.2|Homo sapiens ubiquitin D (UBD), mRNA
		GATTGCTTGAGGAGAGAAGTATGTGATCAGAAAGCATTCTTTGTCTATTAACTCCTGCCCAGCAAAAGTG
		AAAGAAAATTCATGGGAGCATGCAAGAACAAAGAGCACAGCAAAGCTGGACAAACACAGCAATCCAGGCA
		GGGGATTTCCAACTCAACTCTGGTATGTAAGCTGCATGCAAAGTCCTTTTTCTGTCTCTGGTTTCTGGCC
		CCTTGTCTGCAGAGATGGCTCCCAATGCTTCCTGCCTCTGTGTGCATGTCCGTTCCGAGGAATGGGATTT
		AATGACCTTTGATGCCAACCCATATGACAGCGTGAAAAAAATCAAAGAACATGTCCGGTCTAAGACCAAG
		GTTCCTGTGCAGGACCAGGTTCTTTTGCTGGGCTCCAAGATCTTAAAGCCACGGAGAAGCCTCTCATCTT
		ACGGCATTGACAAAGAGAAGACCATCCACCTTACCCTGAAAGTGGTGAAGCCCAGTGATGAGGAGCTGCC
		CTTGTTTCTTGTGGAGTCAGGTGATGAGGCAAAGAGGCACCTCCTCCAGGTGCGAAGGTCCAGCTCAGTG
		GCACAAGTGAAAGCAATGATCGAGACTAAGACGGGTATAATCCCTGAGACCCAGATTGTGACTTGCAATG
		GAAAGAGACTGGAAGATGGGAAGATGATGGCAGATTACGGCATCAGAAAGGGCAACTTACTCTTCCTGGC
		ATCTTATTGTATTGGAGGGTGACCACCCTGGGCATGGGGTGTTGGCAGGGGTCAAAAAGCTTATTTCTTT
		TAATCTCTTACTCAACGAACACATCTTCTGATGATTTCCCAAAATTAATGAGAATGAGATGAGTAGAGTA
		AGATTTGGGTGGGATGGGTAGGATGAAGTATATTGCCCAACTCTATGTTTCTTTGATTCTAACACAATTA
		ATTAAGTGACATGATTTTTACTAATGTATTACTGAGACTAGTAAATAAATTTTTAAGCCAA
7	signal transducer	>gi|21618332|ref|NM_003151.2|Homo sapiens signal transducer and activator
	and activator of	of transcription 4 (STAT4), mRNA
	transcription 4	AGAGGACGCCCGGTGAAGGGGCTCCAGCCTGGCAGTTTCTGCGTGTTAGCATTTCTAGAATAGAGTGGGT
		GGGAACTGACCCAAGTAAAGTCCCAGAGACTCGAACACTGACGCACAGGAAAGCCTCAAGTGGGAGGAGA
		AATGCAAATCCCCTACTGATGATGGCGTCAGCGGCTTTCTCCTAGGGACTGTGAGGGGCGCTTCTGACTT
		TGGACTTGAGCACTGCCTGGGACCTGTGCTGAGAGAGCGCTAGCATGTCTCAGTGGAATCAAGTCCAACA
		GTTAGAAATCAAGTTTTTGGAGCAGGTGGATCAATTCTATGATGACAACTTTCCCATGGAAATTCGGCAT
		CTGTTGGCCCAATGGATTGAAAATCAAGACTGGGAGGCAGCTTCTAACAATGAAACCATGGCAACGATTC
		TTCTTCAAAACTTGTTAATACAACTGGATGAACAGTTAGGTCGTGTTTCCAAAGAGAAAAACCTACTCTT
		GATACACAATCTAAAAAGAATTAGGAAGGTCCTTCAGGGAAAATTTCATGGAAATCCAATGCATGTAGCT
		GTGGTTATTTCAAACTGTTTAAGGGAAGAGAGGAGAATATTGGCTGCAGCCAACATGCCTGTCCAGGGGC
		CTCTAGAGAAATCCTTACAAAGTTCTTCAGTTTCAGAAAGACAGAGGAATGTGGAGCACAAAGTGGCTGC
		CATTAAAAACAGTGTGCAGATGACAGAACAAGATACCAAATACTTAGAAGATCTGCAAGACGAATTTGAC
		TACAGGTATAAAACAATTCAGACAATGGATCAGAGTGACAAGAATAGTGCCATGGTGAATCAGGAAGTTT
		TGACACTGCAGGAAATGCTTAACAGCCTCGATTTCAAGAGAAAGGAGGCTCTCAGTAAAATGACCCAAAT
		CATCCATGAGACAGACCTGTTAATGAACACCATGCTCATAGAAGAGCTGCAAGACTGGAAGCGGCGGCAG
		CAAATCGCCTGCATCGGGGGTCCACTCCACAATGGGCTCGACCAGCTTCAGAACTGCTTTACACTATTGG
		CAGAAAGTCTTTTCCAACTGAGAAGGCAATTGGAGAAACTAGAGGAGCAATCTACCAAAATGACATATGA
		AGGTGATCCCATTCCAATGCAAAGAACTCACATGCTAGAAAGAGTCACCTTCTTGATCTACAACCTTTTC
		AAGAACTCATTTGTGGTTGAGCGACAGCCATGTATGCCAACCCACCCTCAGAGGCCGTTGGTACTTAAAA
		CCCTAATTCAGTTCACTGTAAAACTAAGGCTACTAATAAAATTGCCAGAACTAAACTATCAGGTAAAGGT
		TAAGGCATCAATTGACAAGAATGTTTCAACTCTAAGCAACCGAAGATTTGTACTTTGTGGAACTAATGTC
		AAAGCCATGTCTATTGAAGAATCTTCCAATGGGAGTCTCTCAGTAGAATTTCGACATTTGCAACCAAAGG
		AAATGAAGTCCAGTGCTGGAGGTAAAGGAAATGAGGGCTGTCACATGGTGACTGAAGAACTTCATTCCAT
		AACGTTTGAAACACAGATCTGCCTCTATGGCCTGACCATAGATTTGGAGACCAGCTCATTGCCTGTGGTG
		ATGATTTCCAATGTCAGTCAGTTACCTAATGCTTGGGCATCCATCATTTGGTACAACGTGTCAACCAACG
		ATTCCCAGAACTTGGTTTTCTTTAATAATCCTCCACCTGCCACATTGAGTCAACTACTGGAGGTGATGAG
		CTGGCAGTTTTCATCGTACGTTGGTCGTGGTCTTAACTCAGATCAACTCCATATGCTGGCAGAGAAGCTT
		ACAGTCCAATCTAGCTACAGTGATGGTCACCTCACCTGGGCCAAGTTCTGCAAGGAACATTTACCTGGTA
		AATCATTTACCTTTTGGACATGGCTTGAAGCAATATTGGATCTAATTAAGAAACACATTCTTCCCCTTTG
		GATTGATGGGTATGTCATGGGCTTTGTTAGCAAAGAGAAGGAACGGCTGTTGCTAAAGGATAAAATGCCT
		GGCACCTTTTTATTAAGATTCAGTGAAAGCCATCTCGGAGGAATAACTTTCACCTGGGTGGACCATTCTG
		AAAGTGGGGAAGTGAGATTCCACTCTGTAGAACCCTACAATAAAGGCCGGTTGTCTGCTCTGCCATTCGC
		TGACATCCTGCGAGACTACAAAGTTATTATGGCTGAAAACATTCCTGAAAACCCTCTGAAGTACCTATAT
		CCTGACATTCCCAAAGACAAAGCCTTCGGTAAACACTACAGCTCTCAGCCTTGCGAAGTTTCAAGACCAA
		CAGAAAGGGGTGACAAAGGTTATGTTCCTTCTGTTTTTATCCCCATCTCAACAATCCGAAGTGATTCAAC
		AGAGCCACATTCTCCATCAGACCTTCTTCCCATGTCTCCAAGTGTGTATGCGGTGTTGAGAGAAAACCTG
		AGTCCCACAACAATTGAAACTGCAATGAAGTCTCCTTATTCTGCTGAATGACAGGATAAACTCTGACGCA
		CCAAGAAAGGAAGCAAATGAAAAAGTTTAAAGACTGTTCTTTGCCCAATAACCACATTTTATTTCTTCAG
		CTTTGTAAATACCAGGTTCTAGGAAATGTTTGACATCTGAAGCTCTCTTCACACTCCCGTGGCACTCCTC
		AATTGGGAGTGTTGTGACTGAAATGCTTGAAACCAAAGCTTCAGATAAACTTGCAAGATAAGACAACTTT
		AAGAAACCAGTGTTAATAACAATATTAACAG
8	granzyme K	>gi|73747815|ref|NM_002104.2|Homo sapiens granzyme K (granzyme 3;
	(granzyme 3;	tryptase II) (GZMK), mRNA
	tryptase II)///	GATCAACACATTTCATCTGGGCTTCTTAAATCTAAATCTTTAAAATGACTAAGTTTTCTTCCTTTTCTCT
	granzyme K	GTTTTTCCTAATAGTTGGGGCTTATATGACTCATGTGTGTTTCAATATGGAAATTATTGGAGGGAAAGAA
	(granzyme 3;	GTGTCACCTCATTCCAGGCCATTTATGGCCTCCATCCAGTATGGCGGACATCACGTTTGTGGAGGTGTTC
	tryptase II)	TGATTGATCCACAGTGGGTGCTGACAGCAGCCCACTGCCAATATCGGTTTACCAAAGGCCAGTCTCCCAC
		TGTGGTTTTAGGCGCACACTCTCTCTCAAAGAATGAGGCCTCCAAACAAACACTGGAGATCAAAAAATTT
		ATACCATTCTCAAGAGTTACATCAGATCCTCAATCAAATGATATCATGCTGGTTAAGCTTCAAACAGCCG
		CAAAACTCAATAAACATGTCAAGATGCTCCACATAAGATCCAAAACCTCTCTTAGATCTGGAACCAAATG
		CAAGGTTACTGGCTGGGGAGCCACCGATCCAGATTCATTAAGACCTTCTGACACCCTGCGAGAAGTCACT
		GTTACTGTCCTAAGTCGAAAACTTTGCAACAGCCAAAGTTACTACAACGGCGACCCTTTTATCACCAAAG
		ACATGGTCTGTGCAGGAGATGCCAAAGGCCAGAAGGATTCCTGTAAGGGTGACTCAGGGGGCCCCTTGAT
		CTGTAAAGGTGTCTTCCACGCTATAGTCTCTGGAGGTCATGAATGTGGTGTTGCCACAAAGCCTGGAATC
		TACACCCTGTTAACCAAGAAATACCAGACTTGGATCAAAAGCAACCTTGTCCCGCCTCATACAAATTAAG
		TTACAAATAATTTTATTGGATGCACTTGCTTCTTTTTTCCTAATATGCTCGCAGGTTAGAGTTGGGTGTA
		AGTAAAGCAGAGCACATATGGGGTCCATTTTTGCACTTGTAAGTCATTTTATTAAGGAATCAAGTTCTTT
		TTCACTTGTATCACTGATGTATTTCTACCATGCTGGTTTTATTCTAAATAAAATTTAGAAGACTCAAAAA
		AAAAAAAAAAAAAAAAAAAAAAAA
9	CD3G antigen, gamma	>gi|4557428|ref|NM_000073.1|Homo sapiens CD3g molecule, gamma (CD3-TCR
	polypeptide (TiT3	complex) (CD3G), mRNA
	complex)	GGGCTGCTCCACGCTTTTGCCGGAGACAGAGACTGACATGGAACAGGGGAAGGGCCTGGCTGTCCTCATC
		CTGGCTATCATTCTTCTTCAAGGTACTTTGGCCCAGTCAATCAAAGGAAACCACTTGGTTAAGGTGTATG
		ACTATCAAGAAGATGGTTCGGTACTTCTGACTTGTGATGCAGAAGCCAAAAATATCACATGGTTTAAAGA
		TGGGAAGATGATCGGCTTCCTAACTGAAGATAAAAAAAAATGGAATCTGGGAAGTAATGCCAAGGACCCT
		CGAGGGATGTATCAGTGTAAAGGATCACAGAACAAGTCAAAACCACTCCAAGTGTATTACAGAATGTGTC
		AGAACTGCATTGAACTAAATGCAGCCACCATATCTGGCTTTCTCTTTGCTGAAATCGTCAGCATTTTCGT
		CCTTGCTGTTGGGGTCTACTTCATTGCTGGACAGGATGGAGTTCGCCAGTCGAGAGCTTCAGACAAGCAG
		ACTCTGTTGCCCAATGACCAGCTCTACCAGCCCCTCAAGGATCGAGAAGATGACCAGTACAGCCACCTTC
		AAGGAAACCAGTTGAGGAGGAATTGAACTCAGGACTCAGAGTAGTCCAGGTGTTCTCCTCCTATTCAGTT
		CCCAGAATCAAAGCAATGCATTTTGGAAAGCTCCTAGCAGAGAGACTTTCAGCCCTAAATCTAGACTCAA
		GGTTCCCAGAGATGACAAATGGAGAAGAAAGGCCATCAGAGCAAATTTGGGGGTTTCTCAAATAAAATAA
		AAATAAAAACAAATACTGTGTTTCAGAAGCGCCACCTATTGGGGAAAATTGT
10	G protein-coupled	>gi|31377771|ref|NM_013308.2|Homo sapiens G protein-coupled receptor 171
	receptor 171	(GPR171), mRNA
		GGTTGCTACTGCTGCGGCTAACCAAACAGCTCATGCTTCTCTGAAGACTTGCAGCAAGGTTTGCTGAGGC
		TCACAGAAGATAGCCCCAGTGTTTTGGAGTGGTTTTGAATGTGATTCTGAGATCAGACTGACTGAGCTGG
		AATCCTGGCTTTATATCTTACCAGCTACACAACCTTGGAGTCTTAGAAATTTTTTCTTTTCAATAAGCAG
		TCATCCTTACTTTCCCTCAAGATGACAAACAGTTCGTTCTTCTGCCCAGTTTATAAAGATCTGGAGCCAT
		TCACGTATTTTTTTTATTTAGTTTTCCTTGTTGGAATTATTGGAAGTTGTTTTGCAACCTGGGCTTTTAT
		ACAGAAGAATACGAATCACAGGTGTGTGAGCATCTACTTAATTAATTTGCTTACAGCCGATTTCCTGCTT
		ACTCTGGCATTACCAGTGAAAATTGTTGTTGACTTGGGTGTGGCACCTTGGAAGCTGAAGATATTCCACT
		GCCAAGTAACAGCCTGCCTCATCTATATCAATATGTATTTATCAATTATCTTCTTAGCATTTGTCAGCAT
		TGACCGCTGTCTTCAGCTGACACACAGCTGCAAGATCTACCGAATACAAGAACCCGGATTTGCCAAAATG
		ATATCAACCGTTGTGTGGCTAATGGTCCTTCTTATAATGGTGCCAAATATGATGATTCCCATCAAAGACA
		TCAAGGAAAAGTCAAATGTGGGTTGTATGGAGTTTAAAAAGGAATTTGGAAGAAATTGGCATTTGCTGAC
		AAATTTCATATGTGTAGCAATATTTTTAAATTTCTCAGCCATCATTTTAATATCCAATTGCCTTGTAATT
		CGACAGCTCTACAGAAACAAAGATAATGAAAATTACCCAAATGTGAAAAAGGCTCTCATCAACATACTTT
		TAGTGACCACGGGCTACATCATATGCTTTGTTCCTTACCACATTGTCCGAATCCCGTATACCCTCAGCCA
		GACAGAAGTCATAACTGATTGCTCAACCAGGATTTCACTCTTCAAAGCCAAAGAGGCTACACTGCTCCTG
		GCTGTGTCGAACCTGTGCTTTGATCCTGTCCTGTACTATCACCTCTCAAAAGCATTCCGCTCAAAGGTCA
		CTGAGACTTTTGCCTCACCTAAAGAGACCAAGGCTCAGAAAGAAAAATTAAGATGTGAAAATAATGCATA
		AAAGACAGGATTTTTGTGCTACCAATTCTGGCCTTACTGGACCATAAAGTTAATTATAGCTTTGAAAGAT
		AAAAAAAAAAAAAAAAACAAAAAAAAACTCAGTATGAAAAAATACAGTTAGCTAGCAAATATGGACAGGT
		TTACTTAGAAATCCTGTTTCTAAATGCAAGTCAAGCTTTATTGTTAGGCTTGCTGCTACTCATTAACCCA
		AATATTTGTACAAAAAACTAAAGAGTCTCATTGAACGAATGTAAAATCCTGCAATATCCTTGAAATCCAA
		AAGAGGTCCATGACATAGACCCAAAGGTATTCATGAGTTATTCATTTAAATGCCTGGAACTGACTTCTTG
		ATAAAAATATAAAAAATAATTTCCATGTAAGTTACCAGAAAGCCCACCAGCAACATAATTTTAAAGCCTT
		TCGGATTACTTTTAAAAAATGCAGCTTACATATAACAACTTGTGCCTATTTTATTTCTAATCTATCACTT
		CAAAAGATGGTAATCTTTCAACTCATTATTCCTCCAATTTTTAATGTCGAATTTTTTTCTAACACAATAA
		CCAAAAGCTTTTATTTATAAAAAGGCTTGAAAAATATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
		AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
11	Protein kinase C,	>gi|89353296|ref|NM_001183.4|Homo sapiens ATPase, H+ transporting,
	beta 1	lysosomal accessory protein 1 (ATP6AP1), mRNA
		GGGGGCAACGGTCACCTGATCTGCGGCTGTCGAGGCCGCTGAGGCAGTGGAGGCTGAGGCTATGATGGCG
		GCCATGGCGACGGCTCGAGTGCGGATGGGGCCGCGATGCGCCCAGGCGCTCTGGCGCATGCCGTGGCTGC
		CGGTGTTTTTGTCGTTGGCGGCGGCGGCGGCGGCGGCAGCGGCGGAGCAGCAGGTCCCGCTGGTGCTGTG
		GTCGAGTGACCGGGACTTGTGGGCTCCTGCGGCCGACACTCATGAAGGCCACATCACCAGCGACTTGCAG
		CTCTCTACCTACTTAGATCCCGCCCTGGAGCTGGGTCCCAGGAATGTGCTGCTGTTCCTGCAGGACAAGC
		TGAGCATTGAGGATTTCACAGCATATGGCGGTGTGTTTGGAAACAAGCAGGACAGCGCCTTTTCTAACCT
		AGAGAATGCCCTGGACCTGGCCCCCTCCTCACTGGTGCTTCCTGCCGTCGACTGGTATGCAGTCAGCACT
		CTGACCACTTACCTGCAGGAGAAGCTCGGGGCCAGCCCCTTGCATGTGGACCTGGCCACCCTGCGGGAGC
		TGAAGCTCAATGCCAGCCTCCCTGCTCTGCTGCTCATTCGCCTGCCCTACACAGCCAGCTCTGGTCTGAT
		GGCACCCAGGGAAGTCCTCACAGGCAACGATGAGGTCATCGGGCAGGTCCTGAGCACACTCAAGTCCGAA
		GATGTCCCATACACAGCGGCCCTCACAGCGGTCCGCCCTTCCAGGGTGGCCCGTGATGTAGCCGTGGTGG
		CCGGAGGGCTAGGTCGCCAGCTGCTACAAAAACAGCCAGTATCACCTGTGATCCATCCTCCTGTGAGTTA
		CAATGACACCGCTCCCCGGATCCTGTTCTGGGCCCAAAACTTCTCTGTGGCGTACAAGGACCAGTGGGAG
		GACCTGACTCCCCTCACCTTTGGGGTGCAGGAACTCAACCTGACTGGCTCCTTCTGGAATGACTCCTTTG
		CCAGGCTCTCACTGACCTATGAACGACTCTTTGGTACCACAGTGACATTCAAGTTCATTCTCGCCAACCG
		CCTCTACCCAGTGTCTGCCCGGCACTGGTTTACCATGGAGCGCCTCGAAGTCCACAGCAATGGCTCCGTC
		GCCTACTTCAATGCTTCCCAGGTCACAGGGCCCAGCATCTACTCCTTCCACTGCGAGTATGTCAGCAGCC
		TGAGCAAGAAGGGTAGTCTCCTCGTGGCCCGCACGCAGCCCTCTCCCTGGCAGATGATGCTTCAGGACTT
		CCAGATCCAGGCTTTCAACGTAATGGGGGAGCAGTTCTCCTACGCCAGCGACTGTGCCAGCTTCTTCTCC
		CCCGGCATCTGGATGGGGCTGCTCACCTCCCTGTTCATGCTCTTCATCTTCACCTATGGCCTGCACATGA
		TCCTCAGCCTCAAGACCATGGATCGCTTTGATGACCACAAGGGCCCCACTATTTCTTTGACCCAGATTGT
		GTGACCCTGTGCCAGTGGGGGGGTTGAGGGTGGGACGGTGTCCGTGTTGTTGCTTTCCCACCCTGCAGCG
		CACTGGACTGAAGAGCTTCCCTCTTCCTACTGCAGCATGAACTGCAAGCTCCCCTCAGCCCATCTTGCTC
		CCTCTTCAGCCCGCTGAGGAGCTTTCTTGGGCTGCCCCCATCTCTCCCAACAAGGTGTACATATTCTGCG
		TAGATGCTAGACCAACCAGCTTCCCAGGGTTCGTCGCTGTGAGGCGTAAGGGACATGAATTCTAGGGTCT
		CCTTTCTCCTTATTTATTCTTGTGGCTACATCATCCCTGGCTGTGGATAGTGCTTTTGTGTAGCAAATGC
		TCCCTCCTTAAGGTTATAGGGCTCCCTGAGTTTGGGAGTGTGGAAGTACTACTTAACTGTCTGTCCTGCT
		TGGCTGTCGTTATCGTTTTCTGGTGATGTTGTGCTAACAATAAGAAGTACACGGGTTTATTTCTGTGGCC
		TGAGAAGGAAGGGACCTCCACGACAGGTGGGCTGGGTGCGATCGCCGGCTGTTTGGCATGTTCCCACCGG
		GAGTGCCGGGCAGGAGCATGGGGTGCTTGGTTGTTTCCTTCCTAATAAAATAAACGCGGGTCGCCATGCA
		AAAAAAAAA
12	major histo-	>gi|52426773|ref|NM_019111.3|Homo sapiens major histocompatibility
	compatibility	complex, class II, DR alpha (HLA-DRA), mRNA
	complex, class	ACATTCTCTTTTCTTTTATTCTTGTCTGTTCTGCCTCACTCCCGAGCTCTACTGACTCCCAACAGAGCGC
	II, DR alpha///	CCAAGAAGAAAATGGCCATAAGTGGAGTCCCTGTGCTAGGATTTTTCATCATAGCTGTGCTGATGAGCGC
	major histo-	TCAGGAATCATGGGCTATCAAAGAAGAACATGTGATCATCCAGGCCGAGTTCTATCTGAATCCTGACCAA
	compatibility	TCAGGCGAGTTTATGTTTGACTTTGATGGTGATGAGATTTTCCATGTGGATATGGCAAAGAAGGAGACGG
	complex, class	TCTGGCGGCTTGAAGAATTTGGACGATTTGCCAGCTTTGAGGCTCAAGGTGCATTGGCCAACATAGCTGT
	II, DR alpha	GGACAAAGCCAACCTGGAAATCATGACAAAGCGCTCCAACTATACTCCGATCACCAATGTACCTCCAGAG
		GTAACTGTGCTCACGAACAGCCCTGTGGAACTGAGAGAGCCCAACGTCCTCATCTGTTTCATAGACAAGT
		TCACCCCACCAGTGGTCAATGTCACGTGGCTTCGAAATGGAAAACCTGTCACCACAGGAGTGTCAGAGAC
		AGTCTTCCTGCCCAGGGAAGACCACCTTTTCCGCAAGTTCCACTATCTCCCCTTCCTGCCCTCAACTGAG
		GACGTTTACGACTGCAGGGTGGAGCACTGGGGCTTGGATGAGCCTCTTCTCAAGCACTGGGAGTTTGATG
		CTCCAAGCCCTCTCCCAGAGACTACAGAGAACGTGGTGTGTGCCCTGGGCCTGACTGTGGGTCTGGTGGG
		CATCATTATTGGGACCATCTTCATCATCAAGGGATTGCGCAAAAGCAATGCAGCAGAACGCAGGGGGCCT
		CTGTAAGGCACATGGAGGTGATGGTGTTTCTTAGAGAGAAGATCACTGAAGAAACTTCTGCTTTAATGGC
		TTTACAAAGCTGGCAATATTACAATCCTTGACCTCAGTGAAAGCAGTCATCTTCAGCATTTTCCAGCCCT
		ATAGCCACCCCAAGTGTGGATATGCCTCTTCGATTGCTCCGTACTCTAACATCTAGCTGGCTTCCCTGTC
		TATTGCCTTTTCCTGTATCTATTTTCCTCTATTTCCTATCATTTTATTATCACCATGCAATGCCTCTGGA
		ATAAAACATACAGGAGTCTGTCTCTGCTATGGAATGCCCCATGGGGCATCTCTTGTGTACTTATTGTTTA
		AGGTTTCCTCAAACTGTGATTTTTCTGAACACAATAAACTATTTTGATGATCTTGGGTGGAAAAAAAAAA
		AAAAAAA
Sequence	Major histo-	>gi|24797068|ref|NM_002123.2|Homo sapiens major histocompatibility
13	compatibility	complex, class II, DQ beta 1 (HLA-DQB1), mRNA
	complex, class	CAGATCCATCAGGTCCGAGCTGTGTTGACTACCACTTTTCCCTTCGTCTCAATTATGTCTTGGAAAAAGG
	II, DQ beta 1///	CTTTGCGGATCCCCGGAGGCCTTCGGGCAGCAACTGTGACCTTGATGCTGTCGATGCTGAGCACCCCAGT
	Major histo-	GGCTGAGGGCAGAGACTCTCCCGAGGATTTCGTGTACCAGTTTAAGGGCATGTGCTACTTCACCAACGGG
	compatibility	ACAGAGCGCGTGCGTCTTGTGAGCAGAAGCATCTATAACCGAGAAGAGATCGTGCGCTTCGACAGCGACG
	complex, class	TGGGGGAGTTCCGGGCGGTGACGCTGCTGGGGCTGCCTGCCGCCGAGTACTGGAACAGCCAGAAGGACAT
	II, DQ beta 1	CCTGGAGAGGAAACGGGCGGCGGTGGACAGGGTGTGCAGACACAACTACCAGTTGGAGCTCCGCACGACC
		TTGCAGCGGCGAGTGGAGCCCACAGTGACCATCTCCCCATCCAGGACAGAGGCCCTCAACCACCACAACC
		TGCTGGTCTGCTCGGTGACAGATTTCTATCCAGCCCAGATCAAAGTCCGGTGGTTTCGGAATGACCAGGA
		GGAGACAGCTGGCGTTGTGTCCACCCCCCTTATTAGGAATGGTGACTGGACCTTCCAGATCCTGGTGATG
		CTGGAAATGACTCCCCAGCGTGGAGACGTCTACACCTGCCACGTGGAGCACCCCAGCCTCCAGAGCCCCA
		TCACCGTGGAGTGGCGGGCTCAATCTGAATCTGCCCAGAGCAAGATGCTGAGTGGCATTGGAGGCTTCGT
		GCTGGGGCTGATCTTCCTCGGGCTGGGCCTTATCATCCATCACAGGAGTCAGAAAGGGCTCCTGCACTGA
		CTCCTGAGACTATTTTAACTGGGATTGGTTATCACTTTTCTGTAACGCCTGCTTGTCCCTGCCCAGAATT
		CCCAGCTGTCTGTGTCAGCCTGTCCCCCTGAGATCAGAGTCCTACAGTGGCTGTCACGCAGCCACCAGGT
		CATCTCCTTTCATCCCCACCTTGAGGCGGATGGCTGTGACCCTACTTCCTGCACTGACCCACAGCCTCTG
		CCTGTGCACGGCCAGCTGCATCTACTCAGGCCCCAAGGGGTTTCTGTTTCTATTCTCTCCTCAGACTGCT
		CAAGAGAAGCACATGAAAACCATTACCTGACTTTAGAGCTTTTTTACATAATTAAACATGATCCTGAGTT
14	alcohol	>gi|34577060|ref|NM_000668.3|Homo sapiens alcohol dehydrogenase IB (class
	dehydrogenase	I), beta polypeptide (ADH1B), mRNA
	IB (class I),	ATGCACTCAAGCAGAGAAGAAATCCACAAAGACTCACAGTCTGCTGGTGGGCAGAGAAGACAGAAACGAC
	beta	ATGAGCACAGCAGGAAAAGTAATCAAATGCAAAGCAGCTGTGCTATGGGAGGTAAAGAAACCCTTTTCCA
	polypeptide	TTGAGGATGTGGAGGTTGCACCTCCTAAGGCTTATGAAGTTCGCATTAAGATGGTGGCTGTAGGAATCTG
		TCACACAGATGACCACGTGGTTAGTGGCAACCTGGTGACCCCCCTTCCTGTGATTTTAGGCCATGAGGCA
		GCCGGCATCGTGGAGAGTGTTGGAGAAGGGGTGACTACAGTCAAACCAGGTGATAAAGTCATCCCGCTCT
		TTACTCCTCAGTGTGGAAAATGCAGAGTTTGTAAAAACCCGGAGAGCAACTACTGCTTGAAAAATGATCT
		AGGCAATCCTCGGGGGACCCTGCAGGATGGCACCAGGAGGTTCACCTGCAGGGGGAAGCCCATTCACCAC
		TTCCTTGGCACCAGCACCTTCTCCCAGTACACGGTGGTGGATGAGAATGCAGTGGCCAAAATTGATGCAG
		CCTCGCCCCTGGAGAAAGTCTGCCTCATTGGCTGTGGATTCTCGACTGGTTATGGGTCTGCAGTTAACGT
		TGCCAAGGTCACCCCAGGCTCTACCTGTGCTGTGTTTGGCCTGGGAGGGGTCGGCCTATCTGCTGTTATG
		GGCTGTAAAGCAGCTGGAGCAGCCAGAATCATTGCGGTGGACATCAACAAGGACAAATTTGCAAAGGCCA
		AAGAGTTGGGTGCCACTGAATGCATCAACCCTCAAGACTACAAGAAACCCATCCAGGAAGTGCTAAAGGA
		AATGACTGATGGAGGTGTGGATTTTTCGTTTGAAGTCATCGGTCGGCTTGACACCATGATGGCTTCCCTG
		TTATGTTGTCATGAGGCATGTGGCACAAGCGTCATCGTAGGGGTACCTCCTGCTTCCCAGAACCTCTCAA
		TAAACCCTATGCTGCTACTGACTGGACGCACCTGGAAGGGGGCTGTTTATGGTGGCTTTAAGAGTAAAGA
		AGGTATCCCAAAACTTGTGGCTGATTTTATGGCTAAGAAGTTTTCACTGGATGCGTTAATAACCCATGTT
		TTACCTTTTGAAAAAATAAATGAAGGATTTGACCTGCTTCACTCTGGGAAAAGTATCCGTACCGTCCTGA
		CGTTTTGAGGCAATAGAGATGCCTTCCCCTGTAGCAGTCTTCAGCCTCCTCTACCCTACAAGATCTGGAG
		CAACAGCTAGGAAATATCATTAATTCAGCTCTTCAGAGATGTTATCAATAAATTACACATGGGGGCTTTC
		CAAAGAAATGGAAATTGATGGGAAATTATTTTTCAGGAAAATTTAAAATTCAAGTGAGAAGTAAATAAAG
		TGTTGAACATCAGCTGGGGAATTGAAGCCAACAAACCTTCCTTCTTAACCATTCTACTGTGTCACCTTTG
		CCATTGAGGAAAAATATTCCTGTGACTTCTTGCATTTTTGGTATCTTCATAATCTTTAGTCATCGAATCC
		CAGTGGAGGGGACCCTTTTACTTGCCCTGAACATACACATGCTGGGCCATTGTGATTGAAGTCTTCTAAC
		TCTGTCTCAGTTTTCACTGTCGACATTTTCCTTTTTCTAATAAAAATGTACCAAATCCCTGGGGTAAAAG
		CTAGGGTAAGGTAAAGGATAGACTCACATTTACAAGTAGTGAAGGTCCAAGAGTTCTAAATACAGGAAAT
		TTCTTAGGAACTCAAATAAAATGCCCCACATTTTACTACAGTAAATGGCAGTGTTTTTATGACTTTTATA
		CTATTTCTTTATGGTCGATATACAATTGATTTTTTAAAATAATAGCAGATTTCTTGCTTCATATGACAAA
		GCCTCAATTACTAATTGTAAAAACTGAACTATTCCCAGAATCATGTTCAAAAAATCTGTAATTTTTGCTG
		ATGAAAGTGCTTCATTGACTAAACAGTATTAGTTTGTGGCTATAAATGATTATTTAGATGATGACTGAAA
		ATGTGTATAAAGTAATTAAAAGTAATATGGTGGCTTTAAGTGTAGAGATGGGATGGCAAATGCTGTGAAT
		GCAGAATGTAAAATTGGTAACTAAGAAATGGCACAAACACCTTAAGCAATATATTTTCCTAGTAGATATA
		TATATACACATACATATATACACATATACAAATGTATATTTTTGCAAAATTGTTTTCAATCTAGAACTTT
		TCTATTAACTACCATGTCTTAAAATCAAGTCTATAATCCTAGCATTAGTTTAATATTTTGAATATGTAAA
		GACCTGTGTTAATGCTTTGTTAATGCTTTTCCCACTCTCATTTGTTAATGCTTTCCCACTCTCAGGGGAA
		GGATTTGCATTTTGAGCTTTATCTCTAAATGTGACATGCAAAGATTATTCCTGGTAAAGGAGGTAGCTGT
		CTCCAAAAATGCTATTGTTGCAATATCTACATTCTATTTCATATTATGAAAGACCTTAGACATAAAGTAA
		AATAGTTTATCATTTACTGTGTGATCTTCAGTAAGTCTCTCAGGCTCTCTGAGCTTGTTCATCCTTTGTT
		TTGAAAAAATTACTCAACCAATCCATTACAGCTTAACCAAGATTAAATGGGATGATGTTAATGAAAGAGC
		TTCGCC
15	T cell receptor	>gi|36944|emb|X02592.1|HSTCRAR Human mRNA for T-cell receptor alpha chain
	alpha constant///	(TCR-alpha)
	T cell receptor	TTTTGAAACCCTTCAAAGGCAGAGACTTGTCCAGCCTAACCTGCCTGCTGCTCCTAGCTCCTGAGGCTCA
	alpha constant	GGGCCCTTGGCTTCTGTCCGCTCTGCTCAGGGCCCTCCAGCGTGGCCACTGCTCAGCCATGCTCCTGCTG
		CTCGTCCCAGTGCTCGAGGTGATTTTTACCCTGGGAGGAACCAGAGCCCAGTCGGTGACCCAGCTTGGCA
		GCCACGTCTCTGTCTCTGAAGGAGCCCTGGTTCTGCTGAGGTGCAACTACTCATCGTCTGTTCCACCATA
		TCTCTTCTGGTATGTGCAATACCCCAACCAAGGACTCCAGCTTCTCCTGAAGTACACATCAGCGGCCACC
		CTGGTTAAAGGCATCAACGGTTTTGAGGCTGAATTTAAGAAGAGTGAAACCTCCTTCCACCTGACGAAAC
		CCTCAGCCCATATGAGCGACGCGGCTGAGTACTTCTGTGCTGTGAGTGATCTCGAACCGAACAGCAGTGC
		TTCCAAGATAATCTTTGGATCAGGGACCAGACTCAGCATCCGGCCAAATATCCAGAACCCTGACCCTGCC
		GTGTACCAGCTGAGAGACTCTAAATCCAGTGACAAGTCTGTCTGCCTATTCACCGATTTTGATTCTCAAA
		CAAATGTGTCACAAAGTAAGGATTCTGATGTGTATATCACAGACAAAACTGTGCTAGACATGAGGTCTAT
		GGACTTCAAGAGCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACTTTGCATGTGCAAACGCCTTCAAC
		AACAGCATTATTCCAGAAGACACCTTCTTCCCCAGCCCAGAAAGTTCCTGTGATGTCAAGCTGGTCGAGA
		AAAGCTTTGAAACAGATACGAACCTAAACTTTCAAAACCTGTCAGTGATTGGGTTCCGAATCCTCCTCCT
		GAAAGTGGCCGGGTTTAATCTGCTCATGACGCTGCGGCTGTGGTCCAGCTGAGATCTGCAAGATTGTAAG
		ACAGCCTGTGCTCCCTCGCTCCTTCCTCTGCATTGCCCCTCTTCTCCCTCTCCAAACAGAGGGAACTCTC
		CTACCCCCAAGGAGGTGAAAGCTGCTACCACCTCTGTGCCCCCCCGGTAATGCCACCAACTGGATCCTAC
		CCGAATTTATGATTAAGATTGCTGAAGAGCTGCCAAACACTGCTGCCACCCCCTCTGTTCCCTTATTGCT
		GCTTGTCACTGCCTGACATTCACGGCAGAGGCAAGGCTGCTGCAGCCTCCCCTGGCTGTGCACATTCCCT
		CCTGCTCCCCAGAGACTGCCTCCGCCATCCCACAGATGATGGATCTTCAGTGGGTTCTCTTGGGCTCTAG
		GTCCTGGAGAATGTTGTGAGGGGTTTATTTTTTTTTAATAGTGTTCATAAAGAAATACATAGTATTCTTC
		TTCTCAAGACGTGGGGGGAAATTATCTCATTATCGAGGCCCTGCTATGCTGTGTGTCTGGGCGTGTTGTA
		TGTCCTGCTGCCGATGCCTTCATTAAAATGATTTGGAA
16	CD69 antigen	>gi|4502680|ref|NM_001781.1|Homo sapiens CD69 molecule (CD69), mRNA
	(p60, early	AGACTCAACAAGAGCTCCAGCAAAGACTTTCACTGTAGCTTGACTTGACCTGAGATTAACTAGGGAATCT
	T-cell	TGAGAATAAAGATGAGCTCTGAAAATTGTTTCGTAGCAGAGAACAGCTCTTTGCATCCGGAGAGTGGACA
	activation	AGAAAATGATGCCACCAGTCCCCATTTCTCAACACGTCATGAAGGGTCCTTCCAAGTTCCTGTCCTGTGT
	antigen)	GCTGTAATGAATGTGGTCTTCATCACCATTTTAATCATAGCTCTCATTGCCTTATCAGTGGGCCAATACA
		ATTGTCCAGGCCAATACACATTCTCAATGCCATCAGACAGCCATGTTTCTTCATGCTCTGAGGACTGGGT
		TGGCTACCAGAGGAAATGCTACTTTATTTCTACTGTGAAGAGGAGCTGGACTTCAGCCCAAAATGCTTGT
		TCTGAACATGGTGCTACTCTTGCTGTCATTGATTCTGAAAAGGACATGAACTTTCTAAAACGATACGCAG
		GTAGAGAGGAACACTGGGTTGGACTGAAAAAGGAACCTGGTCACCCATGGAAGTGGTCAAATGGCAAAGA
		ATTTAACAACTGGTTCAACGTTACAGGGTCTGACAAGTGTGTTTTTCTGAAAAACACAGAGGTCAGCAGC
		ATGGAATGTGAGAAGAATTTATACTGGATATGTAACAAACCTTACAAATAATAAGGAAACATGTTCACTT
		ATTGACTATTATAGAATGGAACTCAAGGAAATCTGTGTCAGTGGATGCTGCTCTGTGGTCCGAAGTCTTC
		CATAGAGACTTTGTGAAAAAAAATTTTATAGTGTCTTGGGAATTTTCTTCCAAACAGAACTATGGAAAAA
		AAGGAAGAAATTCCAGGAAAATCTGCACTGTGGGCTTTTATTGCCATGAGCTAGAAGCATCACAGGTTGA
		CCAATAACCATGCCCAAGAATGAGAAGAATGACTATGCAACCTTTGGATGCACTTTATATTATTTTGAAT
		CCAGAAATAATGAAATAACTAGGCGTGGACTTACTATTTATTGCTGAATGACTACCAACAGTGAGAGCCC
		TTCATGCATTTGCACTACTGGAAGGAGTTAGATGTTGGTACTAGATACTGAATGTAAACAAAGGAATTAT
		GGCTGGTAACATAGGTTTTTAGTCTAATTGAATCCCTTAAACTCAGGGAGCATTTATAAATGGACAAATG
		CTTATGAAACTAAGATTTGTAATATTTCTCTCTTTTTAGAGAAATTTGCCAATTTACTTTGTTATTTTTC
		CCCAAAAAGAATGGGATGATCGTGTATTTATTTTTTTACTTCCTCAGCTGTAGACAGGTCCTTTTCGATG
		GTACATATTTCTTTGCCTTTATAATCTTTTATACAGTGTCTTACAGAGAAAAGACATAAGCAAAGACTAT
		GAGGAATATTTGCAAGACATAGAATAGTGTTGGAAAATGTGCAATATGTGATGTGGCAAATCTCTATTAG
		GAAATATTCTGTAATCTTCAGACCTAGAATAATACTAGTCTTATAATAGGTTTGTGACTTTCCTAAATCA
		ATTCTATTACGTGCAATACTTCAATACTTCATTTAAAATATTTTTATGTGCAATAAAATGTATTTGTTTG
		TATTTTGTGTTCAGTACAATTATAAGCTGTTTTTATATATGTGAAATAAAAGTAGAATAAACACAAAAAA
		AAAAAAAAAAAAAAAAAAAAAA
17	protein kinase	>gi|48255887|ref|NM_006257.2|Homo sapiens protein kinase C, theta
	C, theta	(PRKCQ), mRNA
		AGTCCCCGCGCAGTCCCCGCGCAGTCCCAGCGCCACCGGGCAGCAGCGGCGCCGTGCTCGCTCCAGGGCG
		CAACCATGTCGCCATTTCTTCGGATTGGCTTGTCCAACTTTGACTGCGGGTCCTGCCAGTCTTGTCAGGG
		CGAGGCTGTTAACCCTTACTGTGCTGTGCTCGTCAAAGAGTATGTCGAATCAGAGAACGGGCAGATGTAT
		ATCCAGAAAAAGCCTACCATGTACCCACCCTGGGACAGCACTTTTGATGCCCATATCAACAAGGGAAGAG
		TCATGCAGATCATTGTGAAAGGCAAAAACGTGGACCTCATCTCTGAAACCACCGTGGAGCTCTACTCGCT
		GGCTGAGAGGTGCAGGAAGAACAACGGGAAGACAGAAATATGGTTAGAGCTGAAACCTCAAGGCCGAATG
		CTAATGAATGCAAGATACTTTCTGGAAATGAGTGACACAAAGGACATGAATGAATTTGAGACGGAAGGCT
		TCTTTGCTTTGCATCAGCGCCGGGGTGCCATCAAGCAGGCAAAGGTCCACCACGTCAAGTGCCACGAGTT
		CACTGCCACCTTCTTCCCACAGCCCACATTTTGCTCTGTCTGCCACGAGTTTGTCTGGGGCCTGAACAAA
		CAGGGCTACCAGTGCCGACAATGCAATGCAGCAATTCACAAGAAGTGTATTGATAAAGTTATAGCAAAGT
		GCACAGGATCAGCTATCAATAGCCGAGAAACCATGTTCCACAAGGAGAGATTCAAAATTGACATGCCACA
		CAGATTTAAAGTCTACAATTACAAGAGCCCGACCTTCTGTGAACACTGTGGGACCCTGCTGTGGGGACTG
		GCACGGCAAGGACTCAAGTGTGATGCATGTGGCATGAATGTGCATCATAGATGCCAGACAAAGGTGGCCA
		ACCTTTGTGGCATAAACCAGAAGCTAATGGCTGAAGCGCTGGCCATGATTGAGAGCACTCAACAGGCTCG
		CTGCTTAAGAGATACTGAACAGATCTTCAGAGAAGGTCCGGTTGAAATTGGTCTCCCATGCTCCATCAAA
		AATGAAGCAAGGCCGCCATGTTTACCGACACCGGGAAAAAGAGAGCCTCAGGGCATTTCCTGGGAGTCTC
		CGTTGGATGAGGTGGATAAAATGTGCCATCTTCCAGAACCTGAACTGAACAAAGAAAGACCATCTCTGCA
		GATTAAACTAAAAATTGAGGATTTTATCTTGCACAAAATGTTGGGGAAAGGAAGTTTTGGCAAGGTCTTC
		CTGGCAGAATTCAAGAAAACCAATCAATTTTTCGCAATAAAGGCCTTAAAGAAAGATGTGGTCTTGATGG
		ACGATGATGTTGAGTGCACGATGGTAGAGAAGAGAGTTCTTTCCTTGGCCTGGGAGCATCCGTTTCTGAC
		GCACATGTTTTGTACATTCCAGACCAAGGAAAACCTCTTTTTTGTGATGGAGTACCTCAACGGAGGGGAC
		TTAATGTACCACATCCAAAGCTGCCACAAGTTCGACCTTTCCAGAGCGACGTTTTATGCTGCTGAAATCA
		TTCTTGGTCTGCAGTTCCTTCATTCCAAAGGAATAGTCTACAGGGACCTGAAGCTAGATAACATCCTGTT
		AGACAAAGATGGACATATCAAGATCGCGGATTTTGGAATGTGCAAGGAGAACATGTTAGGAGATGCCAAG
		ACGAATACCTTCTGTGGGACACCTGACTACATCGCCCCAGAGATCTTGCTGGGTCAGAAATACAACCACT
		CTGTGGACTGGTGGTCCTTCGGGGTTCTCCTTTATGAAATGCTGATTGGTCAGTCGCCTTTCCACGGGCA
		GGATGAGGAGGAGCTCTTCCACTCCATCCGCATGGACAATCCCTTTTACCCACGGTGGCTGGAGAAGGAA
		GCAAAGGACCTTCTGGTGAAGCTCTTCGTGCGAGAACCTGAGAAGAGGCTGGGCGTGAGGGGAGACATCC
		GCCAGCACCCTTTGTTTCGGGAGATCAACTGGGAGGAACTTGAACGGAAGGAGATTGACCCACCGTTCCG
		GCCGAAAGTGAAATCACCATTTGACTGCAGCAATTTCGACAAAGAATTCTTAAACGAGAAGCCCCGGCTG
		TCATTTGCCGACAGAGCACTGATCAACAGCATGGACCAGAATATGTTCAGGAACTTTTCCTTCATGAACC
		CCGGGATGGAGCGGCTGATATCCTGAATCTTGCCCCTCCAGAGACAGGAAAGAATTTGCCTTCTCCCTGG
		GAACTGGTTCAAGAGACACTGCTTGGGTTCCTTTTTCAACTTGGAAAAAGAAAGAAACACTCAACAATAA
		AGACTGAGACCCGTTCGCCCCCATGTGACTTTTATCTGTAGCAGAAACCAAGTCTACTTCACTAATGACG
		ATGCCGTGTGTCTCGTCTCCTGACATGTCTCACAGACGCTCCTGAAGTTAGGTCATTACTAACCATAGTT
		ATTTACTTGAAAGATGGGTCTCCGCACTTGGAAAGGTTTCAAGACTTGATACTGCAATAAATTATGGCTC
		TTCACCTGGGCGCCAACTGCTGATCAATGAAATGCTTGTTGAATCAGGGGCAAACGGAGTACAGACGTCT
		CAAGACTGAAACGGCCCCATTGCCTGGTCTAGTAGCGGATCTCACTCAGCCGCAGACAAGTAATCACTAA
		CCCGTTTTATTCTATTCCTATCTGTGGATGTGTAAATGGCTGGGGGGCCAGCCCTGGATAGGTTTTTATG
		GGAATTCTTTACAATAAACATAGCTTGTAACTTGAGATCTACAAATCCATTCATCCTGATTGGGCATGAA
		ATCCATGGTCAAGAGGACAAGTGGAAAGTGAGAGGGAAGGTTTGCTAGACACCTTCGCTTGTTATCTTGT
		CAAGATAGAAAAGATAGTATCATTTCACCCTTGCCAGTAAAAACCTTTCCATCCACCCATTCTCAGCAGA
		CTCCAGTATTGGCACAGTCACTCACTGCCATTCTCACACTATAACAAGAAAAGAAATGAAGTGCATAAGT
		CTCCTGGGAAAAGAACCTTAACCCCTTCTCGTGCCATGACTGGTGATTTCATGACTCATAAGCCCCTCCG
		TAGGCATCATTCAAGATCAATGGCCCATGCATGCTGTTTGCAGCAGTCAATTGAGTTGAATTAGAATTCC
		AACCATACATTTTAAAGGTATTTGTGCTGTGTGTATATTTTGATAAAATGTTGTGACTTCATGGCAAACA
		GGTGGATGTGTAAAAATGGAATAAAAAAAAAAAAAGAGTCAAAAAAAAAAAAA
18	T cell receptor	>gi|339011|gb|M15564.1|HUMTCBYZ Human T-cell receptor rearranged beta-
	beta variable	chain V-region (V-D-J) mRNA, complete cds
	19///T cell	GTAAAGCTCCCATCCTGCCCTGACCCTGCCATGGGCACCAGCCTCCTCTGCTGGATGGCCCTGTGTCTCC
	receptor beta	TGGGGGCAGATCACGCAGATACTCGAGTCTCCCAGAACCCCAGACACAACATCACAAAGAGGGGACAGAA
	constant 1	TGTAACTTTCAGGTGTGATCCAATTTCTGAACACAACCGCCTTTATTGGTACCGACAGACCCTGGGGCAG
		GGCCCAGAGTTTCTGACTTACTTCCAGAATGAAGCTCAACTAGAAAAATCAAGGCTGCTCAGTGATCGGT
		TCTCTGCAGAGAGGCCTAAGGGATCTTTCTCCACCTTGGAGATCCAGCGCACAGAGCAGGGGGACTCGGC
		CATGTATCTCTGTGCCAGCAGCTTAGCAGGGTTGAATCAGCCCCAGCATTTTGGTGATGGGACTCGACTC
		TCCATCCTAGAGGACCTGAACAAGGTGTTCCCACCCGAGGTCGCTGTGTTTGAGCCATCAGAAGCAGAGA
		TCTCCCACACCCAAAAGGCCACACTGGTGTGCCTGGCCACAGGTATCTTCCCTGACCACGTGGAGCTGAG
		CTGGTGGGTGAATGGGAAGGAGGTGCACAGTGGGGTCAGCACGGACCCGCAGCCCCTCAAGGAGCAGCCC
		GCCCTCAATGACTCCAGATACTGCCTGAGCAGCCGCCTGAGGGTCTCGGCCACCTTCTGGCAGAACCCCC
		GCAACCACTTCCGCTGTCAAGTCCAGTTCTACGGGCTCTCGGAGAATGACGAGTGGACCCAGGATAGGGC
		CAAACCCGTCACCCAGATCGTCAGCGCCGAGGCCTGGGGTAGAGCAGACTGTGGCTTTACCTCGGTGTCC
		TACCAGCAAGGGGTCCTGTCTGCCACCATCCTCTATGAGATCCTGCTAGGGAAGGCCACCATGTATGCTG
		TGCTGGTCAGCGCCCTTGTGTTGATGGCCATGGTCAAGAGAAAGGATTTCTGAAGGCAGCCCTGGAAGTG
		GAGTTAGGAGCTTCTAACCCGTCATGGTTTCAATACACATTCTTCTTTTGCCAGCGCTTCTGAAGAGCTG
		CTCTCACCTCTCTGCATCCCAATA
19	T cell receptor	>gi|338765|gb|M15565.1|HUMTCAYE Human T-cell receptor rearranged alpha-
	alpha locus///T	chain V-region (V-D-J) mRNA, complete cds
	cell receptor	TCCAAAATGAAGGGTCTGTGGAAGGACATGAATAAAGCACAGGAGGTTGAAGTCAGATTTGCAGCTTTCT
	delta variable	AGGCAGGAGACAAGACAATCTGCATCTTCACAGGAGGGATGGCCATGCTCCTGGGGGCATCAGTGCTGAT
	2///T cell	TCTGTGGCTTCAGCCAGACTGGGTAAACAGTCAACAGAAGAATGATGACCAGCAAGTTAAGCAAAATTCA
	receptor alpha	CCATCCCTGAGCGTCCAGGAAGGAAGAATTTCTATTCTGAACTGTGACTATACTAACAGCATGTTTGATT
	variable 20///T	ATTTCCTATGGTACAAAAAATACCCTGCTGAAGGTCCTACATTCCTGATATCTATAAGTTCCATTAAGGA
	cell receptor	TAAAAATGAAGATGGAAGATTCACTGTCTTCTTAAACAAAAGTGCCAAGCACCTCTCTCTGCACATTGTG
	alpha joining	CCCTCCCAGCCTGGAGACTCTGCAGTGTACTTCTGTGCAGCAAACGGGGCCGGCACTGCCAGTAAACTCA
	17///T cell	CCTTTGGGACTGGAACAAGACTTCAGGTCACGCTCGATATCCAGAACCCTGACCCTGCCGTGTACCAGCT
	receptor alpha	GAGAGACTCTAAATCCAGTGACAAGTCTGTCTGCCTATTCACCGATTTTGATTCTCAAACAAATGTGTCA
	constant	CAAAGTAAGGATTCTGATGTGTATATCACAGACAAAACTGTGCTAGACATGAGGTCTATGGACTTCAAGA
		GCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACTTTGCATGTGCAAACGCCTTCAACAACAGCATTAT
		TCCAGAAGACACCTTCTTCCCCAGCCCAGAAAGTTCCTGTGATGTCAAGCTGGTCGAGAAAAGCTTTGAA
		ACAGATACGAACCTAAACTTTCAAAACCTGTCAGTGATTGGGTTCCGAATCCTCCTCCTGAAAGTGGCCG
		GGTTTAATCTGCTCATGACGCTGCGGCTGTGGTCCAGCTGAGATCTGCAAGATTGTAAGACAGCCTGTGC
		TCCCTCGCTCCTTCCTCTGCATTGCCCCTCTTCTCCCTCTCCAAACAGAGGGAACTCTCCCACCCCCAAG
		GAGGTGAAAGCTGCTACCACCCTGTGTGCC
20	T cell receptor	>gi|339406|gb|M30894.1|HUMTCRGAD Human T-cell receptor Ti rearranged
	gamma constant 2	gamma-chain mRNA V-J-C region, complete cds
		GAATCAGGAAGACCAGCTCCTCCTACTGTCTTCTGTGTTACGGGATCAGCGTTCCTTGTTGAGTGGGACC
		TGAGTTTTGAGAGGGTCTTCTGCTCCTCTTGGTCTGGTCCCTTACTTCCAAGAGCCCCAGAGAGGAAGGC
		ATGCTGTTGGCTCTAGCTCTGCTTCTAGCTTTCCTGCCTCCTGCCAGTCAGAAATCTTCCAACTTGGAAG
		GGAGAACAAAGTCAGTCACCAGGCCAACTGGGTCATCAGCTGTAATCACTTGTGATCTTCCTGTAGAAAA
		TGCCGTCTACACCCACTGGTACCTACACCAGGAGGGGAAGGCCCCACAGCGTCTTCTGTACTATGACTCC
		TACAACTCCAGGGTTGTGTTGGAATCAGGAATCAGTCGAGAAAAGTATCATACTTATGCAAGCACAGGGA
		AGAGCCTTAAATTTATACTGGAAAATCTAATTGAACGTGACTCTGGGGTCTATTACTGTGCCACCTGGAA
		GGATTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTGTTGTCACAGATAAACAACTTGATGCAGAT
		GTTTCCCCCAAGCCCACTATTTTTCTTCCTTCGATTGCTGAAACAAAACTCCAGAAGGCTGGAACATATC
		TTTGTCTTCTTGAGAAATTTTTCCCAGATATTATTAAGATACATTGGCAAGAAAAGAAGAGCAACACGAT
		TCTGGGATCCCAGGAGGGGAACACCATGAAGACTAACGACACATACATGAAATTTAGCTGGTTAACGGTG
		CCAGAAGAGTCACTGGACAAAGAACACAGATGTATCGTCAGACATGAGAATAATAAAAACGGAATTGATC
		AAGAAATTATCTTTCCTCCAATAAAGACAGATGTCACCACAGTGGATCCCAAAGACAGTTATTCAAAAGA
		TGCAAATGATGTCACCACAGTGGATCCCAAATACAATTATTCAAAGGATGCAAATGATGTCATCACAATG
		GATCCCAAAGACAATTGGTCAAAAGATGCAAATGATACACTACTGCTGCAGCTCACAAACACCTCTGCAT
		ATTACATGTACCTCCTCCTGCTCCTCAAGAGTGTGGTCTATTTTGCCATCATCACCTGCTGTCTGCTTGG
		AAGAACGGCTTTCTGCTGCAATGGAGAGAAATCATAACAGACGGTGGCACAAGGAGGCCATCTTTTCCTC
		ATCGGTTATTGTCCCTAGAAGCGTCTTCTGAGGATCTAGTTGGGCTTTCTTTCTGGGTTTGGGCCATTTC
		AGTTCTCATGTGTGtACTATTCTATCATTATTGTATAATGGTTTTCAAACCAGTGGGCACACAGAGAACC
		TCAGTCTGTAATAACAATGAGGAATAGCCATGGCGATCTCCAGCACCAATCTCTCCATGTTTTCCACAGC
		TCCTCCAGCCAACCCAAATAGCGCCTGCTATAGTGTAGACAGCCTGCGGCTTCTAGCCTTGTCCCTCTCT
		TAGTGTTCTTTAATCAGATAACTGCCTGGAAGCCTTTCATTTTACACGCCCTGAAGCAGTCTTCTTTGCT
		AGTTGAATTATGTGGTGTGTTTTTCCGTAATAAGCAAAATAAATTT
21	T cell receptor	>gi|3002924|gb|AF043179.1|AF043179 Homo sapiens T cell receptor beta
	beta variable	chain (TCRBV13S1-TCRBJ2S1) mRNA, complete cds
	21-1///T cell	ATGAGCATCGGCCTCCTGTGCTGTGCAGCCTTGTCTCTCCTGTGGGCAGGTCCAGTGAATGCTGGTGTCA
	receptor beta	CTCAGACCCCAAAATTCCAGGTCCTGAAGACAGGACAGAGCATGACACTGCAGTGTGCCCAGGATATGAA
	variable 19///	CCATGAATACATGTCCTGGTATCGACAAGACCCAGGCATGGGGCTGAGGCTGATTCATTACTCAGTTGGT
	T cell receptor	GCTGGTATCACTGACCAAGGAGAAGTCCCCAATGGCTACAATGTCTCCAGATCAACCACAGAGGATTTCC
	beta variable	CGCTCAGGCTGCTGTCGGCTGCTCCCTCCCAGACATCTGTGTACTTCTGTGCCAGCAGTTTCCCCCGGCA
	5-4///T cell	GCCGTCCTACAATGAGCAGTTCTTCGGGCCAGGGACACGGCTCACCGTGCTAGAGGACCTGAAAAACGTG
	receptor beta	TTCCCACCCGAGGTCGCTGTGTTTGAGCCATCAGAAGCAGAGATCTCCCACACCCAAAAGGCCACACTGG
	variable 3-1///	TGTGCCTGGCCACAGGTTTCTACCCCGACCACGTGGAGCTGAGCTGGTGGGTGAATGGGAAGGAGGTGCA
	T cell receptor	CAGTGGGGTCAGCACAGACCCGCAGCCCCTCAAGGAGCAGCCCGCCCTCAATGACTCCAGATACTGCCTG
	beta constant 1	AGCAGCCGCCTGAGGGTCTCGGCCACCTTCTGGCAGAACCCCCGCAACCACTTCCGCTGTCAAGTCCAGT
		TCTACGGGCTCTCGGAGAATGACGAGTGGACCCAGGATAGGGCCAAACCTGTCACCCAGATCGTCAGCGC
		CGAGGCCTGGGGTAGAGCAGACTGTGGCTTCACCTCCGAGTCTTACCAGCAAGGGGTCCTGTCTGCCACC
		ATCCTCTATGAGATCTTGCTAGGGAAGGCCACCTTGTATGCTGTGCTGGTCAGTGCCCTCGTGCTGATGG
		CCATGGTCAAGAGAAAGGATTCCAGAGGCTGA
22	T cell receptor	>gi|1100165|gb|L34703.1|HUMTCRAZ Homo sapiens T-cell receptor alpha chain
	alpha locus	(TCRA) mRNA (HLA-A1, 24; B7, 8; DR 1, 3), complete cds
		ATGGCATGCCCTGGCTTCCTGTGGGCACTTGTGATCTCCACCTGTCTTGAATTTAGCATGGCTCAGACAG
		TCACTCAGTCTCAACCAGAGATGTCTGTGCAGGAGGCAGAGACCGTGACCCTGAGCTGCACATATGACAC
		CAGTGAGAGTGATTATTATTTATTCTGGTACAAGCAGCCTCCCAGCAGGCAGATGATTCTCGTTATTCGC
		CAAGAAGCTTATAAGCAACAGAATGCAACAGAGAATCGTTTCTCTGTGAACTTCCAGAAAGCAGCCAAAT
		CCTTCAGTCTCAAGATCTCAGACTCACAGCTGGGGGATGCCGCGATGTATTTCTGTGCTTATAGGAGTGC
		ATACTCTGGGGCTGGGAGTTACCAACTCACTTTCGGGAAGGGGACCAAACTCTCGGTCATACCAAATATC
		CAGAACCCTGACCCTGCCGTGTACCAGCTGAGAGACTCTAAATCCAGTGACAAGTCTGTCTGCCTATTCA
		CCGATTTTGATTCTCAAACAAATGTGTCACAAAGTAAGGATTCTGATGTGTATATCACAGACAAAACTGT
		GCTAGACATGAGGTCTATGGACTTCAAGAGCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACTTTGCA
		TGTGCAAACGCCTTCAACAACAGCATTATTCCAGAAGACACCTTCTTCCCCAGCCCAGAAAGTTCCTGTG
		ATGTCAAGCTGGTCGAGAAAAGCTTTGAAACAGATACGAACCTAAACTTTCAAAACCTGTCAGTGATTGG
		GTTCCGAATCCTCCTCCTGAAAGTGGCCGGGTTTAATCTGCTCATGACGCTGCGGTTGTGGTCCAGCTGA
23	T cell receptor	>gi|46184507|gb|AL559122.3|AL559122 AL559122 Homo sapiens T CELLS (JURKAT
	beta variable	CELL LINE) COT 10-NORMALIZED Homo sapiens cDNA clone CS0DJ014YE01 5-PRIME,
	19///T cell	mRNA sequence
	receptor beta	TGCCTGGCCACAGGCTTCTTCCCCGACCACGTGGAGCTGAGCTGGTGGGTGAATGGGAAGGAGGTGCACA
	variable 19///	ATGGGGTCAACACAGACCCGCAGCCCCTCAAAGAACAGCCCGCCCTCAATGACTCCAAATAMTGCCTGAG
	T cell receptor	CAGCCGCCTGAGGGTCTCGGCCACCTTCTGGCAGAACCCCCGCAACCACTTCCGCTGTCAAGTCCAGTTC
	beta constant	TACGGGCTCTCGGAGAATGACGAGTGGACCCAGGATAGGGCCAAACCCGTCACCCAAATCGTCAGCGCCG
	1///T cell	AGGCCTGGGGTAPAGCARAMTGTGGCTTTACCTCGGTGTCCTACCAACAAGGGGTCCTGTCTGCCACCAT
	receptor beta	CCTCTATGARATCCTGCTAGGGAAGGCCACCCTGTATGCTGTGCTGGTCAGCGCCCTTGTGTTGATGGCC
	constant 1	ATGGTCAAGAGAAAGGATTTCTGAAGGCAGCCCTGGAAGTGGAATTAAGAACTTCTAACCCGTCATGGTT
		TCAATACACATTCTTCTTTTGCCAGCGCTTCTGAAGAGCTGCTCTCACCTCTCTGCATCCCAATAGATAT
		CCCCCTATGTGCATGCACACCTGCACACTCACGGCTGAAATCTCCCTAACCCAGGCGGACCTTAGCATGC
		CTAAGTGACTAAACCAATAAAAATGTTCTGGTCTGGCCTGA
24	CD3D antigen,	>gi|98985799|ref|NM_000732.41|Homo sapiens CD3d molecule, delta (CD3-TCR
	delta polypep-	complex) (CD3D), transcript variant 1, mRNA
	tide (TiT3)	AGAGAAGCAGACATCTTCTAGTTCCTCCCCCACTCTCCTCTTTCCGGTACCTGTGAGTCAGCTAGGGGAG
	complex)	GGCAGCTCTCACCCAGGCTGATAGTTCGGTGACCTGGCTTTATCTACTGGATGAGTTCCGCTGGGAGATG
		GAACATAGCACGTTTCTCTCTGGCCTGGTACTGGCTACCCTTCTCTCGCAAGTGAGCCCCTTCAAGATAC
		CTATAGAGGAACTTGAGGACAGAGTGTTTGTGAATTGCAATACCAGCATCACATGGGTAGAGGGAACGGT
		GGGAACACTGCTCTCAGACATTACAAGACTGGACCTGGGAAAACGCATCCTGGACCCACGAGGAATATAT
		AGGTGTAATGGGACAGATATATACAAGGACAAAGAATCTACCGTGCAAGTTCATTATCGAATGTGCCAGA
		GCTGTGTGGAGCTGGATCCAGCCACCGTGGCTGGCATCATTGTCACTGATGTCATTGCCACTCTGCTCCT
		TGCTTTGGGAGTCTTCTGCTTTGCTGGACATGAGACTGGAAGGCTGTCTGGGGCTGCCGACACACAAGCT
		CTGTTGAGGAATGACCAGGTCTATCAGCCCCTCCGAGATCGAGATGATGCTCAGTACAGCCACCTTGGAG
		GAAACTGGGCTCGGAACAAGTGAACCTGAGACTGGTGGCTTCTAGAAGCAGCCATTACCAACTGTACCTT
		CCCTTCTTGCTCAGCCAATAAATATATCCTCTTTCACTCAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
		A
25	T cell receptor	>gi|339168|gb|M13231.1|HUMTCGXH Human T-cell receptor aberrantly
	gamma constant	rearranged gamma-chain mRNA from cell line HPB-MLT
	2///T cell	GGCATGCGGTGGGCCCTACTGGTGCTTCTAGCTTTCCTGTCTCCTGCCAGTCAGAAATCTTCCAACTTGG
	receptor gamma	AAGGGAGAACGAAGTCAGTCACCAGGCAGACTGGGTCATCTGCTGAAATCACTTGCGATCTTACTGTAAC
	variable 9///	AAATACCTTCTACATCCACTGGTACCTACACCAGGAGGGGAAGGCCCCACAGCGTCTTCTGTACTATGAC
	similar to T-	GTCTCCACTGCAAGGGATGTGTTGGAATCAGGACTCAGTCCAGGAAAGTATTATACTCATACACCCAGGA
	cell receptor	GGTGGAGCTGGATATTGAGACTGCAAAATCTAATTGAAAATGATTCTGGGGTCTATTACTGTGCCACCTG
	gamma chain C	GGACAGGCAAAAATTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTGTTGTCACAGATAAACAACT
	region PT-	TGATGCAGATGTTTCCCCCAAGCCCACTATTTTTCTTCCTTCAATTGCTGAAACAAAACTCCAGAAGGCT
	gamma-½///	GGAACATACCTTTGTCTTCTTGAGAAATTTTTCCCAGATATTATTAAGATACATTCGCAAGAAAAGAAGA
	similar to T-	GCAACACGATTCTGGGATCCCAGGAGGGGAACACCATGAAGACTAACGACACATACATGAAATTTAGCTG
	cell receptor	GTTAACGGTGCCAGAAGAGTCACTGGACAAAGAACACAGATGTATCGTCAGACATGAGAATAATAAAAAC
	gamma chain V	GGAATTGATCAAGAAATTATCTTTCCTCCAATAAAGACAGATGTCACCACAGTGGATCCCAAAGACAGTT
	region PT-	ATTCAAAAGATGCAAATGATGTCATCACAATGGATCCCAAAGACAATTGGTCAAAAGATGCAAATGATAC
	gamma-½	ACTACTGCTGCAGCTCACAAACACCTCTGCATATTACATGTACCTCCTCCTGCTCCTCAAGAGTGTGGTC
	precursor///	TATTTTGCCATCATCACCTGCTGTCTGCTTGGAAGAACGGCTTTGTGCTGCAATGGAGAGAAATCATAAC
	TCR gamma	AGACGGTGGCACAAGGAGGCCATCTTTTCCTCATCGGTTATTGTCCCTAGAAGCGTCTTCTGAGGATCTA
	alternate	GTTGGGCTTTCTTTCTGGGTTTGGGCCATTTCAGTTCTCATGTGTGTAGTATTCTATCATTATTGTATAA
	reading frame	TGGTTTTCAAACCAGTGGGCACACAGAGAACCTCAGTCTGTAATAACAATGAGGAATAGCCATGGCGATC
	protein	TCCAGCACCAATCTCTCCATGTTTTCCACAGCTCCTCCAGCCAACCCAAATAGCGCCTGCTATAGTGTAG
		ACAGCCTGCGGCTTCTAGCCTTGTCCCTCTCTTAGTGTTCTTTAATCAGATAACTGCCTCGAAGCCTTTC
		ATTTTACACGCCCTGAAGCAGTCTTCTTTGCTAGTTGAATTATGTGGTGTGTTTTTCCGTAATAAGCAAA
		ATAAATTTAAAAAAATGAAAA
26	pyrin and HIN	>gi|10437303|dbj|AK024890.1|Homo sapiens cDNA: FLJ21237 fis, clone
	domain family,	COL01114
	member 1	GTCAAAGGAATAATCCCATCTAAAAAGACGAAACAGAAAGAAGTGTATCCTGCTACACCTGCATGCACCC
		CAAGCAACCGTCTCACAGCTAAAGGAGCAGAGGAGACTCTTGGACCTCAGGTAAGCTTCAGGAAGAGGAG
		CAGGCTTCAAGTCTCACAGTGGAAGCTCTGCTGTGGCTGTTCCACTCAATCTGTCCAGCAGGCAGTTATT
		TCTTCATATGTTTCCCATCAAGTTTCAGATTTATCAAATTACATAATAATTGATCATCTTTCTGCAAGGC
		AACAAGTTAAACGCTTTAGTAAACATAATGTAAATATACATAAAATAAATATAATATTTTCATCTCCAAT
		AGAGAAGGATGTTAACTTGAGAGTCAGATAAAAAAACGTTTGCCTATGTTTACAAAAGCCTAGTTTCTTA
		ACTGCAAGTCAGCATATCCCAAAACACAAGTAATTAAGGAATGATGTGTGTTACTTTCTCTGCTCCCTTT
		TTAAAAATGAAACCATCTATGCCATGTTCTTTCAATTGGCCTGGGGATGTACTTAAGTTTCCAAGAAAAA
		CAATTTATATACAATAAATATATTACCTTGTAATGAAAATGTGCTCTGCTTCATTTGACACTGAAAGTAA
		TTAACAAGAAAAATAAACTACTTGTAGAAAAGAAAAAAACCATCTGAAGAAGAGACTGGAACCAAAAGGA
		GTAAGATGTCCAAAGAGCAGACTCGGCCTTCCTGCTCTGCAGGAGCCAGCACGTCCACAGCCATGGGCCG
		TTCCCCACCTCCCCAGACCTCATCATCAGCTCCACCCAACACTTCCTCAACTGAGGTACACTCTTCCTGG
		TCCCCTTTTGATTCATTTTCTTCAACCCAAAATGTAGGAATCTGATTTCATCTTCTACTGAAAAATGACA
		TCAATCATCAGCCAGTAAATCAAATGTATAGACTGAGAATTAACTGCATTTTAATCTTTTGCTTCCACAG
		GCATATTTGATGAACTTGACATTATCTCTGACTGCAGGAAGTTTTCTGTCCTGTGCTGTTTGGGGAAGAG
		ACAGAGAACTGCGGAATCTGGAACTTTCAGCAACAGACTCACTGTCTACTGCCCCCATCTATTATACACC
		CATTCCCTTTGCTCACTAATTTGTTCAAGTTTCTCTGACATACACCATGCTCCTTTTTCCTTTAGGATTT
		TCACACACCATATTTCTTTCACCTTTAAACTCTTACCTGGCCAACCCTATCCACCCTCTGGATCCCAATA
		TTGAGATCTTATCCTCAGGGAATCCTCACTTAGACCCCTGTAACAGGTTAAATCTTCATGGTGTTCTGTT
		TCCTAGGAACTTCTTTCTTTTCTACTGTTTATGACAACTGAAGTTAATAAGTGTTTATCTTTCCCACCTA
		CTCAAAGTAGTTCCAAGATTAGGGCTAGTTTGTAATTCTGTGGACCACTGTAAACGAGGGCCTAGTTCAG
		TGTCTGCCTCATGGGAAGCTTCCAATAAATACCTTTGCTCAACGAAAAAATGAAAACCCAGTGGCTCACG
		CCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGTGGATTGCCTGAGGTCAGGAGTTTGAGACTAGTCT
		GGCCAACATGGTGAAACACTATCTCTACTAAAAATACAAAAAAATTAGCTGGGTATGGTGGCTTACGCCT
		ATAATCCCAGCTACTCAGGAGGCTGAGGCAGGGGAATTGCTTGAACCAGGGAGGTGGAGGTTGCAGTGAG
		CTGAGATCGCACCACTGCACTCCAGCCTGGGTGACAGAGCGAGACTCCATCTCAAAATAAAAAAGTAAAA
		AAAAAAAAAAAAAA
27	T cell receptor	>gi|54607136|ref|NM_016388.2|Homo sapiens T cell receptor associated
	associated	transmembrane adaptor 1 (TRAT1), mRNA
	transmembrane	GAGGCACAGATAAAGATAAGTTTTACTGTCATGCTGCTTTTAACATAACAGAGCAACATCACCTAGGAAA
	adaptor 1	AAAGTTTGTAGGAGGATTTTTAATCCATATATTTGTCTTATGGCTAGATAAAGATTTCTCTGAAAAAAAG
		AAGCATGTCAGGAATCTCTGGGTGCCCCTTTTTCCTCTGGGGACTTCTAGCATTGTTGGGCTTGGCTTTG
		GTTATATCACTGATCTTCAATATTrCCCACTATGTCGAAAAGCAACGACAAGATAAAATGTACAGCTACT
		CCAGTGACCACACCAGGGTTGATGAGTATTATATTGAAGACACACCAATTTATGGTAACTTAGATGATAT
		GATTTCAGAACCAATGGATGAAAATTGCTATGAACAAATGAAAGCCCGACCAGAGAAATCTGTAAATAAG
		ATGCAGGAAGCCACCCCATCTGCACAGGCAACCAATGAAACACAGATGTGCTACGCCTCACTTGATCACA
		GCGTTAAGGGGAAGCGTAGAAAGCCCAGGAAACAGAATACTCATTTCTCAGACAAGGATGGAGATGAGCA
		ACTACATGCAATAGATGCCAGCGITTCTAAGACCACCTTAGTAGACAGTTTCTCCCCAGAAAGCCAGGCA
		GTAGAGGAAAACATTCATGATGATCCCATCAGACTGTTTGGATTGATCCGTGCTAAGAGAGAACCTATAA
		ACTAGCTGGACCATGATCTAGTTCAATGATTTGGCTCCTATTGAAGATGGCTTCTAAGAAAACAAGATGC
		ACAGAGGACACAGAAGGACTTGGCAGCAGGGTGATGACCTGATCATTTGTTGATGGGATGGTGGCTTACC
		TCTTATTCACAGCTTACACTTATGCATGCCAAATGTAAGGCCATGAAAATCAGTATTTCAAATAACTTAA
		AAAATGCTTTACTACTAAAATGTAAAAAATTAATGTGCTCACCTCGGCAGCACATATACTAAAAATTAAT
		AAGACCCAGCTTGAAAATTGAGCCTGATAACAAGATTACAAATTCACAATACCTAATACTTAGGGAAATA
		TAAAAATTTAAGCATGAATGCGTTCTGGAACACGTTAGAAGAAAAATAAAAGCCAATGAGTTTTTTTTTA
		ATTCTCCTTTCTCACCAATGGGCAATAGCCCATAATTGAIATAAATTTCTGATTGAAAGGTATAGGAAAC
		ATTAAAATGCATTACTAAGAGAAGTAATATAATTTTCTTACAAAGTATTTTTCCCAAAGATAGCTTTACT
		ATTTCAAAAATTGTCAAATTAATGCATGCTCCTTACAACAAACAAATATCAAAAAGAGTTTAGGAATTCT
		ACTAGCCAGAGATAGTCACTTGGAGAAACTTTCTATATATCCTTCTAAATATTTTTCTGGGCATGCTTAT
		GTATGTACATCAGTTGTTTCTTTTTATTTTGAACCAAAAATGTGGTTTCTTTTGTACACATTACTTAAAC
		TTTCTTTCCAGTCAACAATATATTGTGGATTTATTTTCACTGTTATATTTAACTATATATAAATACGCAT
		ATATTGTAATTTTAATGTCTGCTTAGCACCCCACTGATAACCAAATCACAGTTTATTTAAATAATTTTAA
		TGACTTTTCAAAAACAATTTATTGATGCAAAAAGCAAGGTTGAGATGACAATGTTTCTTTCAATAATTAA
		AAAATACTGCTTCAC
28	SLAM family	>gi|19923571|ref|NN_021181.3|Homo sapiens SLAM family member 7 (SLAMF7),
	member 7	mRNA
		CTTCCAGAGAGCAATATGGCTGGTTCCCCAACATGCCTCACCCTCATCTATATCCTTTGGCAGCTCACAG
		GGTCAGCAGCCTCTGGACCCGTGAAAGAGCTGGTCGGTTCCGTTGGTGGGGCCGTGACTTTCCCCCTGAA
		GTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAACCCCTCTTGTCACCATACAGCCA
		GAAGGGGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGTAGACTTCCCAGATGGAGGCTACT
		CCCTGAAGCTCAGCAAACTGAAGAAGAATGACTCAGGGATCTACTATGTGGGGATATACAGCTCATCACT
		CCAGCAGCCCTCCACCCAGGAGTACGTGCTGCATGTCTACGAGCACCTGTCAAAGCCTAAAGTCACCATG
		GGTCTGCAGAGCAATAAGAATGGCACCTGTGTGACCAATCTGACATGCTGCATGGAACATGGGGAAGAGG
		ATGTGATTTATACCTGGAAGGCCcTGGGGCAAGCAGCCAATGAGTCCCATAATGGGTCCATCCTCCCCAT
		CTCCTGGAGATGGGGAGAAAGTGATATGACCTTCATCTGCGTTGCCAGGAACCCTGTCAGCAGAAACTTC
		TCAAGCCCCATCCTTGCCAGGAAGCTCTGTGAAGGTGCTGCTGATGACCCAGATTCCTCCATGGTCcTCC
		TGTGTCTCcTGTTGGTGCCCCTCCTGCTCAGTCTCTTTGTACTGGGGCTATTTCTTTGGTTTCTGAAGAG
		AGAGAGACAAGAAGAGTACATTGAAGAGAAGAAGAGAGTGGACATTTGTCGGGAAACTCCTAACATATGC
		CCCCATTCTGGAGAGAACACAGAGTACGACACAATCCCTCACACTAATAGAACAATCCTAAAGGAAGATC
		CAGCAAATACGGTTTACTCCACTGTGGAAATACCGAAAAAGATGGAAAATCCCCACTCACTGCTCACGAT
		GCCAGACACACCAAGGCTATTTGCCTATGAGAATGTTATCTAGACAGCAGTGCACTCCCCTAAGTCTCTG
		CTCAAAAAAAAAACAATTCTCGGCCCAAAGAAAACAATCAGAAGAATTCACTGATTTGACTAGAAACATC
		AAGGAAGAATGAAGAACGTTGACTTTTTTCCAGGATAAATTATCTCTGATGCTTCTTTAGATTTAAGAGT
		TCATAATTCCATCCACTGCTGAGAAATCTCCTCAAACCCAGAAGGTTTAATCACTTCATCCCAAAAATGG
		GATTGTGAATGTCAGCAAACCATAAAAAAAGTGCTTAGAAGTATTCCTATAGAAATGTAAATGCAAGGTC
		ACACATATTAATGACAGCCTGTTGTATTAATGATGGCTCCAGGTCAGTGTCTGGAGTTTCATTCCATCCC
		AGGGCTTGGATGTAAGGATTATACCAAGAGTCTTGCTACCAGGAGGGCAAGAAGACCAAAACAGACAGAC
		AAGTCCAGCAGAAGCAGATGCACCTGACAAAAATGGATGTATTAATTGGCTCTATAAACTATGTGCCCAG
		CACTATGCTGAGCTTACACTAATTGGTCAGACGTGCTGTCTGCCCTCATGAAATTGGCTCCAAATGAATG
		AACTACTTTCATGAGCAGTTGTAGCAGGCCTGACCACAGATTCCCAGAGGGCCAGGTGTGGATCCACACG
		ACTTGAAGGTCAAAGTTCACAAAGATGAAGAATCAGGGTAGCTGACCATGTTTGGCAGATACTATAATGG
		AGACACAGAAGTGTGCATGGCCCAAGGACAAGGACCTCCAGCCAGGCTTCATTTATGCACTTGTGCTGCA
		AAAGAAAAGTCTAGGTTTTAAGGCTGTGCCAGAACCCATCCCAATAAAGAGACCGAGTCTGAAGTCACAT
		TGTAAATCTAGTGTAGGAGACTTGGAGTCAGGCAGTGAGACTGGTGGGGCACGGGGGGCAGTGGGTACTT
		GTAAACCTTTAAAGATGGTTAATTCATTCAATAGATATTTATTAAGAACCTATGCGGCCCGGCATGGTGG
		CTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGTGGGTCATCTGAGGTCAGGAGTTCAAGAC
		CAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAGATACAAAAATTTGCTGAGCGTGGTGGTGTGC
		ACCTGTAATCCCAGCTACTCGAGAGGCCAAGGCATGAGAATCGCTTGAACCTGGGAGGTGGAGGTTGCAG
		TGAGCTGAGATGGCACCACTGCACTCCGGCCTAGGCAACGAGAGCAAAACTCCAATACAAACAAACAAAC
		AAACACCTGTGCTAGGTCAGTCTGGCACGTAAGATGAACATCCCTACCAACACAGAGCTCACCATCTCTT
		ATACTTAAGTGAAAAACATGGGGAAGGGGAAAGGGGAATGGCTGCTTTTGATATGTTCCCTGACACATAT
		CTTGAATGGAGACCTCCCTACCAAGTGATGAAAGTGTTGAAAAACTTAATAACAAATGCTTGTTGGGCAA
		GAATGGGATTGAGGATTATCTTCTCTCAGAAAGGCATTGTGAAGGAATTGAGCCAGATCTCTCTCCCTAC
		TGCAAAACCCTATTGTAGTAAAAAAGTCTTCTTTACTATCTTAATAAAACAGATATTGTGAGATTCAAAA
		AAAAAAAAAAAA
29	chromosome 4 open	>gi|50428928|ref|NM_152997.2|Homo sapiens chromosome 4 open reading frame
	reading frame 7	7 (C4orf7), mRNA
		TAAAACAGCTACAATATTCCAGGGCCAGTCACTTGCCATTTCTCATAACAGCGTCAGAGAGAAAGAACTG
		ACTGAAACGTTTGAGATGAAGAAAGTTCTCCTCCTGATCACAGCCATCTTGGCAGTGGCTGTTGGTTTCC
		CAGTCTCTCAAGACCAGGAACGAGAAAAAAGAAGTATCAGTGACAGCGATGAATTAGCTTCAGGGTTTTT
		TGTGTTCCCTTACCCATATCCATTTCGCCCACTTCCACCAATTCCATTTCCAAGATTTCCATGGTTTAGA
		CGTAATTTTCCTATTCCAATACCTGAATCTGCCCCTACAACTCCCCTTCCTAGCGAAAAGTAAACAAGAA
		GGAAAAGTCACGATAAACCTGGTCACCTGAAATTGAAATTGAGCCACTTCCTTGAAGAATCAAAATTCCT
		GTTAATAAAAGAAAAACAAATGTAATTGAAATAGCACACAGCATTCTCTAGTCAATATCTTTAGTGATCT
		TCTTTAATAAACTTGAAAGCAAAGATTTTGGTTTCTTAATTTCCACAAA
30	Major histo-	>gi|52426772|ref|NM_002122.3|Homo sapiens major histocompatibility
	compatibility	complex, class II, DQ alpha 1 (HLA-DQA1), mRNA
	complex, class	ACAATTACTCTACAGCTCAGAACACCAACTGCTGAGGCTGCCTTGGGAAGAGGATGATCCTAAACAAAGC
	II, DQ alpha 1	TCTGCTGCTGGGGGCCCTCGCTCTGACCACCGTGATGAGCCCCTGTGGAGGTGAAGACATTGTGGCTGAC
		CACGTTGCCTCTTGTGGTGTAAACTTGTACCACTTTTACGGTCCCTCTGGCCAGTACACCCATGAATTTG
		ATGGAGATGAGCAGTTCTACGTGGACCTGGAGAGGAAGGAGACTGCCTGOCGGTGGCCTGAGTTCAGCAA
		ATTTGGAGGTTTTGACCCGCAGGGTGCACTGAGAAACATGGCTGTGGCAAAACACAACTTGAACATCATG
		ATTAAACGCTACAACTCTACCGCTGCTACCAATGAGGTTCCTGAGGTCACAGTGTTTTCCAAGTCTCCCG
		TGACACTGGGTCAGCCCAACACCCTCATTTGTCTTGTGGACAACATCTTTCcTCCTGTGGTCAACATCAC
		ATGGCTGAGCAATGGGCAGTCAGTCACAGAAGGTGTTTCTGAGACCAGCTTCCTCTCCAAGAGTGATCAT
		TCCTTCTTCAAGATCAGTTACCTCACCTTCCTCCCTTCTGCTGATGAGATTTATGACTGCAAGGTGGAGC
		ACTGGGGCCTGGACCAGCCTCTTGTGAAACACTGGGAGCCTGAGATTCCAGCCCCTATGTCAGAGCTCAC
		AGAGACTGTGGTCTGTGCCCTGGGGTTGTCTGTGGGCCTCATGGGCATTGTGGTGGGCACTGTCTTCATC
		ATCCAAGGCCTGCGTTCAGTTGGTGCTTCCAGACACCAAGGGCCATTGTGAATCCCATCCTGGAAGGGAA
		GGTGCATCGCCATCTACAGGAGCAGAAGAATGGACTTGCTAAATGACCTAGCACTATTCTCTGGCCCGAT
		TTATCATATCCCTTTTCTCCTCCAAATATTTCTCCTCTCACCTTTTCTCTGGGACTTAAGCTGCTATATC
		CCCTCAGAGCTCACAAATGCCTTTACATTCTTTCCCTGACCTCCTGATTTTTTTTTTCTTTTCTCAAATG
		TTACCTACAAAGACATGCCTGGGGTAAGCCACCCGGCTACCTAATTCCTCAGTAACCTCCATCTAAAATC
		TCCAAGGAAGCAATAAATTCCTTTTATGAGATCTATGTCAAATTTTTCCATCTTTCATCCAGGGCTGACT
		GAAACTATGGCTAATAATTGGGGTACTCTTATGTTTCAATCCAATTTAACCTCATTTCCCAGATCATTTT
		TCATGTCCAGTAACACAGAAGCCACCAAGTACAGTATAGCCTGATAATATGTTGATTTCTTAGCTGACAT
		TAATATTTCTTGCTTCCTTGTGTTCCCACCCTTGGCACTGCCACCCACCCCTCAATTCAGGCAACAATGA
		AATTAATGGATACCGTCTGCCCTTGGCCCAGAATTGTTATAGCAAAAATTTTAGAACCAAAAAATAAGTC
		TGTACTAATTTCAATGTGGCTTTTAAAAGTATGACAGAGAAATAAGTTAGGATAAAGGAAATTTGAATCT
		CA
31	Transcribed locus	>gi|3807951|gb|AI225238.1|AI225238 qx12c04.x1 NCI_CGAP_Lym12 Homo sapiens
		cDNA clone IMAGE: 2001126 3′, mRNA sequence
		AGCGGCCGCCCTTTTTTTTTTTTTTTGAATGTTTTTATATTTTTATGTTTTTCTCTCTCACCACATTAGA
		GATTCACATGTCAAAAAAAAAGTTCAAAGATTCCACTTAAATGGTAGTCAAAATTAAAAGCATGTTGTTT
		AATTTGCCAACTATTCCATAAATCCTGTGCTTGAAGCACTACCTTTTATCAACCACTTGAAAGGAAGGAA
		TATGAAGTGTGACTCTTGAGGATTGCAGTTCCATTTCTCCACAGACATAGCAGGGTGTGTAGTTCCAAAT
		GGGTTTCTTCCAAAGTCATCTCCTCAGAGTAGGACTGTCTGAGTAGTCATTCTGATAATGTTGCCATTAA
		CTACAAGCACATCTGAGAACCCTCGTAAGGAAGTGCCATTAGATTCAGA
32	Amphiphysin (Stiff-	>gi|51466133|ref|XM_499518.1|PREDICTED: Homo sapiens LOC442534
	Man syndrome with	(LOC442534), mRNA
	breast cancer	GGCCCAGCCCTAGGAGGGGGCAGTCCCACAGCAGGCTCACACCCTGCCCTTCAGAGTTGCAGCAGCTAAT
	128 kDa autoantigen)	GCTGATGCCAGGACCTTGTCCTGCCAGGAAGCCTCTGATTAGGGCTGTGAACCAACTTCCTTTTCACATC
		TGCAAGGACTCTGCTCTAAGCTCAAATTTTGCAGTTTCTGCTGTCATCACAGCTGGGAATGAGAAAGGGA
		AGGGGCTCCAGTTGGTCTCCCTCTGCCTCTGGAGCACACGTGGAGGACATGAGGCTTCCGCAGGAACAGC
		TCTGAAAGCTGAGTTCTCGGGTCCCTGTGAAGGAGGGAAGCTTGCCTGCCTTGGAGCGTGAAAAAGTCTT
		GCTGGACAGAAGTCTCACGGTTTAAAACTGGGAAGGGAGAGGATTGAGATCACACTAGAATGCACAGAAA
		ATTCTT
33	dendritic cell-	>gi|40548404|ref|NM_172004.2|Homo sapiens dendritic cell-associated
	associated lectin-1	lectin-1 (DCAL1), mRNA
		ATGGTTAGTAATTTCTTCCATGTCATACAAGTATTCGAGAAATCTGCTACCTTGATTAGTAAGACTGAAC
		ACATTGGTTTTGTCATTTATTCATGGAGGAAGTCCACCACCCACTTGGGGAGCAGAAGGAAATTTGCCAT
		CTCAATTTACTTATCAGAAGTTTCTTTGCAGAAATATGATTGTCCCTTCAGTGGGACATCATTTGTGGTC
		TTCTCTCTCTTTTTGATCTGTGCAATGGCTGGAGATGTAGTCTACGCTGACATCAAAACTGTTCGGACTT
		CCCCGTTAGAACTCGCGTTTCCACTTCAGAGATCTGTTTCTTTCAACTTTTCTACTGTCCATAAATCATG
		TCCTGCCAAAGACTGGAAGGTGCATAAGGGAAAATGTTACTGGATTGCTGAAACTAAGAAATCTTGGAAC
		AAAAGTCAAAATGACTGTGCCATAAACAATTCATATCTCATGGTGATTCAAGACATTACTGCTATGGTGA
		GATTTAACATTTAGAGGTGACAGCATCCCCCACACTGGCAGTGAATTTTTTGTGCTACAAACTTGGCAAA
		AGTCTGTGAAAAGAAGTTTCAACTTCATGTGTTATTAACTATACAAATATTAGTTGAATGAATTGTTGAA
		TTACAAAAAAAAAAAAAAA

TABLE 1B
Probes for identifying genes of Table 1 (and their fold upregulation in Mage cancer patients)
Probe				Fold
set ID	Gene name	Probeset sequence	Full gene sequence	change
1558972_	chromosome	ttctaagacccacatttggttatt	>gi|58218985|ref|NM_001010923.1|Homo sapiens	44.93
s_at	6 open	gaaggccacagcgaatcttaacct	chromosome 6 open reading frame 190 (C6orf190),
	reading	aacagccttgac	mRNA
	frame 190	aaactgcaccataggtgtttttag	ATACTTACAATTACGAGATTTATATTTGCATTAGTCTCTTTGGCTGG
		actcatataatttgttatttttca	TGGGTAGGGGTGAGAGGCTCTTC
		aacaatagtgaa	CTGGATCCCTTATTTTCTACAGGAGAGGAGGAAAACACCTGGGATGC
		taattaatattnttgtttggaatt	TCCAGTGCTCTTACGCAGATAAT
		tgagnacaattaaatttgtacttt	GATCATTAACATCAGCCTCTCTGATCAAAGAGCTACTCCACCCCACT
		tagtaactacca	CTGGCTGTAGTGTGACATTCCTG
		ttctttgattagaaaattaagaga	CCTGCCTGAGGAAGAAATGGTGAGCAGGGGCTGCAATTGCAGACAAG
		atgcatatcttactttggttgtaa	TGTCACCCAGAAGCCACAAGTTT
		attatcaagggc	CTGTGAGCACCAGGTCTACAAACTACCCAAGGCATAGCAATGGCATT
		tttctaatagaaatcatatataac	ATCACTGGAAGAATTCGTCCACT
		atttctaaatataagtcctttcac	CCCTTGACCTCAGGACCCTACCCAGGGTTCTAGAAATCCAGGCAGGC
		atactgtgtttc	ATCTATCTTGAAGGCTCTATTTA
		cagttgtcttgatattgaaaagtg	TGAAATGTTTGGAAATGAATGCTGTTTTTCAACAGGAGAAGTGATTA
		taataaacttcatgctcacctat	AAATTACTGGTCTCAAAGTTAAG
		[Seq ID No 49]	AAGATCATAGCTGAAATTTGTGAGCAGATTGAAGGTTGTGAGTCTCT
			ACAGCCATTTGAACTGCCTATGA
			ATTTTCCAGGTCTTTTTAAGATTGTGGCTGATAAAACTCCATACCTT
			ACTATGGAAGAAATCACAAGGAC
			CATTCATATTGGACCAAGTAGACTAGGGCATCCTTGCTTCTATCATC
			AGAAGGATATAAAACTAGAGAAC
			CTCATCATAAAGCAGGGTGAGCAAATCATGCTCAACTCAGTTGAAGA
			GATTGATGGAGAAATAATGGTGA
			GCTGTGCAGTAGCAAGGAATCATCAAACTCACTCATTTAATTTGCCT
			TTGTCACAAGAAGGAGAATTCTA
			CGAGTGTGAAGATGAACGTATTTACACTCTAAAGGAGATTGTTGAAT
			GGAAGATTCCTAAGAACAGAACA
			AGAACTGTAAACCTTACAGATTTTTCAAATAAGTGGGACTCAACGAA
			TCCATTTCCTAAAGACTTTTATG
			GTACCCTGATTCTCAAGCCTGTTTATGAAATTCAAGGTGTGATGAAA
			TTTCGAAAAGATATAATCCGCAT
			CCTCCCCAGTCTAGATGTCGAAGTCAAAGACATCACTGATTCTTACG
			ATGCTAACTGGTTTCTTCAGCTG
			TTATCAACAGAAGATCTTTTTGAAATGACTAGTAAAGAGTTCCCCAT
			AGTGACTGAAGTCATAGAAGCAC
			CTGAAGGAAACCACCTGCCCCAAAGCATTTTACAGCCTGGGAAAACC
			ATTGTGATCCACAAAAAGTACCA
			GGCATCAAGAATCTTAGCTTCAGAAATTAGAAGCAATTTTCCTAAAA
			GACACTTCTTGATCCCCACTAGC
			TATAAAGGCAAGTTCAAGCGGCGACCGAGGGAGTTCCCAACGGCCTA
			TGACCTAGAGATCGCTAAGAGTG
			AAAAGGAGCCTCTTCACGTGGTGGCCACCAAAGCGTTTCATTCCCCT
			CATGACAAGCTGTCATCCGTATC
			TGTTGGGGACCAGTTTCTGGTGCATCAGTCAGAGACGACTGAAGTCC
			TCTGTGAGGGAATAAAAAAAGTG
			GTGAATGTTCTGGCCTGTGAAAAAATCCTCAAAAAGTCCTATGAGGC
			TGCGCTGCTCCCTTTGTACATGG
			AAGGAGGTTTTGTAGAGGTGATTCATGATAAGAAACAGTACCCGATT
			TCTGAGCTCTGTAAACAGTTCCG
			TTTGCCCTTCAATGTGAAGGTGTCTGTCAGGGATCTTTCCATTGAAG
			AGGACGTGTTGGCTGCCACACCA
			GGACTGCAGTTGGAGGAGGACATTACAGACTCTTACCTACTCATAAG
			TGACTTTGCCAACCCCACGGAGT
			GCTGGGAAATTCCTGTGGGCCGCTTGAATATGACTGTTCAGTTAGTT
			AGTAATTTCTCTAGGGATGCAGA
			ACCATTTCTAGTCAGGACTCTGGTAGAAGAGATCACTGAAGAGCAAT
			ATTACATGATGCGGAGATATGAA
			AGCTCAGCCTCACATCCCCCACCTCGCCCTCCGAAACACCCCTCAGT
			AGAGGAAACAAAGTTAACCCTGC
			TAACCTTAGCAGAAGAAAGGACGGTAGACCTGCCCAAGTCTCCCAAG
			CGTCATCACGTAGACATAACCAA
			GAAACTTCACCCAAATCAAGCTGGCCTGGATTCAAAAGTACTGATTG
			GTAGTCAGAATGATTTGGTGGAT
			GAAGAGAAAGAAAGGAGCAACCGTGGGGCCACAGCAATAGCAGAAAC
			ATTCAAAAATGAAAAACATCAAA
			AATAACAAGATGTGACAGAAGCCACTTAGGCAGCAAACATAAATGTT
			GCAGTGAAAAAAGAAGCTAGCCT
			TCTAGCTGAAAAACGAGTATTCCCCAATGGACTCCAGAAGAAACTTG
			ATTCATCGCTGCAAAGGAAAGAA
			CAACCTTAAAACTTTTAACAGATAAAACTTACAGAAACCTATGATAT
			AGAATTCATATAGTCTATTCTGT
			TGTGTCTAAATCTGTAGGCATTGTGTTGTTGTTCTTTAGGACGTATT
			TATTTAACTTGCACATTTTTTCA
			GATTCTTATTTCTACTACCAACAACTAAGTAATTGGGAAATAATTCT
			GTATTTCAGTTTCTGAGTAAAAC
			CAGTCTGAAATAGGATAAAAGCCACCAAATATTTTCTTTTTTTTCCA
			GAATTTGTTTTGCCATTTTTTAG
			TGCTATCATCATTCCTAACAAGACTAACTTACAGAAAAATAATTATA
			TCTGACTGATTTAAAATGTTCAG
			GTTTCTTATCCAAATCCCTTGGAACTATGGAAAGGAGTTTGATTTCA
			CATTCACAGTGTATTTACAAAAT
			ACGCTGTGTCATAAATATGTTTGAATTCCAACAGCCAAAGCCATTGA
			GAGTCATAGGAGTTTTCCATAAC
			CTTCTCTTCTATGACCCAACAACAAGCTCATGACTGAAATTTCACCA
			GATTTCTGAGACGATGTCTTAAT
			ATTCTATGTGCTATGTACCAGATAATTCTTTAGATGAATGTTTCTTA
			GGATTGTAGGAAAATTATCTAGT
			TAATCATAATATTTGATGGAAAGAAAAAGACAATAAAATTGTAATAT
			AATAAATTTGGCTGACAAGAAAC
			CAAAGTGATTCTTAATTAGTATACATCAGAATGATGCTCTTATAGTT
			GTACCATCTATAAAAATTACTTT
			AAGGGCTCTCACATTTTAATAATTTATCTTATTATGTATTAAGTATA
			CAGGAACAATATTATTTTTCCTT
			TAACAAAATGAAGAGACAGGCTATCTGGTTAATGTTACATAGGAATT
			TAATAGTAATGCTTGAACTTCAT
			CCATAGATCATACTCTGTACAAAATTTGTTAGCTAACATCCTATCTC
			ATAATTATTTTATGTTTTGTGGA
			GAAATTTGTTGATTTTGTACCAAAGTGTTTCTGAAGACAATAAATTG
			TGAGTCAACTTTAGAACAAAAAA
			AATTAGAGTTTTTTCAATGTTTATATTCTGATTAAGCTTACTTTACC
			TTACATTTTTTCTAAGTAACAAT
			GAATCCTGATTTCTAGTGTCCTAAAAATTGCTTAGTGATTTGATTGT
			GGTAATATCATTTCTTATCTACA
			ATGTCTAAAGTTTTATGGGACAGTTTTTCTTTTATTTATTTTGCCTG
			TTTGTGCAGATAAGAACAGAAAC
			TTTTCTAAGACCCACATTTGGTTATTGAAGGCCACAGCGAATCTTAA
			CCTAACAGCCTTGACAAACTGCA
			CCATAGGTGTTTTTAGACTCATATAATTTGTTATTTTTCAAACAATA
			GTGAATAATTAATATTTTTGTTT
			GGAATTTGAGAACAATTAAATTTGTACTTTTAGTAACTACCATTCTT
			TGATTAGAAAATTAAGAGAATGC
			ATATCTTACTTTGGTTGTAAATTATCAAGGGCTTTCTAATAGAAATC
			ATATATAACATTTCTAAATATAA
			GTCCTTTCACATACTGTGTTTCCAGTTGTCTTGATATTGAAAAGTGT
			AATAAACTTCATGCTCACCTATT
			GGAGATTTGGGAAGGTTGAAAATAAACTTCCTAATTTTTAAAAAAAA
			AA
202957_	hematopoietic	ttgctggcttctcttatactaacc	>gi|37059786|ref|NM_005335.3|Homo sapiens	19.09
_at	cell-	cagagtttgtcattaatgtgtagg	hematopoietic cell-specific Lyn substrate 1
	specific	tgaatgcaaact	(HCLS1), mRNA
	Lyn	ccatcgttgagcctggggtgtaag	GTGGACGCGAGGAGCCGGGCGCTTAGAACAGAGGCTTGCACAGGTGG
	substrate 1	acttcaagccaagcgtatgtatca	AGATGTGGAAGTCTGTAGTGGGC
		attctagtcttc	CATGATGTGTCTGTTTCCGTGGAGACCCAGGGTGATGATTGGGACAC
		caggattcacggtgcacatgctgg	AGATCCTGACTTTGTGAATGACA
		cattcaacatgtggaaagcttgtc	TCTCTGAAAAGGAGCAACGATGGGGAGCCAAGACCATCGAGGGGTCT
		ttagaggccttt	GGACGCACAGAACACATCAACAT
		cttgtatgtgtagcttgctagttt	CCACCAGCTGAGGAACAAAGTATCAGAGGAGCATGATGTTCTCAGGA
		gttttctacatttgaaaatgttta	AGAAAGAGATGGAGTCAGGGCCC
		gtttagaataag	AAAGCATCCCATGGCTATGGAGGTCGGTTTGGAGTAGAAAGAGACCG
		cgcattatccaattatagaggtac	AATGGACAAGAGTGCAGTGGGCC
		aattttccaaacttccagaaactc	ATGAGTATGTTGCCGAGGTGGAGAAGCACTCTTCTCAGACGGATGCT
		atcaaatgaaca	GCCAAAGGCTTTGGGGGCAAGTA
		gacaatgtcaaaactactgtgtct	CGGAGTTGAGAGGGACAGGGCAGACAAGTCAGCAGTCGGCTTTGATT
		gataccaaaatgcttcagtatttg	ATAAAGGAGAAGTGGAGAAGCAT
		taatttttcaag	ACATCTCAGAAAGATTACTCTCGTGGCTTTGGTGGCCGGTACGGGGT
		tcagaagctgatgttcctggtaaa	GGAGAAGGATAAATGGGACAAAG
		agtt	CAGCTCTGGGATATGACTACAAGGGAGAGACGGAGAAACACGAGTCC
		[Seq ID No 50]	CAGAGAGATTATGCCAAGGGCTT
			TGGTGGCCAGTATGGAATCCAGAAGGACCGAGTGGATAAGAGCGCTG
			TCGGCTTCAATGAAATGGAGGCC
			CCGACCACAGCTTATAAGAAGACGACGCCCATAGAAGCCGCTTCTAG
			TGGTGCCCGTGGGCTGAAGGCGA
			AATTTGAGTCCATGGCTGAGGAGAAGAGGAAGCGAGAGGAAGAGGAG
			AAGGCACAGCAGGTGGCCAGGAG
			GCAACAGGAGCGAAAGGCTGTGACAAAGAGGAGCCCTGAGGCTCCAC
			AGCCAGTGATAGCTATGGAAGAG
			CCAGCAGTACCGGCCCCACTGCCCAAGAAAATCTCCTCAGAGGCCTG
			GCCTCCAGTTGGGACTCCTCCAT
			CATCAGAGTCTGAGCCTGTGAGAACCAGCAGGGAACACCCAGTGCCC
			TTGCTGCCCATTAGGCAGACTCT
			CCCGGAGGACAATGAGGAGCCCCCAGCTCTGCCCCCTAGGACTCTGG
			AAGGCCTCCAGGTGGAGGAAGAG
			CCAGTGTACGAAGCAGAGCCTGAGCCTGAGCCCGAGCCTGAGCCCGA
			GCCTGAGAATGACTATGAGGACG
			TTGAGGAGATGGACAGGCATGAGCAGGAGGATGAACCAGAGGGGGAC
			TATGAGGAGGTGCTCGAGCCTGA
			AGATTCTTCTTTTTCTTCTGCTCTGGCTGGATCATCAGGCTGCCCGG
			CTGGGGCTGGGGCTGGGGCTGTG
			GCTCTGGGGATCTCAGCTGTGGCTCTATATGATTACCAAGGAGAGGG
			AAGTGATGAGCTTTCCTTTGATC
			CGGACGACGTAATCACTGACATTGAGATGGTGGACGAGGGCTGGTGG
			CGGGGACGTTGCCATGGCCACTT
			TGGACTCTTCCCTGCAAATTATGTCAAGCTTCTGGAGTGACTAGAGC
			TCACTGTCTACTGCAACTGTGAT
			TTCCCATGTCCAAAGTGGCTCTGCCTCCACCCCCTCCCTATTCCTGA
			TGCAAATGTCTAACCAGATGAGT
			TTCTGGACAGACTTCCCTCTCCTGCTTCATTAAGGGCTTGGGGCAGA
			GACAGCATGGGGAAGGAGGTCCC
			CTTCCCCAAGAGTCCTCTCTATCCTGGATGAGCTCATGAACATTTCT
			CTTGTGTTCCTGACTCCTTCCCA
			ATGAACACCTCTCTGCCACCCCAAGCTCTGCTCTCCTCCTCTGTGAG
			CTCTGGGCTTCCCAGTTTGTTTA
			CCCGGGAAAGTACGTCTAGATTGTGTGGTTTGCCTCATTGTGCTATT
			TGCCCACTTTCCTTCCCTGAAGA
			AATATCTGTGAACCTTCTTTCTGTTCAGTCCTAAAATTCGAAATAAA
			GTGAGACTATGGTTCACCTGTAA
			AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
			AAAAAAAAAAAAAAAAAAAAAA
204116_	interleukin	ttctggctggaacggacgatgccc	>gi|4557881|ref|NM_00206.1|Homo sapiens	61.98
at	2 receptor,	cgaattcccaccctgaagaaccta	interleukin 2 receptor, gamma (severe combined
	gamma	gaggatcttgtt	immunodeficiency) (IL2RG), mRNA
	(severe	actgaataccacgggaacttttcg	GAAGAGCAAGCGCCATGTTGAAGCCATCATTACCATTCACATCCCTC
	combined	gcctggagtggtgtgtctaaggga	TTATTCCTGCAGCTGCCCCTGCT
	immuno-	ctggctgagagtctgcagccagac	GGGAGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAG
	deficiency)	tacagtgaacgactctgcctcgtc	ACACCACAGCTGATTTCTTCCTG
		agtgagattcccccaaaaggaggg	ACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCC
		gcccttggggaggggcctggggcc	AGAGGTTCAGTGTTTTGTGTTCA
		tccccatgcaaccagcatagcccc	ATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCCCAG
		tactgggcccccccatgttacacc	CCTACCAACCTCACTCTGCATTA
		ctaaagcctgaaacctgaacccca	TTGGTACAAGAACTCGGATAATGATAAAGTCCAGAAGTGCAGCCACT
		atcctctgacagaagaaccccagg	ATCTATTCTCTGAAGAAATCACT
		gtcctgtagccctaagtggtacta	TCTGGCTGTCAGTTGCAAAAAAAGGAGATCCACCTCTACCAAACATT
		actttccttcattcaacccacctg	TGTTGTTCAGCTCCAGGACCCAC
		cgtctcatactcacctcaccccac	GGGAACCCAGGAGACAGGCCACACAGATGCTAAAACTGCAGAATCTG
		tgtggctgatttggaattttgtgc	GTGATCCCCTGGGCTCCAGAGAA
		ccccatgtaagcacc	CCTAACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGA
		[Seq ID No 51]	ACAACAGATTCTTGAACCACTGT
			TTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGAC
			TGAACAATCAGTGGATTATAGAC
			ATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACGTTT
			CGTGTTCGGAGCCGCTTTAACCC
			ACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGGAGCCACCCAATCC
			ACTGGGGGAGCAATACTTCAAAA
			GAGAATCCTTTCCTGTTTGCATTGGAAGCCGTGGTTATCTCTGTTGG
			CTCCATGGGATTGATTATCAGCC
			TTCTCTGTGTGTATTTCTGGCTGGAACGGACGATGCCCCGAATTCCC
			ACCCTGAAGAACCTAGAGGATCT
			TGTTACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTA
			AGGGACTGGCTGAGAGTCTGCAG
			CCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAA
			AGGAGGGGCCCTTGGGGAGGGGC
			CTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCCCCA
			TGTTACACCCTAAAGCCTGAAAC
			CTGAACCCCAATCCTCTGACAGAAGAACCCCAGGGTCCTGTAGCCCT
			AAGTGGTACTAACTTTCCTTCAT
			TCAACCCACCTGCGTCTCATACTCACCTCACCCCACTGTGGCTGATT
			TGGAATTTTGTGCCCCCATGTAA
			GCACCCCTTCATTTGGCATTCCCCACTTGAGAATTACCCTTTTGCCC
			CGAACATGTTTTTCTTCTCCCTC
			AGTCTGGCCCTTCCTTTTCGCAGGATTCTTCCTCCCTCCCTCTTTCC
			CTCCCTTCCTCTTTCCATCTACC
			CTCCGATTGTTCCTGAACCGATGAGAAATAAAGTTTCTGTTGATAAT
			CATC
204661_	CD52	acagccacgaagatcctaccaaaa	>gi|68342029|ref|NM_001803.2|Homo sapiens CD52	30.71
at	antigen	tgaagcgcttcctcttcctcctac	molecule (CD52), mRNA
	(CAMPATH-1	tcaccatcagcc	CTCCTGGTTCAAAAGCAGCTAAACCAAAAGAAGCCTCCAGACAGCCC
	antigen)///	tcctggttatggtacagatacaaa	TGAGATCACCTAAAAAGCTGCAT
	CD52	ctggactctcaggacaaaacgaca	CCAAGACAGCCACGAAGATCCTACCAAAATGAAGCGCTTCCTCTTCC
	antigen	ccagccaaaccagcagcccctcag	TCCTACTCACCATCAGCCTCCTG
	(CAMPATH-1	catccagcagcatgagcggaggca	GTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAG
	antigen)	ttttccttttcttcgtggccaatg	CCAAACCAGCAGCCCCTCAGCAT
		ccataatccacctcttctgcttca	CCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCC
		gttgaggtgacacgtctcagcctt	ATAATCCACCTCTTCTGCTTCAG
		agccctgtgccc	TTGAGGTGACACGTCTCAGCCTTAGCCCTGTGCCCCCTGAAACAGCT
		cctgaaacagctgccaccatcact	GCCACCATCACTCGCAAGAGAAT
		cgcaagagaatcccctccatcttt	CCCCTCCATCTTTGGGAGGGGTTGATGCCAGACATCACCAGGTTGTA
		gggaggggttgatgccagacatca	GAAGTTGACAGGCAGTGCCATGG
		ccaggttgtagaagttgacaggca	GGGCAACAGCCAAAATAGGGGGGTAATGATGTAGGGGCCAAGCAGTG
		gtgccatgggggcaacagccaaaa	CCCAGCTGGGGGTCAATAAAGTT
		taggggggtaatgatgtaggggcc	ACCCTTGTACTTGCAAAAAAAAAAAAAAAAAAA
		aagc
		[Seq ID No 52]
205831_	CD2	agacctcgagttcagccaaaacct	>gi|31542293|ref|NM_001767.2|Homo sapiens CD2	22.66
at	antigen	ccccatggggcagcagaaaactca	molecule (CD2), mRNA
	(p50),	ttgtccccttcctctaattaaaaa	ACCAACCCCTAAGATGAGCTTTCCATGTAAATTTGTAGCCAGCTTCC
	sheep red	agatagaaactgtctttttcaata	TTCTGATTTTCAATGTTTCTTCC
	blood cell	aaaagcactgtggatttctgccct	AAAGGTGCAGTCTCCAAAGAGATTACGAATGCCTTGGAAACCTGGGG
	receptor///	cctgatgtgcatatccgtacttcc	TGCCTTGGGTCAGGACATCAACT
	CD2	atgaggtgttttctgtgtgcagaa	TGGACATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAA
	antigen	cattgtcacctc	TGGGAAAAAACTTCAGACAAGAA
	(p50),	ctgaggctgtgggccacagccacc	AAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAAAAAG
	sheep red	tctgcatcttcgaactcagccatg	ATACATATAAGCTATTTAAAAAT
	blood cell	tggtcaacatct	GGAACTCTGAAAATTAAGCATCTGAAGACCGATGATCAGGATATCTA
	receptor	ggagtttttggtctcctcagagag	CAAGGTATCAATATATGATACAA
		ctccatcacaccagtaaggagaag	AAGGAAAAAATGTGTTGGAAAAAATATTTGATTTGAAGATTCAAGAG
		caatataagtgt	AGGGTCTCAAAACCAAAGATCTC
		gattgcaagaatggtagaggaccg	CTGGACTTGTATCAACACAACCCTGACCTGTGAGGTAATGAATGGAA
		agcacagaaatcttagagatttct	CTGACCCCGAATTAAACCTGTAT
		tgtcccctctca	CAAGATGGGAAACATCTAAAACTTTCTCAGAGGGTCATCACACACAA
		ggtcatgtgtagatgcgataaatc	GTGGACCACCAGCCTGAGTGCAA
		aagtgattggtgtgcctgggtctc	AATTCAAGTGCACAGCAGGGAACAAAGTCAGCAAGGAATCCAGTGTC
		actacaagcagc	GAGCCTGTCAGCTGTCCAGAGAA
		ctatctgc	AGGTCTGGACATCTATCTCATCATTGGCATATGTGGAGGAGGCAGCC
		[Seq ID No 53]	TCTTGATGGTCTTTGTGGCACTG
			CTCGTTTTCTATATCACCAAAAGGAAAAAACAGAGGAGTCGGAGAAA
			TGATGAGGAGCTGGAGACAAGAG
			CCCACAGAGTAGCTACTGAAGAAAGGGGCCGGAAGCCCCAACAAATT
			CCAGCTTCAACCCCTCAGAATCC
			AGCAACTTCCCAACATCCTCCTCCACCACCTGGTCATCGTTCCCAGG
			CACCTAGTCATCGTCCCCCGCCT
			CCTGGACACCGTGTTCAGCACCAGCCTCAGAAGAGGCCTCCTGCTCC
			GTCGGGCACACAAGTTCACCAGC
			AGAAAGGCCCGCCCCTCCCCAGACCTCGAGTTCAGCCAAAACCTCCC
			CATGGGGCAGCAGAAAACTCATT
			GTCCCCTTCCTCTAATTAAAAAAGATAGAAACTGTCTTTTTCAATAA
			AAAGCACTGTGGATTTCTGCCCT
			CCTGATGTGCATATCCGTACTTCCATGAGGTGTTTTCTGTGTGCAGA
			ACATTGTCACCTCCTGAGGCTGT
			GGGCCACAGCCACCTCTGCATCTTCGAACTCAGCCATGTGGTCAACA
			TCTGGAGTTTTTGGTCTCCTCAG
			AGAGCTCCATCACACCAGTAAGGAGAAGCAATATAAGTGTGATTGCA
			AGAATGGTAGAGGACCGAGCACA
			GAAATCTTAGAGATTTCTTGTCCCCTCTCAGGTCATGTGTAGATGCG
			ATAAATCAAGTGATTGGTGTGCC
			TGGGTCTCACTACAAGCAGCCTATCTGCTTAAGAGACTCTGGAGTTT
			CTTATGTGCCCTGGTGGACACTT
			GCCCACCATCCTGTGAGTAAAAGTGAAATAAAAGCTTTGACTAGAAA
			AAAAAAAAAAAAAAAAAAAAAAA
			AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
205890_	ubiquitin D	Gatcttaaagccacggagaagcct	>gi|50355987|ref|NM_006398.2|Homo sapiens	30.29
s_at		ctcatcttatggcattgacaaaga	ubiquitin D (UBD), mRNA
		gaagaccatccaccttaccctgaa	GATTGCTTGAGGAGAGAAGTATGTGATCAGAAAGCATTCTTTGTCTA
		agtggtgaagcccagtgatgagga	TTAACTCCTGCCCAGCAAAAGTG
		gctgcccttgtttcttgtggagtc	AAAGAAAATTCATGGGAGCATGCAAGAACAAAGAGCACAGCAAAGCT
		aggtgatgaggcaaagaggcacct	GGACAAACACAGCAATCCAGGCA
		cctccaggtgcgaaggtccagctc	GGGGATTTCCAACTCAACTCTGGTATGTAAGCTGCATGCAAAGTCCT
		agtggcacaagtgaaagcaatgat	TTTTCTGTCTCTGGTTTCTGGCC
		cgagactaagacgggtataatccc	CCTTGTCTGCAGAGATGGCTCCCAATGCTTCCTGCCTCTGTGTGCAT
		tgagacccagattgtgacttgcaa	GTCCGTTCCGAGGAATGGGATTT
		tggaaagagactggaagatgggaa	AATGACCTTTGATGCCAACCCATATGACAGCGTGAAAAAAATCAAAG
		gatgatggcagattacggcatcag	AACATGTCCGGTCTAAGACCAAG
		aaagggcaacttactcttcctggc	GTTCCTGTGCAGGACCAGGTTCTTTTGCTGGGCTCCAAGATCTTAAA
		atcttattgtattggagggtgacc	GCCACGGAGAAGCCTCTCATCTT
		accctggggatggggtgttggcag	ACGGCATTGACAAAGAGAAGACCATCCACCTTACCCTGAAAGTGGTG
		gggtcaaaaagcttatttctttta	AAGCCCAGTGATGAGGAGCTGCC
		atctcttactcaacgaacacatct	CTTGTTTCTTGTGGAGTCAGGTGATGAGGCAAAGAGGCACCTCCTCC
		tctgatgatttcccaaaattaatg	AGGTGCGAAGGTCCAGCTCAGTG
		agaatgagatgagtagagtaagat	GCACAAGTGAAAGCAATGATCGAGACTAAGACGGGTATAATCCCTGA
		ttgggtgggatgggtaggatgaag	GACCCAGATTGTGACTTGCAATG
		tatattgcccaactctatgtttct	GAAAGAGACTGGAAGATGGGAAGATGATGGCAGATTACGGCATCAGA
		ttga	AAGGGCAACTTACTCTTCCTGGC
		[Seq ID No 54]	ATCTTATTGTATTGGAGGGTGACCACCCTGGGCATGGGGTGTTGGCA
			GGGGTCAAAAAGCTTATTTCTTT
			TAATCTCTTACTCAACGAACACATCTTCTGATGATTTCCCAAAATTA
			ATGAGAATGAGATGAGTAGAGTA
			AGATTTGGGTGGGATGGGTAGGATGAAGTATATTGCCCAACTCTATG
			TTTCTTTGATTCTAACACAATTA
			ATTAAGTGACATGATTTTTACTAATGTATTACTGAGACTAGTAAATA
			AATTTTTAAGCCAA
206118_	signal	gctgacatcctgcgagactacaaa	>gi|21618332|ref|NM_003151.2|Homo sapiens	13.56
at	transducer	gttattatggctgaaaacattcct	signal transducer and activator of
	and	gaaaaccctctg	transcription 4 (STAT4), mRNA
	activator	aagtacctatatcctgacattccc	AGAGGACGCCCGGTGAAGGGGCTCCAGCCTGGCAGTTTCTGCGTGTT
	of tran-	aaagacaaagccttcggtaaacac	AGCATTTCTAGAATAGAGTGGGT
	scription 4	tacagct ctcag	GGGAACTGACCCAAGTAAAGTCCCAGAGACTCGAACACTGACGCACA
		ccttgcgaagtttcaagaccaaca	GGAAAGCCTCAAGTGGGAGGAGA
		gaaaggggtgacaaaggttatgtt	AATGCAAATCCCCTACTGATGATGGCGTCAGCGGCTTTCTCCTAGGG
		ccttctgttttt	ACTGTGAGGGGCGCTTCTGACTT
		atccccatctcaacaatccgaagt	TGGACTTGAGCACTGCCTGGGACCTGTGCTGAGAGAGCGCTAGCATG
		gattcaacagagccacattctcca	TCTCAGTGGAATCAAGTCCAACA
		tcagaccttctt	GTTAGAAATCAAGTTTTTGGAGCAGGTGGATCAATTCTATGATGACA
		cccatgtctccaagtgtgtatgcg	ACTTTCCCATGGAAATTCGGCAT
		gtgttgagagaaaacctgagtccc	CTGTTGGCCCAATGGATTGAAAATCAAGACTGGGAGGCAGCTTCTAA
		acaacaattgaa	CAATGAAACCATGGCAACGATTC
		actgcaatgaagtctccttattct	TTCTTCAAAACTTGTTAATACAACTGGATGAACAGTTAGGTCGTGTT
		gctgaatgacaggataaactctga	TCCAAAGAGAAAAACCTACTCTT
		cgcaccaagaaa	GATACACAATCTAAAAAGAATTAGGAAGGTCCTTCAGGGAAAATTTC
		ggaagcaaatgaaaaagtttaaag	ATGGAAATCCAATGCATGTAGCT
		actgttctttgcccaataaccaca	GTGGTTATTTCAAACTGTTTAAGGGAAGAGAGGAGAATATTGGCTGC
		ttttatttcttc	AGCCAACATGCCTGTCCAGGGGC
		agctttgtaaataccaggttctag	CTCTAGAGAAATCCTTACAAAGTTCTTCAGTTTCAGAAAGACAGAGG
		gaaatgtttgacatctgaagctct	AATGTGGAGCACAAAGTGGCTGC
		cttcacactccc	CATTAAAAACAGTGTGCAGATGACAGAACAAGATACCAAATACTTAG
		gtggcactcctcaattgggag	AAGATCTGCAAGACGAATTTGAC
		[Seq ID No 55]	TACAGGTATAAAACAATTCAGACAATGGATCAGAGTGACAAGAATAG
			TGCCATGGTGAATCAGGAAGTTT
			TGACACTGCAGGAAATGCTTAACAGCCTCGATTTCAAGAGAAAGGAG
			GCTCTCAGTAAAATGACCCAAAT
			CATCCATGAGACAGACCTGTTAATGAACACCATGCTCATAGAAGAGC
			TGCAAGACTGGAAGCGGCGGCAG
			CAAATCGCCTGCATCGGGGGTCCACTCCACAATGGGCTCGACCAGCT
			TCAGAACTGCTTTACACTATTGG
			CAGAAAGTCTTTTCCAACTGAGAAGGCAATTGGAGAAACTAGAGGAG
			CAATCTACCAAAATGACATATGA
			AGGTGATCCCATTCCAATGCAAAGAACTCACATGCTAGAAAGAGTCA
			CCTTCTTGATCTACAACCTTTTC
			AAGAACTCATTTGTGGTTGAGCGACAGCCATGTATGCCAACCCACCC
			TCAGAGGCCGTTGGTACTTAAAA
			CCCTAATTCAGTTCACTGTAAAACTAAGGCTACTAATAAAATTGCCA
			GAACTAAACTATCAGGTAAAGGT
			TAAGGCATCAATTGACAAGAATGTTTCAACTCTAAGCAACCGAAGAT
			TTGTACTTTGTGGAACTAATGTC
			AAAGCCATGTCTATTGAAGAATCTTCCAATGGGAGTCTCTCAGTAGA
			ATTTCGACATTTGCAACCAAAGG
			AAATGAAGTCCAGTGCTGGAGGTAAAGGAAATGAGGGCTGTCACATG
			GTGACTGAAGAACTTCATTCCAT
			AACGTTTGAAACACAGATCTGCCTCTATGGCCTGACCATAGATTTGG
			AGACCAGCTCATTGCCTGTGGTG
			ATGATTTCCAATGTCAGTCAGTTACCTAATGCTTGGGCATCCATCAT
			TTGGTACAACGTGTCAACCAACG
			ATTCCCAGAACTTGGTTTTCTTTAATAATCCTCCACCTGCCACATTG
			AGTCAACTACTGGAGGTGATGAG
			CTGGCAGTTTTCATCGTACGTTGGTCGTGGTCTTAACTCAGATCAAC
			TCCATATGCTGGCAGAGAAGCTT
			ACAGTCCAATCTAGCTACAGTGATGGTCACCTCACCTGGGCCAAGTT
			CTGCAAGGAACATTTACCTGGTA
			AATCATTTACCTTTTGGACATGGCTTGAAGCAATATTGGATCTAATT
			AAGAAACACATTCTTCCCCTTTG
			GATTGATGGGTATGTCATGGGCTTTGTTAGCAAAGAGAAGGAACGGC
			TGTTGCTAAAGGATAAAATGCCT
			GGCACCTTTTTATTAAGATTCAGTGAAAGCCATCTCGGAGGAATAAC
			TTTCACCTGGGTGGACCATTCTG
			AAAGTGGGGAAGTGAGATTCCACTCTGTAGAACCCTACAATAAAGGC
			CGGTTGTCTGCTCTGCCATTCGC
			TGACATCCTGCGAGACTACAAAGTTATTATGGCTGAAAACATTCCTG
			AAAACCCTCTGAAGTACCTATAT
			CCTGACATTCCCAAAGACAAAGCCTTCGGTAAACACTACAGCTCTCA
			GCCTTGCGAAGTTTCAAGACCAA
			CAGAAAGGGGTGACAAAGGTTATGTTCCTTCTGTTTTTATCCCCATC
			TCAACAATCCGAAGTGATTCAAC
			AGAGCCACATTCTCCATCAGACCTTCTTCCCATGTCTCCAAGTGTGT
			ATGCGGTGTTGAGAGAAAACCTG
			AGTCCCACAACAATTGAAACTGCAATGAAGTCTCCTTATTCTGCTGA
			ATGACAGGATAAACTCTGACGCA
			CCAAGAAAGGAAGCAAATGAAAAAGTTTAAAGACTGTTCTTTGCCCA
			ATAACCACATTTTATTTCTTCAG
			CTTTGTAAATACCAGGTTCTAGGAAATGTTTGACATCTGAAGCTCTC
			TTCACACTCCCGTGGCACTCCTC
			AATTGGGAGTGTTGTGACTGAAATGCTTGAAACCAAAGCTTCAGATA
			AACTTGCAAGATAAGACAACTTT
			AAGAAACCAGTGTTAATAACAATATTAACAG
206666_	granzyme K	aaacctctcttagatctggaacca	>gi|73747815|ref|NM_002104.2|Homo sapiens	18.25
at	(granzyme	aatgcaaggttactggctggggag	granzyme K (granzyme 3; tryptase II) (GZMK),
	3; tryptase	ccaccgatccagattcattaagac	mRNA
	II)///	cttctgacaccctgcgagaagtca	GATCAACACATTTCATGTGGGCTTCTTAAATCTAAATCTTTAAAATG
	granzyme K	ctgttactgtcctaagtcgaaaac	ACTAAGTTTTCTTCCTTTTCTCT
	(granzyme	tttgcaacagccaaagttactaca	GTTTTTCCTAATAGTTGGGGCTTATATGACTCATGTGTGTTTCAATA
	3; tryptase	acggcgacccttttatcaccaaag	TGGAAATTATTGGAGGGAAAGAA
	II)	acatggtctgtg	GTGTCACCTCATTCCAGGCCATTTATGGCCTCCATCCAGTATGGCGG
		caggagatgccaaaggccagaagg	ACATCACGTTTGTGGAGGTGTTC
		attcctgtaagggtgactcagggg	TGATTGATCCACAGTGGGTGCTGACAGCAGCCCACTGCCAATATCGG
		gccccttgatctgtaaaggtgtct	TTTACCAAAGGCCAGTCTCCCAC
		tccacgctatagtctctggaggtc	TGTGGTTTTAGGCGCACACTCTCTCTCAAAGAATGAGGCCTCCAAAC
		atgaatgtggtgttgccacaaagc	AAACACTGGAGATCAAAAAATTT
		ctggaatctacaccctgttaacca	ATACCATTCTCAAGAGTTACATCAGATCCTCAATCAAATGATATCAT
		agaaataccagacttggatcaaaa	GCTGGTTAAGCTTCAAACAGCCG
		gcaaccttgtcccgcctcatacaa	CAAAACTCAATAAACATGTCAAGATGCTCCACATAAGATCCAAAACC
		attaagttacaaataattttattg	TCTCTTAGATCTGGAACCAAATG
		gatgcacttgcttcttttttccta	CAAGGTTACTGGCTGGGGAGCCACCGATCCAGATTCATTAAGACCTT
		atatgctcgcaggttagagttggg	CTGACACCCTGCGAGAAGTCACT
		tgtaagtaaagcagagcacatatg	GTTACTGTCCTAAGTCGAAAACTTTGCAACAGCCAAAGTTACTACAA
		gggtccattttt	CGGCGACCCTTTTATCACCAAAG
		gcacttgta	ACATGGTCTGTGCAGGAGATGCCAAAGGCCAGAAGGATTCCTGTAAG
		[Seq ID No 56]	GGTGACTCAGGGGGCCCCTTGAT
			CTGTAAAGGTGTCTTCCACGCTATAGTCTCTGGAGGTCATGAATGTG
			GTGTTGCCACAAAGCCTGGAATC
			TACACCCTGTTAACCAAGAAATACCAGACTTGGATCAAAAGCAACCT
			TGTCCCGCCTCATACAAATTAAG
			TTACAAATAATTTTATTGGATGCACTTGCTTTTTTTTTCCTAATATG
			CTCGCAGGTTAGAGTTGGGTGTA
			AGTAAAGCAGAGCACATATGGGGTCCATTTTTGCACTTGTAAGTCAT
			TTTATTAAGGAATCAAGTTCTTT
			TTCACTTGTATCACTGATGTATTTCTACCATGCTGGTTTTATTCTAA
			ATAAAATTTAGAAGACTCAAAAA
			AAAAAAAAAAAAAAAAAAAAAAAA
206804_	CD3G	gtaatgccaaggaccctcgaggga	>gi|4557428|ref|NM_000073.1|Homo sapiens CD3g	23.86
at	antigen	tgtatcagtgtaaaggatcacaga	molecule, gamma (CD3-TCR complex) (CD3G), mRNA
	gamma	acaagtcaaaaccactccaagtgt	GGGCTGCTCCACGCTTTTGCCGGAGACAGAGACTGACATGGAACAGG
	polypeptide	attacagaatgtgtcagaactgca	GGAAGGGCCTGGCTGTCCTCATC
	(TiT3	ttgaactaaatgcagccaccatat	CTGGCTATCATTCTTCTTCAAGGTACTTTGGCCCAGTCAATCAAAGG
	complex)	ctggctttctctttgctgaaatcg	AAACCACTTGGTTAAGGTGTATG
		tcagcattttcgtccttgctgttg	ACTATCAAGAAGATGGTTCGGTACTTCTGACTTGTGATGCAGAAGCC
		gggtctacttca	AAAAATATCACATGGTTTAAAGA
		ttgctggacaggatggagttcgcc	TGGGAAGATGATCGGCTTCCTAACTGAAGATAAAAAAAAATGGAATC
		agtcgagagcttcagacaagcaga	TGGGAAGTAATGCCAAGGACCCT
		ctctgttgcccaatgaccagctct	CGAGGGATGTATCAGTGTAAAGGATCACAGAACAAGTCAAAACCACT
		accagcccctcaaggatcgagaag	CCAAGTGTATTACAGAATGTGTC
		atgaccagtacagccaccttcaag	AGAACTGCATTGAACTAAATGCAGCCACCATATCTGGCTTTCTCTTT
		gaaaccagttgaggaggaattgaa	GCTGAAATCGTCAGCATTTTCGT
		ctcaggactcagagtagtccaggt	CCTTGCTGTTGGGGTCTACTTCATTGCTGGACAGGATGGAGTTCGCC
		gttctcctcctattcagttcccag	AGTCGAGAGCTTCAGACAAGCAG
		aatcaaagcaatgcattttggaaa	ACTCTGTTGCCCAATGACCAGCTCTACCAGCCCCTCAAGGATCGAGA
		gctcctagcagagagactttcagc	AGATGACCAGTACAGCCACCTTC
		cctaaatctagactcaaggttccc	AAGGAAACCAGTTGAGGAGGAATTGAACTCAGGACTCAGAGTAGTCC
		agagatgac	AGGTGTTCTCCTCCTATTCAGTT
		[Seq ID No 57]	CCCAGAATGAAAGCAATGCATTTTGGAAAGCTCCTAGCAGAGAGACT
			TTCAGCCCTAAATCTAGACTCAA
			GGTTCCCAGAGATGACAAATGGAGAAGAAAGGCCATCAGAGCAAATT
			TGGGGGTTTCTCAAATAAAATAA
			AAATAAAAACAAATACTCTGTTTCAGAAGCGCCACCTATTGGGGAAA
			ATTGT
207651_	G protein-	ttgccttgtaattcgacagctcta	>gi|31377771|ref|NM_013308.2|Homo sapiens G	46.65
at	coupled	cagaaacaaagataatgaaaatta	protein-coupled receptor 171 (GPR171), mRNA
	receptor	cccaaatgtgaa	GGTTGCTACTGCTGCGGCTAACCAAACAGCTCATGCTTCTCTGAAGA
	171	aaaggctctcatcaacatactttt	CTTGCAGCAAGGTTTGCTGAGGC
		agtgaccacgggctacatcatatg	TCACAGAAGATAGCCCCAGTGTTTTGGAGTGGTTTTGAATGTGATTC
		ctttgttcctta	TGAGATCAGACTGACTGAGCTGG
		ccacattgtccgaatcccgtatac	AATCCTGGCTTTATATCTTACCAGCTACACAACCTTGGAGTCTTAGA
		cctcagccagacagaagtcataac	AATTTTTTCTTTTCAATAAGCAG
		tgattgctcaac	TCATCCTTACTTTCCCTCAAGATGACAAACAGTTCGTTCTTCTGCCC
		caggatttcactcttcaaagccaa	AGTTTATAAAGATCTGGAGCCAT
		agaggctacactgctcctggctgt	TCACGTATTTTTTTTTTTTAGTTTTCCTTGTTGGAATTATTGGAAGT
		gtcgaacctgtg	TGTTTTGCAACCTGGGCTTTTAT
		ctttgatcctatcctgtactatca	ACAGAAGAATACGAATCACAGGTGTGTGAGCATCTACTTAATTAATT
		cctctcaaaagcattccgctcaaa	TGCTTACAGCCGATTTCCTGCTT
		ggtcactgagac	ACTCTGGCATTACCAGTGAAAATTGTTGTTGACTTGGGTGTGGCACC
		ttttgcctcacctaaagagaccaa	TTGGAAGCTGAAGATATTCCACT
		ggctcagaaagaaaaattaagatg	GCCAAGTAACAGCCTGCCTCATCTATATCAATATGTATTTATCAATT
		tgaaaataatgc	ATCTTCTTAGCATTTGTCAGCAT
		ataaaagacaggattttttgtgct	TGACCGCTGTCTTCAGCTGACACACAGCTGCAAGATCTACCGAATAC
		accaattctggccttactgga	AAGAACCCGGATTTGCCAAAATG
		[Seq ID No 58]	ATATCAACCGTTGTGTGGCTAATGGTCCTTCTTATAATGGTGCCAAA
			TATGATGATTCCCATCAAAGACA
			TCAAGGAAAAGTCAAATGTGGGTTGTATGGAGTTTAAAAAGGAATTT
			GGAAGAAATTGGCATTTGCTGAC
			AAATTTCATATGTGTAGCAATATTTTTAAATTTCTCAGCCATCATTT
			TAATATCCAATTGCCTTGTAATT
			CGACAGCTCTACAGAAACAAAGATAATGAAAATTACCCAAATGTGAA
			AAAGGCTCTCATCAACATACTTT
			TAGTGACCACGGGCTACATCATATGCTTTGTTCCTTACCACATTGTC
			CGAATCCCGTATACCCTCAGCCA
			GACAGAAGTCATAACTGATTGCTCAACCAGGATTTCACTCTTCAAAG
			CCAAAGAGGCTACACTGCTCCTG
			GCTGTGTCGAACCTGTGCTTTGATCCTGTCCTGTACTATCACCTCTC
			AAAAGCATTCCGCTCAAAGGTCA
			CTGAGACTTTTGCCTCACCTAAAGAGACCAAGGCTCAGAAAGAAAAA
			TTAAGATGTGAAAATAATGCATA
			AAAGACAGGATTTTTGTGCTACCAATTCTGGCCTTACTGGACCATAA
			AGTTAATTATAGCTTTGAAAGAT
			AAAAAAAAAAAAAAAAACAAAAAAAAACTCAGTATGAAAAAATACAG
			TTAGCTAGCAAATATGGACAGGT
			TTACTTAGAAATCCTGTTTCTAAATGCAAGTCAAGCTTTATTGTTAG
			GCTTGCTGCTACTCATTAACCCA
			AATATTTGTACAAAAAACTAAAGAGTCTCATTGAACGAATGTAAAAT
			CCTGCAATATCCTTGAAATCCAA
			AAGAGGTCCATGACATAGACCCAAAGGTATTCATGAGTTATTCATTT
			AAATGCCTGGAACTGACTTCTTG
			ATAAAAATATAAAAAATAATTTCCATGTAAGTTACCAGAAAGCCCAC
			CAGCAACATAATTTTAAAGCCTT
			TCGGATTACTTTTAAAAAATGCAGCTTACATATAACAACTTGTGCCT
			ATTTTATTTCTAATCTATCACTT
			CAAAAGATGGTAATCTTTCAACTCATTATTCCTCCAATTTTTAATGT
			CGAATTTTTTTCTAACACAATAA
			CCAAAAGCTTTTATTTATAAAAAGGCTTGAAAAATATAAAAAAAAAA
			AAAAAAAAAAAAAAAAAAAAAAA
			AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
207957_	Protein	tgatgagctttcctttgatccgga	>gi|89353296|ref|NM_001183.4|Homo sapiens	34.17
s_at	kinase C,	cgacgtaatcactgacattgagat	ATPase, H+ transporting, lysosomal accessory
	beta 1	ggtggacgaggg	protein 1 (ATP6AP1), mRNA
		ctggtggcggggacgttgccatgg	GGGGGCAACGGTCACCTGATCTGCGGCTGTCGAGGCCGCTGAGGCAG
		ccactttggactcttccctgcaaa	TGGAGGCTGAGGCTATGATGGCG
		ttatgtcaagct	GCCATGGCGACGGCTCGAGTGCGGATGGGGCCGCGATGCGCCCAGGC
		tctggagtgactagagctcactgt	GCTCTGGCGCATGCCGTGGCTGC
		ctactgcaactgtgatttcccatg	CGGTGTTTTTGTCGTTGGCGGCGGCGGCGGCGGCGGCAGCGGCGGAG
		tccaaagtggct	CAGCAGGTCCCGCTGGTGCTGTG
		ctgctccaccccctccctattcct	GTCGAGTGACCGGGACTTGTGGGCTCCTGCGGCCGACACTCATGAAG
		gatgcaaatgtctaaccagatgag	GCCACATCACCAGCGACTTGCAG
		tttctggacaga	CTCTCTACCTACTTAGATCCCGCCCTGGAGCTGGGTCCCAGGAATGT
		cttccctctcctgcttcattaagg	GCTGCTGTTCCTGCAGGACAAGC
		gcttggggcagagacagcatgggg	TGAGCATTGAGGATTTCACAGCATATGGCGGTGTGTTTGGAAACAAG
		aaggaggtccccttccccaagagt	CAGGACAGCGCCTTTTCTAACCT
		cctctctatcctggatgagctcat	AGAGAATGCCCTGGACCTGGCCCCCTCCTCACTGGTGCTTCCTGCCG
		gaacatttctcttgtgttcctgac	TCGACTGGTATGCAGTCAGCACT
		tccttcccaatgaacacctctctg	CTGACCACTTACCTGCAGGAGAAGCTCGGGGCCAGCCCCTTGCATGT
		ccaccccaagctctgctctcctcc	GGACCTGGCCACCCTGCGGGAGC
		tctgtgagctct	TGAAGCTCAATGCCAGCCTCCCTGCTCTGCTGCTCATTCGCCTGCCC
		gggcttcccagtttgtttacccgg	TACACAGCCAGCTCTGGTCTGAT
		gaaagtacgtctagattgtgtggt	GGCACCCAGGGAAGTCCTCACAGGCAACGATGAGGTCATCGGGCAGG
		ttgcctcattgt	TCCTGAGCACACTCAAGTCCGAA
		gctatttgcccactttccttccct	GATGTCCCATACACAGCGGCCCTCACAGCGGTCCGCCCTTCCAGGGT
		gaagaaatatctgtgaaccttctt	GGCCCGTGATGTAGCCGTGGTGG
		tctgttcagtcc	CCGGAGGGCTAGGTCGCCAGCTGCTACAAAAACAGCCAGTATCACCT
		ta	GTGATCCATCCTCCTGTGAGTTA
		[Seq Id No 59]	CAATGACACCGCTCCCCGGATCCTGTTCTGGGCCCAAAACTTCTCTG
			TGGCGTACAAGGACCAGTGGGAG
			GACCTGACTCCCCTCACCTTTGGGGTGCAGGAACTCAACCTGACTGG
			CTCCTTCTGGAATGACTCCTTTG
			CCAGGCTCTCACTGACCTATGAACGACTCTTTGGTACCACAGTGACA
			TTCAAGTTCATTCTGGCCAACCG
			CCTCTACCCAGTGTCTGCCCGGCACTGGTTTACCATGGAGCGCCTCG
			AAGTCCACAGCAATGGCTCCGTC
			GCCTACTTCAATGCTTCCCAGGTCACAGGGCCCAGCATCTACTCCTT
			CCACTGCGAGTATGTCAGCAGCC
			TGAGCAAGAAGGGTAGTCTCCTCGTGGCCCGCACGCAGCCCTCTCCC
			TGGCAGATGATGCTTCAGGACTT
			CCAGATCCAGGCTTTCAACGTAATGGGGGAGCAGTTCTCCTACGCCA
			GCGACTGTGCCAGCTTCTTCTCC
			CCCGGCATCTGGATGGGGCTGCTCACCTCCCTGTTCATGCTCTTCAT
			CTTCACCTATGGCCTGCACATGA
			TCCTCAGCCTCAAGACCATGGATCGCTTTGATGACCACAAGGGCCCC
			AGTATTTCTTTGACCCAGATTGT
			GTGACCCTGTGCCAGTGGGGGGGTTGAGGGTGGGACGGTGTCCGTGT
			TGTTGCTTTCCCACCCTGCAGCG
			CACTGGACTGAAGAGCTTCCCTCTTCCTACTGCAGCATGAACTGCAA
			GCTCCCCTCAGCCCATCTTGCTC
			CCTCTTCAGCCCGCTGAGGAGCTTTCTTGGGCTGCCCCCATCTCTCC
			CAACAAGGTGTACATATTCTGCG
			TAGATGCTAGACCAACCAGCTTCCCAGGGTTCGTCGCTGTGAGGCGT
			AAGGGACATGAATTCTAGGGTCT
			CCTTTCTCCTTATTTATTCTTGTGGCTACATCATCCCTGGCTGTGGA
			TAGTGCTTTTGTGTAGCAAATGC
			TCCCTCCTTAAGGTTATAGGGCTCCCTGAGTTTGGGAGTGTGGAAGT
			ACTACTTAACTGTCTGTCCTGCT
			TGGCTGTCGTTATCGTTTTCTGGTGATGTTGTGCTAACAATAAGAAG
			TACACGGGTTTATTTCTGTGGCC
			TGAGAAGGAAGGGACCTCCACGACAGGTGGGCTGGGTGCGATCGCCG
			GCTGTTTGGCATGTTCCCACCGG
			GAGTGCCGGGCAGGAGCATGGGGTGCTTGGTTGTTTCCTTCCTAATA
			AAATAAACGCGGGTCGCCATGCA
			AAAAAAAAA
208894_	major histo-	cgatcaccaatgtacctccagagg	>gi|52426773|ref|NM_09111.3|Homo sapiens	6.11
at	compatibility	taactgtgctcacgaacagccctg	major histocompatibility complex, class II, DR
	complex,	tggaactgagagagcccaacgtcc	alpha (HLA-DRA), mRNA
	class II,	tcatctgtttcatagacaagttca	ACATTCTCTTTTCTTTTATTCTTGTCTGTTCTGCCTCACTCCCGAGC
	DR alpha///	cccca	TCTACTGACTCCCAACAGAGCGC
	major histo-	[Seq Id No 60]	CCAAGAAGAAAATGGCCATAAGTGGAGTCCCTGTGCTAGGATTTTTC
	compatibility		ATCATAGCTGTGCTGATGAGCGC
	complex,		TCAGGAATCATGGGCTATCAAAGAAGAACATGTGATCATCCAGGCCG
	class II,		AGTTCTATCTGAATCCTGACCAA
	DR alpha		TCAGGCGAGTTTATGTTTGACTTTGATGGTGATGAGATTTTCCATGT
			GGATATGGCAAAGAAGGAGACGG
			TCTGGCGGCTTGAAGAATTTGGACGATTTGCCAGCTTTGAGGCTCAA
			GGTGCATTGGCCAACATAGCTGT
			GGACAAAGCCAACCTGGAAATCATGACAAAGCGCTCCAACTATACTC
			CGATCACCAATGTACCTCCAGAG
			GTAACTGTGCTCACGAACAGCCCTGTGGAACTGAGAGAGCCCAACGT
			CCTCATCTGTTTCATAGACAAGT
			TCACCCCACCAGTGGTCAATGTCACGTGGCTTCGAAATGGAAAACCT
			GTCACCACAGGAGTGTCAGAGAC
			AGTCTTCCTGCCCAGGGAAGACCACCTTTTCCGCAAGTTCCACTATC
			TCCCCTTCCTGCCCTCAACTGAG
			GACGTTTACGACTGCAGGGTGGAGCACTGGGGCTTGGATGAGCCTCT
			TCTCAAGCACTGGGAGTTTGATG
			CTCCAAGCCCTCTCCCAGAGACTACAGAGAACGTGGTGTGTGCCCTG
			GGCCTGACTGTGGGTCTGGTGGG
			CATCATTATTGGGACCATCTTCATCATCAAGGGATTGCGCAAAAGCA
			ATGCAGCAGAACGCAGGGGGCCT
			CTGTAAGGCACATGGAGGTGATGGTGTTTCTTAGAGAGAAGATCACT
			GAAGAAACTTCTGCTTTAATGGC
			TTTACAAAGCTGGCAATATTACAATCCTTGACCTCAGTGAAAGCAGT
			CATCTTCAGCATTTTCCAGCCCT
			ATAGCCACCCCAAGTGTGGATATGCCTCTTCGATTGCTCCGTACTCT
			AACATCTAGCTGGCTTCCCTGTC
			TATTGCCTTTTCCTGTATCTATTTTCCTCTATTTCCTATCATTTTAT
			TATCACCATGCAATGCCTCTGGA
			ATAAAACATACAGGAGTCTGTCTCTGCTATGGAATGCCCCATGGGGC
			ATCTCTTGTGTACTTATTGTTTA
			AGGTTTCCTCAAACTGTGATTTTTCTGAACACAATAAACTATTTTGA
			TGATCTTGGGTGGAAAAAAAAAA
			AAAAAAA
209480_	Major histo-	aaaaaaggaaatcgctgcagaatg	>gi|24797068|ref|NM_002123.2|Homo sapiens	12.55
at	compatibility	aaggaatatcccttgaggtgaccc	major histocompatibility complex, class II, DQ
	complex,	agccaacctgtggccagaaggagg	beta 1 (HLA-DQB1), mRNA
	class II,	gttgtacct:gaaaagaccactga	CAGATCCATCAGGTCCGAGCTGTGTTGACTACCACTTTTCCCTTCGT
	DQ beta 1///	aagcattttggggtgtcaagtaag	CTCAATTATGTCTTGGAAAAAGG
	Major histo-	ggtgggcagaggaggtagaaaatc	CTTTGCGGATCCCCGGAGGCCTTCGGGCAGCAACTGTGACCTTGATG
	compatibility	aattcaattgtcgcatcattcatg	CTGTCGATGCTGAGCACCCCAGT
	complex,	gttctttaatattgatgctcagtg	GGCTGAGGGCAGAGACTCTCCCGAGGATTTCGTGTACCAGTTTAAGG
	class II,	cattggccttagaatatcccagcc	GCATGTGCTACTTCACCAACGGG
	DQ beta 1	tctcttctggtttggtgagtgctg	ACAGAGCGCGTGCGTCTTGTGAGCAGAAGCATCTATAACCGAGAAGA
		tgtaagtaagcatggtagaattgt	GATCGTGCGCTTCGACAGCGACG
		ttggagacatatatagtgatcctt	TGGGGGAGTTCCGGGCGGTGACGCTGCTGGGGCTGCCTGCCGCCGAG
		ggtcactggtgt	TACTGGAACAGCCAGAAGGACAT
		ttcaaacattctggaaagtcacat	CCTGGAGAGGAAACGGGCGGCGGTGGACAGGGTGTGCAGACACAACT
		cgatcaagaatatttttt	ACCAGTTGGAGCTCCGCACGACC
		[Seq Id No 61]	TTGCAGCGGCGAGTGGAGCCCACAGTGACCATCTCCCCATCCAGGAC
			AGAGGCCCTCAACCACCACAACC
			TGCTGGTCTGCTCGGTGACAGATTTCTATCCAGCCCAGATCAAAGTC
			CGGTGGTTTCGGAATGACCAGGA
			GGAGACAGCTGGCGTTGTGTCCACCCCCCTTATTAGGAATGGTGACT
			GGACCTTCCAGATCCTGGTGATG
			CTGGAAATGACTCCCCAGCGTGGAGACGTCTACACCTGCCACGTGGA
			GCACCCCAGCCTCCAGAGCCCCA
			TCACCGTGGAGTGGCGGGCTCAATCTGAATCTGCCCAGAGCAAGATG
			CTGAGTGGCATTGGAGGCTTCGT
			GCTGGGGCTGATCTTCCTCGGGCTGGGCCTTATCATCCATCACAGGA
			GTCAGAAAGGGCTCCTGCACTGA
			CTCCTGAGACTATTTTAACTGGGATTGGTTATCACTTTTCTGTAACG
			CCTGCTTGTCCCTGCCCAGAATT
			CCCAGCTGTCTGTGTCAGCCTGTCCCCCTGAGATCAGAGTCCTACAG
			TGGCTGTCACGCAGCCACCAGGT
			CATCTCCTTTCATCCCCACCTTGAGGCGGATGGCTGTGACCCTACTT
			CCTGCACTGACCCACAGCCTCTG
			CCTGTGCACGGCCAGCTGCATCTACTCAGGCCCCAAGGGGTTTCTGT
			TTCTATTCTCTCCTCAGACTGCT
			CAAGAGAAGCACATGAAAACCATTACCTGACTTTAGAGCTTTTTTAC
			ATAATTAAACATGATCCTGAGTT
209613_	alcohol	gcagatttcttgcttcatatgaca	>gi|34577060|ref|NM_000668.3|Homo sapiens	58.89
s_at	dehydrogenase	aagcctcaattactaattgtaaaa	alcohol dehydrogenase IB (class I), beta
	IB	actgaactattc	polypeptide (ADH1B), mRNA
	(class I),	ccagaatcatgttcaaaaaatctg	ATGCACTCAAGCAGAGAAGAAATCCACAAAGACTCACAGTCTGCTGG
	beta poly-	taatttttgctgatcgaaagtgct	TGGGCAGAGAAGACAGAAACGAC
	peptide	tcattgactaaa	ATGAGCACAGCAGGAAAAGTAATCAAATGCAAAGCAGCTGTGCTATG
		cagtattagtttgtggctataaat	GGAGGTAAAGAAACCCTTTTCCA
		gattatttagatgatgactgaaaa	TTGAGGATGTGGAGGTTGCACCTCCTAAGGCTTATGAAGTTCGCATT
		tgtgtataaagt	AAGATGGTGGCTGTAGGAATCTG
		aattaaaagtaatatggtggcttt	TCACACAGATGACCACGTGGTTAGTGGCAACCTGGTGACCCCCCTTC
		aagtgtagagatgggatggcaaat	CTGTGATTTTAGGCCATGAGGCA
		gctgtgaatgca	GCCGGCATCGTGGAGAGTGTTGGAGAAGGGGTGACTACAGTCAAACC
		gaatgtaaaattggtaactaagaa	AGGTGATAAAGTCATCCCGCTCT
		atggcacaaacaccttaagcaata	TTACTCCTCAGTGTGGAAAATGCAGAGTTTGTAAAAACCCGGAGAGC
		tattttcctagt	AACTACTGCTTGAAAAATGATCT
		agatatatatatacacatacatat	AGGCAATCCTCGGGGGACCCTGCAGGATGGCACCAGGAGGTTCACCT
		atacacatatacaaatgtatattt	GCAGGGGGAAGCCCATTCACCAC
		ttgcaaaattgt	TTCCTTGGCACCAGCACCTTCTCCCAGTACACGGTGGTGGATGAGAA
		tttcaatctagaacttttctatta	TGCAGTGGCCAAAATTGATGCAG
		actaccatgtcttaaaatcaagtc	CCTCGCCCCTGGAGAAAGTCTGCCTCATTGGCTGTGGATTCTCGACT
		tataatcctagc	GGTTATGGGTCTGCAGTTAACGT
		attagtttaatattttgaatatgt	TGCCAAGGTCACCCCAGGCTCTACCTGTGCTGTGTTTGGCCTGGGAG
		aaacacctgtgttaatgctttgtt	GGGTCGGCCTATCTGCTGTTATG
		aatgcttttccc	GGCTGTAAAGCAGCTGGAGCAGCCAGAATCATTGCGGTGGACATCAA
		actctcatttgttaatgctttccc	CAAGGACAAATTTGCAAAGGCCA
		actctcgggaaggatttgcatttt	AAGAGTTGGGTGCCACTGAATGCATCAACCCTCAAGACTACAAGAAA
		gagctttatctc	CCCATCCAGGAAGTGCTAAAGGA
		taaatgtgacatgca	AATGACTGATGGAGGTGTGGATTTTTCGTTTGAAGTCATCGGTCGGC
		[Seq Id No 62]	TTGACACCATGATGGCTTCCCTG
			TTATGTTGTCATGAGGCATGTGGCACAAGCGTCATCGTAGGGGTACC
			TCCTGCTTCCCAGAACCTCTCAA
			TAAACCCTATGCTGCTACTGACTGGACGCACCTGGAAGGGGGCTGTT
			TATGGTGGCTTTAAGAGTAAAGA
			AGGTATCCCAAAACTTGTGGCTGATTTTATGGCTAAGAAGTTTTCAC
			TGGATGCGTTAATAACCCATGTT
			TTACCTTTTGAAAAAATAAATGAAGGATTTGACCTGCTTCACTCTGG
			GAAAAGTATCCGTACCGTCCTGA
			CGTTTTGAGGCAATAGAGATGCCTTCCCCTGTAGCAGTCTTCAGCCT
			CCTCTACCCTACAAGATCTGGAG
			CAACAGCTAGGAAATATCATTAATTCAGCTCTTCAGAGATGTTATCA
			ATAAATTACACATGGGGGCTTTC
			CAAAGAAATGGAAATTGATGGGAAATTATTTTTCAGGAAAATTTAAA
			ATTCAAGTGAGAAGTAAATAAAG
			TGTTGAACATCAGCTGGGGAATTGAAGCCAACAAACCTTCCTTCTTA
			ACCATTCTACTGTGTCACCTTTG
			CCATTGAGGAAAAATATTCCTGTGACTTCTTGCATTTTTGGTATCTT
			CATAATCTTTAGTCATCGAATCC
			CAGTGGAGGGGACCCTTTTACTTGCCCTGAACATACACATGCTGGGC
			CATTGTGATTGAAGTCTTCTAAC
			TCTGTCTCAGTTTTCACTGTCGACATTTTCCTTTTTCTAATAAAAAT
			GTACCAAATCCCTGGGGTAAAAG
			CTAGGGTAAGGTAAAGGATAGACTCACATTTACAAGTAGTGAAGGTC
			CAAGAGTTCTAAATACAGGAAAT
			TTCTTAGGAACTCAAATAAAATGCCCCACATTTTACTACAGTAAATG
			GCAGTGTTTTTATGACTTTTATA
			CTATTTCTTTATGGTCGATATACAATTGATTTTTTAAATAATAGCA
			GATTTCTTGCTTCATATGACAAA
			GCCTCAATTACTAATTGTAAAAACTGAACTATTCCCAGAATCATGTT
			CAAAAAATCTGTAATTTTTGCTG
			ATGAAAGTGCTTCATTGACTAAACAGTATTAGTTTGTGGCTATAAAT
			GATTATTTAGATGATGACTGAAA
			ATGTGTATAAAGTAATTAAAAGTAATATGGTGGCTTTAAGTGTAGAG
			ATGGGATGGCAAATGCTGTGAAT
			GCAGAATGTAAAATTGGTAACTAAGAAATGGCACAAACACCTTAAGC
			AATATATTTTCCTAGTAGATATA
			TATATACACATACATATATACACATATACAAATGTATATTTTTGCAA
			AATTGTTTTCAATCTAGAACTTT
			TCTATTAACTACCATGTCTTAAAATCAAGTCTATAATCCTAGCATTA
			GTTTAATATTTTGAATATGTAAA
			GACCTGTGTTAATGCTTTGTTAATGCTTTTCCCACTCTCATTTGTTA
			ATGCTTTCCCACTCTCAGGGGAA
			GGATTTGCATTTTGAGCTTTATCTCTAAATGTGACATGCAAAGATTA
			TTCCTGGTAAAGGAGGTAGCTGT
			CTCCAAAAATGCTATTGTTGCAATATCTACATTCTATTTCATATTAT
			GAAAGACCTTAGACATAAAGTAA
			AATAGTTTATCATTTACTGTGTGATCTTCAGTAAGTCTCTCAGGCTC
			TCTGAGCTTGTTCATCCTTTGTT
			TTGAAAAAATTACTCAACCAATCCATTACAGCTTAACCAAGATTAAA
			TGGGATGATGTTAATGAAAGAGC
			TTCGCC
209670_	T cell	caactggatcctacccgaatttat	>gi|36944|emb|X02592.1|HSTCRAR Human mRNA for	24.26
at	receptor	gattaagattgctgaagagctgcc	receptor alpha chain (TCR-alpha)
	alpha	aaacactgctgc	TTTTGAAACCCTTCAAAGGCAGAGACTTGTCCAGCCTAACCTGCCTG
	constant///	caccccctctgttcccttattgct	CTGCTCCTAGCTCCTGAGGCTCA
	T cell	gcttgtcactgcctgacattcacg	GGGCCCTTGGCTTCTGTCCGCTCTGCTCAGGGCCCTCCAGCGTGGCC
	receptor	gcagaggcaagg	ACTGCTCAGCCATGCTCCTGCTG
	alpha	ctgctgcagcctcccctggctgtg	CTCGTCCCAGTGCTCGAGGTGATTTTTACCCTGGGAGGAACCAGAGC
	constant	cacattccctcctgctccccagag	CCAGTCGGTGACCCAGCTTGGCA
		actgcctccgcc	GCCACGTCTCTGTCTCTGAAGGAGCCCTGGTTCTGCTGAGGTGCAAC
		atcccacagatgatggatcttcag	TACTCATCGTCTGTTCCACCATA
		tgggttctcttgggctctaggtcc	TCTCTTCTGGTATGTGCAATACCCCAACCAAGGACTCCAGCTTCTCC
		tggagaatgttg	TGAAGTACACATCAGCGGCCACC
		tgaggggtttatttttttttaata	CTGGTTAAAGGCATCAACGGTTTTGAGGCTGAATTTAAGAAGAGTGA
		gtgttcataaagaaatacatagta	AACCTCCTTCCACCTGACGAAAC
		ttcttcttctca	CCTCAGCCCATATGAGCGACGCGGCTGAGTACTTCTGTGCTGTGAGT
		agacgtggggggaaattatctcat	GATCTCGAACCGAACAGCAGTGC
		tatcgaggccctgctatgctgtgt	TTCCAAGATAATCTTTGGATCAGGGACCAGACTCAGCATCCGGCCAA
		gtctgggcgtgt	ATATCCAGAACCCTGACCCTGCC
		tgtatgtcctgc	GTGTACCAGCTGAGAGACTCTAAATCCAGTGACAAGTCTGTCTGCCT
		[Seq Id No 63]	ATTCACCGATTTTGATTCTCAAA
			CAAATGTGTCACAAAGTAAGGATTCTGATGTGTATATCACAGACAAA
			ACTGTGCTAGACATGAGGTCTAT
			GGACTTCAAGAGCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACT
			TTGCATGTGCAAACGCCTTCAAC
			AACAGCATTATTCCAGAAGACACCTTCTTCCCCAGCCCAGAAAGTTC
			CTGTGATGTCAAGCTGGTCGAGA
			AAAGCTTTGAAACAGATACGAACCTAAACTTTCAAAACCTGTCAGTG
			ATTGGGTTCCGAATCCTCCTCCT
			GAAAGTGGCCGGGTTTAATCTGCTCATGACGCTGCGGCTGTGGTCCA
			GCTGAGATCTGCAAGATTGTAAG
			ACAGCCTGTGCTCCCTCGCTCCTTCCTCTGCATTGCCCCTCTTCTCC
			CTCTCCAAACAGAGGGAACTCTC
			CTACCCCCAAGGAGGTGAAAGCTGCTACCACCTCTGTGCCCCCCCGG
			TAATGCCACCAACTGGATCCTAC
			CCGAATTTATGATTAAGATTGCTGAAGAGCTGCCAAACACTGCTGCC
			ACCCCCTCTGTTCCCTTATTGCT
			GCTTGTCACTGCCTGACATTCACGGCAGAGGCAAGGCTGCTGCAGCC
			TCCCCTGGCTGTGCACATTCCCT
			CCTGCTCCCCAGAGACTGCCTCCGCCATCCCACAGATGATGGATCTT
			CAGTGGGTTCTCTTGGGCTCTAG
			GTCCTGGAGAATGTTGTGAGGGGTTTATTTTTTTTTAATAGTGTTCA
			TAAAGAAATACATAGTATTCTTC
			TTCTCAAGACGTGGGGGGAAATTATCTCATTATCGAGGCCCTGCTAT
			GCTGTGTGTCTGGGCGTGTTGTA
			TGTCCTGCTGCCGATGCCTTCATTAAAATGATTTGGAA
209795_	CD69	tagtctaattgaatcccttaaact	>gi|4502680|ref|NM_001781.1|Homo sapiens CD69	30.48
at	antigen	cagggagcatttataaatggcaaa	molecule (CD69), mRNA
	(p60, early	tgcttatgaaac	AGACTCAACAAGAGCTCCAGCAAAGACTTTCACTGTAGCTTGACTTG
	T-cell	taagatttgtaatatttctctctt	ACCTGAGATTAACTAGGGAATCT
	activation	tttagagaaatttgccaatttact	TGAGAATAAAGATGAGCTCTGAAAATTGTTTCGTAGCAGAGAACAGC
	antigen)	ttgttatttttc	TCTTTGCATCCGGAGAGTGGACA
		cccaaaaagaatgggatgatcgtg	AGAAAATGATGCCACCAGTCCCCATTTCTCAACACGTCATGAAGGGT
		tatttatttttttacttcctcagc	CCTTCCAAGTTCCTGTCCTGTGT
		tgtagacaggtc	GCTGTAATGAATGTGGTCTTCATCACCATTTTAATCATAGCTCTCAT
		cttttcgatggtacatatttcttt	TGCCTTATCAGTGGGCCAATACA
		gcctttataatcttttatacagtg	ATTGTCCAGGCCAATACACATTCTCAATGCCATCAGACAGCCATGTT
		tcttacagagaa	TCTTCATGCTCTGAGGACTGGGT
		aagacataagcaaagactatgagg	TGGCTACCAGAGGAAATGCTACTTTATTTCTACTGTGAAGAGGAGCT
		aatatttgcaagacatagaatagt	GGACTTCAGCCCAAAATGCTTGT
		gttggaaaatgt	TCTGAACATGGTGCTACTCTTGCTGTCATTGATTCTGAAAAGGACAT
		gcaatatgtgatgtggcaaatctc	GAACTTTCTAAAACGATACGCAG
		tattaggaaatattctgtaatctt	GTAGAGAGGAACACTGGGTTGGACTGAAAAAGGAACCTGGTCACCCA
		cagacatagaat	TGGAAGTGGTCAAATGGCAAAGA
		aatactagtcttataataggtttg	ATTTAACAACTGGTTCAACGTTACAGGGTCTGACAAGTGTGTTTTTC
		tgactttcctaaatcaattctatt	TGAAAAACACAGAGGTCAGCAGC
		acgtgcaatact	ATGGAATGTGAGAAGAATTTATACTGGATATGTAACAAACCTTACAA
		tcaatacttcat	ATAATAAGGAAACATGTTCACTT
		[Seq Id No 64]	ATTGACTATTATAGAATGGAACTCAAGGAAATCTGTGTCAGTGGATG
			CTGCTCTGTGGTCCGAAGTCTTC
			CATAGAGACTTTGTGAAAAAAAATTTTATAGTGTCTTGGGAATTTTC
			TTCCAAACAGAACTATGGAAAAA
			AAGGAAGAAATTCCAGGAAAATCTGCACTGTGGGCTTTTATTGCCAT
			GAGCTAGAAGCATCACAGGTTGA
			CCAATAACCATGCCCAAGAATGAGAAGAATGACTATGCAACCTTTGG
			ATGCACTTTATATTATTTTGAAT
			CCAGAAATAATGAAATAACTAGGCGTGGACTTACTATTTATTGCTGA
			ATGACTACCAACAGTGAGAGCCC
			TTCATGCATTTGCACTACTGGAAGGAGTTAGATGTTGGTACTAGATA
			CTGAATGTAAACAAAGGAATTAT
			GGCTGGTAACATAGGTTTTTAGTCTAATTGAATCCCTTAAACTCAGG
			GAGCATTTATAAATGGACAAATG
			CTTATGAAACTAAGATTTGTAATATTTCTCTCTTTTTAGAGAAATTT
			GCCAATTTACTTTGTTATTTTTC
			CCCAAAAAGAATGGGATGATCGTGTATTTATTTTTTTACTTCCTCAG
			CTGTAGACAGGTCCTTTTCGATG
			GTACATATTTCTTTGCCTTTATAATCTTTTATACAGTGTCTTACAGA
			GAAAAGACATAAGCAAAGACTAT
			GAGGAATATTTGCAAGACATAGAATAGTGTTGGAAAATGTGCAATAT
			GTGATGTGGCAAATCTCTATTAG
			GAAATATTCTGTAATCTTCAGACCTAGAATAATACTAGTCTTATAAT
			AGGTTTGTGACTTTCCTAAATCA
			ATTCTATTACGTGCAATACTTCAATACTTCATTTAAAATATTTTTAT
			GTGCAATAAAATGTATTTGTTTG
			TATTTTGTGTTCAGTACAATTATAAGCTGTTTTTATATATGTGAAAT
			AAAAGTAGAATAAACACAAAAAA
			AAAAAAAAAAAAAAAAAAAAAA
210038_	protein	aatccattcatcctgattgggcat	>gi|48255887|ref|NM_006257.2|Homo sapiens	19.42
at	kinase C,	gaaatccatggtcaagaggacaag	protein kinase C, theta (PRKCQ), mRNA
	theta	tggaaagtgagagggaaggtttgc	AGTCCCCGCGCAGTCCCCGCGCAcTCCCAGCGCCACCGGGCAGCAGC
		tagacaccttcgcttgttatcttg	GGCGCCGTGCTCGCTCCAGGGCG
		tcaagatagaaaagatagtatcat	CAACCATGTCGCCATTTCTTCGGATTGGCTTGTCCAACTTTGACTGC
		ttcacccttgccagtaaaaacctt	GCGTCCTGCCAGTCTTGTCAGGG
		tccatccacccattctcagcagac	CGAGGCTGTTAACCCTTACTGTGCTGTGCTCGTCAAAGAGTATGTCG
		tccagtattggc	AATCAGAGAACGGGCAGATGTAT
		acagtcactcactgccattctcac	ATCCAGAAAAAGCCTACCATGTACCCACCCTGGGACAGCACTTTTGA
		actataacaagaaaagaaatgaag	TGCCCATATCAACAAGGGAAGAG
		tgcataagtctc	TCATGCAGATCATTGTGAAAGGCAAAAACGTGGACCTCATCTCTGAA
		ctgggaaaagaaccttaacccctt	ACCACCGTGGAGCTCTACTCGCT
		ctcgtgccatgactggtgatttca	GGCTGAGAGGTGCAGGAAGAACAACGGGAAGACAGAAATATGGTTAG
		tgactcataagc	AGCTGAAACCTCAAGGCCGAATG
		ccctccgtaggcatcattcaagat	CTAATGAATGCAAGATACTTTCTGGAAATGAGTGACACAAAGGACAT
		caatggcccatgcatgctgtttgc	GAATGAATTTGAGACGGAAGGCT
		agca	TCTTTGCTTTGCATCAGCGCCGGGGTGCCATCAAGCAGGCAAAGGTC
		[Seq Id No 65]	CACCACGTCAAGTGCCACGAGTT
			CACTGCCACCTTCTTCCCACAGCCCACATTTTGCTCTGTCTGCCACG
			AGTTTGTCTGGGGCCTGAACAAA
			CAGGGCTACCAGTGCCGACAATGCAATGCAGCAATTCACAAGAAGTG
			TATTGATAAAGTTATAGCAAAGT
			GCACAGGATCAGCTATCAATAGCCGAGAAACCATGTTCCACAAGGAG
			AGATTCAAAATTGACATGCCACA
			CAGATTTAAAGTCTACAATTACAAGAGCCCGACCTTCTGTGAACACT
			GTGGGACCCTGCTGTGGGGACTG
			GCACGGCAAGGACTCAAGTGTGATGCATGTGGCATGAATGTGCATCA
			TAGATGCCAGACAAAGGTGGCCA
			ACCTTTGTGGCATAAACCAGAAGCTAATGGCTGAAGCGCTGGCCATG
			ATTGAGAGCACTCAACAGGCTCG
			CTGCTTAAGAGATACTGAACAGATCTTCAGAGAAGGTCCGGTTGAAA
			TTGGTCTCCCATGCTCCATCAAA
			AATGAAGCAAGGCCGCCATGTTTACCGACACCGGGAAAAAGAGAGCC
			TCAGGGCATTTCCTGGGAGTCTC
			CGTTGGATGAGGTGGATAAAATGTGCCATCTTCCAGAACCTGAACTG
			AACAAAGAAAGACCATCTCTGCA
			GATTAAACTAAAAATTGAGGATTTTATCTTGCACAAAATGTTGGGGA
			AAGGAAGTTTTGGCAAGGTCTTC
			CTGGCAGAATTCAAGAAAACCAATCAATTTTTCGCAATAAAGGCCTT
			AAAGAAAGATGTGGTCTTGATGG
			ACGATGATGTTGAGTGCACGATGGTAGAGAAGAGAGTTCTTTCCTTG
			GCCTGGGAGCATCCGTTTCTGAC
			GCACATGTTTTGTACATTCCAGACCAAGGAAAACCTCTTTTTTGTGA
			TGGAGTACCTCAACGGAGGGGAC
			TTAATGTACCACATCCAAAGCTGCCACAAGTTCGACCTTTCCAGAGC
			GACGTTTTATGCTGCTGAAATCA
			TTCTTGGTCTGCAGTTCCTTCATTCCAAAGGAATAGTCTACAGGGAC
			CTGAAGCTAGATAACATCCTGTT
			AGACAAAGATGGACATATCAAGATCGCGGATTTTGGAATGTGCAAGG
			AGAACATGTTAGGAGATGCCAAG
			ACGAATACCTTCTGTGGGACACCTGACTACATCGCCCCAGAGATCTT
			GCTGGGTCAGAAATACAACCACT
			CTGTGGACTGGTGGTCCTTCGGGGTTCTCCTTTATGAAATGCTGATT
			GGTCAGTCGCCTTTCCACGGGCA
			GGATGAGGAGGAGCTCTTCCACTCCATCCGCATGGACAATCCCTTTT
			ACCCACGGTGGCTGGAGAAGGAA
			GCAAAGGACCTTCTGGTGAAGCTCTTCGTGCGAGAACCTGAGAAGAG
			GCTGGGCGTGAGGGGAGACATCC
			GCCAGCACCCTTTGTTTCGGGAGATCAACTGGGAGGAACTTGAACGG
			AAGGAGATTGACCCACCGTTCCG
			GCCGAAAGTGAAATCACCATTTGACTGCAGCAATTTCGACAAAGAAT
			TCTTAAACGAGAAGCCCCGGCTG
			TCATTTGCCGACAGAGCACTGATCAACAGCATGGACCAGAATATGTT
			CAGGAACTTTTCCTTCATGAACC
			CCGGGATGGAGCGGCTGATATCCTGAATCTTGCCCCTCCAGAGACAG
			GAAAGAATTTGCCTTCTCCCTGG
			GAACTGGTTCAAGAGACACTGCTTGGGTTCCTTTTTCAACTTGGAAA
			AAGAAAGAAACACTCAACAATAA
			AGACTGAGACCCGTTCGCCCCCATGTGACTTTTATCTGTAGCAGAAA
			CCAAGTCTACTTCACTAATGACG
			ATGCCGTGTGTCTCGTCTCCTGACATGTCTCACAGACGCTCCTGAAG
			TTAGGTCATTACTAACCATAGTT
			ATTTACTTGAAAGATGGGTCTCCGCACTTGGAAAGGTTTCAAGACTT
			GATACTGCAATAAATTATGGCTC
			TTCACCTGGGCGCCAACTGCTGATCAATGAAATGCTTGTTGAATCAG
			GGGCAAACGGAGTACAGACGTCT
			CAAGACTGAAACGGCCCCATTGCCTGGTCTAGTAGCGGATCTCACTC
			AGCCGCAGACAAGTAATCACTAA
			CCCGTTTTATTCTATTCCTATCTGTGGATGTGTAAATGGCTGGGGGG
			CCAGCCCTGGATAGGTFTTTATG
			GGAATTCTTTACAATAAACATAGCTTGTAACTTGAGATCTACAAATC
			CATTCATCCTGATTGGGCATGAA
			ATCCATGGTCAAGAGGACAAGTGGAAAGTGAGAGGGAAGGTTTGCTA
			GACACCTTCGCTTGTTATCTTGT
			CAAGATAGAAAAGATAGTATCATTTCACCCTTGCCAGTAAAAACCTT
			TCCATCCACCCATTCTCAGCAGA
			CTCCAGTATTGGCACAGTCACTCACTGCCATTCTCACACTATAACAA
			GAAAAGAAATGAAGTGCATAAGT
			CTCCTGGGAAAAGAACCTTAACCCCTTCTCGTGCCATGACTGGTGAT
			TTCATGACTCATAAGCCCCTCCG
			TAGGCATCATTCAAGATCAATGGCCCATGCATGCTGTTTGCAGCAGT
			CAATTGAGTTGAATTAGAATTCC
			AACCATACATTTTAAAGGTATTTGTGCTGTGTGTATATTTTGATAAA
			ATGTTGTGACTTCATGGCAAACA
			GGTGGATGTGTAAAAATGGAATAAAAAAAAAAAAAGAGTCAAAAAAA
			AAAAAA
210915_	T cell	Aaaggccacactggtgtgcctggc	>gi|339011|gb|M15564.1|HUMTCBYZ Human T-cell	48.45
x_at	receptor	cacaggtatcttccctgaccacgt	receptor rearranged beta-chain V-region (V-D-J)
	beta	ggagctgagctggtgggtgaatgg	mRNA, complete cds
	variable	gaaggaggtgcacagtggggtcag	GTAAAGCTCCCATCCTGCCCTGACCCTGCCATGGGCACCAGCCTCCT
	19///T	cacggacccgcagcccctcaagga	CTGCTGGATGGCCCTGTGTCTCC
	cell	gcagcccgccctcaatgactccag	TGGGGGCAGATCACGCAGATACTGGAGTCTCCCAGAACCCCAGACAC
	receptor	atactgcctgagcagccgcctgag	AACATCACAAAGAGGGGACAGAA
	beta	ggtctcggccaccttctggcagaa	TGTAACTTTCAGGTGTGATCCAATTTCTGAACACAACCGCCTTTATT
	constant 1	cccccgcaaccacttccgctgtca	GGTACCGACAGACCCTGGGGCAG
		agtccagttctacgggctctcgga	GGCCCAGAGTTTCTGACTTACTTCCAGAATGAAGCTCAACTAGAAAA
		gaatgacgagtggacccaggatag	ATCAAGGCTGCTCAGTGATCGGT
		ggccaaacccgtcacccagatcgt	TCTCTGCAGAGAGGCCTAAGGGATCTTTCTCCACCTTGGAGATCCAG
		cagcgccgaggcctggggtagagc	CGCACAGAGCAGGGGGACTCGGC
		agactgtggctttacctcggtgtc	CATGTATCTCTGTGCCAGCAGCTTAGCAGGGTTGAATCAGCCCCAGC
		ctaccagcaaggggtcctgtctgc	ATTTTGGTGATGGGACTCGACTC
		caccatcctctatgagatcctgct	TCCATCCTAGAGGACCTGAACAAGGTGTTCCCACCCGAGGTCGCTGT
		agggaaggccaccatgtatgctgt	GTTTGAGCCATCAGAAGCAGAGA
		gctggtcagcgcccttgtgttgat	TCTCCCACACCCAAAAGGCCACACTGGTGTGCCTGGCCACAGGTATC
		ggccatggtcaagagaaaggattt	TTCCCTGACCACGTGGAGCTGAG
		ctgaaggcagccctggaagtggag	CTGGTGGGTGAATGGGAAGGAGGTGCACAGTGGGGTCAGCACGGACC
		ttaggagcttctaacccgtcatgg	CGCAGCCCCTCAAGGAGCAGCCC
		tttcaatacacattcttcttttgc	GCCCTCAATGACTCCAGATACTGCCTGAGCAGCCGCCTGAGGGTCTC
		cagc	GGCCACCTTCTGGCAGAACCCCC
		[Seq Id No 66]	GCAACCACTTCCGCTGTCAAGTCCAGTTCTACGGGCTCTCGGAGAAT
			GACGAGTGGACCCAGGATAGGGC
			CAAACCCGTCACCCAGATCGTCAGCGCCGAGGCCTGGGGTAGAGCAG
			ACTGTGGCTTTACCTCGGTGTCC
			TACCAGCAAGGGGTCCTGTCTGCCACCATCCTCTATGAGATCCTGCT
			AGGGAAGGCCACCATGTATGCTG
			TGCTGGTCAGCGCCCTTGTGTTGATGGCCATGGTCAAGAGAAAGGAT
			TTCTGAAGGCAGCCCTGGAAGTG
			GAGTTAGGAGCTTCTAACCCGTCATGGTTTCAATACACATTCTTCTT
			TTGCCAGCGCTTCTGAAGAGCTG
			CTCTCACCTCTCTGCATCCCAATA
210972_	T cell	ggaacaagacttcaggtcacgctc	>gi|338765|gb|M15565.1|HUMTCAYE Human T-cell	26.45
x_at	receptor	gatatccagaaccctgaccctgcc	receptor rearranged alpha-chain V-region (V-D-
	alpha	gtgtaccagctgagagactctaaa	J) mRNA, complete cds
	locus///	tccagtgacaagtctgtctgccta	TCCAAAATGAACGGTCTGTGGAAGGACATGAATAAAGCACAGGAGGT
	T cell	ttcaccgattttgattctcaaaca	TGAAGTCAGATTTGCAGCTTTCT
	receptor	aatgtgtcacaaagtaaggattct	AGGCAGGAGACAAGACAATCTGCATCITcACAGGAGGGATGGCCATG
	delta	gatgtgtatatcacagacaaaact	CTCCTGGGGGCATcAGTGCTGAT
	variable	gtgctagacatg	TCTGTGGCTTCAGCCAGACTGGGTAAACAGTCAACAGAAGAATGATG
	2///T cell	aggtctatggacttcaagagcaac	ACCAGCAAGTTAAGCAAAATTCA
	receptor	agtgctgtggcctggagcaacaaa	CCATCCCTGAGCGTCCAGGAAGGAAGAATTTcTATTCTGAACTGTGA
	alpha	tctgactttgcatgtgcaaacgcc	CTATACTAACAGCATGTTTGATT
	variable	ttcaacaacagcattattccagaa	ATTTCCTATGGTACAAAAAATACCCTGCTGAAGGTCCTACATTCCTG
	20///T	gacaccttcttccccagcccagaa	ATATCTATAAGTTCCATTAAGGA
	cell	agttcctgtgatgtcaagctggtc	TAAAAATGAAGATGGAAGATTCACTGTCTTCTTAAACAAAAGTGCCA
	receptor	gagaaaagctttgaaacagatacg	AGCACCTCTCTCTGCACATTGTG
	alpha	aacctaaacttt	CCCTCCCAGCCTGGAGACTCTGCAGTGTACTTCTGTGCAGCAAAGGG
	joining	caaaacctgtcagtgattgggttc	GGCCGGCACTGCCAGTAAACTCA
	17///T	cgaatcctcctcctgaaagtggcc	CCTTTGGGACTGGAACAAGACTTCAGGTCACGCTCGATATCCAGAAC
	cell	gggtttaatctg	CCTGACCCTGCCGTGTACCAGCT
	receptor	ctcatgacgctgcggctgtggtcc	GAGAGACTCTAAATCCAGTGACAAGTCTGTCTGCCTATTCACCGATT
	alpha	agctgagatctgcaagattgtaag	TTGATTCTCAAACAAATGTGTCA
	constant	acagcctgtgct	CAAAGTAAGGATTCTGATGTGTATATCACAGACAAAACTGTGCTAGA
		ccct	CATGAGGTCTATGCACTTCAAGA
		[Seq Id No 67]	GCAACAGTGCTGTGGCCTGOAGCAACAAATCTGACTTTGCATGTGCA
			AACGCCTTCAACAACAGCATTAT
			TCCAGAAGACACCTTCTTCCCCAGCCCAGAAAGTTCCTGTGATGTCA
			AGCTGGTCGAGAAAAGGTTTGAA
			ACAGATACGAACCTAAACTTTCAAAACCTGTCAGTGATTGGGTTCCG
			AATCCTCCTCCTGAAAGTGGCCG
			GGTTTAATCTGCTCATGACGCTGCGGCTGTGGTCCAGCTGAGATCTG
			CAAGATTGTAAGACAGCCTGTGC
			TCCCTCGCTCCTTCCTCTGCATTGCCCCTCTTCTCCCTCTCcAJAACA
			GAGGGAACTCTCCCACCCCCAAG
			GAGGTGAAAGCTGCTACCACCCTCTGTGCC
211144_	T cell	aaatgatacactactgctgcagct	>gi|339406|gb|M30894.1|HUMTCRGAD Human T-cell	17.38
x_at	receptor	cacaaacacctctgcatattacat	receptor Ti rearranged gamma-chain mRNA V-J-C
	gamma	gtacctcctcct	region, complete cds
	constant 2	gctcctcaagagtgtggtctattt	GAATCAGGAAGACCAGCTCCTCCTACTGTCTTCTGTGTTACGGGATC
		tgccatcatcacctgctgtctgct	AGCGTTCCTTGTTGAGTGGGACC
		tggaagaacggc	TGAGTTTTGAGAGGGTCTTCTGCTCCTCTTGGTCTGGTCCCTTACTT
		tttctgctgcaatggagagaaatc	CCAAGAGCCCCAGAGAGGAAGGC
		ataacagacggtggcacaaggagg	ATGCTGTTGGCTCTAGCICTGCTTCTAGCTTTCCTGCCTCCTGCCAG
		ccatcttttcct	TCAGAAATCTTCCAACTTGGAAG
		catcggttattgtccctagaagcg	GGAGAACAAAGTCAGTCACCAGGCCAACTGGGTCATCAGCTGTAATC
		tcttctgaggatctagttgggctt	ACTTGTGATCTTCCTGTAGAAAA
		tctttctgggtt	TGCCGTCTACACCCACTGGTACCTACACCAGGAGGGGAAGGCCCCAC
		tgggccatttcagttctcatgtgt	AGCGTCTTCTGTACTATGACTCC
		gtactattctatcattattgtata	TACAACTCCAGGGTTGTGTTGGAATCAGGAATCAGTCGAGAAAAGTA
		atggttttcaaa	TCATACTTATGCAAGCACAGGGA
		ccagtgggcacacagagaacctca	AGAGCCTTAAATTTATACTGGAAAATCTAATTGAACGTGACTCTGGG
		gtctgtaataacaatgaggaatag	GTCTATTACTGTGCCACCTGGAA
		ccatggcgatctccagcaccaatc	GGATTATTATAAGAAAGTCTTTGGCAGTGGAACAACACTTGTTGTCA
		tctccatgttttccacagctcctc	CAGATAAACAACTTGATGCAGAT
		cagccaacccaaatagcgcctgct	GTTTCCCCCAAGCCCAcTATTTTTCTTCCTTCGATTGCTGAAACAAA
		atagtgtagacagcctgcggcttc	ACTCCAGAAGGCTGGAACATATC
		tagccttgtccctctcttagtgtt	TTTGTCTTCTTGAGAAATTTTTCCCAGATATTATTAAGATACATTGG
		ctttaatcagat	CAAGAAAAGAAGAGCAACACGAT
		aactgcctggaagcctttcatttt	TCTGGGATCCCAGGAGGGGAACACCATGAAGACTAACGACACATACA
		acacgccc	TGAAATTTAGCTGGTTAACGGTG
		[Seq Id No 68]	CCAGAAGAGTCACTGGACAAAGAACACAGATGTATCGTCAGACATGA
			GAATAATAAAAACGGAATTGATC
			AAGAAATTATCTTTCCTCCAATAAAGACAGATGTCACCACAGTGGAT
			CCCAAAGACAGTTATTCAAAAGA
			TGCAAATGATGTCACCACAGTGGATCCCAAATACAATTATTCAAAGG
			ATGCAAATGATGTCATCACAATG
			GATCCCAAAGACAATTGGTCAAAAGATGCAAATGATACACTACTGCT
			GCAGCTCACAAACACCTCTGCAT
			ATTACATGTACCTCCTCCTGCTCCTCAAGAGTGTGGTCTATTTTGCC
			ATCATCACCTGCTGTCTGCTTGG
			AAGAACGGCTTTCTGCTGCAATGGAGAGAAATCATAACAGACGGTGG
			CACAAGGAGGCCATCTTTTCCTC
			ATCGGTTATTGTCCCTAGAAGCGTCTTCTGAGGATCTAGTTGGGCTT
			TCTTTCTGGGTTTGGGCCATTTC
			AGTTCTCATGTGTGTACTATTCTATCATTATTGTATAATGGTTTTCA
			AACCAGTGGGCACACAGAGAACC
			TCAGTCTGTAATAACAATGAGGAATAGCCATGGCGATCTCCAGCACC
			AATCTCTCCATGTTTTCCACAGC
			TCCTCCAGCCAACCCAAATAGCGCCTGCTATAGTGTAGACAGCCTGC
			GGCTTCTAGCCTTGTCCCTCTCT
			TAGTGTTCTTTAATCAGATAACTGCCTGGAAGCCTTTCATTTTACAC
			GCCCTGAAGCAGTCTTCTTTGCT
			AGTTGAATTATGTGGTGTGTTTTTCCGTAATAAGCAAAATAAATTT
211796_	T cell	gccatcagaagcagagatctccca	>gi|3002924|gb|AF043179.1|AF043179 Homo sapiens	63.34
s_at	receptor	cacccaaaaggccacactggtgtg	T cell receptor beta chain (TCRBV13S1-TCRBJ2S1)
	beta	cctggccacaggtttctaccccga	mRNA, complete cds
	variable	ccacgtggagctgagctggtgggt	ATGAGCATCGGCCTCCTGTGCTGTGCAGCCTTGTCTCTCCTGTGGGC
	21-1///T	gaatgggaaggaggtgcacagtgg	AGGTCCAGTGAATGCTGGTGTCA
	cell	ggtcagcacagacccgcagcccct	CTCAGACCCCAAAATTCCAGGTCCTGAAGACAGGACAGAGCATGACA
	receptor	caaggagcagcccgccctcaatga	CTGCAGTGTGCCCAGGATATGAA
	beta	ctccagatactgcctgagcagccg	CCATGAATACATGTCCTGGTATCGACAAGACCCAGGCATGGGGCTGA
	variable	cctgagggtctcggccaccttctg	GGCTGATTCATTACTCAGTTCGT
	19///T	gcagaacccccgcaaccacttccg	GCTGGTATCACTGACCAAGGAGAAGTCCCCAATGGCTACAATGTCTC
	cell	ctgtcaagtccagttctacgggct	CAGATCAACCACAGAGGATTTCC
	receptor	ctcggagaatgacgagtggaccca	CGCTCAGGCTGCTGTCGGCTGCTCCCTCCCAGACATCTGTGTACTTC
	beta	ggatagggccaaacctgtcaccca	TGTGCCAGCAGTTTCCCCCGGCA
	variable	gatcgtcagcgccgaggcctgggg	GCCGTCCTACAATGAGCAGTTCTTCGGGCCAGGGACACGGCTCACCG
	5-4///T	tagagcagactgtggcttcacctc	TGCTAGAGGACCTGAAAAACGTG
	cell	cgagtcttaccagcaaggggtcct	TTCCCACCCGAGGTCGCTGTGTTTGAGCCATCAGAAGCAGAGATCTC
	receptor	gtctgccaccatcctctatgagat	CCACACCCAAAAGGCCACACTGG
	beta	cttgctagggaaggccaccttgta	TGTGCCTGGCCACAGGTTTCTACCCCGACCACGTGGAGCTGAGCTGG
	variable	tgctgtgctggtcagtgccctcgt	TGGGTGAATGGGAAGGAGGTGCA
	3-1///T	gctgatggccatggtcaagagaaa	CAGTGGGGTCAGCACAGACCCGCAGCCCCTCAAGGAGCAGCCCGCCC
	cell	gga	TCAATGACTCCAGATACTGCCTG
	receptor	[Seq Id No 69]	AGCAGCCGCCTGAGGGTCTCGGCCACCTTCTGGCAGAACCCCCGCAA
	beta		CCACTTCCGCTGTCAAGTCCAGT
	constant 1		TCTACGGGCTCTCGGAGAATGACGAGTGGACCCAGGATAGGGCCAAA
			CCTGTCACCCAGATCGTCAGCGC
			CGAGGCCTGGGGTAGAGCAGACTGTGGCTTCACCTCCGAGTCTTACC
			AGCAAGGGGTCCTGTCTGCCACC
			ATCCTCTATGAGATCTTGCTAGGGAAGGCCACCTTGTATGCTGTGCT
			GGTCAGTGCCCTCGTGCTGATGG
			CCATGGTCAAGAGAAAGGATTCCAGAGGCTGA
211902_	T cell	gaatcgtttctctgtgaacttcca	>gi|1100165|gb|L34703.1|HUMTCRAZ Homo sapiens	20.68
x_at	receptor	gaaagcagccaaatccttcagtct	T-cell receptor alpha chain (TCRA) mRNA (HLA
	alpha	caagatctcaga	A1, 24; B7, 8; DR 1, 3), complete cds
	locus	ctcacagctgggggatgccgcgat	ATGGCATGCCCTGGCTTCCTGTGGGCACTTGTGATCTCCACCTGTCT
		gtatttctgtgcttataggagtgc	TGAATTTAGCATGGCTCAGACAG
		atactctggggc	TCACTCAGTCTCAACCAGAGATGTCTGTGCAGGAGGCAGAGACCGTG
		tgggagttaccaactcactttcgg	ACCCTGAGCTGCACATATGACAC
		gaaggggaccaaactctcggtcat	CAGTGAGAGTGATTATTATTTATTCTGGTACAAGCAGCCTCCCAGCA
		accaaatatccagaaccctgaccc	GGCAGATGATTCTCGTTATTCGC
		tgccgtgtaccagctgagagactc	CAAGAAGCTTATAAGCAACAGAATGCAACAGAGAATCGTTTCTCTGT
		taaatccagtgacaagtctgtctg	GAACTTCCAGAAAGCAGCCAAAT
		cctattcaccgattttgattctca	CCTTCAGTCTCAAGATCTCAGACTCACAGCTGGGGGATGCCGCGATG
		aacaaatgtgtcacaaagtaagga	TATTTCTGTGCTTATAGGAGTGC
		ttctgatgtgta	ATACTCTGGGGCTGGGAGTTACCAACTCACTTTCGGGAAGGGGACCA
		tatcacagacaaaactgtgctaga	AACTCTCGGTCATACCAAATATC
		catgaggtctatggacttcaagag	CAGAACCCTGACCCTGCCGTGTACCAGCTGAGAGACTCTAAATCCAG
		caacagtgctgt	TGACAAGTCTGTCTGCCTATTCA
		ggcctggagcaacaaatctgactt	CCGATTTTGATTCTCAAACAAATGTGTCACAAAGTAAGGATTCTGAT
		tgcatgtgcaaacgccttcaacaa	GTGTATATCACAGACAAAACTGT
		cagcattattcc	GCTAGACATGAGGTCTATGGACTTCAAGAGCAACAGTGCTGTGGCCT
		agaagacaccttcttccccagccc	GGAGCAACAAATCTGACTTTGCA
		agaaagttcctgtgatgtcaagct	TGTGCAAACGCCTTCAACAACAGCATTATTCCAGAAGACACCTTCTT
		ggtcgagaaaagctttgaaacaga	CCCCAGCCCAGAAAGTTCCTGTG
		tacgaacctaaactttcaaaacct	ATGTCAAGCTGGTCGAGAAAAGCTTTGAAACAGATACGAACCTAAAC
		gtcagtgattgggttccgaatcct	TTTCAAAACCTGTCAGTGATTGG
		cctcctgaaagtggccgggtttaa	GTTCCGAATCCTCCTCCTGAAAGTGGCCGGGTTTAATCTGCTCATGA
		tctgctcatgacgctgcggttgtg	CGCTGCGGTTGTGGTCCAGCTGA
		gtcc
		[Seq Id No 70]
212999_	Major histo-	cactgcagaatgaaggaacatccc	>gi|24797068|ref|NM_002123.2|Homo sapiens	15.79
x_at	compatibility	ttgaggtgacccagccaacctgtg	major histocompatibility complex, class II, DQ
	complex,	gccagaaggagqnttgtaccttga	beta 1 (HLA-DQB1), mRNA
	class II,	aaagacactgaaagcattttggng	CAGATCCATCAGGTCCGAGCTGTGTTGACTACCACTTTTCCCTTCGT
	DQ beta 1///	tgtnaagtaagggtgggcagagga	CTCAATTATGTCTTGGAAAAAGG
	Major histo-	ggtagaaaatcaattcaattgtcg	CTTTGCGGATCCCCGGAGGCCTTCGGGCAGCAACTGTGACCTTGATG
	compatibility	catcattcatggttctttaatatt	CTGTCGATGCTGAGCACCCCAGT
	complex,	gatgctcagtgcantggcctnaga	GGCTGAGGGCAGAGACTCTCCCGAGGATTTCGTGTACCAGTTTAAGG
	class II,	atatcccagcctctcttctggttt	GCATGTGCTACTTCACCAACGGG
	DQ beta 1	gntgagtgctntntaagtaagcat	ACAGAGCGCGTGCGTCTTGTGAGCAGAAGCATCTATAACCGAGAAGA
		ggtngaattgtttggggncanata	GATCGTGCGCTTCGACAGCGACG
		tagtganccttggtcactggtgtt	TGGGGGAGTTCCGGGCGGTGACGCTGCTGGGGCTGCCTGCCGCCGAG
		tcaaacattctg	TACTGGAACAGCCAGAAGGACAT
		gnaagtcacatcnatcaagaatan	CCTGGAGAGGAAACGGGCGGCGGTGGACAGGGTGTGCAGACACAACT
		tttttanttttaagaaagcataac	ACCAGTTGGAGCTCCGCACGACC
		cagcaataaa	TTGCAGCGGCGAGTGGAGCCCACAGTGACCATCTCCCCATCCAGGAC
		[Seq Id No 71]	AGAGGCCCTCAACCACCACAACC
			TGCTGGTCTGCTCGGTGACAGATTTCTATCCAGCCCAGATCAAAGTC
			CGGTGGTTTCGGAATGACCAGGA
			GGAGACAGCTGGCGTTGTGTCCACCCCCCTTATTAGGAATGGTGACT
			GGACCTTCCAGATCCTGGTGATG
			CTGGAAATGACTCCCCAGCGTGGAGACGTCTACACCTGCCACGTGGA
			GCACCCCAGCCTCCAGAGCCCCA
			TCACCGTGGAGTGGCGGGCTCAATCTGAATCTGCCCAGAGCAAGATG
			CTGAGTGGCATTGGAGGCTTCGT
			GCTGGGGCTGATCTTCCTCGGGCTGGGCCTTATCATCCATCACAGGA
			GTCAGAAAGGGCTCCTGCACTGA
			CTCCTGAGACTATTTTAACTGGGATTGGTTATCACTTTTCTGTAACG
			CCTGCTTGTCCCTGCCCAGAATT
			CCCAGCTGTCTGTGTCAGCCTGTCCCCCTGAGATCAGAGTCCTACAG
			TGGCTGTCACGCAGCCACCAGGT
			CATCTCCTTTCATCCCCACCTTGAGGCGGATGGCTGTGACCCTACTT
			CCTGCACTGACCCACAGCCTCTG
			CCTGTGCACGGCCAGCTGCATCTACTCAGGCCCCAAGGGGTTTCTGT
			TTCTATTCTCTCCTCAGACTGCT
			CAAGAGAAGCACATGAAAACCATTACCTGACTTTAGAGCTTTTTTAC
			ATAATTAAACATGATCCTGAGTT
213193_	T cell	Tgactccagatactgcctgagcag	>gi|46184507|gb|AL559122.3|AL559122 AL559122	44.75
x_at	receptor	ccgcctgagggtctcggccacctt	Homo sapiens T CELLS (JURKAT CELL LINE) COT 10-
	beta	ctggcagaacccccgcaaccactt	NORMALIZED Homo sapiens cDNA clone CS0DJ014YE01
	variable	ccgctgtcaagtccagttctacgg	5-PRIME, mRNA sequence
	19///T	gctctcggagaatgacgagtggac	TGCCTGGCCACAGGCTTCTTCCCCGACCACGTGGAGCTGAGCTGGTG
	cell	ccaggatagggccaaacccgtcac	GGTGAATGGGAAGGAGGTGCACA
	receptor	ccagatcqtcagcgccgaggcctg	ATGGGGTCAACACAGACCCGCAGCCCCTCAAAGAACAGCCCGCCCTC
	beta	gggtagagcagactgtggctttac	AATGACTCCAAATAMTGCCTGAG
	variable	ctcggtgtcctaccagcaaggggt	CAGCCGCCTGAGGGTCTCGGCCACCTTCTGGCAGAACCCCCGCAACC
	19///T	cctgtctgccaccatcctctatga	ACTTCCGCTGTCAAGTCCAGTTC
	cell	gatcctgctagggaaggccaccct	TACGGGCTCTCGGAGAATGACGAGTGGACCCAGGATAGGGCCAAACC
	receptor	gtatgctgtgctggtcagcnccct	CGTCACCCAAATCGTCAGCGCCG
	beta	tgtgttgatggccatggtcaagag	AGGCCTGGGGTARAGCARAMTGTGGCTTTACCTCGGTGTCCTACCAA
	constant	aaaggatttctgaaggcagccctg	CAAGGGGTCCTGTCTGCCACCAT
	1///T	gaagtggagttaggagcttctaac	CCTCTATGARATCCTGcTAGGGAAGGCCACCcTGTATGCTGTGCTGG
	cell	ccgtcatggtttcaatacacattc	TCAGCGCCCTTGTGTTGATGGCC
	receptor	ttcttttgccagcgcttctgaaga	ATGGTCAAGAGAAAGGATTTCTGAAGGCAGCCCTGGAAGTGGAATTA
	beta	gctgctctcacctctctgcatccc	AGAACTTCTAACCCGTCATGGTT
	constant 1	aatagatatccccctatgtgcatg	TCAATACACATTCTTCTTTTGCCAGCGCTTCTGAAGAGCTGCTCTCA
		cacacctgcacactcacggctgaa	CCTCTCTGCATCCCAATAGATAT
		atctccctaacccagggggacctt	CCCCCTATGTGCATGCACACCTGCACACTCACGGCTGAAATCTCCCT
		agcatgcctaagtga	AACCCAGGOGGACCTTACCATGC
		[Seq Id No 72]	CTAAGTGACTAAACCAATAAAAATGTTCTGGTCTGGCCTGA
213539_	CD3D	gggaacactgctctcagacattac	>gi|98985799|ref|NM_000732.4|Homo sapiens CD3d	34.66
at	antigen,	aagactggacctgggaaaacgcat	molecule, delta (CD3-TCR complex) (CD3D),
	delta poly-	cctggacccacgaggaatatatag	transcript variant 1, mRNA
	peptide	gtgtaatgggacagatatatacaa	AGAGAAGCAGACATCTTCTAGTTCCTCCCCCACTCTCCTCTTTCCGG
	(TiT3	ggacaaagaatctaccgtgcaagt	TACCTGTGAGTCAGCTAGGGGAG
	complex)	tcattatcgaatgtgccagagctg	GGCAGCTCTCACCCAGGCTGATAGTTCGGTGACCTGGCTTTATCTAC
		tgtggagctggatccagccaccgt	TGGATGAGTTCCGCTGGGAGATG
		ggctggcatcattgtcactgatgt	GAACATAGCACGTTTCTCTCTGCCCTGGTACTGGCTACCCTTCTCTC
		cattgccactctgctccttgcttt	GCAAGTGAGCCCCTTCAAGATAC
		gggagtcttctgctttgctggaca	CTATAGAGGAACTTGAGGACAGAGTGTTTGTGAATTGCAATACCAGC
		tgagactggaaggctgtctggggc	ATCACATGGGTAGAGGGAACGGT
		tgccgacacacaagctctgttgag	GGGAACACTGCTCTCAGACATTACAAGACTGGACCTGGGAAAACGCA
		gaatgaccaggtctatcagcccct	TCCTGGACCCACGAGGAATATAT
		ccgagatcgagatgatgctcagta	AGGTGTAATGGGACAGATATATACAAGGACAAAGAATCTACCGTGCA
		cagccaccttggaggaaactgggc	AGTTCATTATCGAATGTGCCAGA
		tcggaacaagtgaacctgagactg	GCTGTGTGAGCTGGATCCAGCCACCGTGGCTGGCATCATTGTCACT
		gtggcttctagaagcagccattac	GATGTCATTGCCACTCTGCTCCT
		caactgtacct	TGCTTTGGGAGTCTTCTGCTTTGCTGGACATGAGACTGGAAGGCTGT
		[Seq Id No 73]	CTGGGGCTGCCGACACACAAGCT
			CTGTTGAGGAATGACCAGGTCTATCAGCCCCTCCGAGATCGAGATGA
			TGCTCAGTACAGCCACCTTGGAG
			GAAACTGGGCTCGGAACAAGTGAACCTGAGACTGGTGGCTTCTAGAA
			GCAGCCATTACCAACTGTACCTT
			CCCTTCTTGCTCAGCCAATAAATATATCCTCTTTCACTCAGAAAAAA
			AAAAAAAAAAAAAAAAAAAAAAA
			A
215806_	T cell	aaatgatacactactgctgcagct	>gi|339168|gb|M13231.1|HUMTCGXH Human T-cell	19.96
x_at	receptor	cacaaacacctctgcatattacat	receptor aberrantly rearranged gamma-chain mRNA
	gamma	gtacctcctcct	from cell line HPB-MLT
	constant	gctcctcaagagtgtggtctattt	GGCATGCGGTGGGCCCTACTGGTGCTTCTAGCTTTCCTGTCTCCTGC
	2///T cell	tgccatcatcacctgctgtctgcn	CAGTCAGAAATCTTCCAACTTGG
	receptor	tgnaagaacggc	AAGCGAGAACGAAGTCAGTCACCAGGCAGACTGGGTCATCTGCTGAA
	gamma	nnnctgctgcaatggagagaantc	ATCACTTGCGATCTTACTGTAAC
	variable	ataacagacggtggcacaaggagg	AAATACCTTCTACATCCACTGGTACCTACACCAGGAGGGGAAGGCCC
	9///	ccnncntntcctcatcggnnattg	CACAGCGTCTTCTGTACTATGAC
	similar to	tccctagaagcgtcttctgaggat	GTCTCCACTGCAAGGGATGTGTTGGAATCAGGACTCAGTCCAGGAAA
	T-cell	ctagttgggctttctttctgggtt	GTATTATACTCATACACCCAGGA
	receptor	tgggccatttcagttctcatgtgt	GGTGGAGCTGGATATTGAGACTGCAAAATCTAATTGAAAATGATTCT
	gamma	gtactattctatcattattgtata	GGGGTCTATTACTGTGCCACCTG
	chain C	atggttttcaaa	GGACAGGCAAAAATTATTATAAGAAACTCTTTGGCAGTGGAACAACA
	region PT-	ccagtgggcacacagagaacctca	CTTGTTGTCACAGATAAACAACT
	gamma-	gtctgtaataacaatgaggaatag	TGATGCAGATGTTTCCCCCAAGCCCACTATTTTTCTTCCTTCAATTG
	½///	ccatggcgatctccagcaccaatc	CTGAAACAAAACTCCAGAAGGCT
	similar to	tctccatgttttccacagctcctc	GGAACATACCTTTGTCTTCTTGAGAAATTTTTCCCAGATATTATTAA
	T-cell	cagccaacccaaatagcgcctgct	GATACATTGGCAAGAAAAGAAGA
	receptor	atagtgtaganannctgcggcttc	GCAACACGATTCTGGGATCCCAGGAGGGGAACACCATGAAGACTAAC
	gamma	tagccttgtccctctcttagtgtt	GACACATACATGAAATTTAGCTG
	chain V	ctttaatcagat	GTTAACGGTGCCAGAAGAGTCACTGGACAAAGAACACAGATGTATCG
	region PT-	aactgcctggaagcctttcatttt	TCAGACATGAGAATAATAAAAAC
	gamma-	acacgccctgaagcagtcttcttt	GGAATTGATCAAGAAATTATCTTTCCTCCAATAAAGACAGATGTCAC
	½ pre-	gcta	CACAGTGGATCCCAAAGACAGTT
	cursor///	[Seq Id No 74]	ATTCAAAAGATGCAAATGATGTCATCACAATGGATCCCAAAGACAAT
	TCR gamma		TGGTCAAAAGATGCAAATGATAC
	alternate		ACTACTGCTGCAGCTCACAAACACCTCTGCATATTACATGTACCTCC
	reading		TCCTGCTCCTCAAGAGTGTGGTC
	frame		TATTTTGCCATCATCACCTGCTGTCTGCTTGGAAGAACGGCTTTCTG
	protein		CTGCAATGGAGAGAAATCATAAC
			AGACGGTGGCACAAGGAGGCCATCTTTTCCTCATCGGTTATTGTCCC
			TAGTAGAAGCGTCTTCTGAGGATCTA
			GTTGGGCTTTCTTTCTGGGTTTGGGCCATTTCAGTTCTCATGTGTGT
			ACTATTCTATCATTATTGTATAA
			TGGTTTTCAAACCAGTGGGCACACAGAGAACCTCAGTCTGTAATAAC
			AATGAGGAATAGCCATGCCGATC
			TCCAGCACCAATCTCTCCATGTTTTCCACAGCTCCTCCAGCCAACCC
			AAATAGCGCCTGCTATAGTGTAG
			ACAGCCTGCGGCTTCTAGCCTTGTCCCTCTCTTAGTGTTCTTTAATC
			AGATAACTGCCTGGAAGCCTTTC
			ATTTTACACGCCCTGAAGCAGTCTTCTTTGCTAGTTGAATTATGTGG
			TGTGTTTTTCCGTAATAAGCAAA
			ATAAATTTAAAAAAATGAAAA
216748_	pyrin and	ccaccctctggatcccaatattga	>gi|10437303|dbj|AK024890.1|Homo sapiens cDNA:	10.74
at	HIN domain	gatcttatcctcagggaatcctca	FLJ21237 fis, clone COL01114
	family	cttagacccctg	GTCAAAGGAATAATCCCATCTAAAAAGACGAAACAGAAAGAAGTGTA
	member 1	taacaggttaaatcttcatggtgt	TCCTGCTACACCTGCATGCACCC
		tctgtttcctaggaacttctttct	CAAGCAACCGTCTCACAGCTAAAGGAGCAGAGGAGACTCTTGGACCT
		tttctactgttt	CAGGTAAGCTTCAGGAAGAGGAG
		atgacaactgaagttaataagtgt	CAGGCTTCAAGTCTCACAGTGGAAGCTCTGCTGTGGCTGTTCCACTC
		ttatctttcccacctactcaaagt	AATCTGTCCAGCAGGCAGTTATT
		agttccaagatt	TCTTCATATGTTTCCCATCAAGTTTCAGATTTATCAAATTACATAAT
		agggctagtttgtaattctgtgga	AATTGATCATCTTTCTGCAAGGC
		ccactgtaaacgagggcctagttc	AACAAGTTAAACGCTTTAGTAAACATAATGTAAATATACATAAAATA
		agtgtctgcctc	AATATAATATTTTCATCTCCAAT
		atgggaagcttccaataaatacct	AGAGAAGGATGTTAACTTGAGAGTCAGATAAAAAAACGTTTGCCTAT
		ttg	GTTTACAAAAGCCTAGTTTCTTA
		[Seq Id No 75]	ACTGCAAGTCAGCATATCCCAAAACACAAGTAATTAAGGAATGATGT
			GTGTTACTTTCTCTGCTCCCTTT
			TTAAAAATGAAACCATCTATGCCATGTTCTTTCAATTGGCCTGGGGA
			TGTACTTAAGTTTCCAAGAAAAA
			CAATTTATATACAATAAATATATTACCTTGTAATGAAAATGTGCTCT
			GCTTCATTTGACACTGAAAGTAA
			TTAACAAGAAAAATAAACTACTTGTAGAAAAGAAAAAAACCATCTGA
			AGAAGAGACTGGAACCAAAAGGA
			GTAAGATGTCCAAAGAGCAGACTCGGCCTTCCTGCTCTGCAGGAGCC
			AGCACGTCCACAGCCATGGGCCG
			TTCCCCACCTCCCCAGACCTCATCATCAGCTCCACCCAACACTTCCT
			CAACTGAGGTACACTCTTCCTGG
			TCCCCTTTTGATTCATTTTCTTCAACCCAAAATGTAGGAATCTGATT
			TCATCTTCTACTGAAAAATGACA
			TCAATCATCAGCCAGTAAATCAAATGTATAGACTGAGAATTAACTGC
			ATTTTAATCTTTTGCTTCCACAG
			GCATATTTGATGAACTTGACATTATCTCTGACTGCAGGAAGTTTTCT
			GTCCTGTGCTGTTTGGGGAAGAG
			ACAGAGAACTGCGGAATCTGGAACTTTCAGCAACAGACTCACTGTCT
			ACTGCCCCCATCTATTATACACC
			CATTCCCTTTGCTCACTAATTTGTTCAAGTTTCTCTGACATACACCA
			TGCTCCTTTTTCCTTTAGGATTT
			TCACACACCATATTTCTTTCACCTTTAAACTCTTACCTGGCCAACCC
			TATCCACCCTCTGGATCCCAATA
			TTGAGATCTTATCCTCAGGGAATCCTCACTTAGACCCCTGTAACAGG
			TTAAATCTTCATGGTGTTCTGTT
			TCCTAGGAACTTCTTTCTTTTCTACTGTTTATGACAACTGAAGTTAA
			TAAGTGTTTATCTTTCCCACCTA
			CTCAAAGTAGTTCCAAGATTAGGGCTAGTTTGTAATTCTGTGGACCA
			CTGTAAACGAGGGCCTAGTTCAG
			TGTCTGCCTCATGGGAAGCTTCCAATAAATACCTTTGCTCAACGAAA
			AAATGAAAACCCAGTGGCTCACG
			CCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGTGGATTGCCTGA
			GGTCAGGAGTTTGAGACTAGTCT
			GGCCAACATGGTGAAACACTATCTCTACTAAAAATACAAAAAAATTA
			GCTGGGTATGGTGGCTTACGCCT
			ATAATCCCAGCTACTCAGGAGGCTGAGGCAGGGGAATTGCTTGAACC
			AGGGAGGTGGAGGTTGCAGTGAG
			CTGAGATCGCACCACTGCACTCCAGCCTGGGTGACAGAGCGAGACTC
			CATCTCAAAATAAAAAAGTAAAA
			AAAAAAAAAAAAAA
217147_	T cell	tctcctttctcaccaatgggcaat	>gi|54607136|ref|NM_016388.2|Homo sapiens T	24.16
s_at	receptor	agcccataattgaaataaatttct	cell receptor associated transmembrane adaptor
	associated	gattgaaaggta	1 (TRAT1), mRNA
	transmembrane	taggaaacattaaaatgcattact	GAGGCACAGATAAAGATAAGTTTTACTGTCATGCTGCTTTTAACATA
	adaptor 1	aagagaagtaatataattttctta	ACAGAGCAACATCACCTAGGAAA
		caaagtattttt	AAAGTTTGTAGGAGGATTTTTAATCCATATATTTGTCTTATGGCTAG
		cccaaagatagctttactatttca	ATAAAGATTTCTCTGAAAAAAAG
		aaaattgtcaaattaatgcatgct	AAGCATGTCAGGAATCTCTGGGTGCCCCTTTTTCCTCTGGGGACTTC
		ccttacaacaaa	TAGCATTGTTGGGCTTGGCTTTG
		caaatatcaaaaagagtttaggaa	GTTATATCACTGATCTTCAATATTTCCCACTATGTGGAAAAGCAACG
		ttctactagccagagatagtcact	ACAAGATAAAATGTACAGCTACT
		tggagaaacttt	CCAGTGACCACACCAGGGTTGATGAGTATTATATTGAAGACACACCA
		ctatatatccttctaaatattttt	ATTTATGGTAACTTAGATGATAT
		ctgggcatgctcatgtatgtacat	GATTTCAGAACCAATGGATGAAAATTGCTATGAACAAATGAAAGCCC
		cagttgtttctt	GACCAGAGAAATCTGTAAATAAG
		tttattttgaaccaaaaatgtggt	ATGCAGGAAGCCACCCCATCTGCACACGCAACCAATGAAACACAGAT
		ttcttttgtacacattacttaaac	GTGCTACGCCTCACTTGATCACA
		tttctttccagt	GCGTTAACGGGAAGCGTAGAAAGCCCAGGAAACAGAATACTCATTTC
		caacaatatattgtggatttattt	TCAGACAAGGATGGAGATGAGCA
		tcactgttatatttaactatatat	ACTACATGCAATAGATGCCAGCGTTTCTAAGACCACCTTAGTAGACA
		aaatacgcatat	GTTTCTCCCCAGAAAGCCAGGCA
		attgtaattttaatgtctgcttag	GTAGAGGAAAACATTCATGATGATCCCATCAGACTGTTTGGATTGAT
		caccccactgataaccaaatcaca	CCGTGCTAAGAGAGAACCTATAA
		g	ACTAGCTGGACCATGATCTAGTTCAATGATTTGGCTCCTATTGAAGA
		[Seq Id No 76]	TGGCTTCTAAGAAAACAAGATGC
			ACAGAGGACACAGAAGGACTTGGCAGCAGGGTGATGACCTGATCATT
			TGTTGATGGGATGGTGGCTTACC
			TCTTATTCACAGCTTACACTTATGCATGCCAAATGTAAGGCCATGAA
			AATCAGTATTTCAAATAACTTAA
			AAAATGCTTTACTACTAAAATGTAAAAAATTAATGTGCTCACCTCGG
			CAGCACATATACTAAAAATTAAT
			AAGACCCAGCTTGAAAATTGAGCCTGATAACAAGATTACAAATTCAC
			AATACCTAATACTTAGGCAAATA
			TAAAAATTTAAGCATGAATGCGTTCTGGAACACGTTAGAAGAAAAAT
			AAAAGCCAATGAGTTTTTTTTTA
			ATTCTCCTTTCTCACCAATGGGCAATAGCCCATAATTGAAATAAATT
			TCTGATTGAAAGGTATAGGAAAC
			ATTAAAATGCATTACTAAGAGAAGTAATATAATTTTCTTACAAAGTA
			TTTTTCCCAAAGATAGCTTTACT
			ATTTCAAAAATTGTCAAATTAATGCATGCTCCTTACAACAAACAAAT
			ATCAAAAAGAGTTTAGGAATTCT
			ACTAGCCAGAGATAGTCACTTGGAGAAACTTTCTATATATCCTTCTA
			AATATTTTTCTGGGCATGCTTAT
			GTATGTACATCAGTTGTTTCTTTTTATTTTGAACCAAAAATGTGGTT
			TCTTTTGTACACATTACTTAAAC
			TTTCTTTCCAGTCAACAATATATTGTGGATTTATTTTCACTGTTATA
			TTTAACTATATATAAATACGCAT
			ATATTGTAATTTTAATGTCTGCTTAGCACCCCACTGATAACCAAATC
			ACAGTTTATTTAAATAATTTTAA
			TGACTTTTCAAAAACAATTTATTGATGCAAAAAGCAAGGTTGAGATG
			ACAATGTTTCTTTCAATAATTAA
			AAAATACTGCTTCAC
219159_	SLAM	Gagagtggacatttgtcgggaaac	>gi|19923571|ref|NM_021181.3|Homo sapiens SLAM	15.84
s_at	family	tcctaacatatgcccccattctgg	family member 7 (SLAMF7), mRNA
	member 7	agagaacacagagtacgacacaat	CTTCCAGAGAGCAATATGGCTGGTTCCCCAACATGCCTCACCCTCAT
		ccctcacactaatagaacaatcct	CTATATCCTTTGGCAGCTCACAG
		a	GGTCAGCAGCCTCTGGACCCGTGAAAGAGCTGGTCGGTTCCGTTGGT
		[Seq Id No 77]	GGGGCCGTGACTTTCCCCCTGAA
			GTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAA
			CCCCTCTTGTCACCATACAGCCA
			GAAGGGGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGT
			AGACTTCCCAGATGGAGGCTACT
			CCCTGAAGCTCAGCAAACTGAAGAAGAATGACTCAGGGATCTACTAT
			GTGGGGATATACAGCTCATCACT
			CCAGCAGCCCTCCACCCAGGAGTACGTGCTGCATGTCTACGAGCACC
			TGTCAAAGCCTAAAGTCACCATG
			GGTCTGCAGAGCAATAAGAATGGCACCTGTGTGACCAATCTGACATG
			CTGCATGGAACATGGGGAAGAGG
			ATGTGATTTATACCTGGAAGGCCCTGGGGCAAGCAGCCAATGAGTCC
			CATAATGGGTCCATCCTCCCCAT
			CTCCTGGAGATGGGGAGAAAGTGATATGACCTTCATCTGCGTTGCCA
			GCAACCCTGTCAGCAGAAACTTC
			TCAAGCCCCATCCTTGCCAGGAAGCTCTGTGAAGGTGCTGCTGATGA
			CCCAGATTCCTCCATGGTCCTCC
			TGTGTCTCCTGTTGGTGCCCCTCCTGCTCAGTCTCTTTGTACTGGGG
			CTATTTCTTTGGTTTCTGAAGAG
			AGAGAGACAAGAAGAGTACATTGAAGAGAAGAAGAGAGTGGACATTT
			GTCGGGAAACTCCTAACATATGC
			CCCCATTCTGGAGAGAACACAGAGTACGACACAATCCCTCACACTAA
			TAGAACAATCCTAAAGGAAGATC
			CAGCAAATACGGTTTACTCCACTGTGGAAATACCGAAAAAGATGGAA
			AATCCCCACTCACTGCTCACGAT
			GCCAGACACACCAAGGCTATTTGCCTATGAGAATGTTATCTAGACAG
			CAGTGCACTCCCCTAAGTCTCTG
			CTCAAAAAAAAAACAATTCTCGGCCCAAAGAAAACAATCAGAAGAAT
			TCACTGATTTGACTAGAAACATC
			AAGGAAGAATGAAGAACGTTGACTTTTTTCCAGGATAAATTATCTCT
			GATGCTTCTTTAGATTTAAGAGT
			TCATAATTCCATCCACTGCTGAGAAATCTCCTCAAACCCAGAAGGTT
			TAATCACTTCATCCCAAAAATGG
			GATTGTGAATGTCAGCAAACCATAAAAAAAGTGCTTAGAAGTATTCC
			TATAGAAATGTAAATGCAAGGTC
			ACACATATTAATGACAGCCTGTTGTATTAATGATGGCTCCAGGTCAG
			TGTCTGGAGTTTCATTCCATCCC
			AGGGCTTGGATGTAAGGATTATACCAAGAGTCTTGCTACCAGGAGGG
			CAAGAAGACCAAAACAGACAGAC
			AAGTCCAGCAGAAGCAGATGCACCTGACAAAAATGGATGTATTAATT
			GGCTCTATAAACTATGTGCCCAG
			CACTATGCTGAGCTTACACTAATTGGTCAGACGTGCTGTCTGCCCTC
			ATGAAATTGGCTCCAAATGAATG
			AACTACTTTCATGAGCAGTTGTAGCAGGCCTGACCACAGATTCCCAG
			AGGGCCAGGTGTGGATCCACAGG
			ACTTGAAGGTCAAAGTTCACAAAGATGAAGAATCAGGGTAGCTGACC
			ATGTTTGGCAGATACTATAATGG
			AGACACAGAAGTGTGCATGGCCCAAGGACAAGGACCTCCAGCCAGGC
			TTCATTTATGCACTTGTGCTGCA
			AAAGAAAAGTCTAGGTTTTAAGGCTGTGCCAGAACCCATCCCAATAA
			AGAGACCGAGTCTGAAGTCACAT
			TGTAAATCTAGTGTAGGAGACTTGGAGTCAGGCAGTGAGACTGGTGG
			GGCACGGGGGGCAGTGGGTACTT
			GTAAACCTTTAAAGATGGTTAATTCATTCAATAGATATTTATTAAGA
			ACCTATGCGGCCCGGCATGGTGG
			CTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGTGGGTC
			ATCTGAGGTCAGGAGTTCAAGAC
			CAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAGATACAAAA
			ATTTGCTGAGCGTGGTGGTGTGC
			ACCTGTAATCCCAGCTACTCGAGAGGCCAAGGCATGAGAATCGCTTG
			AACCTGGGAGGTGGAGGTTGCAG
			TGAGCTGAGATGGCACCACTGCACTCCGGCCTAGGCAACGAGAGCAA
			AACTCCAATACAAACAAACAAAC
			AAACACCTGTGCTAGGTCAGTCTGGCACGTAAGATGAACATCCCTAC
			CAACACAGAGCTCACCATCTCTT
			ATACTTAAGTGAAAAACATGGGGAAGGGGAAAGGGGAATGGCTGCTT
			TTGATATGTTCCCTGACACATAT
			CTTGAATGGAGACCTCCCTACCAAGTGATGAAAGTGTTGAAAAACTT
			AATAACAAATGCTTGTTGGGCAA
			GAATGGGATTGAGGATTATCTTCTCTCAGAAAGGCATTGTGAAGGAA
			TTGAGCCAGATCTCTCTCCCTAC
			TGCAAAACCCTATTGTAGTAAAAAAGTCTTCTTTACTATCTTAATAA
			AACAGATATTGTGAGATTCAAAA
			AAAAAAAAAAAA
222838_	SLAM	aacacctgtgctaggtcagtctgg	>gi|19923571|ref|NM_021181.3|Homo sapiens SLAM	22.54
at	family	cacgtaagatgaacatccctacca	family member 7 (SLAMF7), mRNA
	member 7	acacagagctcaccatctcttata	CTTCCAGAGAGCAATATGGCTGGTTCCCCAACATGCCTCACCCTCAT
		cttaagtgaaaaacatggggaagg	CTATATCCTTTGGCAGCTCACAG
		ggaaaggggaatggctgcttttga	GGTCAGCAGCCTCTGGACCCGTGAAAGAGCTGGTCGGTTCCGTTGGT
		tatgttccctgacacatatcttga	GGGGCCGTGACTTTCCCCCTGAA
		atggagacctccctaccaagtgat	GTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAA
		gaaagtgttgaa	CCCCTCTTGTCACCATACAGCCA
		aaacttaataacaaatgcttgttg	GAAGGGGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGT
		ggcaagaatgggattgaggattat	AGACTTCCCAGATGGAGGCTACT
		cttctctcagaa	CCCTGAAGCTCAGCAAACTGAAGAAGAATGACTCAGGGATCTACTAT
		aggcattgtgaagaattgagcca	GTGGGGATATACAGCTCATCACT
		gatctctctccctactgcaaaacc	CCAGCAGCCCTCCACCCAGGAGTACGTGCTGCATGTCTACGAGCACC
		ctattgtagta	TGTCAAAGCCTAAAGTCACCATG
		[Seq Id No 78]	GGTCTGCAGAGCAATAAGAATGGCACCTGTGTGACCAATCTGACATG
			CTGCATGGAACATGGGGAAGAGG
			ATGTGATTTATACCTGGAAGGCCCTGGGGCAAGCAGCCAATGAGTCC
			CATAATGGGTCCATCCTCCCCAT
			CTCCTGGAGATGGGGAGAAAGTCATATGACCTTCATCTGCGTTGCCA
			GGAACCCTGTCAGCAGAAACTTC
			TCAAGCCCCATCCTTGCCAGGAAGCTCTGTGAAGGTGCTGCTGATGA
			CCCAGATTCCTCCATGGTCCTCC
			TGTGTCTCCTGTTGGTGCCCCTCCTGCTCAGTCTCTTTGTACTGGGG
			CTATTTCTTTGGTTTCTGAAGAG
			AGAGACACAAGAAGAGTACATTGAAGAGAAGAAGAGAGTGGACATTT
			GTCGGGAAACTCCTAACATATGC
			CCCCATTCTGGAGAGAACACAGAGTACGACACAATCCCTCACACTAA
			TAGAACAATCCTAAAGGAAGATC
			CAGCAAATACGGTTTACTCCACTGTGGAAATACCGAAAAAGATGGAA
			AATCCCCACTCACTGCTCACGAT
			GCCAGACACACCAAGGCTATTTGCCTATGAGAATGTTATCTAGACAG
			CAGTGCACTCCCCTAAGTCTCTG
			CTCAAAAAAAAAACAATTCTCGGCCCAAAGAAAACAATCAGAAGAAT
			TCACTGATTTGACTAGAAACATC
			AAGGAAGAATGAAGAACGTTGACTTTTTTCCAGGATAAATTATCTCT
			GATGCTTCTTTAGATTTAAGAGT
			TCATAATTCCATCCACTGCTGAGAAATCTCCTCAAACCCAGAAGGTT
			TAATCACTTCATCCCAAAAATGG
			GATTGTGAATGTCAGCAAACCATAAAAAAAGTGCTTAGAAGTATTCC
			TATAGAAATGTAAATGCAAGGTC
			ACACATATTAATGACAGCCTGTTGTATTAATGATGGCTCCAGGTCAG
			TGTCTGGAGTTTCATTCCATCCC
			AGGGCTTGGATGTAAGGATTATACCAAGAGTCTTGCTACCAGGAGGG
			CAAGAAGACCAAAACAGACAGAC
			AAGTCCAGCAGAAGCAGATGCACCTGACAAAAATGGATGTATTAATT
			GGCTCTATAAACTATGTGCCCAG
			CACTATGCTGAGCTTACACTAATTGGTCAGACGTGCTGTCTGCCCTC
			ATGAAATTGGCTCCAAATGAATG
			AACTACTTTCATGAGCAGTTGTAGCAGGCCTGACCACAGATTCCCAG
			AGGGCCAGGTGTGGATCCACAGG
			ACTTGAGGTCAAAGTTCACAAAGATGAAGAATCAGGGTAGCTGACC
			ATGTTTGGCAGATACTATAATGG
			AGACACAGAAGTGTGCATGGCCCAAGGACAAGGACCTCCAGCCAGGC
			TTCATTTATGCACTTGTGCTGCA
			AAAGAAAAGTCTAGGTTTTAAGGCTGTGCCAGAACCCATCCCAATAA
			AGAGACCGAGTCTGAAGTCACAT
			TGTAAATCTAGTGTAGGAGACTTGGAGTCAGGCAGTGAGACTGGTGG
			GGCACGGGGGGCAGTGGGTACTT
			GTAAACCTTTAAAGATGGTTAATTCATTCAATAGATATTTATTAAGA
			ACCTATGCGGCCCGGCATGGTGG
			CTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGTGGGTC
			ATCTGAGGTCAGGAGTTCAAGAC
			CAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAGATACAAAA
			ATTTGCTGAGCGTCGTGGTGTGC
			ACCTGTAATCCCAGCTACTCGAGAGGCCAAGGCATGAGAATCGCTTG
			AACCTGGGAGGTGGAGGTTGCAG
			TGAGCTGAGATGGCACCACTGCACTCCGGCCTAGGCAACGAGAGCAA
			AACTCCAATACAAACAAACAAAC
			AAACACCTGTGCTAGGTCAGTCTGGCACGTAAGATGAACATCCCTAC
			CAACACAGAGCTCACCATCTCTT
			ATACTTAAGTGAAAAACATGGGGAAGGGGAAAGGGGAATGGCTGCTT
			TTGATATGTTCCCTGACACATAT
			CTTGAATGGAGACCTCCCTACCAAGTGATGAAAGTGTTGAAAAACTT
			AATAACAAATGCTTGTTGGGCAA
			GAATGGGATTGAGGATTATCTTGTCTCAGAAAGGCATTGTGAAGGAA
			TTGAGCCAGATCTCTCTCCCTAC
			TGCAAAACCCTATTGTAGTAAAAAAGTCTTCTTTACTATCTTAATAA
			AACAGATATTGTGAGATTCAAAA
			AAAAAAAAAAAA
229152_	chromosome	tgaagaaagttctcctcctgatca	>gi|50428928|ref|NM_152997.2|Homo sapiens	154.05
at	4 open	cagccatcttggcagtggctgttg	chromosome 4 open reading frame 7 (C4orf7),
	reading	gtttcccagtct	mRNA
	frame 7	ctcaagaccaggaacgagaaaaaa	TAAAACAGCTACAATATTCCAGGGCCAGTCACTTGCCATTTCTCATA
		gaagtatcagtgacagcgatgaat	ACAGCGTCAGAGAGAAAGAACTG
		tagcttcagggttttttgtgttcc	ACTGAAACGTTTGAGATGAAGAAAGTTCTCCTCCTGATCACAGCCAT
		cttacccatatccatttcgcccac	CTTGGCAGTGGCTGTTGGTTTCC
		ttccaccaattccatttccaagat	CAGTCTCTCAAGACCAGGAACGAGAAAAAAGAAGTATCAGTGACAGC
		ttccatggtttagacgtaattttc	GATGAATTAGCTTCAGGGTTTTT
		ctattccaatacctgaatctgccc	TGTGTTCCCTTACCCATATCCATTTCGCCCACTTCCACCAATTCCAT
		ctacaactcccc	TTCCAAGATTTCCATGGTTTAGA
		ttcctagcgaaaagtaaacaagaa	CGTAATTTTCCTATTCCAATACCTGAATCTGCCCCTACAACTCCCCT
		ggaaaagtcacgataaacctggtc	TCCTAGCGAAAAGTAAACAAGAA
		acctgaaattgaaattgagccact	GGAAAAGTCACGATAAACCTGGTCACCTGAAATTGAAATTGAGCCAC
		tccttgaagaatcaaaattcctgt	TTCCTTGAAGAATCAAAATTCCT
		taataaaagaaaaacaaatgtaat	GTTAATAAAAGAAAAACAAATGTAATTGAAATAGCACACAGCATTCT
		tgaaatagcacacagcattctcta	CTAGTCAATATCTTTAGTGATCT
		gtcaatatctttagtgatcttctt	TCTTTAATAAACTTGAAAGCAAAGATTTTGGTTTCTTAATTTCCACA
		taata	AA
		[Seq Id No 79]
236203_	Major histo-	atgtcaggtttgtacctaccacat	>gi|52426772|ref|NM_002122.3|Homo sapiens	38.77
at	compatibility	ttaaaatagggacttgaagaatta	major histocompatibility complex, class II, DQ
	complex,	aacattttatta	alpha 1 (HLA-DQA1), mRNA
	class II,	caaatgaagcacttcatgcacaga	ACAATTACTCTACAGCTCAGAACACCAACTGCTGAGGCTGCCTTGGG
	DQ alpha 1	ctggcacatagtaagtagtcgata	AAGAGGATGATCCTAAACAAAGC
		ggtgttaacaat	TCTGCTGCTGGGGGCCCTCGCTCTGACCACCGTGATGAGCCCCTGTG
		ttgtgttattgttattttctggag	GAGGTGAAGACATTGTGGCTGAC
		tccaactaacaaatcccacagtga	CACGTTGCCTCTTGTGGTGTAAACTTGTACCAGTTTTACGGTCCCTC
		atgacatcacag	TGGCCAGTACACCCATGAATTTG
		ggatgcaaccaacaagatccagaa	ATGGAGATGAGCAGTTCTACGTGGACCTGGAGAGGAAGGAGACTGCC
		tatggaaacttctactagataaac	TGGCGGTGGCCTGAGTTCAGCAA
		aactccatttct	ATTTGGAGGTTTTGACCCGCAGGGTGCACTGAGAAACATGGCTGTGG
		tcagcaacaattcaagagagagag	CAAAACACAACTTGAACATCATG
		agaagagaagctatacattttaaa	ATTAAACGCTACAACTCTACCGCTGCTACCAATGAGGTTCCTGAGGT
		aggctgaagaaatatatgaaccaa	CACAGTGTTTTCCAAGTCTCCCG
		atttgtatgaggcaatcagaaaaa	TGACACTGGGTCAGCCCAACACCCTCATTTGTCTTGTGGACAACATC
		ctgacaccgactgtattaaggaat	TTTCCTCCTGTGGTCAACATCAC
		tatctaattttagtgtggtaatga	ATGGCTGAGCAATGGGCAGTCAGTCACAGAAGGTGTTTCTGAGACCA
		gattgctgttatgttttctaa	GCTTCCTCTCCAAGAGTGATCAT
		[Seq Id No 80]	TCCTTCTTCAAGATCAGTTACCTCACCTTCCTCCCTTCTGCTGATGA
			GATTTATGACTGCAAGGTGGAGC
			ACTGGGGCCTGGACCAGCCTCTTCTGAAACACTGGGAGCCTGAGATT
			CCAGCCCCTATGTCAGAGCTCAC
			AGAGACTGTGGTCTGTGCCCTGGGGTTGTCTGTGGGCCTCATGGGCA
			TTGTGGTGGGCACTGTCTTCATC
			ATCCAAGGCCTGCGTTCAGTTGGTGCTTCCAGACACCAAGGGCCATT
			GTGAATCCCATCCTGGAAGGGAA
			GGTGCATCGCCATCTACAGGAGCAGAAGAATGGACTTGCTAAATGAC
			CTAGCACTATTCTGTGGCCCGAT
			TTATCATATCCCTTTTCTCCTCCAAATATTTCTCCTCTCACCTTTTC
			TCTGGGACTTAAGCTGCTATATC
			CCCTCAGAGCTCACAAATGCCTTTACATTCTTTCCCTGACCTCCTGA
			TTTTTTTTTTCTTTTCTCAAATG
			TTACCTACAAAGACATGCCTGGGGTAAGCCACCCGGCTACCTAATTC
			CTCAGTAACCTCCATCTAAAATC
			TCCAAGGAAGCAATAAATTCCTTTTATGAGATCTATGTCAAATTTTT
			CCATCTTTCATCCAGGGCTGACT
			GAAACTATGGCTAATAATTGGGGTACTCTTATGTTTCAATCCAATTT
			AACCTCATTTCCCAGATCATTTT
			TCATGTCCAGTAACACAGAAGCCACCAAGTACAGTATAGCCTGATAA
			TATGTTGATTTCTTAGCTGACAT
			TAATATTTCTTGCTTCCTTGTGTTCCCACCCTTGGCACTGCCACCCA
			CCCCTCAATTCAGGCAACAATGA
			AATTAATGGATACCGTCTGCCCTTGGCCCAGAATTGTTATAGCAAAA
			ATTTTAGAACCAAAAAATAAGTC
			TGTACTAATTTCAATGTGGCTTTTAAAAGTATGACAGAGAAATAAGT
			TAGGATAAAGGAAATTTGAATCT
			CA
236280_	Transcribe	aaaagatctctcactgggaaaaga	>gi|3807951|gb|AI225238.1|AI225238 qx12c04.x1	77.63
at	d locus	aaaagttatgcatttataaagtaa	NCI_CGAP_Lym12 Homo sapiens cDNA clone
		ttaaactggttt	IMAGE: 2001126 3′, mRNA sequence
		tccttgtactttattaatctgaat	AGCGGCCGCCCTTTTTTTTTTTTTTTGAATGTTTTTATATTTTTATG
		ctaatggcacttccttacgagggt	TTTTTCTCTCTCACCACATTAGA
		tttcagatgtgc	GATTCACATGTCAAAAAAAAAGTTCAAAGATTCCACTTAAATGGTAG
		ttgtagttaatggcaacattatca	TCAAAATTAAAAGCATGTTGTTT
		gaatgactacacagacagtcctac	AATTTGCCAACTATTCCATAAATCCTGTGCTTGAAGCACTACCTTTT
		tctgaggagatg	ATCAACCACTTGAAAGGAAGGAA
		actttggaagaaacccatttggaa	TATGAAGTGTGACTCTTGAGGATTGCAGTTCCATTTCTCCACAGACA
		ctacacaccctgctatgtctgtgg	TAGCAGGGTGTGTAGTTCCAAAT
		agaaatggaact	GGGTTTCTTCCAAAGTCATCTCCTCAGAGTAGGACTGTCTGAGTAGT
		gcaatcctcaagagtcacacttca	CATTCTGATAATGTTGCCATTAA
		tattccttcctttcaagtggttga	CTACAAGCACATCTGAGAACCCTCGTAAGGAAGTGCCATTAGATTCA
		taaaaggtagtg	GA
		cttcaagcacaggatttatggaat
		agttggcaaattaaacaacatgct
		ttttattttgac
		tacca
		[Seq Id No 81]
239237_	Amphiphysin	ttatcaccattaatccatgccagt	>gi|51466133|ref|XM_A99518.1|PREDICTED: Homo	25.87
at	(Stiff-Man	tatgtacagttttgcatgtttgtt	sapiens LOC442534 (LOC442534), mRNA
	syndrome	ttttattttact	GGCCCAGCCCTAGGAGGGGGCAGTCCCACAGCAGGCTCACACCCTGC
	with	cttttctctccttcattccctatt	CCTTCAGAGTTGCAGCAGCTAAT
	breast	cctgttcccccataggtgcccagt	GCTGATGCCAGGACCTTGTCCTGCCAGGAAGCCTCTGATTAGGGCTG
	cancer	ctaatgtatttg	TGAACCAACTTCCTTTTCACATC
	128 kDa	atatctgtccttagagcctccgta	TGCAAGGACTCTGCTCTAAGCTCAAATTTTGCAGTTTCTGCTGTCAT
	autoantigen)	tctgtgaagactagagtcatgcac	CACAGCTGGGAATGAGAAAGGGA
		ttcatcacattt	AGGGGCTCCAGTTGGTCTCCCTCTGCCTCTGGAGCACACGTGGAGGA
		cagtaacgatgggccgcatgtacc	CATGAGGCTTCCGCAGGAACAGC
		acagtcccatgagatgatagaggt	TCTGAAAGCTGAGTTCTCGGGTCCCTGTGAAGGAGGGAAGCTTGCCT
		gcagaaaaattcctgtcatctagt	GCCTTGGAGCGTGAAAAAGTCTT
		gacatcgtagccatcataacatnn	GCTGGACAGAAGTCTCACGGTTTAAAACTGGGAAGGGAGAGGATTGA
		caacacgactctcatttgtggtga	GATCACACTAGAATGCACAGAAA
		ccctggtgtacacaaacctac	ATTCTT
		[Seq Id No 82]
244413_	dendritic	atggctggagatgtagtctacgct	>gi|40548404|ref|NM_172004.2|Homo sapiens	12.75
at	cell-	gacatcaaaactgttcggacttcc	dendritic cell-associated lectin-1 (DCAL1),
	associated	ccgttagaactc	mRNA
	lectin-1	gcgtttccacttcagagatctgtt	ATGGTTAGTAATTTCTTCCATGTCATACAAGTATTCGAGAAATCTGC
		tctttcaacttttctactgtccat	TACCTTGATTAGTAAGACTGAAC
		aaatcatgtcct	ACATTGGTTTTGTCATTTATTCATGGAGGAAGTCCACCACCCACTTG
		gccaaagactggaaggtgcataag	GGGAGCAGAAGGAAATTTGCCAT
		ggaaaatgttactggattgctgaa	CTCAATTTACTTATCAGAAGTTTCTTTGCAGAAATATGATTGTCCCT
		actaagaaatcttggaacaaaagt	TCAGTGGGACATCATTTGTGGTC
		caaaatgactgtgccataaacaat	TTCTCTCTCTTTTTGATCTGTGCAATGGCTGGAGATGTAGTCTACGC
		tcatatctcatggtgattcaagac	TGACATCAAAACTGTTCGGACTT
		attactgctatggtgagatttaac	CCCCGTTAGAACTCGCGTTTCCACTTCAGAGATCTGTTTCTTTCAAC
		atttagaggtgacagcatccccca	TTTTCTACTGTCCATAAATCATG
		cactggcagtga	TCCTGCCAAAGACTGGAAGGTGCATAAGGGAAAATGTTACTGGATTG
		attttttgtgctacaaacttggca	CTGAAACTAAGAAATCTTGGAAC
		aaagtctgtgaaaagaagtttcaa	AAAAGTCAAAATGACTGTGCCATAAACAATTCATATCTCATGGTGAT
		cttcatgtgtta	TCAAGACATTACTGCTATGGTGA
		ttaact	GATTTAACATTTAGAGGTGACAGCATCCCCCACACTGGCAGTGAATT
		[Seq Id No 83]	TTTTGTGCTACAAACTTGGCAAA
			AGTCTGTGAAAAGAAGTTTCAACTTCATGTGTTATTAACTATACAAA
			TATTAGTTGAATGAATTGTTGAA
			TTACAAAAAAAAAAAAAAA
34210_	CD52	Taatcggctcactataggaatttg	>gi|68342029|ref|NM_001803.2|Homo sapiens CD52	31.41
at	antigen	cntcgaggccaagattcgnacgag	molecule (CD52), mRNA
	(CAMPATH-1	aagaagcctccagacagccctgag	CTCCTGGTTCAAAAGCAGCTAAACCAAAAGAAGCCTCCAGACAGCCC
	antigen)	atcacctaaaaagctgctaccaag	TGAGATCACCTAAAAAGCTGCTA
		acagccacgaagatcctaccaaaa	CCAAGACAGCCACGAAGATCCTACCAAAATGAAGCGCTTCCTCTTCC
		tgaagcgcttcctcttcctcctac	TCCTACTCACCATCAGCCTCCTG
		tcaccatcagcctcctggttatgg	GTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAG
		tacagatacaaactggactctcag	CCAAACCAGCAGCCCCTCAGCAT
		gacaaaacgacaccagccaaacca	CCAGCAACATAAGCGGAGGCATITTCCTTTTCTTCGTGGCCAATGCC
		gcagcccctcagcatacagcagca	ATAATCCACCTCTTCTGCTTCAG
		tgagcggaggcattttccttttct	TTGAGGTGACACGTCTCAGCCTTAGCCCTGTGCCCCCTGAAACAGCT
		tcgtggccaatgccataatccacc	GCCACCATCACTCGCAAGAGAAT
		tcttctgcttcagttgaggtgaca	CCCCTCCATCTTTGGGAGGGGTTGATGCCAGACATCACCAGGTTGTA
		cgtctcagccttagccctgtgccc	GAAGTTGACAGGCAGTGCCATGG
		cctgaaacannnnnnnnnnnnnnn	GGGCAACAGCCAAAATAGGGGGGTAATGATGTAGGGGCCAAGCAGTG
		nnnnagagaatcccctccatcttt	CCCAGCTGGGGGTCAATAAAGTT
		gggaggggttgatgccagacatca	ACCCTTGTACTTGAAAAAAAAAAAAAAAAAAAA
		ccaggttgtagaagttgacaggca
		gtgccatggggncaacagccaaaa
		taggggggtaatgatgtaggggcc
		aagcagtgcccagctgggggtcaa
		taaagttacccttgtacttg
		[Seq Id No 84]

TABLE 3A
List of 13 probe sets suitable for identify the genes listed in Table 3
Probe	Gene
Set ID	Symbol	Gene Title	Gene Sequences
204661_at	CD52	CD52 molecule ///	Acagccacgaagatcctaccaaaatgaagcgcttcctcttcctcctactcaccatcagcctcc
		CD52 molecule	tggttatggtacagatacaaactggactctcaggacaaaacgacaccagccaaaccagcagcc
			cctcagcatccagcagcatgagcggaggcattttccttttcttcgtggccaatgccataatcc
			acctcttctgcttcagttgaggtgacacgtctcagccttagccctgtgccccctgaaacagct
			gccaccatcactcgcaagagaatcccctccatctttgggaggggttgatgccagacatcacca
			ggttgtagaagttgacaggcagtgccatgggggcaacagccaaaataggggggtaatgatgta
			ggggccaagc
			[Seq Id No 85]
205890_s_at	UBD	gamma-	Gatcttaaagccacggagaagcctctcatcttatggcattgacaaagagaagaccatccacct
		aminobutyric acid	taccctgaaagtggtgaagcccagtgatgaggagctgcccttgtttcttgtggagtcaggtga
		(GABA) B	tgaggcaaagaggcacctcctccaggtgcgaaggtccagctcagtggcacaagtgaaagcaat
		receptor, 1 ///	gatcgagactaagacgggtataatccctgagacccagattgtgacttgcaatggaaagagact
		ubiquitin D	ggaagatgggaagatgatggcagattacggcatcagaaagggcaacttactcttcctggcatc
			ttattgtattggagggtgaccaccctggggatggggtgttggcaggggtcaaaaagcttattt
			cttttaatctcttactcaacgaacacatcttctgatgatttcccaaaattaatgagaatgaga
			tgagtagagtaagatttgggtgggatgggtaggatgaagtatattgcccaactctatgtttct
			ttga
			[Seq Id No 86]
206118_at	STAT4	signal transducer	Gctgacatcctgcgagactacaaagttattatggctgaaaacattcctgaaaaccctctgaag
		and activator of	tacctatatcctgacattcccaaagacaaagccttcggtaaacactacagctctcagccttgc
		transcription 4	gaagtttcaagaccaacagaaaggggtgacaaaggttatgttccttctgtttttatccccatc
			tcaacaatccgaagtgattcaacagagccacattctccatcagaccttcttcccatgtctcca
			agtgtgtatgcggtgttgagagaaaacctgagtcccacaacaattgaaactgcaatgaagtct
			ccttattctgctgaatgacaggataaactctgacgcaccaagaaaggaagcaaatgaaaaagt
			ttaaagactgttctttgcccaataaccacattttatttcttcagctttgtaaataccaggttc
			taggaaatgtttgacatctgaagctctcttcacactcccgtggcactcctcaattgggag
			[Seq Id No 87]
206666_at	GZMK	granzyme K	aaacctctcttagatctggaaccaaatgcaaggttactggctggggagccaccgatccagatt
		(granzyme 3;	cattaagaccttctgacaccctgcgagaagtcactgttactgtcctaagtcgaaaactttgca
		tryptase II) ///	acagccaaagttactacaacggcgacccttttatcaccaaagacatggtctgtgcaggagatg
		granzyme K	ccaaaggccagaaggattcctgtaagggtgactcagggggccccttgatctgtaaaggtgtct
		(granzyme 3;	tccacgctatagtctctggaggtcatgaatgtggtgttgccacaaagcctggaatctacaccct
		tryptase II)	gttaaccaagaaataccagacttggatcaaaagcaaccttgtcccgcctcatacaaattaagtt
			acaaataattttattggatgcacttgcttcttttttcctaatatgctcgcaggttagagttggg
			tgtaagtaaagcagagcacatatggggtccatttttgcacttgta
			[Seq Id No 88]
207651_at	GPR171	G protein-coupled	Ttgccttgtaattcgacagctctacagaaacaaagataatgaaaattacccaaatgtgaaaaa
		receptor 171	ggctctcatcaacatacttttagtgaccacgggctacatcatatgctttgttccttaccacat
			tgtccgaatcccgtataccctcagccagacagaagtcataactgattgctcaaccaggatttc
			actcttcaaagccaaagaggctacactgctcctggctgtgtcgaacctgtgctttgatcctat
			cctgtactatcacctctcaaaagcattccgctcaaaggtcactgagacttttgcctcacctaa
			agagaccaaggctcagaaagaaaaattaagatgtgaaaataatgcataaaagacaggattttt
			tgtgctaccaattctggccttactgga
			[Seq Id No 89]
210038_at	PRKCQ	protein kinase C,	Aatccattcatcctgattgggcatgaaatccatggtcaagaggacaagtggaaagtgagaggg
		theta	aaggtttgctagacaccttcgcttgttatcttgtcaagatagaaaagatagtatcatttcacc
			cttgccagtaaaaacctttccatccacccattctcagcagactccagtattggcacagtcact
			cactgccattctcacactataacaagaaaagaaatgaagtgcataagtctcctgggaaaagaa
			ccttaaccccttctcgtgccatgactggtgatttcatgactcataagcccctccgtaggcatc
			attcaagatcaatggcccatgcatgctgtttgcagca
			[Seq Id No 90]
210972_x_at	TRA@	T cell receptor	Ggaacaagacttcaggtcacgctcgatatccagaaccctgaccctgccgtgtaccagct
	///	alpha locus /// T	gagagactctaaatccagtgacaagtctgtctgcctattcaccgattttgattctcaaa
	TRDV2	cell receptor	caaatgtgtcacaaagtaaggattctgatgtgtatatcacagacaaaactgtgctagac
	///	delta variable 2	atgaggtctatggacttcaagagcaacagtgctgtggcctggagcaacaaatctgactt
	TRAV20	/// T cell	tgcatgtgcaaacgccttcaacaacagcattattccagaagacaccttcttccccagcc
	///	receptor alpha	cagaaagttcctgtgatgtcaagctggtcgagaaaagctttgaaacagatacgaaccta
	TRAC	variable 20 /// T	aactttcaaaacctgtcagtgattgggttccgaatcctcctcctgaaagtggccgggtt
		cell receptor	taatctgctcatgacgctgcggctgtggtccagctgagatctgcaagattgtaagacag
		alpha constant	cctgtgctccct
			[Seq Id No 91]
211144_x_at	TRGC2	T cell receptor	Aaatgatacactactgctgcagctcacaaacacctctgcatattacatgtacctcctcct
	///	gamma constant 2	gctcctcaagagtgtggtctattttgccatcatcacctgctgtctgcttggaagaacggc
	TRGV2	/// T cell	tttctgctgcaatggagagaaatcataacagacggtggcacaaggaggccatcttttcct
	///	receptor gamma	catcggttattgtccctagaagcgtcttctgaggatctagttgggctttctttctgggtt
	TRGV9	variable 2 /// T	tgggccatttcagttctcatgtgtgtactattctatcattattgtataatggttttcaaa
	///	cell receptor	ccagtgggcacacagagaacctcagtctgtaataacaatgaggaatagccatggcgatct
	TARP	gamma variable 9	ccagcaccaatctctccatgttttccacagctcctccagccaacccaaatagcgcctgct
	///	/// TCR gamma	atagtgtagacagcctgcggcttctagccttgtccctctcttagtgttctttaatcagat
	LOC642	alternate reading	aactgcctggaagcctttcattttacacgccc
	083	frame protein III	[Seq Id No 92]
		hypothetical
		protein L0C642083
211796_s_at	TRBV21-1	T cell receptor	gccatcagaagcagagatctcccacacccaaaaggccacactggtgtgcctggccacaggtt
	///	beta variable 21-	tctaccccgaccacgtggagctgagctggtgggtgaatgggaaggaggtgcacagtggggtc
	TRBV19	1 /// T cell	agcacagacccgcagcccctcaaggagcagcccgccctcaatgactccagatactgcctgag
	///	receptor beta	cagccgcctgagggtctcggccaccttctggcagaacccccgcaaccacttccgctgtcaag
	TRBV5-	variable 19 /// T	tccagttctacgggctctcggagaatgacgagtggacccaggatagggccaaacctgtcacc
	4 ///	cell receptor	cagatcgtcagcgccgaggcctggggtagagcagactgtggcttcacctccgagtcttacca
	TRBV3-	beta variable 5-4	gcaaggggtcctgtctgccaccatcctctatgagatcttgctagggaaggccaccttgtatg
	1 ///	/// T cell	ctgtgctggtcagtgccctcgtgctgatggccatggtcaagagaaagga
	TRBC1	receptor beta	[Seq Id No 93]
		variable 3-1 ///
		T cell receptor
		beta constant 1
		/// similar to T-
		cell receptor
		beta chain V
		region CTL-L17
		precursor
213193_x_at	TRBV19	T cell receptor	Tgactccagatactgcctgagcagccgcctgagggtctcggccaccttctggcagaaccg
	///	beta variable 19	cccgcaaccacttccctgtcaagtccagttctacgggctctcggagaatgacgagtggac
	TRBC1	/// T cell	ccaggatagggccaaacccgtcacccagatcgtcagcgccgaggcctggggtagagcaga
		receptor beta	ctgtggctttacctcggtgtcctaccagcaaggggtcctgtctgccaccatcctctatga
		variable 19 /// T	gatcctgctagggaaggccaccctgtatgctgtgctggtcagcncccttgtgttgatggc
		cell receptor	catggtcaagagaaaggatttctgaaggcagccctggaagtggagttaggagcttctaac
		beta constant 1	ccgtcatggtttcaatacacattcttcttttgccagcgcttctgaagagctgctctcacc
		/// T cell	tctctgcatcccaatagatatccccctatgtgcatgcacacctgcacactcacggctgaa
		receptor beta	atctccctaacccagggggaccttagcatgcctaagtga
		constant 1	[Seq Id No 94]
213539_at	CD3D	CD3d molecule,	gggaacactgctctcagacattacaagactggacctgggaaaacgcatcctggacccacg
		delta (CD3-TCR	aggaatatataggtgtaatgggacagatatatacaaggacaaagaatctaccgtgcaagt
		complex)	tcattatcgaatgtgccagagctgtgtggagctggatccagccaccgtggctggcatcat
			tgtcactgatgtcattgccactctgctccttgctttgggagtcttctgctttgctggaca
			tgagactggaaggctgtctggggctgccgacacacaagctctgttgaggaatgaccaggt
			ctatcagcccctccgagatcgagatgatgctcagtacagccaccttggaggaaactgggc
			tcggaacaagtgaacctgagactggtggcttctagaagcagccattaccaactgtacct
			[Seq Id No 95]
217147_s_at	TRAT1	T cell receptor	Tctcctttctcaccaatgggcaatagcccataattgaaataaatttctgattgaaaggt
		associated	ataggaaacattaaaatgcattactaagagaagtaatataattttcttacaaagtattt
		transmembrane	ttcccaaagatagctttactatttcaaaaattgtcaaattaatgcatgctccttacaac
		adaptor 1	aaacaaatatcaaaaagagtttaggaattctactagccagagatagtcacttggagaaa
			ctttctatatatccttctaaatatttttctgggcatgctcatgtatgtacatcagttgt
			ttctttttattttgaaccaaaaatgtggtttcttttgtacacattacttaaactttctt
			tccagtcaacaatatattgtggatttattttcactgttatatttaactatatataaata
			cgcatatattgtaattttaatgtctgcttagcaccccactgataaccaaatcacag
			[Seq Id No 96]
34210_at	CD52	CD52 molecule	Taatcggctcactataggaatttgcntcgaggccaagattcgnacgagnnngttcaaaa
			gcagctaaaccaaaagaagcctccagacagccctgagatcacctaaaaagctgctacca
			agacagccacgaagatcctaccaaaatgaagcgcttcctcttcctcctactcaccatca
			gcctcctggttatggtacagatacaaactggactctcaggacaaaacgacaccagccaa
			accagcagcccctcagcatccagcagcatgagcggaggcattttccttttcttcgtggc
			caatgccataatccacctcttctgcttcagttgaggtgacacgtctcagccttagccct
			gtgccccctgaaacannnnnnnnnnnnnnnnnnnagagaatcccctccatctttgggag
			gggttgatgccagacatcaccaggttgtagaagttgacaggcagtgccatggggncaac
			agccaaaataggggggtaatgatgtaggggccaagcagtgcccagctgggggtcaataa
			agttacccttgtacttg
			[Seq Id No 97]

TABLE 4A
Table linking probe set id and the gene list of Table 4.
Probe Set ID	Gene Symbol	Gene Name
218802_at	FLJ20647	NA (not applicable)
224774_s_at	NAV1	neuron navigator 1
207651_at	GPR171	G protein-coupled receptor 171
205392_s_at	CCL14	chemokine (C-C motif) ligand 14
1555229_a_at	C1S	complement component 1, s subcomponent
209774_x_at	CXCL2	chemokine (C—X—C motif) ligand 2
211796_s_at	TRBV3-1	T cell receptor beta variable 3-1
210972_x_at	TRDV2	T cell receptor delta variable 2
210251_s_at	RUFY3	RUN and FYVE domain containing 3
225502_at	DOCK8	dedicator of cytokinesis 8
204224_s_at	GCH1	GTP cyclohydrolase 1 (dopa-responsive dystonia)
218950_at	CENTD3	centaurin, delta 3
218322_s_at	ACSL5	acyl-CoA synthetase long-chain family member 5
228094_at	AMICA1	adhesion molecule, interacts with CXADR antigen 1
204116_at	IL2RG	interleukin 2 receptor, gamma (severe combined
		immunodeficiency)
202643_s_at	TNFAIP3	tumor necrosis factor, alpha-induced protein 3
209606_at	PSCDBP	pleckstrin homology, Sec7 and coiled-coil domains, binding
		protein
205225_at	ESR1	estrogen receptor 1
213193_x_at	TRBC1	T cell receptor beta constant 1
204661_at	CD52	CD52 antigen (CAMPATH-1 antigen)
216920_s_at	LOC442535	NA
210915_x_at	TRBV19	T cell receptor beta variable 19
226218_at	IL7R	interleukin 7 receptor
209670_at	TRAC	T cell receptor alpha constant
209949_at	NCF2	neutrophil cytosolic factor 2 (65 kDa, chronic granulomatous
		disease, autosomal 2)
226697_at	LOC92689	NA
206666_at	GZMK	c(“granzyme K (granzyme 3”, “tryptase II)”)
235831_at	NA	NA
1555630_a_at	RAB34	RAB34, member RAS oncogene family
207977_s_at	DPT	dermatopontin
1558290_a_at	PVT1	Pvt1 oncogene homolog, MYC activator (mouse)
215806_x_at	TRGC2	T cell receptor gamma constant 2
64064_at	GIMAP5	GTPase, IMAP family member 5
34210_at	CD52	CD52 antigen (CAMPATH-1 antigen)
213539_at	CD3D	CD3d antigen, delta polypeptide (TiT3 complex)
232313_at	TMEM132C	transmembrane protein 132C
201502_s_at	NFKBIA	nuclear factor of kappa light polypeptide gene enhancer in B-
		cells inhibitor, alpha
211902_x_at	TRA@	T cell receptor alpha locus
217147_s_at	TRAT1	T cell receptor associated transmembrane adaptor 1
211144_x_at	LOC442535	NA
224710_at	RAB34	RAB34, member RAS oncogene family
209795_at	CD69	CD69 antigen (p60, early T-cell activation antigen)
232843_s_at	DOCK8	dedicator of cytokinesis 8
218805_at	GIMAP5	GTPase, IMAP family member 5
204057_at	IRF8	interferon regulatory factor 8
214470_at	KLRB1	killer cell lectin-like receptor subfamily B, member 1
236280_at	NA	NA
201474_s_at	ITGA3	integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3
		receptor)
235421_at	MAP3K8	mitogen-activated protein kinase kinase kinase 8
228532_at	C1orf162	chromosome 1 open reading frame 162
205890_s_at	UBD	ubiquitin D
209813_x_at	TRGV9	T cell receptor gamma variable 9
224772_at	NAV1	neuron navigator 1
224451_x_at	ARHGAP9	Rho GTPase activating protein 9
226117_at	TIFA	NA
213068_at	DPT	dermatopontin
1569942_at	NA	NA
219243_at	GIMAP4	GTPase, IMAP family member 4
202957_at	HCLS1	hematopoietic cell-specific Lyn substrate 1
218764_at	PRKCH	protein kinase C, eta
206118_at	STAT4	signal transducer and activator of transcription 4
236203_at	HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1
206170_at	ADRB2	adrenergic, beta-2-, receptor, surface
239237_at	NA	NA
214450_at	CTSW	cathepsin W (lymphopain)
201497_x_at	MYH11	myosin, heavy polypeptide 11, smooth muscle
219777_at	GIMAP6	GTPase, IMAP family member 6
211654_x_at	HLA-DQB1	major histocompatibility complex, class II, DQ beta 1
205758_at	CD8A	CD8 antigen, alpha polypeptide (p32)
202644_s_at	TNFAIP3	tumor necrosis factor, alpha-induced protein 3
1558034_s_at	CP	ceruloplasmin (ferroxidase)
223235_s_at	SMOC2	SPARC related modular calcium binding 2
232234_at	C20orf24	chromosome 20 open reading frame 24
1559584_a_at	C16orf54	chromosome 16 open reading frame 54
205831_at	CD2	CD2 antigen (p50), sheep red blood cell receptor
203812_at	SLIT3	slit homolog 3 (Drosophila)
222780_s_at	BAALC	brain and acute leukemia, cytoplasmic
218145_at	TRIB3	tribbles homolog 3 (Drosophila)
242881_x_at	LOC440160	NA
1558972_s_at	C6orf190	chromosome 6 open reading frame 190
229723_at	TAGAP	T-cell activation GTPase activating protein
235391_at	FAM92A1	family with sequence similarity 92, member A1
219938_s_at	PSTPIP2	proline-serine-threonine phosphatase interacting protein 2
212587_s_at	PTPRC	protein tyrosine phosphatase, receptor type, C
210982_s_at	HLA-DRA	major histocompatibility complex, class II, DR alpha
211200_s_at	EFCAB2	EF-hand calcium binding domain 2
210260_s_at	TNFAIP8	tumor necrosis factor, alpha-induced protein 8
228869_at	SLIC1	NA
205987_at	CD1C	CD1c antigen
213888_s_at	TRAF3IP3	TRAF3 interacting protein 3
212671_s_at	HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1
242986_at	NAV1	neuron navigator 1
212999_x_at	HLA-DQB1	major histocompatibility complex, class II, DQ beta 1
212588_at	PTPRC	protein tyrosine phosphatase, receptor type, C
212592_at	IGJ	immunoglobulin J polypeptide, linker protein for
		immunoglobulin alpha and mu polypeptides
203471_s_at	PLEK	pleckstrin
209671_x_at	TRA@	T cell receptor alpha locus
228054_at	TMEM44	transmembrane protein 44
216191_s_at	TRA@	T cell receptor alpha locus
205419_at	EBI2	Epstein-Barr virus induced gene 2 (lymphocyte-specific G
		protein-coupled receptor)
220330_s_at	SAMSN1	SAM domain, SH3 domain and nuclear localisation signals, 1
213008_at	KIAA1794	KIAA1794
201425_at	ALDH2	aldehyde dehydrogenase 2 family (mitochondrial)
1552613_s_at	CDC42SE2	CDC42 small effector 2
205696_s_at	GFRA1	GDNF family receptor alpha 1
211339_s_at	ITK	IL2-inducible T-cell kinase
208894_at	HLA-DRA	major histocompatibility complex, class II, DR alpha
228071_at	GIMAP7	GTPase, IMAP family member 7
222496_s_at	FLJ20273	NA
206687_s_at	PTPN6	protein tyrosine phosphatase, non-receptor type 6
210375_at	PTGER3	prostaglandin E receptor 3 (subtype EP3)
219440_at	RAI2	retinoic acid induced 2
208450_at	LGALS2	lectin, galactoside-binding, soluble, 2 (galectin 2)
203665_at	HMOX1	heme oxygenase (decycling) 1
227995_at	NA	NA
227346_at	ZNFN1A1	zinc finger protein, subfamily 1A, 1 (Ikaros)
205159_at	CSF2RB	colony stimulating factor 2 receptor, beta, low-affinity
		(granulocyte-macrophage)
205559_s_at	PCSK5	proprotein convertase subtilisin/kexin type 5
212886_at	CCDC69	coiled-coil domain containing 69
1552612_at	CDC42SE2	CDC42 small effector 2
205488_at	GZMA	granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated
		serine esterase 3)
217767_at	C3	complement component 3
208296_x_at	TNFAIP8	tumor necrosis factor, alpha-induced protein 8
223484_at	C15orf48	chromosome 15 open reading frame 48
204070_at	RARRES3	retinoic acid receptor responder (tazarotene induced) 3
214719_at	LOC283537	NA
209687_at	CXCL12	chemokine (C—X—C motif) ligand 12 (stromal cell-derived
		factor 1)
224773_at	NAV1	neuron navigator 1
231882_at	NA	NA
215223_s_at	SOD2	superoxide dismutase 2, mitochondrial
232617_at	CTSS	cathepsin S
210554_s_at	CTBP2	C-terminal binding protein 2
219528_s_at	BCL11B	B-cell CLL/lymphoma 11B (zinc finger protein)
207861_at	CCL22	chemokine (C-C motif) ligand 22
222592_s_at	ACSL5	acyl-CoA synthetase long-chain family member 5
1554966_a_at	DOC1	NA
204204_at	SLC31A2	solute carrier family 31 (copper transporters), member 2
219926_at	POPDC3	popeye domain containing 3
204135_at	DOC1	NA
217995_at	SQRDL	sulfide quinone reductase-like (yeast)
230233_at	RASGEF1B	RasGEF domain family, member 1B
227265_at	FGL2	fibrinogen-like 2
228372_at	C10orf128	chromosome 10 open reading frame 128
204912_at	IL10RA	interleukin 10 receptor, alpha
219454_at	EGFL6	EGF-like-domain, multiple 6
206295_at	IL18	interleukin 18 (interferon-gamma-inducing factor)
226219_at	ARHGAP30	Rho GTPase activating protein 30
218736_s_at	PALMD	palmdelphin
223322_at	RASSF5	Ras association (RalGDS/AF-6) domain family 5
209603_at	GATA3	GATA binding protein 3
204687_at	DKFZP564O0823	NA
222895_s_at	BCL11B	B-cell CLL/lymphoma 11B (zinc finger protein)
201010_s_at	TXNIP	thioredoxin interacting protein
226818_at	DTX4	deltex 4 homolog (Drosophila)
208335_s_at	DARC	Duffy blood group, chemokine receptor
213566_at	RNASE6	ribonuclease, RNase A family, k6
205685_at	CD86	CD86 antigen (CD28 antigen ligand 2, B7-2 antigen)
201531_at	ZFP36	zinc finger protein 36, C3H type, homolog (mouse)
202391_at	BASP1	brain abundant, membrane attached signal protein 1
201804_x_at	CKAP1	cytoskeleton associated protein 1
206082_at	HCP5	HLA complex P5
206204_at	GRB14	growth factor receptor-bound protein 14
228563_at	GJA7	gap junction protein, alpha 7, 45 kDa (connexin 45)
219054_at	FLJ14054	NA
205844_at	VNN1	vanin 1
203741_s_at	ADCY7	adenylate cyclase 7
223280_x_at	MS4A6A	membrane-spanning 4-domains, subfamily A, member 6A
205624_at	CPA3	carboxypeptidase A3 (mast cell)
209193_at	PIM1	pim-1 oncogene
210072_at	CCL19	chemokine (C-C motif) ligand 19
226068_at	SYK	spleen tyrosine kinase
216155_at	NAV1	neuron navigator 1
205484_at	SIT1	signaling threshold regulating transmembrane adaptor 1
228812_at	NA	NA
219368_at	NAP1L2	nucleosome assembly protein 1-like 2
206407_s_at	CCL13	chemokine (C-C motif) ligand 13
203761_at	SLA	Src-like-adaptor
236295_s_at	NOD3	NA
206099_at	PRKCH	protein kinase C, eta
217143_s_at	TRD@	T cell receptor delta locus
218899_s_at	BAALC	brain and acute leukemia, cytoplasmic
229391_s_at	RP1-93H18.5	NA
219093_at	FLJ20701	NA
219710_at	SH3TC2	SH3 domain and tetratricopeptide repeats 2
206978_at	CCR2	chemokine (C-C motif) receptor 2
204655_at	CCL5	chemokine (C-C motif) ligand 5
211991_s_at	HLA-DPA1	major histocompatibility complex, class II, DP alpha 1
223922_x_at	MS4A6A	membrane-spanning 4-domains, subfamily A, member 6A
208983_s_at	PECAM1	platelet/endothelial cell adhesion molecule (CD31 antigen)
222108_at	AMIGO2	adhesion molecule with Ig-like domain 2
1553102_a_at	CCDC69	coiled-coil domain containing 69
221698_s_at	CLEC7A	C-type lectin domain family 7, member A
206637_at	P2RY14	purinergic receptor P2Y, G-protein coupled, 14
226459_at	PIK3AP1	phosphoinositide-3-kinase adaptor protein 1
209613_s_at	ADH1B	alcohol dehydrogenase IB (class I), beta polypeptide
225802_at	TOP1MT	topoisomerase (DNA) I, mitochondrial
224859_at	CD276	CD276 antigen
209480_at	HLA-DQB1	major histocompatibility complex, class II, DQ beta 1
219213_at	JAM2	junctional adhesion molecule 2
208747_s_at	C1S	complement component 1, s subcomponent
224356_x_at	MS4A6A	membrane-spanning 4-domains, subfamily A, member 6A
226625_at	TGFBR3	transforming growth factor, beta receptor III (betaglycan,
		300 kDa)
1554240_a_at	ITGAL	c(“integrin, alpha L (antigen CD11A (p180), lymphocyte
		function-associated antigen 1”, “alpha polypeptide)”)
202948_at	IL1R1	interleukin 1 receptor, type I
219666_at	MS4A6A	membrane-spanning 4-domains, subfamily A, member 6A
215193_x_at	HLA-DRB1	major histocompatibility complex, class II, DR beta 1
232024_at	GIMAP2	GTPase, IMAP family member 2
1559263_s_at	ZC3H12D	zinc finger CCCH-type containing 12D
219737_s_at	PCDH9	protocadherin 9
222838_at	SLAMF7	SLAM family member 7
227983_at	MGC7036	NA
223809_at	RGS18	regulator of G-protein signalling 18
213831_at	HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1
203416_at	CD53	CD53 antigen
226841_at	MPEG1	NA
228552_s_at	SSBP4	single stranded DNA binding protein 4
231262_at	NA	NA
206898_at	CDH19	cadherin 19, type 2
210835_s_at	CTBP2	C-terminal binding protein 2
227584_at	NAV1	neuron navigator 1
223059_s_at	FAM107B	family with sequence similarity 107, member B
221671_x_at	IGKC	immunoglobulin kappa constant
205786_s_at	ITGAM	integrin, alpha M (complement component 3 receptor 3
		subunit)
216194_s_at	CKAP1	cytoskeleton associated protein 1
209312_x_at	HLA-DRB1	major histocompatibility complex, class II, DR beta 1
235639_at	CDH19	cadherin 19, type 2
233562_at	MGC16291	NA
232476_at	DDEF2	development and differentiation enhancing factor 2
202510_s_at	TNFAIP2	tumor necrosis factor, alpha-induced protein 2
222484_s_at	CXCL14	chemokine (C—X—C motif) ligand 14
207277_at	CD209	CD209 antigen
204724_s_at	COL9A3	collagen, type IX, alpha 3
239196_at	ANKRD22	ankyrin repeat domain 22
209734_at	NCKAP1L	NCK-associated protein 1-like
212977_at	CMKOR1	chemokine orphan receptor 1
204670_x_at	HLA-DRB5	major histocompatibility complex, class II, DR beta 5
208885_at	LCP1	lymphocyte cytosolic protein 1 (L-plastin)
209612_s_at	ADH1B	alcohol dehydrogenase IB (class I), beta polypeptide
233955_x_at	CXXC5	CXXC finger 5
228776_at	GJA7	gap junction protein, alpha 7, 45 kDa (connexin 45)
1553906_s_at	FGD2	FYVE, RhoGEF and PH domain containing 2
221760_at	MAN1A1	mannosidase, alpha, class 1A, member 1
223361_at	C6orf115	chromosome 6 open reading frame 115
229390_at	RP1-93H18.5	NA
203915_at	CXCL9	chemokine (C—X—C motif) ligand 9
223058_at	FAM107B	family with sequence similarity 107, member B
219789_at	NPR3	natriuretic peptide receptor C/guanylate cyclase C
		(atrionatriuretic peptide receptor C)
205285_s_at	FYB	FYN binding protein (FYB-120/130)
203868_s_at	VCAM1	vascular cell adhesion molecule 1
204236_at	FLI1	Friend leukemia virus integration 1
224516_s_at	CXXC5	CXXC finger 5
202368_s_at	TRAM2	translocation associated membrane protein 2
224795_x_at	IGKC	immunoglobulin kappa constant
235238_at	SHC4	SHC (Src homology 2 domain containing) family, member 4
227791_at	SLC9A9	solute carrier family 9 (sodium/hydrogen exchanger), member 9
207238_s_at	PTPRC	protein tyrosine phosphatase, receptor type, C
204897_at	PTGER4	prostaglandin E receptor 4 (subtype EP4)
213975_s_at	LILRB1	leukocyte immunoglobulin-like receptor, subfamily B (with
		TM and ITIM domains), member 1
228964_at	PRDM1	PR domain containing 1, with ZNF domain
228362_s_at	RP1-93H18.5	NA
244061_at	ARHGAP15	Rho GTPase activating protein 15
1553313_s_at	SLC5A3	solute carrier family 5 (inositol transporters), member 3
212538_at	DOCK9	dedicator of cytokinesis 9
226043_at	GPSM1	G-protein signalling modulator 1 (AGS3-like, C. elegans)
1405_i_at	CCL5	chemokine (C-C motif) ligand 5
204222_s_at	GLIPR1	GLI pathogenesis-related 1 (glioma)
221087_s_at	APOL3	apolipoprotein L, 3
203932_at	HLA-DMB	major histocompatibility complex, class II, DM beta
225895_at	SYNPO2	synaptopodin 2
221651_x_at	NA	NA
231929_at	NA	NA
229543_at	RP1-93H18.5	NA
211367_s_at	CASP1	caspase 1, apoptosis-related cysteine peptidase (interleukin 1,
		beta, convertase)
210038_at	PRKCQ	protein kinase C, theta
205403_at	IL1R2	interleukin 1 receptor, type II
220066_at	CARD15	caspase recruitment domain family, member 15
1555812_a_at	ARHGDIB	Rho GDP dissociation inhibitor (GDI) beta
208306_x_at	HLA-DRB4	major histocompatibility complex, class II, DR beta 4
218854_at	SART2	squamous cell carcinoma antigen recognized by T cells 2
203523_at	LSP1	lymphocyte-specific protein 1
207992_s_at	AMPD3	adenosine monophosphate deaminase (isoform E)
228660_x_at	SEMA4F	sema domain, immunoglobulin domain (Ig), transmembrane
		domain (TM) and short cytoplasmic domain, (semaphorin) 4F
218170_at	ISOC1	isochorismatase domain containing 1
1555759_a_at	CCL5	chemokine (C-C motif) ligand 5
227253_at	HPS3	Hermansky-Pudlak syndrome 3
211990_at	HLA-DPA1	major histocompatibility complex, class II, DP alpha 1
212998_x_at	HLA-DQB1	major histocompatibility complex, class II, DQ beta 1
204778_x_at	HOXB7	homeobox B7
204834_at	FGL2	fibrinogen-like 2
205039_s_at	ZNFN1A1	zinc finger protein, subfamily 1A, 1 (Ikaros)
232543_x_at	ARHGAP9	Rho GTPase activating protein 9
209710_at	GATA2	GATA binding protein 2
200612_s_at	AP2B1	adaptor-related protein complex 2, beta 1 subunit
201487_at	CTSC	cathepsin C
201939_at	PLK2	polo-like kinase 2 (Drosophila)
203547_at	CD4	CD4 antigen (p55)
228376_at	GGTA1	glycoprotein, alpha-galactosyltransferase 1
207574_s_at	GADD45B	growth arrest and DNA-damage-inducible, beta
213560_at	GADD45B	growth arrest and DNA-damage-inducible, beta
219525_at	FLJ10847	NA
204411_at	KIF21B	kinesin family member 21B
200953_s_at	CCND2	cyclin D2
201859_at	PRG1	proteoglycan 1, secretory granule
223044_at	SLC40A1	solute carrier family 40 (iron-regulated transporter), member 1
213537_at	HLA-DPA1	major histocompatibility complex, class II, DP alpha 1
216841_s_at	SOD2	superoxide dismutase 2, mitochondrial
205081_at	CRIP1	cysteine-rich protein 1 (intestinal)
226382_at	LOC283070	NA
219519_s_at	SIGLEC1	sialic acid binding Ig-like lectin 1, sialoadhesin
1558586_at	ZNF11B	zinc finger protein 11B
217028_at	CXCR4	chemokine (C—X—C motif) receptor 4
217478_s_at	HLA-DMA	major histocompatibility complex, class II, DM alpha
204438_at	MRC1	mannose receptor, C type 1
211366_x_at	CASP1	caspase 1, apoptosis-related cysteine peptidase (interleukin 1,
		beta, convertase)
204249_s_at	LMO2	LIM domain only 2 (rhombotin-like 1)
221081_s_at	DENND2D	DENN/MADD domain containing 2D
32128_at	CCL18	chemokine (C-C motif) ligand 18 (pulmonary and activation-
		regulated)
220005_at	P2RY13	purinergic receptor P2Y, G-protein coupled, 13
209924_at	CCL18	chemokine (C-C motif) ligand 18 (pulmonary and activation-
		regulated)
242458_at	ANGPTL1	angiopoietin-like 1
230391_at	NA	NA
213475_s_at	ITGAL	c(“integrin, alpha L (antigen CD11A (p180), lymphocyte
		function-associated antigen 1”, “alpha polypeptide)”)
207458_at	C8orf51	chromosome 8 open reading frame 51
235306_at	GIMAP8	GTPase, IMAP family member 8
227780_s_at	NA	NA
205841_at	JAK2	Janus kinase 2 (a protein tyrosine kinase)
202687_s_at	TNFSF10	tumor necrosis factor (ligand) superfamily, member 10
212067_s_at	C1R	complement component 1, r subcomponent
236908_at	ACPL2	acid phosphatase-like 2
223827_at	TNFRSF19	tumor necrosis factor receptor superfamily, member 19
213652_at	PCSK5	proprotein convertase subtilisin/kexin type 5
219631_at	LRP12	low density lipoprotein-related protein 12
1557116_at	NA	NA
208981_at	PECAM1	platelet/endothelial cell adhesion molecule (CD31 antigen)
209685_s_at	PRKCB1	protein kinase C, beta 1
238488_at	IPO11	importin 11
1568736_s_at	DLGAP1	discs, large (Drosophila) homolog-associated protein 1
238439_at	PRKAR2B	protein kinase, cAMP-dependent, regulatory, type II, beta
205027_s_at	MAP3K8	mitogen-activated protein kinase kinase kinase 8
211742_s_at	EVI2B	ecotropic viral integration site 2B
202269_x_at	GBP1	guanylate binding protein 1, interferon-inducible, 67 kDa
204533_at	CXCL10	chemokine (C—X—C motif) ligand 10
229163_at	CAMK2N1	calcium/calmodulin-dependent protein kinase II inhibitor 1
1556579_s_at	MED12L	mediator of RNA polymerase II transcription, subunit 12
		homolog (yeast)-like
201566_x_at	ID2	inhibitor of DNA binding 2, dominant negative helix-loop-helix
		protein
201220_x_at	CTBP2	C-terminal binding protein 2
214677_x_at	IGLJ3	immunoglobulin lambda joining 3
235175_at	GBP4	guanylate binding protein 4
232001_at	LOC439949	NA
228427_at	FBXO16	F-box protein 16
214617_at	PRF1	perforin 1 (pore forming protein)
202369_s_at	TRAM2	translocation associated membrane protein 2
202625_at	LYN	v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
213618_at	CENTD1	centaurin, delta 1
209970_x_at	CASP1	caspase 1, apoptosis-related cysteine peptidase (interleukin 1,
		beta, convertase)
218035_s_at	FLJ20273	NA
206715_at	TFEC	transcription factor EC
1563473_at	PPP1R16B	protein phosphatase 1, regulatory (inhibitor) subunit 16B
204118_at	CD48	CD48 antigen (B-cell membrane protein)
201137_s_at	HLA-DPB1	major histocompatibility complex, class II, DP beta 1
230538_at	SHC4	SHC (Src homology 2 domain containing) family, member 4
1568822_at	GTPBP5	GTP binding protein 5 (putative)
229625_at	GBP5	guanylate binding protein 5
212233_at	MAP1B	microtubule-associated protein 1B
209202_s_at	EXTL3	exostoses (multiple)-like 3
209083_at	CORO1A	coronin, actin binding protein, 1A
205226_at	PDGFRL	platelet-derived growth factor receptor-like
227640_s_at	RP9	retinitis pigmentosa 9 (autosomal dominant)
223168_at	RHOU	ras homolog gene family, member U
1553132_a_at	MTAC2D1	membrane targeting (tandem) C2 domain containing 1
214038_at	CCL8	chemokine (C-C motif) ligand 8
219505_at	CECR1	cat eye syndrome chromosome region, candidate 1
214669_x_at	IGKC	immunoglobulin kappa constant
233123_at	SLC40A1	solute carrier family 40 (iron-regulated transporter), member 1
209195_s_at	ADCY6	adenylate cyclase 6
204846_at	CP	ceruloplasmin (ferroxidase)
204642_at	EDG1	endothelial differentiation, sphingolipid G-protein-coupled
		receptor, 1
239744_at	RGS3	regulator of G-protein signalling 3
206545_at	CD28	CD28 antigen (Tp44)
228339_at	NA	NA
218739_at	ABHD5	abhydrolase domain containing 5
224358_s_at	MS4A7	membrane-spanning 4-domains, subfamily A, member 7
1559425_at	PRKCH	protein kinase C, eta
231577_s_at	GBP1	guanylate binding protein 1, interferon-inducible, 67 kDa
231032_at	LOC286071	NA
207655_s_at	BLNK	B-cell linker
242546_at	NA	NA
211066_x_at	PCDHGC3	protocadherin gamma subfamily C, 3
216714_at	CCL13	chemokine (C-C motif) ligand 13
1562031_at	JAK2	Janus kinase 2 (a protein tyrosine kinase)
212763_at	CAMSAP1L1	calmodulin regulated spectrin-associated protein 1-like 1
205440_s_at	NPY1R	neuropeptide Y receptor Y1
227458_at	CD274	CD274 antigen
226303_at	PGM5	phosphoglucomutase 5
204613_at	PLCG2	phospholipase C, gamma 2 (phosphatidylinositol-specific)
202688_at	TNFSF10	tumor necrosis factor (ligand) superfamily, member 10
221477_s_at	SOD2	superoxide dismutase 2, mitochondrial
201236_s_at	BTG2	BTG family, member 2
205569_at	LAMP3	lysosomal-associated membrane protein 3
215121_x_at	IGLC1	immunoglobulin lambda constant 1 (Mcg marker)
202255_s_at	SIPA1L1	signal-induced proliferation-associated 1 like 1
215051_x_at	AIF1	allograft inflammatory factor 1
209138_x_at	IGLC2	immunoglobulin lambda constant 2 (Kern-Oz-marker)
232311_at	B2M	beta-2-microglobulin
1555756_a_at	CLEC7A	C-type lectin domain family 7, member A
221756_at	MGC17330	NA
238544_at	IGF1R	insulin-like growth factor 1 receptor
204512_at	HIVEP1	human immunodeficiency virus type I enhancer binding protein 1
230728_at	FKBP14	FK506 binding protein 14, 22 kDa
201720_s_at	LAPTM5	lysosomal associated multispanning membrane protein 5
223395_at	ABI3BP	ABI gene family, member 3 (NESH) binding protein
200905_x_at	HLA-E	major histocompatibility complex, class I, E
202207_at	ARL4C	ADP-ribosylation factor-like 4C
207076_s_at	ASS	argininosuccinate synthetase
211368_s_at	CASP1	caspase 1, apoptosis-related cysteine peptidase (interleukin 1,
		beta, convertase)
204628_s_at	ITGB3	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
207540_s_at	SYK	spleen tyrosine kinase
213603_s_at	RAC2	ras-related C3 botulinum toxin substrate 2 (rho family, small
		GTP binding protein Rac2)
1557222_at	NA	NA
206804_at	CD3G	CD3g antigen, gamma polypeptide (TiT3 complex)
209542_x_at	IGF1	insulin-like growth factor 1 (somatomedin C)
228858_at	NA	NA
207843_x_at	CYB5A	cytochrome b5 type A (microsomal)
223924_at	TTC25	tetratricopeptide repeat domain 25
1552497_a_at	SLAMF6	SLAM family member 6
241701_at	ARHGAP21	Rho GTPase activating protein 21
213819_s_at	FLOT1	flotillin 1
213095_x_at	AIF1	allograft inflammatory factor 1
228153_at	IBRDC2	IBR domain containing 2
213007_at	KIAA1794	KIAA1794
217525_at	OLFML1	olfactomedin-like 1
204220_at	GMFG	glia maturation factor, gamma
203508_at	TNFRSF1B	tumor necrosis factor receptor superfamily, member 1B
217629_at	NA	NA
226659_at	DEF6	differentially expressed in FDCP 6 homolog (mouse)
200904_at	HLA-E	major histocompatibility complex, class I, E
206571_s_at	MAP4K4	mitogen-activated protein kinase kinase kinase kinase 4
232746_at	CMKOR1	chemokine orphan receptor 1
1563461_at	NA	NA
204233_s_at	CHKA	choline kinase alpha
226865_at	NA	NA
227361_at	HS3ST3B1	heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1
204923_at	CXorf9	chromosome X open reading frame 9
204774_at	EVI2A	ecotropic viral integration site 2A
202270_at	GBP1	guanylate binding protein 1, interferon-inducible, 67 kDa
243099_at	NFAM1	NFAT activating protein with ITAM motif 1
242874_at	NA	NA
229127_at	ATP5J	ATP synthase, H+ transporting, mitochondrial F0 complex,
		subunit F6
224771_at	NAV1	neuron navigator 1
215379_x_at	IGLC2	immunoglobulin lambda constant 2 (Kern-Oz-marker)
222142_at	CYLD	cylindromatosis (turban tumor syndrome)
229367_s_at	GIMAP6	GTPase, IMAP family member 6
212713_at	MFAP4	microfibrillar-associated protein 4
214023_x_at	TUBB2B	tubulin, beta 2B
203413_at	NELL2	NEL-like 2 (chicken)
236583_at	NA	NA
212657_s_at	IL1RN	interleukin 1 receptor antagonist
227231_at	KIAA1211	NA
244023_at	SYK	spleen tyrosine kinase
206134_at	ADAMDEC1	ADAM-like, decysin 1
204894_s_at	AOC3	amine oxidase, copper containing 3 (vascular adhesion protein
		1)
204502_at	SAMHD1	SAM domain and HD domain 1
218002_s_at	CXCL14	chemokine (C—X—C motif) ligand 14
205421_at	SLC22A3	solute carrier family 22 (extraneuronal monoamine transporter),
		member 3
215561_s_at	IL1R1	interleukin 1 receptor, type I
217138_x_at	IGLV3-25	immunoglobulin lambda variable 3-25
1556185_a_at	NA	NA
219681_s_at	RAB11FIP1	RAB11 family interacting protein 1 (class I)
205251_at	PER2	period homolog 2 (Drosophila)
224896_s_at	TTL	tubulin tyrosine ligase
209899_s_at	SIAHBP1	NA
201721_s_at	LAPTM5	lysosomal associated multispanning membrane protein 5
241671_x_at	FLJ22536	NA
218499_at	RP6-	NA
	213H19.1
235804_at	NA	NA
207677_s_at	NCF4	neutrophil cytosolic factor 4, 40 kDa
227609_at	EPSTI1	epithelial stromal interaction 1 (breast)
227035_x_at	LOC441212	NA
206385_s_at	ANK3	ankyrin 3, node of Ranvier (ankyrin G)
1565602_at	PCDH9	protocadherin 9
228908_s_at	C21orf86	chromosome 21 open reading frame 86
223952_x_at	DHRS9	dehydrogenase/reductase (SDR family) member 9
38149_at	ARHGAP25	Rho GTPase activating protein 25
235688_s_at	TRAF4	TNF receptor-associated factor 4
214181_x_at	LST1	leukocyte specific transcript 1
222725_s_at	PALMD	palmdelphin
1555852_at	TAP1	transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
210319_x_at	MSX2	msh homeobox homolog 2 (Drosophila)
220485_s_at	SIRPG	signal-regulatory protein gamma

TABLE 5
Primers and probes used for Q-PCR in standard 96 well plates
Gene
name	Forward primers	Reverse primers	TaqMan Probes
IL7R	TCC-TAC-CAG-CCT-TTG-CCT-CTT	CCA-TAC-TTG-GCT-TTT-CTG-AAG-CA	FAM-CTT-CAA-TGT-GGT-TTC-
			CAT-GGG-MGB
CD3D	GTT-GAG-GAA-TGA-CCA-GGT-CTA-	AAG-GTG-GCT-GTA-CTG-AGC-ATC-A	FAM-CCT-CCG-AGA-TCG-AG-
	TCA-G		MGB
CD52	TCA-GCC-TCC-TGG-TTA-TGG-TAC-	TGG-TTT-GGC-TGG-TGT-CGT-T	FAM-CAA-ACT-GGA-CTC-TCA-
	AG		GGA-C-MGB
UBD	TGA-GGA-GCT-GCC-CTT-GTT-TC	CTG-GAG-GAG-GTG-CCT-CTT-TG	FAM-CAT-CAC-CTG-ACT-CCA-
			CA-MGB
GPR171	GAA-GTC-ATA-ACT-GAT-TGC-TCA-	GAC-ACA-GCC-AGG-AGC-AGT-GTA-G	FAM-TCA-CTC-TTC-AAA-GCC-
	ACC-A		AAA-GA-MGB
GMZK	GTC-TGT-GCA-GGA-GAT-GGC-AA	GGG-CCC-CCT-GAG-TCA-CC	FAM_TTA-CAG-GAA-TCC-TGG-
			C_MGB
PRKCQ	ATC-CAT-GGT-CAA-GAG-GAC-AAG-	GAC-AAG-ATA-ACA-AGC-GAA-GGT-GTC	FAM_CAA-ACC-TTC-CCT-CTC-
	TGG-A		ACT_MGB
STAT4	GTC-CCA-CAA-CAA-TTG-AAA-CTG-	GTG-CGT-CAG-AGT-TTA-TCC-TGT-CAT	FAM_TGA-AGT-CTC-CTT-ATT-
	C		CTG-CT_MGB
TRDV2	GGT-CGA-GAA-AAG-CTT-TGA-AAC-	GGA-ACC-CAA-TCA-CTG-ACA-GGT-T	FAM_ACG-AAC-CTA-AAC-TTT-
	AG		C_MGB
TRAT1	AAG-CCA-CCC-CAT-CTG-CAC	CTG-TGA-TCA-AGT-GAG-GCG-TAG	FAM_CAA-CCA-ATG-AAA-CAC-
			AGA-TG_MGB
TRBV19	GAG-GCC-TGG-GGT-AGA-GCA-G	AGA-GGA-TGG-TGG-CAG-ACA-GG	FAM_TGT-CCT-ACC-AGC-AAG-
			GG_MGB
CD69	AAT-CAT-AGC-TCT-CAT-TGC-CTT-	TGT-CTG-ATG-GCA-TTG-AGA-ATG-TG	FAM_CCA-ATA-CAA-TTG-TCC-
	ATC-AG		AGG-CC_MGB
INDO1	CCA-GCA-GAC-TGC-TGG-TGG-A	GGC-ATA-TAT-CTT-CTC-ATG-TCC-TGG-A	FAM_ACA-TGC-TGC-TCA-GTT-
			C_MGB
H3F3A	CAG-CTA-TCG-GTG-CTT-TGC-AG	GAT-AGC-ACA-CAG-GTT-GGT-GTC-TTC	FAM_CAA-GTG-AGG-CCT-ATC-
			T_MGB
CD45R	GAG-ATG-CCT-GAT-GGT-TCA-AGT-	TTC-TTC-AAA-CTG-ATT-GTA-TTC-CAC-C	FAM_CAG-TAC-ATC-TTG-ATC-
	AGA-G		CAT-C_MGB
CD45RO	GGC-AAA-GCC-CAA-CAC-CTT-C	CAG-AAG-GGC-TCA-GAG-TGG-TTG-T	FAM_TGC-CTA-CCT-TAA-TGC-
			C_MGB
FoxP3	CAC CTG GCT GGG AAA ATG G	GGAGCC CTT GTC GGA TGA T	FAM_CAA GGC TTC ATC TGT
			G_MGB
CD20	CAT-ACA-ATC-TCT-GTT-CTT-GGG-	TCA-TTC-TCA-ACG-ATG-CCA-GCT-A	FAM_TCA-GTG-ATG-CTG-ATC-
	CAT-T		TT_MGB
TLR9	CGC-CAG-ACC-CTC-TGG-AGA-A	GCC-TGC-ACC-AGG-AGA-GAC-A	FAM_TTC-TGC-CGC-AGC-G_MGB
ITGB3	AAG-TCC-ATC-CTG-TATG-TGG-	GAG-CAG-GAC-CAC-CAG-GAT-GT	FAM_AGT-GTC-CCA-AGG-GC_MGB
	TAG-AAG-AG
TLR3	GGA-AAG-GCT-AGC-AGT-CAT-CCA	GTG-GAG-GAT-GCA-CAC-AGC-AT	FAM_ATG-AGA-CAG-ACT-TTG-
			CC_MGB
ThR4	CCA-GAA-CTG-CAG-GTG-CTG-G	GGT-GGC-TTA-GGC-TCT-GAT-ATG-C	FAM_CCA-GGT-GTG-AAA-TCC-
			AGA-CA_MGB
TLR7	Assay-on-demand Hs00152971_m1 (Applied Biosystens)
TLR10	Assay-on-demand Hs01675179_m1 (Applied Biosystems)
variant 1
IRF1	Assay-on-demand Hs00971965_m1 (Applied Biosystems)

TABLE 6
Gene included into the TaqMan ® Immune Profiling Array
	Gene	Target
Assay ID	Symbol	Exons	NCBI Gene Reference
Hs00174092_m1	IL1A	6	NM_000575, M15329, X02531, X02851, X56086, CR457414, BC035169, BC013142,
			BT007014
Hs00174097_m1	IL1B	5	NM_000576, K02770, M15330, M54933, X02532, X56087, AF043335, BC008678,
			CR407679, BT007213
Hs00174114_m1	1L2	2	NM_000586, U25676,,V00564,,X01586,,S82692, S77835, S77834, AF228636,
			BC066255, BC066256, BC06
			C066254, AY523040, BC070338 A14844
Hs00174117_m1	1L3	2	NM_000588, M17115, M14743, M20137, BC066274, BC066276, BC066272, BC066273,
			BC069472
Hs00174122_m1	1L4	3	NM_172348, NM_000589, M13982, X81851, AF043336, BC066277, BC067514, BC067515,
			BC070123, AB1
Hs00174200_m1	ILS	2	NM_000879, X12705, X04688, BC066282
Hs00174131_m1	1L6	3	NM_000600, X04403, M14584, M18403, M29150, X04430, X04602, M54894, S56892,
			CR450296, BT019748
			9749, A09363, BC015511
Hs00174202_m1	1L7	2	NM_000880, J04156, BC047698
Hs00174103_m1	1L8	1	NM_000584, M17017, M26383, Z11686, Y00787, CR542151, AK131067, BC013615,
			BT007067
Hs00174125_m1	1L9	3	NM_000590, M30134, X17543, S63356, BC066284, BC066283, BC066285, BC066286
Hs99999901_s1	18S	1	X03205
Hs00174086_m1	IL10	3	NM_000572, M57627, AF043333, AY029171, CR541993
Hs00168405_m1	IL12A	2	NM_000882, M65271, M65291, AF101062, AF180562, BG702253
Hs00233688_m1	IL12B	3	NM_002187, M65272, M65290, AF180563, BC067501, BC067498, BC067499, BC067500,
			BC067502, BC07
Hs00174379_m1	IL13	1	NM_002188, L06801, X69079, BC096141, BC096139
Hs00174106_m1	1L15	1	NM_000585, U14407
Hs00174383_m1	IL17	2	NM_002190, Z58820, U32659, BC066251 ,BC066252, BC066253, BC067504, BC067503,
			BC067505
Hs00155517_m1	IL18	4	NM_001562, D49950, U90434, AF077611, AY266351, CR541973, CR542001, AY044641,
			BCO15863, BC00
Hs00234142_m1	CCL3	1	NM_002983, M25315, D63785, M23452, D00044, X03754, BC071834
Hs00171149_m1	CCL19	1	NM_006274, AB000887, U77180, U88321, CR456868, BC027968
Hs00234140_m1	CCL2	1	NM_002982, M24545, M28226, X14768, S69738, S71513, AV733621, BC009716,
			BT007329
Hs00174575_m1	CCL5	2	NM_002985, M21121, AF043341, BC008600, AF266753
Hs00174150_m1	CCR2	1	NM_000647, U03882, BC074751
Hs99999919_m1	CCR4	N/A	NM_005508, BC069139, BC071751, BC074935
Hs00152917_m1	CCR5	2	NM_000579, U54994, BC038398
Hs00171054_m1	CCR7	1	NM_001838, L31581, L08176, BC035343, AK127810
Hs00171041_m1	CXCR3	1	NM_001504, X95876
Hs00171042_m1	CXCLI0	1	NM_001565, X02530, BC010954
Hs00171138_m1	CXCL11	1	NM_005409, Y15220, U59286, AF030514, AF002985, U66096, BC005292, AF352781,
			BC012532, BT00678
Hs00174164_m1	CSF1	4	NM_172210, NM_172211, NM_172212, NM_000757, U22386, M37435, M76453, M64592,
			M27087, X05825,
Hs00171266_m1	CSF2	3	NM_000758, M10663, M11220, AY720441, AF510855
Hs00357085_g1	CSF3	1	NM_172219, NM_000759, M17706, X03438, X03655, CR541891
Hs00234174_m1	STAT3	N/A	NM_139276, AJ012463, L29277, BC014482
Hs00174517_m1	NFKB2	6	NM_002502, U09609, X61498, X61499, S76638, BC002844, BT009769
Hs00395088_m1	IKBKB	8	NM_001556, AF029684, AF031416, AF080158, AB209090, BX648165
Hs00167894_m1	CD3E	1	NM_000733, X03884, B1910359
Hs00181217_m1	CD4	2	NM_000616, M12807, BT019791, BT019811, BC025782
Hs00233520_m1	CD8A	5	NM_171827, NM_001768, M12824, M12628, AY039664, AK124156, BC025715, AK097942
Hs00174333_m1	CD19	4	NM_001770, M21097, XI3312, BC006338, AK130657, BC052294
Hs00166229_m1	IL2RA	1	NM_000417, X01057, K03122, AK223313
Hs00174796_m1	CD28	2	NM_006139, J02988, BC093698
Hs00233552_m1	CD38	1	NM_001775, D84276, M34461, BC007964, CD688069
Hs00374176_m1	CD40	1	NM_152854, NM_001250, AJ300189, BC064518, BC012419, BM761221, AK222896
Hs00365634_g1	PTPRC	1	NM_080921, NM_080922, NM_080923, NM_002838, Y00062, BC017863, BC014239
Hs00154355_m1	CD68	6	NM_001251, S57235, BC015557, BT009923, AK222492, AK222514
Hs00175478_m1	CD80	2	NM_005191, M27533, AY197777, AY197778, AY081815, BC042665
Hs00199349_m1	CD86	2	NM_175862, NM_006889, L25259, U04343, CR541844, BC040261
Hs00175480_m1	CTLA4	1	NM_005214, L15006, BC069566, BC070162, BC074842, BC074893, AY209009,
			AF414120, AF486806
Hs00163934_m1	CD40LG	4	NM_000074, L07414, X67878, Z15017, X68550, BC071754, BC074950
Hs00219575_m1	HLA-DRA	1	NM_019111, J00194, M60334, M35979, K01171, M60333, CR457013, BC071659,
			BC032350
Hs99999917_m1	HLA-DRB1	N/A	NM_002124,M11161, M33600, X03069, DQ002917
Hs00203436_m1	TBX21	1	NM_013351, AF093098, AF241243, BC039739, AK223634
Hs00188346_m1	TNFRSF18	2	NM_148901, NM_148902, NM_004195, AF117297, AF125304, AF241229, BT019531,
			BT019532, AY358877
Hs00359999_m1	ICOS	1	NM_012092, AB023135, AJ277832, BC028006, BC028210
Hs00167248_m1	NOS2A	11	NM_153292, NM_000625, AB022318, U05810, D26525, L24553, X73029, U20141,
			U31511, S75615
Hs00153350_m1	BCL2	1	NM_000633, M13994, M14745, X06487, BC027258
Hs00169141_m1	BCL2L1	1	NM 001191, Z23116
Hs00180269_m1	BAX	3	NM_138761, NM_138763, NM_138765, NM_004324, L22473, L22474, U19599, AF247393,
			AF250190, AJ586909, AJ586910, BM706954, BC014175, AJ417988
Hs00164932_m1	ICAM1	2	NM_000201, M24283, J03132, X06990, AF340038, AF340039, BC015969, AK130659, BT006854
Hs00174583_m1	SELP	1	NM_003005, M25322, BC068533
Hs00174057_m1	SELE	4	NM_000450, M24736, M30640
Hs00157965_m1	HM0X1	2	NM_002133, M23041, X06985, CR456505, CR541945, CR541968, BT019785, BC001491
Hs00153133_m1	PTGS2	5	NM_000963, M90100, L15326, AJ634912, AY462100, BC013734, AY151286
Hs00166915_m1	REN	1	NM_000537, CR536498, BC047752, BC033474
Hs00189742_m1	LRP2	17	NM_004525, U33837, AY265357, AY265358
Hs00411908_m1	MYH6	23	NM_002471, D00943
Hs00192564_m1	RPL3L	3	NM_005061, U65581, BC050413
Hs00167927_m1	CYP1A2	2	NM_000761, M55053, Z00036, AF182274, BC067425, BC067427, BC067424, BC067429,
			BC067426, BC067428
Hs00167982_m1	CYP7A1	3	NM_000780, X56088, M93133
Hs00174143_m1	IFNG	1	NM_000619, X13274, V00543, X87308, BC070256, AY255837, AY255839, AY044154,
			AF506749
Hs00169473_m1	PRF1	1	NM_005041, M28393, X13224, BC063043, BC047695
indicates data missing or illegible when filed

TABLE 7A
Geomean ratio between responder and non-responder groups
	Gene	Ratio	LL	UL
	CCL5	7.83	3.09	19.84
	FASLG	7.57	2.77	20.70
	GNLY	8.82	3.61	21.56
	GZMB	12.15	4.38	33.71
	PRF1	11.07	4.85	25.28
	IFNG	21.19	5.36	83.86
	ICOS	13.44	3.44	52.51
	TBX21	13.93	3.63	53.41
	CD8A	11.60	4.22	31.90
	CD3E	12.78	3.55	46.04
	CXCL11	4.71	1.44	15.35
	CXCL10	7.39	2.56	21.39
	CXCR3	16.96	3.10	92.90
	CD20	9.46	1.35	66.42
	FOXP3	5.57	2.58	12.04
	INDO	13.62	2.89	64.20
	CD45Ro	4.02	1.84	8.79
	CD45R	4.92	1.90	12.77
	CD69	5.84	2.00	17.06
	TRBV19	11.15	3.56	34.94
	TRAT1	9.67	2.77	33.80
	TRDV2	7.05	2.79	17.82
	STAT4	3.41	1.75	6.65
	PRKCQ	7.41	3.24	16.94
	GMZK	9.20	2.60	32.49
	GPR171	5.25	2.47	11.17
	UBD	14.68	3.95	54.65
	CD52	6.17	1.96	19.41
	CD3D	10.03	3.07	32.77
	IL7R	6.49	2.08	20.26
	IRF1	5.54	2.83	10.83
	TLR7	3.44	1.50	7.89

TABLE 8 (BELOW)
Correlation matrix between 30 genes
Variable	Ig_IL7R	Ig_CD3D	Ig_CD52	Ig_UBD	Ig_GPR171	Ig_GMZK	Ig_PRKCQ	Ig_STAT4
Ig_IL7R	1.00	0.90	0.91	0.79	0.80	0.80	0.83	0.84
Ig_CD3D	0.90	1.00	0.94	0.93	0.89	0.93	0.88	0.88
Ig_CD52	0.91	0.94	1.00	0.80	0.83	0.82	0.84	0.83
Ig_UBD	0.79	0.93	0.80	1.00	0.82	0.91	0.80	0.82
Ig_GPR17	0.80	0.89	0.83	0.82	1.00	0.81	0.94	0.92
Ig_GMZK	0.80	0.93	0.82	0.91	0.81	1.00	0.83	0.85
Ig_PRKC	0.83	0.88	0.84	0.80	0.94	0.83	1.00	0.93
Ig_STAT4	0.84	0.88	0.83	0.82	0.92	0.85	0.93	1.00
Ig_TRDV2	0.88	0.96	0.91	0.86	0.94	0.87	0.93	0.89
Ig_TRAT1	0.92	0.96	0.89	0.89	0.85	0.95	0.89	0.91
Ig_TRBV1	0.92	0.99	0.95	0.91	0.90	0.92	0.91	0.89
Ig_CD69	0.85	0.92	0.92	0.80	0.80	0.88	0.87	0.87
Ig_CD45R	0.90	0.91	0.88	0.80	0.83	0.88	0.89	0.90
Ig_CD45R	0.84	0.91	0.83	0.83	0.86	0.90	0.89	0.88
Ig_INDO	0.76	0.89	0.79	0.91	0.81	0.87	0.83	0.83
Ig_FOXP3	0.78	0.80	0.75	0.74	0.83	0.78	0.91	0.84
Ig_CD20	0.87	0.82	0.88	0.69	0.67	0.74	0.74	0.74
Ig_CXCR3	0.84	0.89	0.82	0.85	0.74	0.86	0.79	0.78
Ig_CXCL1	0.65	0.84	0.68	0.92	0.76	0.83	0.72	0.73
Ig_CXCL1	0.54	0.74	0.60	0.81	0.75	0.74	0.71	0.77
Ig_CD3E	0.86	0.94	0.92	0.81	0.85	0.87	0.88	0.83
Ig_CD8A	0.77	0.93	0.82	0.89	0.88	0.91	0.91	0.87
Ig_TBX21	0.91	0.97	0.93	0.90	0.83	0.87	0.81	0.81
Ig_ICOS	0.85	0.94	0.87	0.89	0.78	0.87	0.78	0.79
Ig_IFNG	0.75	0.91	0.78	0.92	0.74	0.92	0.75	0.78
Ig_PRF1	0.76	0.92	0.82	0.89	0.88	0.91	0.91	0.87
Ig_GZMB	0.80	0.92	0.89	0.86	0.90	0.84	0.88	0.87
Ig_GNLY	0.74	0.87	0.84	0.77	0.85	0.83	0.88	0.82
Ig_FASLG	0.68	0.87	0.78	0.85	0.82	0.85	0.81	0.81
Ig_CCL5	0.77	0.93	0.83	0.91	0.83	0.92	0.81	0.82
Variable	Ig_TRDV2	Ig_TRAT1	Ig_TRBV19	Ig_CD69	Ig_CD45R	Ig_CD45RO	Ig_INDO	Ig_FOXP3
Ig_IL7R	0.88	0.92	0.92	0.85	0.90	0.84	0.76	0.78
Ig_CD3D	0.96	0.96	0.99	0.92	0.91	0.91	0.89	0.80
Ig_CD52	0.91	0.89	0.95	0.92	0.88	0.83	0.79	0.75
Ig_UBD	0.86	0.89	0.91	0.80	0.80	0.83	0.91	0.74
Ig_GPR17	0.94	0.85	0.90	0.80	0.83	0.86	0.81	0.83
Ig_GMZK	0.87	0.95	0.92	0.88	0.88	0.90	0.87	0.78
Ig_PRKC	0.93	0.89	0.91	0.87	0.89	0.89	0.83	0.91
Ig_STAT4	0.89	0.91	0.89	0.87	0.90	0.88	0.83	0.84
Ig_TRDV2	1.00	0.92	0.97	0.88	0.91	0.91	0.83	0.85
Ig_TRAT1	0.92	1.00	0.96	0.92	0.95	0.93	0.87	0.82
Ig_TRBV1	0.97	0.96	1.00	0.93	0.92	0.91	0.87	0.83
Ig_CD69	0.88	0.92	0.93	1.00	0.92	0.90	0.80	0.79
Ig_CD45R	0.91	0.95	0.92	0.92	1.00	0.97	0.83	0.86
Ig_CD45R	0.91	0.93	0.91	0.90	0.97	1.00	0.86	0.83
Ig_INDO	0.83	0.87	0.87	0.80	0.83	0.86	1.00	0.80
Ig_FOXP3	0.85	0.82	0.83	0.79	0.86	0.83	0.80	1.00
Ig_CD20	0.76	0.83	0.83	0.86	0.78	0.69	0.66	0.65
Ig_CXCR3	0.84	0.88	0.89	0.83	0.82	0.82	0.78	0.73
Ig_CXCL1	0.79	0.77	0.81	0.69	0.68	0.75	0.82	0.64
Ig_CXCL1	0.72	0.68	0.70	0.67	0.64	0.70	0.74	0.59
Ig_CD3E	0.94	0.91	0.95	0.93	0.87	0.86	0.76	0.75
Ig_CD8A	0.92	0.89	0.93	0.88	0.85	0.87	0.82	0.81
Ig_TBX21	0.92	0.92	0.97	0.87	0.86	0.87	0.82	0.72
Ig_ICOS	0.89	0.90	0.93	0.87	0.83	0.84	0.78	0.68
Ig_IFNG	0.82	0.88	0.89	0.83	0.78	0.82	0.87	0.71
Ig_PRF1	0.91	0.89	0.92	0.88	0.84	0.88	0.83	0.81
Ig_GZMB	0.91	0.87	0.93	0.87	0.83	0.85	0.80	0.77
Ig_GNLY	0.86	0.83	0.87	0.87	0.80	0.82	0.78	0.78
Ig_FASLG	0.86	0.83	0.87	0.86	0.79	0.85	0.75	0.68
Ig_CCL5	0.88	0.88	0.92	0.87	0.80	0.84	0.81	0.68
Variable	Ig_CD20	Ig_CXCR3	Ig_CXCL10	Ig_CXCL11	Ig_CD3E	Ig_CD8A	Ig_TBX21	Ig_ICOS
Ig_IL7R	0.87	0.84	0.65	0.54	0.86	0.77	0.91	0.85
Ig_CD3D	0.82	0.89	0.84	0.74	0.94	0.93	0.97	0.94
Ig_CD52	0.88	0.82	0.68	0.60	0.92	0.82	0.93	0.87
Ig_UBD	0.69	0.85	0.92	0.81	0.81	0.89	0.90	0.89
Ig_GPR17	0.67	0.74	0.76	0.75	0.85	0.88	0.83	0.78
Ig_GMZK	0.74	0.86	0.83	0.74	0.87	0.91	0.87	0.87
Ig_PRKC	0.74	0.79	0.72	0.71	0.88	0.91	0.81	0.78
Ig_STAT4	0.74	0.78	0.73	0.77	0.83	0.87	0.81	0.79
Ig_TRDV2	0.76	0.84	0.79	0.72	0.94	0.92	0.92	0.89
Ig_TRAT1	0.83	0.88	0.77	0.68	0.91	0.89	0.92	0.90
Ig_TRBV1	0.83	0.89	0.81	0.70	0.95	0.93	0.97	0.93
Ig_CD69	0.86	0.83	0.69	0.67	0.93	0.88	0.87	0.87
Ig_CD45R	0.78	0.82	0.68	0.64	0.87	0.85	0.86	0.83
Ig_CD45R	0.69	0.82	0.75	0.70	0.86	0.87	0.87	0.84
Ig_INDO	0.66	0.78	0.82	0.74	0.76	0.82	0.82	0.78
Ig_FOXP3	0.65	0.73	0.64	0.59	0.75	0.81	0.72	0.68
Ig_CD20	1.00	0.73	0.51	0.47	0.82	0.68	0.79	0.74
Ig_CXCR3	0.73	1.00	0.81	0.73	0.87	0.89	0.89	0.90
Ig_CXCL1	0.51	0.81	1.00	0.90	0.73	0.87	0.81	0.84
Ig_CXCL1	0.47	0.73	0.90	1.00	0.65	0.81	0.67	0.72
Ig_CD3E	0.82	0.87	0.73	0.65	1.00	0.91	0.92	0.91
Ig_CD8A	0.68	0.89	0.87	0.81	0.91	1.00	0.88	0.90
Ig_TBX21	0.79	0.89	0.81	0.67	0.92	0.88	1.00	0.95
Ig_ICOS	0.74	0.90	0.84	0.72	0.91	0.90	0.95	1.00
Ig_IFNG	0.67	0.82	0.89	0.73	0.83	0.89	0.87	0.90
Ig_PRF1	0.68	0.85	0.86	0.79	0.91	0.98	0.87	0.88
Ig_GZMB	0.71	0.85	0.80	0.75	0.90	0.92	0.89	0.90
Ig_GNLY	0.68	0.77	0.74	0.69	0.89	0.89	0.80	0.83
Ig_FASLG	0.63	0.78	0.83	0.81	0.87	0.93	0.85	0.88
Ig_CCL5	0.68	0.89	0.91	0.81	0.91	0.96	0.91	0.94
	Variable	Ig_IFNG	Ig_PRF1	Ig_GZMB	Ig_GNLY	Ig_FASLG	Ig_CCL5
	Ig_IL7R	0.75	0.76	0.80	0.74	0.68	0.77
	Ig_CD3D	0.91	0.92	0.92	0.87	0.87	0.93
	Ig_CD52	0.78	0.82	0.89	0.84	0.78	0.83
	Ig_UBD	0.92	0.89	0.86	0.77	0.85	0.91
	Ig_GPR17	0.74	0.88	0.90	0.85	0.82	0.83
	Ig_GMZK	0.92	0.91	0.84	0.83	0.85	0.92
	Ig_PRKC	0.75	0.91	0.88	0.88	0.81	0.81
	Ig_STAT4	0.78	0.87	0.87	0.82	0.81	0.82
	Ig_TRDV2	0.82	0.91	0.91	0.86	0.86	0.88
	Ig_TRAT1	0.88	0.89	0.87	0.83	0.83	0.88
	Ig_TRBV1	0.89	0.92	0.93	0.87	0.87	0.92
	Ig_CD69	0.83	0.88	0.87	0.87	0.86	0.87
	Ig_CD45R	0.78	0.84	0.83	0.80	0.79	0.80
	Ig_CD45R	0.82	0.88	0.85	0.82	0.85	0.84
	Ig_INDO	0.87	0.83	0.80	0.78	0.75	0.81
	Ig_FOXP3	0.71	0.81	0.77	0.78	0.68	0.68
	Ig_CD20	0.67	0.68	0.71	0.68	0.63	0.68
	Ig_CXCR3	0.82	0.85	0.82	0.77	0.78	0.89
	Ig_CXCL1	0.89	0.86	0.80	0.74	0.83	0.91
	Ig_CXCL1	0.73	0.79	0.75	0.69	0.81	0.81
	Ig_CD3E	0.83	0.91	0.90	0.89	0.87	0.91
	Ig_CD8A	0.89	0.98	0.92	0.89	0.93	0.96
	Ig_TBX21	0.87	0.87	0.89	0.80	0.85	0.91
	Ig_ICOS	0.90	0.88	0.90	0.83	0.88	0.94
	Ig_IFNG	1.00	0.90	0.85	0.82	0.84	0.93
	Ig_PRF1	0.90	1.00	0.94	0.92	0.93	0.95
	Ig_GZMB	0.85	0.94	1.00	0.92	0.91	0.92
	Ig_GNLY	0.82	0.92	0.92	1.00	0.86	0.88
	Ig_FASLG	0.84	0.93	0.91	0.86	1.00	0.93
	Ig_CCL5	0.93	0.95	0.92	0.88	0.93	1.00
	indicates data missing or illegible when filed

TABLE 9A
18 best models obtained by logistic regression.
	Predictor	R2 (%)	Chi-square Score
	PRF1	55	16
	IRF1	50	14
	GZMB	46	14
	GNLY	45	14
	CD8A	46	14
	PRKCQ	45	14
	FOXP3	42	13
	IFNG	52	13
	CCL5	45	13
	GPR171	41	12
	TRBV19	44	11
	CD3E	39	11
	TBX21	44	11
	FASLG	39	11
	CXCL10	35	10
	ICOS	39	10
	CXCR3	35	9
	CXCL11	22	6

TABLE 10
Percentage of correct classification calculated using the
logistic regression model for some genes.
Model  Percentage of patients correctly classified
PRF1   86.6%
IRF1   89.7%
GZMB   82.8%
GNLY   82.8%
CD8A   82.8%
PRKCQ  89.7%
FOXP3  86.2%
IFNG   89.7%
CCL5   79.3%
GPR171 82.8%
TRBV19 86.2%
CDE3   75.9%
TBX21  82.8%
FASLG  75.9%
CXCL10 75.9%
ICOS   75.9%
CXR3   75.9%
CXCL11 72.4%

TABLE 11A
Probe		Gene	Patient Identity Number
Set	Gene Title	Symbol	14	52	66	37	16	13	55	56	5	60
1555759_a_at	chemokine (C-C	CCL5	3.148	3.204	3.208	3.096	3.055	3.049	3.096	3.208	2.664	2.835
	motif) ligand 5
1555834_at	Ubiquitin	UCHL1	7.911	2.4	2.324	5.169	5.06	2.401	3.561	2.627	4.868	2.401
	carboxyl-
	terminal esterase
	L1 (ubiquitin
	thiolesterase)
1558290_a_at	Pvt1 oncogene	PVT1	10.849	10.579	11.312	10.154	9.815	10.752	11.192	9.514	10.132	8.752
	homolog, MYC	///
	activator	LOC441378
	(mouse) ///
	LOC441378
1569942_at	CDNA clone	—	5.295	3.843	4.837	5.187	3.748	5.656	3.518	6.042	6.463	4.378
	IMAGE: 4796388
204661_at	CD52 antigen	CD52	5.673	5.506	8.56	5.104	5.814	5.755	4.087	4.785	3.839	4.29
	(CAMPATH-1
	antigen) ///
	CD52 antigen
	(CAMPATH-1
	antigen)
205890_s_at	ubiquitin D	UBD	4.731	7.003	9.226	4.138	3.687	8.103	3.242	6.126	3.231	7.706
206118_at	signal	STAT4	4.336	3.291	4.142	2.396	3.235	3.291	2.382	2.439	2.663	2.948
	transducer and
	activator of
	transcription 4
206666_at	granzyme K	GZMK	6.187	5.357	7.079	2.659	2.571	5.033	2.225	3.383	2.567	3.104
	(granzyme 3;
	tryptase II) ///
	granzyme K
	(granzyme 3;
	tryptase II)
207072_at	interleukin 18	IL18RAP	2.225	2.237	2.232	2.232	2.231	2.232	2.227	2.237	2.227	2.237
	receptor
	accessory
	protein
207651_at	G protein-	GPR171	3.961	7.086	4.363	4.635	3.271	5.499	3.426	4.679	3.42	4.672
	coupled receptor
	171
209606_at	pleckstrin	PSCDBP	4.553	5.031	5.888	4.679	3.194	3.996	3.036	3.285	3.692	3.473
	homology, Sec7
	and coiled-coil
	domains,
	binding protein
	/// pleckstrin
	homology, Sec7
	and coiled-coil
	domains,
	binding protein
209949_at	neutrophil	NCF2	6.058	6.184	3.286	6.305	4.585	3.866	4.672	3.294	4.457	3.802
	cytosolic factor
	2 (65 kDa,
	chronic
	granulomatous
	disease,
	autosomal 2)
210038_at	protein kinase	PRKCQ	2.362	2.18	2.415	2.178	2.364	2.358	2.577	2.181	2.179	2.191
	C, theta
210629_x_at	leukocyte	LST1	5.649	6.559	6.72	5.368	5.367	3.893	3.484	6.134	4.775	5.283
	specific
	transcript 1
210972_x_at	T cell receptor	TRA@	4.292	6.159	7.116	3.791	4.059	6.091	5.234	5.057	4.291	4.842
	alpha locus /// T	///
	cell receptor	TRDV2
	delta variable 2	///
	/// T cell	TRAV20
	receptor alpha	///
	variable 20 /// T	TRAJ17
	cell receptor	///
	alpha joining 17	TRAC
	/// T cell
	receptor alpha
	constant
211144_x_at	T cell receptor	TRGC2	2.887	2.261	4.452	2.257	2.193	3.203	2.347	2.453	2.332	2.196
	gamma constant 2
211796_s_at	T cell receptor	TRBV21-	3.275	3.556	7.359	2.877	2.424	5.177	2.521	2.728	2.297	2.909
	beta variable 21-	1 ///
	1 /// T cell	TRBV19
	receptor beta	///
	variable 19 /// T	TRBV5-
	cell receptor	4 ///
	beta variable 5-4	TRBV3-
	/// T cell	1 ///
	receptor beta	TRBC1
	variable 3-1 /// T
	cell receptor
	beta constant 1
212671_s_at	major	HLA-	8.1	7.479	6.553	8.223	6.574	7.356	7.347	5.884	6.068	5.558
	histocompatibility	DQA1
	complex, class	///
	II, DQ alpha 1	HLA-
	/// major	DQA2
	histocompatibility
	complex, class
	II, DQ alpha 2
213193_x_at	T cell receptor	TRBV19	4.185	3.787	7.027	3.011	2.962	4.53	3.096	3.192	2.829	3.058
	beta variable 19	///
	/// T cell	TRBC1
	receptor beta
	variable 19 /// T
	cell receptor
	beta constant 1
	/// T cell
	receptor beta
	constant 1
213539_at	CD3D antigen,	CD3D	3.179	4.399	7.52	3.352	3.182	5.87	2.8	3.183	3.178	3.626
	delta
	polypeptide
	(TiT3 complex)
213560_at	Growth arrest	GADD45B	4.967	5.948	6.218	5.528	4.673	5.367	5.49	3.67	5.735	5.048
	and DNA-
	damage-
	inducible, beta
216261_at	integrin, beta 3	ITGB3	8.21	2.588	4.394	3.536	6.237	4.486	3.088	6.729	6.77	2.606
	(platelet
	glycoprotein
	IIIa, antigen
	CD61)
217147_s_at	T cell receptor	TRAT1	3.914	4.251	5.453	2.871	2.292	4.283	2.327	2.887	2.277	2.308
	associated
	transmembrane
	adaptor 1
217478_s_at	major	HLA-	8.989	8.655	8.599	9.516	8.621	7.051	8.181	8.129	7.41	8.04
	histocompatibility	DMA
	complex, class
	II, DM alpha
218950_at	centaurin, delta 3	CENTD3	9.212	7.139	8.794	8.51	8.32	7.438	9.077	8.075	9.012	7.142
220330_s_at	SAM domain,	SAMSN1	4.712	4.228	5.117	4.641	4.804	3.557	2.702	4.246	3.492	3.828
	SH3 domain and
	nuclear
	localisation
	signals, 1
222934_s_at	C-type lectin	CLEC4E	5.382	4.219	2.931	2.753	2.511	3.812	4.494	2.512	3.917	3.417
	domain family
	4, member E
223827_at	tumor necrosis	TNFRSF19	4.16	3.985	5.98	2.86	5.91	3.239	4.301	6.268	5.029	4.931
	factor receptor
	superfamily,
	member 19
224771_at	neuron	NAV1	7.893	6.773	7.352	7.998	8.385	7.571	7.077	7.277	6.956	7.304
	navigator 1
224772_at	neuron	NAV1	10.827	9.319	9.458	9.799	10.771	10.304	9.47	9.943	9.752	9.998
	navigator 1
224773_at	neuron	NAV1	8.959	7.241	7.742	9.332	9.582	8.051	8.427	8.479	7.795	7.564
	navigator 1
224774_s_at	neuron	NAV1	7.288	6.204	7.292	8.109	7.683	6.486	7.056	5.947	6.406	6.181
	navigator 1
227145_at	lysyl oxidase-	LOXL4	11.368	8.235	10.93	12.565	12.636	12.563	7.768	11.858	12.092	11.62
	like 4
227584_at	Neuron	NAV1	11.735	10.222	10.601	10.533	11.778	11.041	10.121	11.247	10.732	11.00
	navigator 1
227812_at	tumor necrosis	TNFRSF19	11.9	11.787	12.618	10.566	12.747	11.729	11.115	12.911	12.125	11.83
	factor receptor
	superfamily,
	member 19
229723_at	T-cell activation	TAGAP	5.224	4.874	5.527	5.091	2.501	3.01	4.398	2.891	3.472	3.425
	GTPase
	activating
	protein
232024_at	GTPase, IMAP	GIMAP2	8.489	7.321	7.275	6.411	7.83	6.861	6.317	8.172	7.42	7.119
	family member 2
238544_at	Insulin-like	IGF1R	6.79	8.031	9.43	5.969	7.331	7.827	8.887	6.322	9.011	7.444
	growth factor 1
	receptor
242886_at	Chromosome 17	C17orf63	10.066	10.766	9.654	8.976	9.813	9.864	10.039	9.839	8.819	9.808
	open reading
	frame 63
242986_at	Neuron	NAV1	9.936	9.155	9.341	10.292	10.071	9.41	9.098	9.552	8.465	8.663
	navigator 1
34210_at	CD52 antigen	CD52	6.58	6.581	9.446	5.799	6.518	6.798	4.246	6.008	3.469	5.289
	(CAMPATH-1
	antigen)
indicates data missing or illegible when filed

TABLE 11B
Probe		Gene	Patient Identity Number
Set	Gene Title	Symbol	75	2	65	20	10
1555759_a_at	chemokine	CCL5	4.665	5.498	7.109	3.207	5.121
	(C-C motif)
	ligand 5
1555834_at	Ubiquitin	UCHL1	2.329	2.36	2.4	2.399	2.358
	carboxyl-
	terminal
	esterase L1
	(ubiquitin
	thiolesterase)
1558290_a_at	Pvt1	PVT1	8.59	7.403	8.63	8.588	9.536
	oncogene	///
	homolog,	LOC441378
	MYC
	activator
	(mouse) ///
	LOC441378
1569942_at	CDNA clone	—	3.605	3.324	4.066	2.849	4.189
	IMAGE: 4796388
204661_at	CD52 antigen	CD52	8.008	8.301	9.702	8.979	9.415
	(CAMPATH-
	1 antigen) ///
	CD52 antigen
	(CAMPATH-
	1 antigen)
205890_s_at	ubiquitin D	UBD	11.687	10.159	11.582	7.52	9.692
206118_at	signal	STAT4	5.794	5.481	4.044	5.157	6.026
	transducer
	and activator
	of
	transcription 4
206666_at	granzyme K	GZMK	7.615	9.057	9.338	6.513	8.013
	(granzyme 3;
	tryptase II) ///
	granzyme K
	(granzyme 3;
	tryptase II)
207072_at	interleukin 18	IL18RAP	4.76	2.358	2.233	3.154	2.235
	receptor
	accessory
	protein
207651_at	G protein-	GPR171	8.491	8.969	8.37	6.884	8.501
	coupled
	receptor 171
209606_at	pleckstrin	PSCDBP	6.808	6.788	8.373	6.524	7.997
	homology,
	Sec7 and
	coiled-coil
	domains,
	binding
	protein ///
	pleckstrin
	homology,
	Sec7 and
	coiled-coil
	domains,
	binding
	protein
209949_at	neutrophil	NCF2	6.928	6.845	7.973	5.572	5.428
	cytosolic
	factor 2
	(65 kDa,
	chronic
	granulomatous
	disease,
	autosomal 2)
210038_at	protein	PRKCQ	4.981	4.768	2.406	2.836	6.907
	kinase C,
	theta
210629_x_at	leukocyte	LST1	7.078	6.711	6.926	5.831	6.424
	specific
	transcript 1
210972_x_at	T cell	TRA@	7.913	8.072	11.25	6.451	10.646
	receptor	///
	alpha locus	TRDV2
	/// T cell	///
	receptor delta	TRAV20
	variable 2 ///	///
	T cell	TRAJ17
	receptor	///
	alpha	TRAC
	variable 20 ///
	T cell
	receptor
	alpha joining
	17 /// T cell
	receptor
	alpha
	constant
211144_x_at	T cell	TRGC2	6.096	4.892	6.456	2.624	6.163
	receptor
	gamma
	constant 2
211796_s_at	T cell	TRBV21-	7.924	8.11	10.708	6.84	9.737
	receptor beta	1 ///
	variable 21-1	TRBV19
	/// T cell	///
	receptor beta	TRBV5-
	variable 19 ///	4 ///
	T cell	TRBV3-
	receptor beta	1 ///
	variable 5-4	TRBC1
	/// T cell
	receptor beta
	variable 3-1
	/// T cell
	receptor beta
	constant 1
212671_s_at	major	HLA-	10.798	9.601	11.257	9.336	8.87
	histocompatibility	DQA1
	complex,	///
	class II, DQ	HLA-
	alpha 1 ///	DQA2
	major
	histocompatibility
	complex,
	class II, DQ
	alpha 2
213193_x_at	T cell	TRBV19	7.553	7.871	10.191	6.704	9.248
	receptor beta	///
	variable 19 ///	TRBC1
	T cell
	receptor beta
	variable 19 ///
	T cell
	receptor beta
	constant 1 ///
	T cell
	receptor beta
	constant 1
213539_at	CD3D	CD3D	8.208	8.038	9.64	7.257	8.387
	antigen, delta
	polypeptide
	(TiT3
	complex)
213560_at	Growth arrest	GADD45B	7.243	5.936	6.794	7.57	6.389
	and DNA-
	damage-
	inducible,
	beta
216261_at	integrin, beta	ITGB3	2.545	2.691	2.651	2.592	2.59
	3 (platelet
	glycoprotein
	IIIa, antigen
	CD61)
217147_s_at	T cell	TRAT1	6.748	6.139	8.028	5.044	7.377
	receptor
	associated
	transmembrane
	adaptor 1
217478_s_at	major	HLA-	10.873	10.838	11.541	9.389	10.193
	histocompatibility	DMA
	complex,
	class II, DM
	alpha
218950_at	centaurin,	CENTD3	7.911	7.983	5.552	6.866	7.456
	delta 3
220330_s_at	SAM	SAMSN1	7.494	6.244	4.271	5.243	7.151
	domain, SH3
	domain and
	nuclear
	localisation
	signals, 1
222934_s_at	C-type lectin	CLEC4E	6.912	6.523	6.984	5.384	4.588
	domain
	family 4,
	member E
223827_at	tumor	TNFRSF19	3.043	3.308	2.721	2.855	3.48
	necrosis
	factor
	receptor
	superfamily,
	member 19
224771_at	neuron	NAV1	6.378	7.607	6.624	6.24	6.483
	navigator 1
224772_at	neuron	NAV1	9.184	10.073	8.059	7.897	8.937
	navigator 1
224773_at	neuron	NAV1	7.427	7.781	5.878	5.855	6.881
	navigator 1
224774_s_at	neuron	NAV1	5.706	7.087	5.432	5.724	5.939
	navigator 1
227145_at	lysyl oxidase-	LOXL4	3.699	7.798	3.703	4.953	8.792
	like 4
227584_at	Neuron	NAV1	10.236	10.828	8.45	9.758	9.512
	navigator 1
227812_at	tumor	TNFRSF19	9.962	9.478	9.706	8.939	11.568
	necrosis
	factor
	receptor
	superfamily,
	member 19
229723_at	T-cell	TAGAP	6.398	6.009	9.043	7.032	8.532
	activation
	GTPase
	activating
	protein
232024_at	GTPasc,	GIMAP2	9.137	9.127	8.794	7.948	9.093
	IMAP family
	member 2
238544_at	Insulin-like	IGF1R	7.023	6.644	6.255	4.359	6.899
	growth factor
	1 receptor
242886_at	Chromosome	C17orf63	9.338	10.004	7.65	7.978	8.744
	17 open
	reading frame
	63
242986_at	Neuron	NAV1	8.777	8.689	8.154	6.863	8.461
	navigator 1
34210_at	CD52 antigen	CD52	9.102	9.324	10.652	10.24	10.103
	(CAMPATH-
	1 antigen)
	Probe	Patient Identity Number
	Set	19	23	26	27	38	8	67
	1555759_a_at	3.656	4.159	4.664	5.256	5.411	3.034	3.11
	1555834_at	2.398	2.463	2.401	2.4	2.4	5.041	2.40
	1558290_a_at	8.46	9.384	9.409	8.504	8.57	10.616	9.90
	1569942_at	2.198	3.972	3.61	3.392	2.944	5.832	4.38
	204661_at	6.144	8.556	8.487	11.34	10.289	4.082	8.69
	205890_s_at	8.088	9.801	12.384	10.657	10.131	3.178	9.54
	206118_at	5.775	6.731	5.845	8.349	6.709	2.383	3.09
	206666_at	7.564	8.532	8.921	8.337	9.328	2.305	6.371
	207072_at	2.264	2.512	2.239	3.2	4.126	2.222	2.23
	207651_at	8.037	8.578	10.668	10.834	9.404	3.046	6.32
	209606_at	7.366	7.301	7.101	10.455	7.959	2.232	7.231
	209949_at	6.643	7.499	6.281	6.48	7.213	3.405	7.449
	210038_at	4.108	5.51	5.272	8.218	4.73	2.179	2.301
	210629_x_at	6.69	7.323	6.834	7.058	8.828	3.779	7.287
	210972_x_at	7.331	8.326	9.727	11.544	8.3	4.292	6.411
	211144_x_at	2.689	6.279	7.941	7.365	6.31	2.189	2.64
	211796_s_at	6.456	8.211	9.022	11.111	8.316	2.293	5.74
	212671_s_at	9.39	9.435	10.008	10.974	10.757	2.679	7.61
	213193_x_at	5.828	7.936	8.266	11.152	7.722	2.83	5.47
	213539_at	6.635	8.381	9.075	10.519	8.841	2.311	6.07
	213560_at	7.236	7.105	6.776	7.114	6.774	3.402	7.12
	216261_at	2.553	2.609	4.561	2.622	2.557	6.05	2.60
	217147_s_at	7.56	6.512	7.612	9.246	8.077	2.281	3.00
	217478_s_at	9.475	10.475	9.998	11.266	10.161	7.109	9.33
	218950_at	5.891	7.35	5.522	5.804	6.245	8.04	8.20
	220330_s_at	6.458	7.429	8.583	8.421	7.405	2.325	6.71
	222934_s_at	6.678	6.941	4.589	4.731	5.877	3.019	7.66
	223827_at	2.8	2.854	2.977	2.796	3.43	4.669	2.99
	224771_at	4.678	6.467	6.537	3.882	5.375	6.798	5.73
	224772_at	8.214	8.963	9.472	7.529	7.742	9.418	8.41
	224773_at	5.668	6.94	7.344	4.953	7.035	7.352	6.47
	224774_s_at	3.907	6.432	6.166	5.262	5.989	6.48	5.91
	227145_at	7.205	9.531	9.214	9.691	3.702	11.838	8.60
	227584_at	8.8	10.254	10.798	8.769	9.367	10.568	9.56
	227812_at	11.39	9.998	10.948	9.083	10.541	12.176	10.5
	229723_at	5.424	7.084	6.786	10.798	7.081	3.21	5.29
	232024_at	9.673	10.09	9.763	10.696	9.891	6.523	8.29
	238544_at	5.442	6.574	4.359	5.264	3.677	9.187	5.44
	242886_at	5.974	8.959	9.284	6.208	7.589	9.344	7.33
	242986_at	5.136	8.727	8.749	4.83	5.92	8.296	6.75
	34210_at	7.423	9.382	9.344	11.944	10.812	2.854	9.44
	indicates data missing or illegible when filed

TABLE 14
Correlation of Patient Identity Numbers and Clinical Outcome
after MAGE Immunotherapy
	Progressive	Stable	Mixed		Too
	Disease	Disease	Responders	Responders	Early
Patient	160	19	20	38	138
ID	30	77	67	136	91
No.	8	127	2	75	124
	109	65	11	120	150
	60	119	53	27	163
	55	23	59	118	122
	100	145	96
	37		10
	52		26/1
	81
	14
	66
	106
	133
	129
	74
	113
	36
	9
	155
	15
	5
	56
	16
	13
	98
	28
	108
	71
	145
	121
	80
	132
	3
	85
	135
	134
	82
	154
	39

APPENDIX A
R object of class nnet for neural network clinical outcome prediction of patients.
$n
	[1]	489	2	1
$nunits
	[1]	493
$nconn
[1]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[19]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[37]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[55]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[73]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[91]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[109]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[127]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[145]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[163]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[181]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[199]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[217]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[235]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[253]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[271]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[289]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[307]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[325]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[343]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[361]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[379]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[397]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[415]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[433]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[451]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[469]	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
[487]	0	0	0	0	0	490	980	983
$conn
[1]	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
[19]	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35
[37]	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53
[55]	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71
[73]	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89
[91]	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
[109]	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125
[127]	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143
[145]	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161
[163]	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179
[181]	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197
[199]	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215
[217]	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233
[235]	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251
[253]	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269
[271]	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287
[289]	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305
[307]	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323
[325]	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341
[343]	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359
[361]	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377
[379]	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395
[397]	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413
[415]	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431
[433]	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449
[451]	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467
[469]	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485
[487]	486	487	488	489	0	1	2	3	4	5	6	7	8	9	10	11	12	13
[505]	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31
[523]	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49
[541]	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67
[559]	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85
[577]	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103
[595]	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121
[613]	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139
[631]	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157
[649]	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175
[667]	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193
[685]	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211
[703]	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229
[721]	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247
[739]	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265
[757]	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283
[775]	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301
[793]	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319
[811]	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337
[829]	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355
[847]	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373
[865]	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391
[883]	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409
[901]	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427
[919]	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445
[937]	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463
[955]	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481
[973]	482	483	484	485	486	487	488	489	0	490	491
$nsunits
[1]	493
$decay
[1]	0
$entropy
[1]	TRUE
$softmax
[1]	FALSE
$censored
[1]	FALSE
$value
[1]	9.930496e−05
$wts
	[1]	−7.822649e−01	−2.605320e−01	−3.445762e−01	1.193835e+00	7.980130e−01
	[6]	−1.454517e−01	−3.852555e−01	−6.038561e−01	3.628980e−01	1.214178e−01
	[11]	6.302635e−01	1.163077e+00	−1.348927e+00	4.313002e−01	−3.439181e−01
	[16]	1.354545e+00	−5.330816e−01	9.006249e−04	−3.553966e−01	−7.807184e−01
	[21]	−2.792791e−01	−3.170041e−01	−7.652292e−01	7.708915e−02	−8.561736e−01
	[26]	5.142947e−01	−2.484503e−01	9.726332e−01	1.778460e−01	−2.21F09e+00
	[31]	1.533794e−01	−9.241165e−01	−1.623889e+00	−1.673846e−01	−3.942404e−01
	[36]	4.839469e−02	−6.068823e−01	−7.231734e−01	2.776973e−01	9.486888e−01
	[41]	−3.606490e−01	−9.814695e−02	−4.978396e−01	6.743036e−01	−6.715348e−01
	[46]	3.743046e−01	1.127027e+00	2.424162e−01	−2.472467e−01	5.103072e−01
	[51]	−2.249262e−01	9.216276e−02	−7.811338e−02	6.543984e−02	−9.300402e−01
	[56]	−1.723861e−01	8.450912e−01	−1.112637e−01	−1.340432e+00	−4.579130e−01
	[61]	−2.000303e−01	−6.724820e−01	3.185803e−02	−8.755603e−01	−1.432133e−01
	[66]	1.734187e−01	−9.095931e−01	−5.779322e−01	−6.239654e−01	5.350169e−01
	[71]	2.660352e−02	7.575969e−01	−5.857182e−01	7.047356e−01	2.619782e−01
	[76]	7.365027e−02	1.085127e+00	−6.649458e−01	1.526824e−02	9.521713e−01
	[81]	2.953514e−01	−5.496499e−02	−7.349885e−01	4.766398e−01	−4.030412e−01
	[86]	8.509923e−01	−2.896527e−02	−4.922158e−02	−1.075633e+00	2.852051e−01
	[91]	−2.040135e−01	7.087471e−01	−7.626716e−01	4.932172e−02	−1.068290e+00
	[96]	4.525142e−01	−3.426858e−01	−5.564159e−01	4.206087e−01	3.702788e−01
	[101]	−8.482293e−01	2.445519e−01	−2.423795e−01	−7.502546e−01	−2.448160e−01
	[106]	−1.029814e−01	−4.534969e−01	−5.680071e−01	−2.278669e−01	4.914741e−01
	[111]	−2.408882e−02	−1.122049e+00	1.637105e+00	−8.674111e−01	−3.993925e−01
	[116]	6.766219e−01	−2.590604e−01	−1.128037e−01	−5.454970e−01	3.117549e−01
	[121]	6.807225e−01	1.767702e+00	1.749150e+00	1.576723e+00	1.000372e+00
	[126]	−3.135498e−01	−3.461115e−01	−1.577623e−01	−3.688724e−03	−5.169024e−01
	[131]	5.209675e−01	6.239938e−01	−6.562843e−01	3.318594e−01	1.073695e+00
	[136]	3.852917e−01	7.445331e−01	6.147421e−01	3.486045e−02	2.328786e−01
	[141]	5.865109e−01	8.789772e−01	2.735659e−01	2.179924e−01	6.546454e−01
	[146]	−7.425786e−02	2.332181e−01	2.026860e−02	1.920527e+00	−2.199749e−01
	[151]	−2.861057e−01	−6.113327e−01	−7.327236e−01	7.630948e−01	−6.725150e−01
	[156]	8.195715e−01	1.354855e−01	7.557001e−01	−6.311882e−01	4.028033e−01
	[161]	−1.095942e−01	2.675720e−02	9.191105e−02	−5.412179e−01	−4.676564e−01
	[166]	−7.538073e−02	−8.129017e−01	−4.018241e−01	−2.996730e−01	−5.965576e−01
	[171]	9.892726e−01	5.105776e−01	1.052146e+00	−2.957608e−01	−4.917327e−01
	[176]	2.512329e−01	−1.016831e−01	1.099494e−02	−6.844977e−01	5.180294e−01
	[181]	5.463099e−02	−5.062577e−01	5.281003e−01	−5.333424e−01	9.727653e−01
	[186]	−8.865765e−01	5.137428e−01	−1.480626e−01	−1.719326e−01	7.033034e−01
	[191]	5.484301e−01	4.860635e−01	−4.432808e−01	6.295423e−01	6.296338e−01
	[196]	3.257622e−01	5.230624e−01	3.651660e−01	7.889078e−01	−1.381056e−02
	[201]	1.092450e−01	9.362120e−01	−9.812814e−02	5.535681e−01	1.927306e−01
	[206]	4.132113e−01	2.483396e−01	−4.509187e−01	−5.662541e−01	6.316726e−01
	[211]	−1.081482e+00	−2.642237e−01	5.756106e−01	7.014808e−01	8.240274e−02
	[216]	1.157531e−01	2.011787e−01	6.522527e−01	1.072262e−01	7.789481e−01
	[221]	−3.298577e−02	−2.177002e+00	−5.493206e−01	−3.840635e−01	−5.162878e−01
	[226]	−3.685617e−01	2.763670e−01	−4.768905e−01	2.604606e−01	3.470977e−01
	[231]	1.882645e−01	−1.529664e−01	−1.141422e+00	−1.192761e+00	9.653415e−01
	[236]	−5.616165e−02	7.073548e−01	1.663138e−01	−1.724516e−02	5.466189e−01
	[241]	8.215863e−02	−2.863819e−01	−7.682638e−01	6.907757e−01	2.953517e−01
	[246]	−8.597825e−02	−1.237122e−01	−1.141088e−00	7.686872e−01	1.278818e−01
	[251]	1.363887e−01	2.012764e−01	−2.660433e−01	−2.356637e−01	−1.108908e+00
	[256]	4.767741e−01	−3.796921e−01	−8.998346e−01	4.556543e−01	−1.754178e−01
	[261]	1.102156e+00	−6.089921e−01	4.790648e−01	−1.378465e+00	−7.794537e−01
	[266]	−4.038758e−01	1.344525e+00	−4.043755e−01	−4.395272e−01	6.362795e−01
	[271]	1.834397e−01	8.358359e−03	−3.857196e−01	7.268706e−01	−7.168161e−01
	[276]	4.306795e−01	7.706614e−01	6.513772e−02	−2.245757e−01	−1.063308e+00
	[281]	1.798277e−01	−1.752740e−01	2.278172e−01	2.965010e−01	5.452244e−01
	[286]	1.543681e−01	1.661905e−01	−2.996078e−01	1.187087e−01	1.133628e−01
	[291]	9.718658e−01	4.520898e−01	9.167133e−01	−3.433412e−01	3.579116e−01
	[296]	6.023363e−03	2.989546e−02	−4.734359e−01	5.843214e−01	−3.799736e−01
	[301]	5.842987e−01	1.525014e+00	1.118956e−01	4.651440e−01	5.483678e−01
	[306]	−3.747111e−02	−6.338612e−01	1.383897e−01	1.423111e−01	8.514850e−01
	[311]	6.421267e−01	1.666450e−01	−2.689546e−01	−1.752850e−01	6.560046e−02
	[316]	3.302397e−01	5.434177e−02	7.720145e−01	−2.185973e−01	−1.400281e−01
	[321]	−3.805316e−01	5.617241e−01	−7.327657e−01	−9.889267e−01	−1.877597e−01
	[326]	−4.126207e−01	−1.432952e+00	−2.641545e−01	−1.279892e−01	3.308045e−01
	[331]	2.947318e−01	3.080860e−01	4.368988e−01	−7.796344e−01	6.472218e−01
	[336]	3.216706e−01	3.220898e−01	−7.642426e−01	7.559186e−01	−7.224366e−02
	[341]	8.057934e−01	−8.280142e−01	5.811389e−01	8.082749e−01	−1.739542e−01
	[346]	1.878581e−01	−9.195490e−01	4.122718e−01	4.458733e−01	−5.164353e−01
	[351]	−2.987246e−01	−2.953580e−02	−1.027130e−00	1.380701e+00	1.015581e+00
	[356]	7.511154e−01	−1.295990e−01	−1.289274e−01	2.716158e−01	4.902457e−01
	[361]	−8.143006e−01	2.466899e−01	−7.051082e−01	−1.421216e+00	7.574016e−01
	[366]	1.062493e+00	3.120192e−01	−8.555016e−01	−2.710965e−01	5.270817e−01
	[371]	−2.772449e−02	−1.164226e+00	−5.875827e−01	4.967017e−01	−9.446788e−02
	[376]	4.286175e−01	6.268223e−01	−3.435110e−01	1.025191e+00	−6.801600e−01
	[381]	−3.224292e−02	−3.193044e−01	−3.950073e−01	−6.430585e−01	−4.542940e−01
	[386]	−8.485502e−01	7.760473e−01	3.202145e−01	6.633763e−01	−5.801942e−01
	[391]	1.306814e−01	1.299666e−01	3.046116e−01	−1.684422e−01	−6.295904e−01
	[396]	1.565646e−01	−1.529663e−01	−1.148021e−02	−4.255510e−01	−4.986614e−01
	[401]	−2.557943e−01	−6.037794e−01	−1.125332e−01	7.177677e−01	−5.615997e−01
	[406]	3.587169e−02	8.140494e−01	−6.603336e−01	5.388208e−02	2.157824e−01
	[411]	8.007642e−01	1.088418e+00	7.859298e−01	−5.836605e−01	−3.394254e−01
	[416]	−7.943000e−01	5.089051e−01	2.668172e−01	−9.942403e−01	−6.977250e−01
	[421]	5.418000e−02	9.294052e−01	−5.541002e−01	−2.663888e−01	1.582470e−01
	[426]	−9.034341e−01	1.796377e−01	−1.666522e+00	−6.447704e−01	−1.460522e−01
	[431]	4.064656e−01	4.535141e−01	−8.493838e−02	4.404440e−01	−6.813737e−01
	[436]	4.246934e−01	4.738893e−01	5.388799e−01	5.893005e−02	8.046329e−01
	[441]	−1.312353e−01	6.065425e−01	4.344549e−01	−1.432887e−01	6.266481e−01
	[446]	2.491106e−01	5.628406e−01	7.156338e−01	−3.341744e−01	−7.083861e−01
	[451]	−3.816457e−01	7.333444e−01	8.614763e−01	1.158857e+00	4.593186e−01
	[456]	−1.059777e−01	−2.820036e−01	5.517071e−01	−3.863232e−01	−1.729483e+00
	[461]	−1.887161e−01	3.810323e−01	7.033161e−02	4.999075e−01	1.066108e−01
	[466]	−1.682395e−01	2.324000e−02	−1.079890e−01	−9.324107e−02	−1.789810e−02
	[471]	−1.151141e+00	1.302142e−01	−4.902189e−01	−9.327821e−03	2.853960e−02
	[476]	3.681996e−01	−5.675777e−02	−1.121354e+00	9.055091e−01	−3.077752e−01
	[481]	1.150414e−01	2.903319e−01	−1.978837e−01	−2.513171e−01	−6.335767e−01
	[486]	1.883908e−01	7.978107e−01	5.193154e−01	4.594379e−01	−5.630128e−01
	[491]	−2.558691e−01	1.399098e−01	2.716841e−01	−1.029870e+00	−3.337377e−01
	[496]	−1.639137e−01	1.084488e+00	−2.009724e−01	2.988744e−02	−9.373952e−03
	[501]	7.188562e−02	1.568801e−01	1.110666e+00	−6.429716e−01	−9.851071e−02
	[506]	−3.954610e−01	6.241091e−01	4.466790e−01	−3.418489e−01	1.129400e+00
	[511]	7.873880e−02	3.685607e−01	1.312878e+00	3.921632e−01	−9.862630e−01
	[516]	7.303611e−01	8.164471e−01	−7.706864e−01	1.701961e−01	9.772512e−01
	[521]	3.345849e−01	5.069341e−01	9.739133e−01	1.608824e+00	1.145627e+00
	[526]	5.074447e−01	2.034436e−01	1.470176e−01	−1.600484e−01	−2.150473e−01
	[531]	1.377926e−01	6.227566e−01	4.094106e−01	4.259897e−01	1.865411e−01
	[536]	−4.727419e−01	−2.291728e−01	1.015483e+00	1.073489e+00	−2.136211e−01
	[541]	−8.307180e−01	−2.981026e−01	1.194316e+00	−1.318526e+00	1.129897e+00
	[546]	−6.792031e−02	−1.136511e−01	1.129797e+00	1.283430e+00	1.225369e+00
	[551]	−4.935841e−01	−5.978041e−01	6.994883e−01	−5.000395e−01	−5.917541e−02
	[556]	8.643770e−01	−8.313903e−02	−7.645437e−01	4.585311e−01	2.760396e−01
	[561]	−9.048995e−01	2.270971e−01	−5.491731e−01	1.485625e−01	5.379235e−01
	[566]	2.400513e−01	−1.398254e+00	2.149663e−01	−9.872386e−01	−2.349650e−01
	[571]	−1.134452e+00	1.084613e+00	−5.258544e−01	−2.309454e−01	−1.118639e+00
	[576]	−6.754324e−01	−1.105271e+00	−3.729548e−01	4.167448e−01	−6.998005e−02
	[581]	−6.067353e−01	−8.627442e−01	−2.747273e−01	−6.861895e−01	−8.294093e−01
	[586]	−7.157550e−01	−1.543888e+00	8.807905e−01	1.449671e−01	6.694883e−01
	[591]	8.768986e−01	−3.354555e−01	−3.288934e−01	−6.713428e−02	−8.535772e−01
	[596]	3.177712e−01	2.302577e−01	6.388607e−01	−8.468490e−01	−6.823332e−01
	[601]	−4.824133e−01	−1.152830e+00	−1.296166e−01	3.876039e−01	−1.264702e−01
	[606]	−6.234923e−01	7.556986e−01	−1.079503e+00	7.462365e−01	−7.156638e−01
	[611]	−6.597890e−01	−9.319472e−01	7.275191e−01	−1.206812e+00	1.462996e−01
	[616]	3.163475e−01	−4.897914e−01	9.590103e−01	4.964603e−01	−2.036444e−01
	[621]	5.536274e−01	−8.859709e−01	4.360544e−01	−1.174303e+00	−7.004479e−01
	[626]	−9.104478e−02	2.520933e−01	1.406452e−01	−5.811733e−01	1.005106e+00
	[631]	−8.395171e−01	2.836866e−01	−6.667517e−01	7.589487e−01	9.250607e−01
	[636]	2.226882e−01	−9.617627e−01	7.764753e−01	−2.592188e−01	−3.870735e−01
	[641]	3.652488e−01	−2.089410e+00	−8.639070e−01	6.041561e−02	−1.249116e−01
	[646]	−1.589578e−01	−9.288991e−01	−1.438925e−01	−1.584532e−01	4.032568e−01
	[651]	−4.542904e−01	4.196369e−01	3.925464e−02	−7.026149e−01	−4.894067e−01
	[656]	1.472926e−01	5.125774e−01	−7.921361e−01	−6.512886e−01	6.268859e−01
	[661]	−8.082803e−01	−1.230153e−01	−1.259874e+00	−7.360178e−01	−4.800681e−01
	[666]	−9.807421e−02	3.650259e−01	−1.110299e+00	−6.785503e−02	8.200076e−02
	[671]	−7.377264e−01	9.628769e−01	−6.621068e−01	−1.064977e+00	1.635347e−01
	[676]	3.436851e−01	−4.931667e−01	1.110185e+00	−5.205865e−01	6.614455e−01
	[681]	−2.341954e−01	−3.812965e−01	−3.107048e−01	−5.694353e−01	2.589693e−01
	[686]	−5.235213e−01	1.573854e−01	−4.416297e−01	2.271200e−01	−9.274423e−01
	[691]	2.991815e−01	−2.355672e−01	−6.642878e−01	−2.300048e−01	3.206771e−01
	[696]	−2.170961e+00	−5.213502e−01	−1.148505e+00	−6.783888e−01	−4.686891e−04
	[701]	7.177564e−01	−3.765768e−02	−1.415048e−02	−2.595464e−01	2.996030e−01
	[706]	−1.233281e−01	−3.676282e−01	−3.679718e−01	−9.210808e−01	4.052164e−01
	[711]	4.585852e−02	1.312361e+00	5.048614e−01	−1.809305e+00	−1.721751e+00
	[716]	−1.669053e+00	1.401519e−01	−8.288580e−01	1.470533e−01	−1.315543e+00
	[721]	6.430333e−02	−7.649410e−01	9.157078e−01	3.640731e−01	−1.306945e−02
	[726]	9.203552e−02	−6.416202e−01	−6.434372e−01	−7.309035e−01	6.760630e−01
	[731]	5.793554e−01	3.266417e−01	−5.467879e−01	1.875603e−02	6.823768e−01
	[736]	6.605321e−01	−2.192790e−01	6.458484e−01	1.256230e−01	−3.446176e−01
	[741]	−7.349580e−01	−3.794139e−01	−5.742886e−01	−7.069700e−01	2.605697e−01
	[746]	−2.759157e+00	−3.153237e−01	6.614816e−01	−1.399808e+00	2.537040e−01
	[751]	−2.566458e−01	−9.300803e−01	−3.258002e−01	1.847266e+00	−8.318504e−01
	[756]	8.032399e−01	−7.391342e−02	−1.458280e−01	1.475066e−01	−2.016509e−01
	[761]	−1.116992e+00	2.565951e−01	−1.417568e+00	−4.075312e−01	−4.624426e−01
	[766]	−3.892320e−01	9.233114e−02	8.039994e−01	1.708351e−01	3.140843e−01
	[771]	1.558756e−01	4.926293e−01	−1.257969e+00	−7.845624e−01	1.556651e−01
	[776]	−1.152795e+00	−1.463677e+00	−8.108185e−01	−8.317870e−02	−1.456545e−01
	[781]	6.954507e−01	−8.047871e−01	−8.898140e−01	−1.254371e+00	−6.563698e−01
	[786]	3.967049e−01	9.335104e−01	1.299258e−02	−2.453240e−01	−5.841076e−01
	[791]	−1.658272e−01	−1.326827e+00	8.844022e−01	−6.606743e−01	4.137678e−01
	[796]	7.360620e−02	−1.241175e+00	1.066117e+00	−1.086576e−01	7.812635e−01
	[801]	−5.793264e−01	3.664636e−02	5.461605e−01	−1.468411e−01	−1.200992e+00
	[806]	7.664790e−02	−9.648972e−01	8.464096e−02	8.781079e−01	−1.329100e−01
	[811]	−3.140853e−01	−3.603208e−01	5.330240e−01	9.776989e−01	1.754023e−01
	[816]	−3.932540e−02	1.381857e+00	4.967358e−01	2.445305e−01	2.033007e−02
	[821]	−1.660898e+00	−3.826148e−01	−1.350548e−01	2.055229e−01	−4.826541e−01
	[826]	−3.437897e−02	−1.131522e+00	−2.924096e−01	1.078663e+00	−3.618922e−01
	[831]	−3.795694e−01	7.062471e−01	1.818627e−01	3.360420e−02	−5.509515e−01
	[836]	2.820342e−01	−5.169129e−01	−7.298595e−01	6.831575e−02	−4.718518e−01
	[841]	−1.177961e−01	3.261549e−01	9.243626e−01	−9.539287e−01	−8.574709e−01
	[846]	8.404623e−01	−1.477904e+00	7.161732e−01	−7.213226e−02	−1.072695e+00
	[851]	1.099245e+00	3.907082e−02	4.707593e−01	−1.037259e+00	−6.337726e−01
	[856]	−6.489972e−01	−8.105587e−01	−1.132535e−01	5.618367e−01	1.120736e+00
	[861]	−1.589420e−01	−4.736779e−01	−3.492589e−01	−5.292510e−01	7.552729e−02
	[866]	6.245302e−01	−1.599877e+00	1.961020e+00	−5.986310e−01	7.907619e−01
	[871]	9.258619e−01	4.602164e−01	−4.456243e−01	2.256970e−01	1.180578e+00
	[876]	−2.202471e−01	−1.595068e+00	−7.650998e−01	1.068712e−01	3.886734e−03
	[881]	3.158598e−02	−7.733971e−01	1.905452e−01	−6.009153e−01	2.211837e−01
	[886]	−5.134809e−02	−8.393086e−01	−1.087550e+00	−3.173469e−01	−1.101492e+00
	[891]	4.972408e−01	1.799967e−01	−2.447001e−01	−8.741257e−01	2.992654e−01
	[896]	−9.245988e−01	9.044085e−02	9.133224e−01	7.446155e−01	−7.193918e−01
	[901]	9.205514e−02	−1.402019e+00	4.976776e−01	−6.959568e−01	4.945441e−01
	[906]	1.286614e−01	−8.543565e−01	−3.603456e−02	4.664471e−01	−7.580873e−03
	[911]	−3.060679e−01	−6.700308e−01	4.941296e−04	−8.978372e−01	−6.954622e−01
	[916]	−3.736479e−01	1.754756e−02	1.567201e+00	8.573695e−01	3.966870e−01
	[921]	−2.215584e−02	−1.169949e−01	4.257213e−01	−2.346597e−01	7.421774e−01
	[926]	−5.966420e−01	5.751260e−02	−2.472787e−01	2.334021e−01	1.300946e+00
	[931]	2.341594e−01	1.049020e+00	−3.269379e−01	−1.269805e−01	−6.880527e−01
	[936]	−3.229197e−01	7.076868e−01	−3.403887e−01	1.676770e−01	−7.620830e−02
	[941]	3.558033e−01	1.459493e−01	−6.244181e−01	1.770295e−01	−1.216517e−01
	[946]	7.426668e−01	−1.385593e−01	−6.277839e−01	−1.879113e−01	9.488544e−02
	[951]	2.351063e−01	1.073347e+00	−4.874189e−01	3.801474e−01	−6.690750e−01
	[956]	−6.047573e−01	−3.134005e−01	−6.000130e−01	−3.197655e−01	6.631834e−01
	[961]	−6.356578e−01	−5.904780e−01	1.097918e+00	6.007569e−01	−2.505695e+00
	[966]	−5.697962e−01	5.674896e−01	4.245279e−01	−1.060281e−01	−1.130024e−01
	[971]	1.595858e+00	1.516974e−01	−3.702457e−02	−1.700967e−01	−3.641777e−01
	[976]	−1.604025e−01	−1.447675e+00	−1.008405e+00	3.365701e−01	2.348416e−01
	[981]	−1.189562e+01	2.427842e+01	−2.275821e+01
	[,1]
$fitted.values
	1	9.999958e−01
	2	0.000000e+00
	3	0.000000e+00
	4	0.000000e+00
	5	0.000000e+00
	6	9.999958e−01
	7	9.999958e−01
	8	9.999958e−01
	9	9.999958e−01
	10	9.999958e−01
	11	9.999958e−01
	12	0.000000e+00
	13	9.999958e−01
	14	0.000000e+00
	15	0.000000e+00
	16	0.000000e+00
	17	9.999958e−01
	18	6.820198e−06
	19	6.825022e−06
	20	3.118923e−05
	21	0.000000e+00
	22	0.000000e+00
	23	9.999958e−01
	24	0.000000e+00
	25	0.000000e+00
	26	9.999958e−01
	27	0.000000e+00
	28	9.999958e−01
	29	9.999958e−01
	30	0.000000e+00
	31	0.000000e+00
$residuals
	1	4.189989e−06
	2	0.000000e+00
	3	0.000000e+00
	4	0.000000e+00
	5	0.000000e+00
	6	4.189989e−06
	7	4.189989e−06
	8	4.189989e−06
	9	4.189989e−06
	10	4.189989e−06
	11	4.189989e−06
	12	0.000000e+00
	13	4.189989e−06
	14	0.000000e+00
	15	0.000000e+00
	16	0.000000e+00
	17	4.189989e−06
	18	−6.820198e−06
	19	−6.825022e−06
	20	−3.118923e−05
	21	0.000000e+00
	22	0.000000e+00
	23	4.189989e−06
	24	0.000000e+00
	25	0.000000e+00
	26	4.189989e−06
	27	0.000000e+00
	28	4.189989e−06
	29	4.189989e−06
	30	0.000000e+00
	31	0.000000e+00
$lev
[1]	“NR” “R”
	$call
	nnet.formula(formula = f ~ .,
	data = data, MaxNWts = 10000,
	maxit = 250, size = 2, skip = FALSE,
	rang = 0.7, decay = 0, Hess = FALSE,
	trace = TRUE, abstol = 1e−04,
	reltol = 1e−08, metric =
	“euclidean”, subset = training)

APPENDIX B
R object of class Ida for linear discriminant analysis clinical outcome
prediction of patients.
NR            R
$prior
0.5862069     0.4137931
$counts
17            12
$scaling
              LD1
X1405_i_at    5.944209e−03
X1552497_a_at −1.489159e−03
X1552612_at   1.928010e−03
X1552613_s_at −3.948620e−03
X1553102_a_at 2.035336e−02
X1553132_a_at −1.048751e−02
X1553313_s_at −3.034153e−02
X1553906_s_at −1.834813e−02
X1554240_a_at 1.365655e−02
X1554966_a_at 3.759930e−03
X1555229_a_at 8.797787e−02
X1555630_a_at −2.791031e−02
X1555756_a_at 1.654466e−02
X1555759_a_at 1.036814e−03
X1555812_a_at 1.278876e−02
X1555852_at   −3.512472e−03
X1556185_a_at 3.025315e−02
X1556579_s_at 4.497852e−02
X1557116_at   4.611121e−03
X1557222_at   2.410949e−02
X1558034_s_at 2.790575e−02
X1558290_a_at −1.523617e−02
X1558586_at   −4.151460e−02
X1558972_s_at 5.561221e−04
X1559263_s_at 7.463183e−03
X1559425_at   1.864440e−03
X1559584_a_at −5.820026e−03
X1562031_at   9.246741e−03
X1563461_at   −2.064194e−02
X1563473_at   4.011858e−03
X1565602_at   −4.884858e−02
X1568736_s_at −2.773483e−02
X1568822_at   2.099681e−03
X1569942_at   6.739294e−03
X200612_s_at  −6.365853e−02
X200904_at    6.387716e−03
X200905_x_at  5.294827e−03
X200953_s_at  −8.671791e−03
X201010_s_at  4.474642e−03
X201137_s_at  −1.506315e−02
X201220_x_at  −2.667959e−02
X2071236_s_at 1.404961e−02
X201425_at    1.554231e−02
X201474_s_at  −6.107372e−03
X201487_at    2.472156e−02
X201497_x_at  7.254710e−04
X201502_s_at  5.696526e−03
X201531_at    1.148431e−02
X201566_x_at  1.794849e−02
X201720_s_at  1.570380e−03
X201721_s_at  −9.613928e−03
X201804_x_at  −2.053567e−02
X201859_at    −1.376084e−04
X201939_at    −3.369784e−02
X202207_at    −1.196899e−02
X202255_s_at  −4.340999e−02
X202269_x_at  −1.833048e−02
X202270_at    −8.686638e−03
X202368_s_at  −2.233262e−02
X202369_s_at  −1.278489e−02
X202391_at    −5.586253e−03
X202510_s_at  1.200980e−02
X202625_at    1.449689e−02
X202643_s_at  2.057522e−02
X202644_s_at  2.044322e−02
X202687_s_at  1.939420e−03
X202688_at    8.690145e−04
X202948_at    −1.822099e−02
X202957_at    −1.143226e−02
X203413_at    −3.803468e−02
X203416_at    −1.189864e−02
X203471_s_at  1.553784e−02
X203508_at    9.486448e−03
X203523_at    5.575011e−03
X203547_at    9.218142e−03
X203665_at    3.487226e−02
X203741_s_at  2.161880e−02
X203761_at    8.568780e−03
X203812_at    4.104549e−02
X203868_s_at  −3.218808e−02
X203915_at    1.356669e−02
X203932_at    −1.767768e−03
X204057_at    1.199848e−02
X204070_at    −8.013273e−04
X204116_at    6.190984e−03
X204118_at    1.625516e−02
X204135_at    4.612466e−03
X204204_at    3.177067e−02
X204220_at    −6.573462e−03
X204222_s_at  8.871953e−03
X204224_s_at  −4.997460e−03
X204233_s_at  −1.586361e−02
X204236_at    5.467904e−03
X204249_s_at  −1.313280e−02
X204411_at    6.579659e−03
X204438_at    2.031749e−02
X204502_at    6.392044e−03
X204512_at    −1.534429e−05
X204533_at    2.287973e−02
X204613_at    5.458783e−03
X204628_s_at  −3.028829e−02
X204642_at    −3.867430e−03
X204655_at    −5.765680e−03
X204661_at    2.636612e−02
X204670_x_at  −1.182992e−02
X204687_at    3.953856e−02
X204724_s_at  −1.982230e−02
X204774_at    −1.596679e−02
X204778_x_at  −2.436425e−02
X204834_at    4.664052e−02
X204846_at    2.224653e−02
X204894_s_at  4.442071e−03
X204897_at    −2.250415e−02
X204912_at    2.155492e−03
X204923_at    −9.860185e−03
X205027_s_at  3.406286e−03
X205039_s_at  1.453129e−03
X205081_at    2.008363e−02
X205159_at    4.374158e−03
X205225_at    −8.687131e−03
X205226_at    −4.151219e−02
X205251_at    2.071759e−02
X205285_s_at  9.469306e−03
X205392_s_at  1.236199e−02
X205403_at    1.344662e−02
X205419_at    −6.256056e−03
X205421_at    1.955389e−02
X205440_s_at  2.903482e−02
X205484_at    −1.026029e−02
X205488_at    2.109358e−02
X205559_s_at  −2.837597e−02
X205569_at    1.407987e−02
X205624_at    2.531892e−02
X205685_at    4.266186e−02
X205696_s_at  −7.143024e−03
X205758_at    9.290501e−03
X205786_s_at  −7.188176e−03
X205831_at    8.970703e−03
X205841_at    −1.024458e−02
X205844_at    2.406034e−02
X205890_s_at  1.526584e−02
X205987_at    5.099598e−03
X206082_at    −2.365415e−02
X206099_at    4.205302e−02
X206118_at    1.153657e−02
X206134_at    −4.474477e−03
X206170_at    −1.785743e−02
X206204_at    1.969866e−02
X206295_at    1.528790e−02
X206385_s_at  −1.655446e−02
X206407_s_at  3.592881e−02
X206545_at    1.272019e−02
X206571_s_at  −3.009919e−02
X206637_at    7.423640e−03
X206666_at    1.204182e−02
X206687_s_at  −1.762981e−02
X206715_at    1.116688e−02
X206804_at    1.234660e−02
X206898_at    −3.907050e−02
X206978_at    −4.979548e−03
X207076_s_at  1.863378e−02
X207238_s_at  −5.780355e−03
X207277_at    2.125419e−02
X207458_at    2.748393e−02
X207540_s_at  −1.283397e−02
X207574_s_at  −2.431727e−03
X207651_at    2.066787e−02
X207655_s_at  5.405012e−04
X207677_s_at  2.230816e−02
X207843_x_at  3.315503e−02
X207861_at    4.377097e−02
X207977_s_at  1.145723e−02
X207992_s_at  6.265461e−03
X208296_x_at  −2.224775e−03
X208306_x_at  −5.132684e−03
X208335_s_at  3.329359e−03
X208450_at    3.811124e−02
X208747_s_at  −7.912263e−03
X208885_at    −1.288364e−02
X208894_at    7.896947e−03
X208981_at    −1.015968e−02
X208983_s_at  −3.056594e−02
X209083_at    4.483265e−04
X209138_x_at  7.183442e−03
X209193_at    1.740572e−02
X209195_s_at  −2.237887e−02
X209202_s_at  8.930806e−03
X209312_x_at  −5.814581e−03
X209480_at    1.848455e−02
X209542_x_at  4.971766e−03
X209603_at    3.004576e−02
X209606_at    5.064024e−03
X209612_s_at  2.595736e−02
X209613_s_at  1.417618e−02
X209670_at    −1.636542e−02
X209671_x_at  2.518135e−03
X209685_s_at  −9.113030e−03
X209687_at    −1.842487e−02
X209710_at    5.230642e−03
X209734_at    −5.196811e−03
X209774_x_at  2.951233e−02
X209795_at    −6.624457e−03
X209813_x_at  2.371992e−02
X209899_s_at  7.998200e−04
X209924_at    3.375216e−02
X209949_at    3.781916e−02
X209970_x_at  2.564418e−02
X210038_at    6.929319e−03
X210072_at    1.293525e−02
X210251_s_at  1.756383e−02
X210260_s_at  −1.082042e−03
X210319_x_at  −1.726655e−02
X210375_at    2.483769e−03
X210554_s_at  −2.077789e−02
X210835_s_at  −7.455480e−03
X210915_x_at  3.172003e−03
X210972_x_at  6.080266e−03
X210982_s_at  9.635875e−03
X211066_x_at  −1.164103e−02
X211144_x_at  4.992137e−02
X211200_s_at  −4.031722e−02
X211339_s_at  −8.002311e−03
X211366_x_at  3.593000e−02
X211367_s_at  6.231728e−02
X211368_s_at  2.045696e−02
X211654_x_at  2.874123e−02
X211742_s_at  −1.282275e−02
X211796_s_at  6.744624e−03
X211902_x_at  1.350420e−03
X211990_at    −1.552756e−02
X211991_s_at  −2.759634e−03
X212067_s_at  −9.461685e−03
X212233_at    8.400376e−03
X212538_at    7.226797e−03
X212587_s_at  −5.979921e−03
X212588_at    −7.824565e−04
X212592_at    3.516261e−03
X212657_s_at  2.978857e−02
X212671_s_at  −2.602076e−02
X212713_at    3.233683e−02
X212763_at    −3.275778e−03
X212886_at    3.683799e−03
X212977_at    9.877644e−03
X212998_x_at  5.090511e−03
X212999_x_at  3.695828e−02
X213007_at    −3.352605e−02
X213008_at    −4.189798e−03
X213068_at    2.658290e−02
X213095_x_at  1.421934e−02
X213193_x_at  2.914348e−03
X213475_s_at  −4.914118e−04
X213537_at    −8.357035e−03
X213539_at    7.487953e−03
X213560_at    −4.020759e−03
X213566_at    5.845149e−03
X213603_s_at  −5.088264e−03
X213618_at    1.305106e−02
X213652_at    8.548287e−03
X213819_s_at  8.196495e−03
X213831_at    1.631173e−02
X213888_s_at  8.134177e−05
X213975_s_at  −2.095655e−02
X214023_x_at  −2.237865e−02
X214038_at    2.389479e−02
X214181_x_at  −8.976012e−03
X214450_at    1.788553e−02
X214470_at    2.213217e−02
X214617_at    1.563590e−02
X214669_x_at  1.972879e−03
X214677_x_at  3.809399e−03
X224719_at    1.439531e−03
X215051_x_at  1.072135e−02
X215121_x_at  4.118073e−03
X215193_x_at  2.105556e−04
X215223_s_at  1.530709e−02
X215379_x_at  7.064224e−03
X215561_s_at  −2.385977e−02
X215806_x_at  1.767858e−02
X216155_at    −3.705145e−02
X216191_s_at  4.747897e−02
X216194_s_at  −4.006836e−02
X216714_at    2.405266e−02
X216841_s_at  8.716417e−03
X216920_s_at  3.911396e−03
X217028_at    5.128469e−03
X217138_x_at  9.357220e−03
X217143_s_at  7.546655e−03
X217147_s_at  −1.958024e−02
X217478_s_at  −1.327997e−02
X217525_at    −1.717356e−02
X217629_at    7.854937e−03
X217767_at    −5.238491e−03
X217995_at    −6.809023e−03
X218002_s_at  9.869321e−03
X218035_s_at  1.245016e−03
X218145_at    −3.291834e−02
X218170_at    −7.323517e−03
X218322_s_at  −8.250237e−03
X218499_at    5.140903e−04
X218736_s_at  2.138520e−02
X218739_at    2.714745e−03
X218764_at    −9.158772e−03
X218802_at    5.152377e−02
X218805_at    −2.574003e−03
X218854_at    3.989147e−03
X218899_s_at  −3.411423e−02
X218950_at    −4.336176e−02
X219054_at    4.975575e−03
X219093_at    2.082412e−02
X219213_at    −4.341432e−03
X219243_at    2.233332e−03
X219368_at    −1.134073e−03
X219440_at    2.580567e−02
X219454_at    3.065280e−02
X219505_at    5.933108e−03
X219519_s_at  2.660637e−02
X219525_at    4.320312e−03
X219528_s_at  1.066797e−02
X219631_at    −2.616546e−02
X219666_at    1.182519e−02
X219681_s_at  8.705075e−03
X219710_at    −1.046131e−02
X219737_s_at  −6.473357e−02
X219777_at    −6.023843e−03
X219789_at    8.550214e−03
X219926_at    −8.456673e−03
X219938_s_at  1.596546e−02
X220005_at    6.859902e−03
X220066_at    7.525339e−03
X220330_s_at  3.751801e−03
X220485_s_at  2.962480e−03
X221081_s_at  −4.394394e−03
X221087_s_at  8.161216e−03
X221477_s_at  1.240372e−02
X221651_x_at  1.118009e−02
X221671_x_at  5.247343e−03
X221698_s_at  −1.058842e−02
X221756_at    −1.209965e−02
X221760_at    −1.764419e−02
X222108_at    4.026916e−02
X222142_at    −3.508958e−02
X222484_s_at  −8.096999e−03
X222496_s_at  −4.133924e−03
X222592_s_at  1.511240e−02
X222725_s_at  2.808005e−02
X222780_s_at  −2.679162e−02
X222838_at    4.550716e−03
X222895_s_at  −2.841100e−02
X223044_at    5.255602e−02
X223058_at    9.381819e−03
X223059_s_at  8.539393e−03
X223168_at    −4.973917e−03
X223235_s_at  4.953002e−04
X223280_x_at  6.016285e−03
X223322_at    −1.188607e−02
X223361_at    −5.418802e−03
X223395_at    1.411881e−02
X223484_at    1.743558e−02
X223809_at    2.119400e−02
X223827_at    −1.852331e−02
X223922_x_at  8.293530e−03
X223924_at    −2.212120e−02
X223952_x_at  3.606709e−02
X224356_x_at  4.977366e−03
X224358_s_at  −9.225797e−04
X224451_x_at  −4.781080e−03
X224516_s_at  −1.494258e−02
X224710_at    −2.279989e−02
X224771_at    −1.243246e−02
X224772_at    −4.059490e−02
X224773_at    −7.626004e−03
X224774_s_at  −1.743111e−02
X224795_x_at  5.385788e−03
X224859_at    −1.540871e−02
X224896_s_at  −4.228341e−03
X225502_at    3.460051e−03
X225802_at    −2.887415e−02
X225895_at    4.741893e−03
X226043_at    1.277772e−02
X226068_at    5.224876e−03
X226117_at    2.490399e−02
X226218_at    −1.341873e−02
X226219_at    4.175131e−03
X226303_at    4.358878e−02
X226382_at    6.264514e−04
X226459_at    4.497883e−03
X226625_at    4.213244e−02
X226659_at    −4.064464e−03
X226697_at    −5.986636e−02
X226818_at    2.581249e−02
X226841_at    1.092228e−02
X226865_at    −2.335927e−02
X227035_x_at  8.655280e−03
X227231_at    −1.692593e−02
X227253_at    1.018350e−02
X227265_at    1.360205e−02
X227346_at    −1.295157e−02
X227361_at    −5.811243e−03
X227458_at    1.893847e−02
X227584_at    −2.425646e−02
X227609_at    3.029790e−02
X227640_s_at  −5.262288e−03
X227780_s_at  1.333635e−02
X227791_at    1.583168e−02
X227983_at    −1.027572e−02
X227995_at    −1.414606e−02
X228054_at    −1.428632e−03
X228071_at    −8.103128e−03
X228094_at    9.305227e−03
X228153_at    1.840560e−02
X228339_at    1.115556e−02
X228362_s_at  1.505306e−02
X228372_at    −1.233323e−02
X228376_at    3.005129e−03
X228427_at    1.441232e−02
X228532_at    −1.984789e−02
X228552_s_at  1.488213e−02
X228563_at    5.478160e−03
X228660_x_at  −3.321971e−03
X228776_at    1.735059e−02
X228812_at    2.966052e−02
X228858_at    8.798795e−03
X228869_at    1.576960e−02
X228908_s_at  1.715903e−02
X228964_at    1.578864e−02
X229127_at    2.437139e−02
X229163_at    −1.306446e−03
X229367_s_at  8.285081e−03
X229390_at    9.455414e−03
X229391_s_at  2.152998e−02
X229543_at    1.337527e−02
X229625_at    1.390034e−02
X229723_at    1.284379e−02
X230233_at    6.517225e−03
X230391_at    −1.165179e−02
X230538_at    −4.922326e−02
X230728_at    −3.921071e−02
X231032_at    1.220460e−02
X231262_at    8.401904e−03
X231577_s_at  −4.352510e−03
X231882_at    −1.597680e−02
X231929_at    −7.190517e−03
X232001_at    −2.527809e−02
X232024_at    1.562502e−02
X232234_at    1.979601e−02
X232311_at    −5.811767e−04
X232313_at    3.438576e−02
X232476_at    −1.156007e−02
X232543_x_at  −6.890048e−03
X232617_at    2.120826e−03
X232746_at    −1.032038e−02
X232843_s_at  −1.582714e−03
X233123_at    3.841746e−02
X233562_at    −6.149035e−02
X233955_x_at  −2.411061e−02
X235175_at    −8.822903e−03
X235238_at    −4.455537e−02
X235306_at    −1.163963e−02
X235391_at    9.692727e−03
X235421_at    −7.303012e−04
X235639_at    −3.367098e−02
X235688_s_at  −1.717805e−03
X235804_at    −1.564079e−03
X235831_at    2.675921e−03
X236203_at    −8.187551e−03
X236280_at    6.197497e−03
X236295_s_at  4.606321e−03
X236583_at    2.311931e−03
X236908_at    −2.109408e−02
X238439_at    3.286334e−02
X238488_at    2.932061e−02
X238544_at    1.183049e−03
X239196_at    4.987304e−02
X239237_at    3.319884e−02
X239744_at    −1.276710e−02
X241671_x_at  −6.586756e−03
X241701_at    −8.761918e−03
X242458_at    −1.194306e−02
X242546_at    4.355118e−03
X242874_at    5.607680e−03
X242881_x_at  −6.062508e−03
X242986_at    2.749620e−03
X243099_at    1.186699e−02
X244023_at    −1.018460e−02
X244061_at    1.229564e−03
X32128_at     2.935196e−02
X34210_at     3.776762e−03
X38149_at     4.937711e−04
X64064_at     −3.336735e−03
$lev
[1] “NR” “R”
$svd
[1] 7.995862
$N
[1] 29
$call
lda(formula = f ~ ., data = datatr)

APPENDIX C
R object of class naiveBayes for naïve Bayes clinical outcome
prediction of patients.
$apriori
Y
	NR	R
	17	12
	Y	[,1]	[,2]
tablestables$X1405_i_at
X1405_i_at
	NR	−0.1639258	0.5851902
	R	0.6748740	0.6631486
tables$X1552497_a_at
X1552497_a_at
	NR	−0.3029996	0.6800071
	R	0.6607734	0.8223674
tables$X1552612_at
X1552612_at
	NR	−0.2523340	0.5485271
	R	0.4450904	0.5434438
tables$X1552613_s_at
X1552613_s_at
	NR	−0.2165343	0.5894093
	R	0.4800677	0.4432806
tables$X1553102_a_at
X1553102_a_at
	NR	−0.2474064	0.5834113
	R	0.7071397	0.7121750
tables$X1553132_a_at
X1553132_a_at
	NR	−0.1377405	0.3946696
	R	0.4961300	0.4509575
tables$X1553313_s_at
X1553313_s_at
	NR	0.2393526	0.6100254
	R	−0.3838373	0.3940848
tables$X1553906_s_at
X1553906_s_at
	NR	−0.3915645	0.6474232
	R	0.2882052	0.3076821
tables$X1554240_a_at
X1554240_a_at
	NR	0.01780307	0.4865912
	R	0.88377535	0.8029798
tables$X1554966_a_at
X1554966_a_at
	NR	−0.1357018	0.3678133
	R	0.6662706	0.6833596
tables$X1555229_a_at
X1555229_a_at
	NR	−0.2263265	0.3882668
	R	0.5467680	0.4361597
tables$X1555630_a_at
X1555630_a_at
	NR	0.2005512	0.3578418
	R	−0.6088957	0.7683101
tables$X1555756_a_at
X1555756_a_at
	NR	−0.2186897	0.5247142
	R	0.4061700	0.5187056
tables$X1555759_a_at
X1555759_a_at
	NR	0.08037061	0.5249017
	R	0.85078348	0.7360755
tables$X1555812_a_at
X1555812_a_at
	NR	−0.4493812	0.8437685
	R	0.4087372	0.6145611
tables$X1555852_at
X1555852_at
	NR	−0.3431720	0.6409197
	R	0.3060830	0.4160286
tables$X1556185_a_at
X1556185_a_at
	NR	−0.3542416	0.4573215
	R	0.3876607	0.8113095
tables$X1556579_s_at
X1556579_s_at
	NR	−0.08046679	0.2880584
	R	0.58371780	0.7445854
tables$X1557116_at
X1557116_at
	NR	−0.4470538	0.6892889
	R	0.3267151	0.4124078
tables$X1557222_at
X1557222_at
	NR	−0.04818824	0.402835
	R	0.74360000	0.863980
tables$X1558034_s_at
X1558034_s_at
	NR	−0.2487822	0.4220782
	R	0.4252406	0.4675114
tables$X1558290_a_at
X1558290_a_at
	NR	0.3179399	0.5555339
	R	−0.4890204	0.4786095
tables$X1558586_at
X1558586_at
	NR	−0.2298781	0.4177707
	R	0.3950435	0.5416909
tables$X1558972_s_at
X1558972_s_at
	NR	−0.2797971	0.5418070
	R	0.4745703	0.5335784
tables$X1559263_s_at
X1559263_s_at
	NR	−0.3833393	0.5703645
	R	0.3494365	0.4676936
tables$X1559425_at
X1559425_at
	NR	−0.2287316	0.5560199
	R	0.4282525	0.4558128
tables$X1559584_a_at
X1559584_a_at
	NR	−0.4622881	0.5846900
	R	0.3021721	0.4028788
tables$X1562031_at
X1562031_at
	NR	−0.3551523	0.4862453
	R	0.1736934	0.4872335
tables$X1563461_at
X1563461_at
	NR	0.3566529	0.5512415
	R	−0.2706966	0.6822506
tables$X1563473_at
X1563473_at
	NR	−0.4074615	0.5896901
	R	0.2254661	0.4096997
tables$X1565602_at
X1565602_at
	NR	0.4490349	0.6371381
	R	−0.1986003	0.5670284
tables$X1568736_s_at
X1568736_s_at
	NR	0.6111740	0.9655418
	R	−0.1669456	0.3464934
tables$X1568822_at
X1568822_at
	NR	0.4611639	0.6061123
	R	−0.1089934	0.3960131
tables$X1569942_at
X1569942_at
	NR	0.4441859	0.7007245
	R	−0.2886340	0.3295043
tables$X200612_s_at
X200612_s_at
	NR	0.2054340	0.4467337
	R	−0.4553481	0.5048914
tables$X200904_at
X200904_at
	NR	−0.2660950	0.4738856
	R	0.3014091	0.4032104
tables$X200905_x_at
X200905_x_at
	NR	−0.1327891	0.5236164
	R	0.4735567	0.3948498
tables$X200953_s_at
X200953_s_at
	NR	−0.2814847	0.8261769
	R	0.5757425	0.6362976
tables$X201010_s_at
X201010_s_at
	NR	−0.3613038	0.7929993
	R	0.4944130	0.2677128
tables$X201137_s_at
X201137_s_at
	NR	−0.3646008	0.7012958
	R	0.3957589	0.4949475
tables$X201220_x_at
X201220_x_at
	NR	0.08672472	0.5177988
	R	−0.48143253	0.5513205
tables$X201236_s_at
X201236_s_at
	NR	−0.1198028	0.5613972
	R	0.5331348	0.5322952
tables$X201425_at
X201425_at
	NR	−0.5116596	0.7193710
	R	0.4964073	0.5304284
tables$X201474_s_at
X201474_s_at
	NR	0.6028068	0.6299064
	R	−0.2457276	0.3007111
tables$X201487_at
X201487_at
	NR	−0.4225210	0.8252371
	R	0.3171429	0.4591150
tables$X201497_x_at
X201497_x_at
	NR	−0.3200855	0.4908815
	R	2.5010094	2.6712499
tables$X201502_s_at
X201502_s_at
	NR	−0.3308824	0.4722939
	R	0.5454167	0.3159327
tables$X201531_at
X201531_at
	NR	−0.1938551	0.3744374
	R	0.5269050	0.5074891
tables$X201566_x_at
X201566_x_at
	NR	−0.2981010	0.6780610
	R	0.3509438	0.5014504
tables$X201720_s_at
X201720_s_at
	NR	−0.1977420	0.6818082
	R	0.5749931	0.7157990
tables$X201721_s_at
X201721_s_at
	NR	−0.1677046	0.5133205
	R	0.4231327	0.5084300
tables$X201804_x_at
X201804_x_at
	NR	0.1992091	0.4851767
	R	−0.4765795	0.5915133
tables$X201859_at
X201859_at
	NR	−0.4216528	0.7283696
	R	0.2486708	0.3163434
tables$X201939_at
X201939_at
	NR	0.2953508	0.5226393
	R	−0.3592031	0.5614863
tables$X202207_at
X202207_at
	NR	−0.4088858	0.6063797
	R	0.2159392	0.2923256
tables$X202255_s_at
X202255_s_at
	NR	−0.5135289	0.8447912
	R	0.3161547	0.6241535
tables$X202269_x_at
X202269_x_at
	NR	−0.4070967	0.6699657
	R	0.3070278	0.3134680
tables$X202270_at
X202270_at
	NR	−0.3598381	0.7402801
	R	0.4664866	0.4311290
tables$X202368_s_at
X202368_s_at
	NR	0.4828523	0.6622996
	R	−0.3498387	0.7337426
tables$X202369_s_at
X202369_s_at
	NR	0.3894707	0.7051767
	R	−0.4762401	0.5968765
tables$X202391_at
X202391_at
	NR	−0.5342313	1.0124766
	R	0.5933123	0.6491928
tables$X202510_s_at
X202510_s_at
	NR	−0.6015966	0.9255712
	R	0.4919973	0.6463912
tables$X202625_at
X202625_at
	NR	−0.2142036	0.7804199
	R	0.6620458	0.7148131
tables$X202643_s_at
X202643_s_at
	NR	−0.4832904	0.5361050
	R	0.3792320	0.4385239
tables$X202644_s_at
X202644_s_at
	NR	−0.3513719	0.5742499
	R	0.4307245	0.3838438
tables$X202687_s_at
X202687_s_at
	NR	−0.4279648	0.7540136
	R	0.3504315	0.4045005
tables$X202688_at
X202688_at
	NR	−0.4163941	0.8163225
	R	0.4027076	0.4386812
tables$X202948_at
X202948_at
	NR	−0.5154460	0.7699102
	R	0.4056092	0.4764355
tables$X202957_at
X202957_at
	NR	−0.3735948	0.5616205
	R	0.4472934	0.5131898
tables$X203413_at
X203413_at
	NR	−0.3383329	0.5941084
	R	0.3196087	0.6292591
tables$X203416_at
X203416_at
	NR	−0.3141917	0.6552882
	R	0.4391612	0.4251811
tables$X203471_s_at
X203471_s_at
	NR	−0.2041767	0.5987281
	R	0.6153344	0.5620431
tables$X203508_at
X203508_at
	NR	−0.2695595	0.5179795
	R	0.2812243	0.4853358
tables$X203523_at
X203523_at
	NR	−0.3791594	0.8958684
	R	0.8117565	0.9246945
tables$X203547_at
X203547_at
	NR	−0.008562598	0.4462166
	R	0.663436693	0.5733365
tables$X203665_at
X203665_at
	NR	−0.2522801	0.5533137
	R	0.6428083	0.7340506
tables$X203741_s_at
X203741_s_at
	NR	−0.1850309	0.5721364
	R	0.6581712	0.6185694
tables$X203761_at
X203761_at
	NR	−0.1852189	0.5956581
	R	0.5255720	0.4369002
tables$X203812_at
X203812_at
	NR	0.0587172	0.3136796
	R	1.0676683	0.8555980
tables$X203868_s_at
X203868_s_at
	NR	−0.3688355	0.6726738
	R	0.2602381	0.3965858
tables$X203915_at
X203915_at
	NR	−0.4061025	0.5236050
	R	0.2301446	0.2415020
tables$X203932_at
X203932_at
	NR	−0.2494244	0.6622825
	R	0.4463418	0.3757829
tables$X204057_at
X204057_at
	NR	−0.3274287	0.5906957
	R	0.4847696	0.4283121
tables$X204070_at
X204070_at
	NR	−0.2719985	0.6097243
	R	0.4394442	0.3954333
tables$X204116_at
X204116_at
	NR	−0.2653059	0.4657288
	R	0.5320249	0.3827573
tables$X204118_at
X204118_at
	NR	−0.2188632	0.5465435
	R	0.4397206	0.4841528
tables$X204135_at
X204135_at
	NR	−0.2511983	0.3620796
	R	0.5582305	0.6587871
tables$X204204_at
X204204_at
	NR	−0.2476304	0.5677727
	R	0.5469376	0.5015591
tables$X204220_at
X204220_at
	NR	−0.4512334	0.9464671
	R	0.4470878	0.4911261
tables$X204222_s_at
X204222_s_at
	NR	−0.2858410	0.8009875
	R	0.4771543	0.4557632
tables$X204224_s_at
X204224_s_at
	NR	−0.4034291	0.533261
	R	0.4591664	0.324186
tables$X204233_s_at
X204233_s_at
	NR	0.1725203	0.526541
	R	−0.4473613	0.498801
tables$X204236_at
X204236_at
	NR	−0.3405471	0.7438102
	R	0.4577420	0.4830432
tables$X204249_s_at
X204249_s_at
	NR	−0.2439368	0.6736956
	R	0.5798690	0.5938803
tables$X204411_at
X204411_at
	NR	−0.1561360	0.5046013
	R	0.5348875	0.6639757
tables$X204438_at
X204438_at
	NR	−0.2155729	0.8013524
	R	0.5238707	0.5465740
tables$X204502_at
X204502_at
	NR	−0.3163975	0.5660414
	R	0.3122723	0.3372872
tables$X204512_at
X204512_at
	NR	−0.3823994	0.7656201
	R	0.3405082	0.3302137
tables$X204533_at
X204533_at
	NR	−0.3432882	0.5411550
	R	0.2820025	0.3529044
tables$X204613_at
X204613_at
	NR	−0.2921141	0.5365989
	R	0.3433918	0.4634024
tables$X204628_s_at
X204628_s_at
	NR	0.2412563	0.5057318
	R	−0.4238494	0.4487938
tables$X204642_at
X204642_at
	NR	−0.3125616	0.7411993
	R	0.6952398	1.0691429
tables$X204655_at
X204655_at
	NR	−0.2716510	0.6208783
	R	0.5579874	0.5183030
tables$X204661_at
X204661_at
	NR	−0.1558546	0.4835795
	R	0.5868508	0.3065469
tables$X204670_x_at
X204670_x_at
	NR	−0.3190668	0.6529019
	R	0.4161121	0.3104711
tables$X204687_at
X204687_at
	NR	0.1167838	0.3453266
	R	1.0001048	0.8753104
tables$X204724_s_at
X204724_s_at
	NR	0.5223107	0.6822646
	R	−0.1768374	0.3008967
tables$X204774_at
X204774_at
	NR	−0.3545849	0.6395887
	R	0.1938959	0.3271488
tables$X204778_x_at
X204778_x_at
	NR	0.3141006	0.5671928
	R	−0.4937885	0.7083350
tables$X204834_at
X204834_at
	NR	−0.2829585	0.5026786
	R	0.2222514	0.2582449
tables$X204846_at
X204846_at
	NR	0.1129389	0.4384144
	R	0.7672991	0.7249123
tables$X204894_s_at
X204894_s_at
	NR	−0.04169668	0.5285664
	R	0.90340136	1.0066307
tables$X204897_at
X204897_at
	NR	−0.5753379	0.7174762
	R	0.2097906	0.3253104
tables$X204912_at
X204912_at
	NR	−0.1581854	0.4616605
	R	0.4406020	0.3673491
tables$X204923_at
X204923_at
	NR	−0.1810564	0.5020173
	R	0.4762799	0.5956602
tables$X205027_s_at
X205027_s_at
	NR	−0.2115740	0.8053652
	R	0.9541627	0.9478824
tables$X205039_s_at
X205039_s_at
	NR	−0.07447284	0.6105666
	R	0.75225499	0.7306959
tables$X205081_at
X205081_at
	NR	−0.4320239	0.6844631
	R	0.4515831	0.6544651
tables$X205159_at
X205159_at
	NR	−0.3955032	0.7064307
	R	0.4559497	0.4821926
tables$X205225_at
X205225_at
	NR	−0.4166425	0.5776734
	R	0.4113626	0.4147703
tables$X205226_at
X205226_at
	NR	−0.07833695	0.4854712
	R	0.44132335	0.7107620
tables$X205251_at
X205251_at
	NR	−0.3110220	0.6899898
	R	0.5272399	0.6253671
tables$X205285_s_at
X205285_s_at
	NR	−0.04432586	0.5000114
	R	0.80925537	0.9021956
tables$X205392_s_at
X205392_s_at
	NR	−0.4220336	0.4956664
	R	0.4657780	0.3693635
tables$X205403_at
X205403_at
	NR	−0.2005647	0.4806835
	R	0.5966667	0.7091052
tables$X205419_at
X205419_at
	NR	−0.2813820	0.5751165
	R	0.5056242	0.4918400
tables$X205421_at
X205421_at
	NR	0.07840435	0.3868954
	R	0.86698828	0.8643222
tables$X205440_s_at
X205440_s_at
	NR	−0.3108277	0.5223075
	R	0.3749281	0.5730182
tables$X205484_at
X205484_at
	NR	−0.2739962	0.5607660
	R	0.4613413	0.4462779
tables$X205488_at
X205488_at
	NR	−0.211302	0.5156343
	R	0.451222	0.3725271
tables$X205559_s_at
X205559_s_at
	NR	−0.1967785	0.4797350
	R	0.4925489	0.5104237
tables$X205569_at
X205569_at
	NR	−0.3112147	0.5708862
	R	0.3356277	0.4533386
tables$X205624_at
X205624_at
	NR	0.005427652	0.4382683
	R	0.763112333	0.7396355
tables$X205685_at
X205685_at
	NR	−0.1946623	0.5288449
	R	0.4467601	0.4223863
tables$X205696_s_at
X205696_s_at
	NR	−0.01091462	0.3565887
	R	0.77207850	0.7974577
tables$X205758_at
X205758_at
	NR	−0.2386930	0.4171697
	R	0.4248193	0.3603297
tables$X205786_s_at
X205786_s_at
	NR	−0.4968271	0.8934640
	R	0.4149078	0.5488123
tables$X205831_at
X205831_at
	NR	0.04447927	0.4259325
	R	0.69838627	0.4833483
tables$X205841_at
X205841_at
	NR	−0.5900546	0.7313311
	R	0.3136276	0.5142651
tables$X205844_at
X205844_at
	NR	−0.1423775	0.4883837
	R	0.4235432	0.4438472
tables$X205890_s_at
X205890_s_at
	NR	−0.3511421	0.4822404
	R	0.3120630	0.2244957
tables$X205987_at
X205987_at
	NR	−0.09413415	0.3978789
	R	0.59504052	0.5335613
tables$X206082_at
X206082_at
	NR	−0.4540809	0.6785699
	R	0.4716106	0.5496119
tables$X206099_at
X206099_at
	NR	−0.0531401	0.3438675
	R	0.5295345	0.5201337
tables$X206118_at
X206118_at
	NR	−0.2013207	0.4883106
	R	0.5011802	0.4695632
tables$X206134_at
X206134_at
	NR	−0.2474317	0.6355258
	R	0.3651382	0.4198818
tables$X206170_at
X206170_at
	NR	−0.4274713	0.5078651
	R	0.3104491	0.3419569
tables$X206204_at
X206204_at
	NR	−0.02057820	0.2205198
	R	0.94769151	0.9338282
tables$X206295_at
X206295_at
	NR	−0.4222879	0.5539909
	R	0.2869025	0.3697476
tables$X206385_s_at
X206385_s_at
	NR	−0.1448051	0.4343064
	R	0.5421084	0.6951307
tables$X206407_s_at
X206407_s_at
	NR	−0.0965811	0.4714271
	R	0.5253937	0.6785424
tables$X206545_at
X206545_at
	NR	−0.2348002	0.6434845
	R	0.3898586	0.5979256
tables$X206571_s_at
X206571_s_at
	NR	0.2964052	0.5266454
	R	−0.5021825	0.7307312
tables$X206637_at
X206637_at
	NR	−0.4929224	0.8293232
	R	0.5561408	0.7415308
tables$X206666_at
X206666_at
	NR	−0.3815276	0.4518748
	R	0.3020703	0.1922297
tables$X206687_s_at
X206687_s_at
	NR	−0.3592461	0.6018756
	R	0.3975221	0.5022615
tables$X206715_at
X206715_at
	NR	−0.2541760	0.6982257
	R	0.4082547	0.3259496
tables$X206804_at
X206804_at
	NR	0.1482064	0.5068781
	R	0.9166047	0.7147839
tables$X206898_at
X206898_at
	NR	0.1056709	0.4682096
	R	−0.5435822	0.5520821
tables$X206978_at
X206978_at
	NR	−0.3496069	0.5339659
	R	0.2843234	0.3287630
tables$X207076_s_at
X207076_s_at
	NR	−0.02361779	0.5694192
	R	1.31170006	1.6322450
tables$X207238_s_at
X207238_s_at
	NR	−0.2571791	0.6182402
	R	0.5089045	0.4856678
tables$X207277_at
X207277_at
	NR	−0.3525872	0.7509863
	R	0.4181711	0.4255746
tables$X207458_at
X207458_at
	NR	0.2419331	0.5735746
	R	−0.3710235	0.4350871
tables$X207540_s_at
X207540_s_at
	NR	−0.2692932	0.5488522
	R	0.3711915	0.4966252
tables$X207574_s_at
X207574_s_at
	NR	−0.3958191	0.7713632
	R	0.4298086	0.3017609
tables$X207651_at
X207651_at
	NR	−0.3101854	0.4462963
	R	0.5275557	0.2883934
tables$X207655_s_at
X207655_s_at
	NR	−0.2656028	0.6249668
	R	0.4038824	0.4984622
tables$X207677_s_at
X207677_s_at
	NR	−0.1067724	0.6536107
	R	0.6251422	0.4735116
tables$X207843_x_at
X207843_x_at
	NR	−0.1980640	0.4840094
	R	0.6923162	1.1190386
tables$X207861_at
X207861_at
	NR	−0.1260775	0.3508021
	R	0.6778354	0.7911460
tables$X207977_s_at
X207977_s_at
	NR	−0.02630196	0.3452417
	R	0.72601762	0.5798353
tables$X207992_s_at
X207992_s_at
	NR	−0.2962782	0.6213732
	R	0.4065298	0.3562586
tables$X208296_x_at
X208296_x_at
	NR	−0.3202962	0.6726712
	R	0.4715979	0.3630417
tables$X208306_x_at
X208306_x_at
	NR	−0.3404445	0.6697022
	R	0.3560108	0.2684112
tables$X208335_s_at
X208335_s_at
	NR	−0.6832978	0.8622729
	R	0.3887120	0.6307942
tables$X208450_at
X208450_at
	NR	0.05646932	0.6161496
	R	0.97349919	0.7211533
tables$X208747_s_at
X208747_s_at
	NR	−0.7269106	1.215719
	R	0.6146325	0.602124
tables$X208885_at
X208885_at
	NR	−0.4878552	0.6970401
	R	0.3000394	0.4132369
tables$X208894_at
X208894_at
	NR	−0.2782715	0.5325159
	R	0.3660963	0.3734728
tables$X208981_at
X208981_at
	NR	−0.3974853	0.7581136
	R	0.3901547	0.3829096
tables$X208983_s_at
X208983_s_at
	NR	−0.3682743	0.6238660
	R	0.3346874	0.3924348
tables$X209083_at
X209083_at
	NR	0.1258308	0.6751235
	R	0.9235844	0.8069453
tables$X209138_x_at
X209138_x_at
	NR	−0.1402324	0.4308172
	R	0.3394879	0.3946554
tables$X209193_at
X209193_at
	NR	−0.2565556	0.5468921
	R	0.4873494	0.4649883
tables$X209195_s_at
X209195_s_at
	NR	0.1800756	0.4677919
	R	−0.4026223	0.3673557
tables$X209202_s_at
X209202_s_at
	NR	0.1964649	0.7379767
	R	−0.5653081	0.5741860
tables$X209312_x_at
X209312_x_at
	NR	−0.2928795	0.6652902
	R	0.4275265	0.3568548
tables$X209480_at
X209480_at
	NR	−0.2841051	0.4380402
	R	0.2693738	0.4024957
tables$X209542_x_at
X209542_x_at
	NR	−0.2363103	0.6011656
	R	0.4349808	0.5810748
tables$X209603_at
X209603_at
	NR	−0.4656699	0.4521237
	R	0.3621330	0.6118526
tables$X209606_at
X209606_at
	NR	−0.2611256	0.5441526
	R	0.5627781	0.3290949
tables$X209612_s_at
X209612_s_at
	NR	−0.2482860	0.4645433
	R	0.3891742	0.5803480
tables$X209613_s_at
X209613_s_at
	NR	−0.3246706	0.4195264
	R	0.2137530	0.4363348
tables$X209670_at
X209670_at
	NR	−0.3904387	0.5757881
	R	0.4960604	0.4286288
tables$X209671_x_at
X209671_x_at
	NR	0.005489902	0.4958616
	R	0.946682909	0.6669064
tables$X209685_s_at
X209685_s_at
	NR	−0.3380362	0.6105057
	R	0.3675781	0.4181149
tables$X209687_at
X209687_at
	NR	−0.5180091	0.5954837
	R	0.3297076	0.5807315
tables$X209710_at
X209710_at
	NR	−0.2868007	0.3941463
	R	0.4039716	0.7769142
tables$X209734_at
X209734_at
	NR	−0.2771824	0.5584141
	R	0.3480342	0.4269202
tables$X209774_x_at
X209774_x_at
	NR	−0.5154483	0.5084051
	R	0.3327482	0.2052511
tables$X209795_at
X209795_at
	NR	−0.5014384	0.5485146
	R	0.2126023	0.2563472
tables$X209813_x_at
X209813_x_at
	NR	−0.02446552	0.4178348
	R	0.66828816	0.5665816
tables$X209899_s_at
X209899_s_at
	NR	0.2607015	0.6973904
	R	−0.4270344	0.5920830
tables$X209924_at
X209924_at
	NR	−0.1412661	0.5234151
	R	0.3997205	0.5359769
tables$X209949_at
X209949_at
	NR	−0.2882600	0.4631077
	R	0.4047160	0.3303257
tables$X209970_x_at
X209970_x_at
	NR	−0.4439942	0.6955252
	R	0.1102440	0.2548926
tables$X210038_at
X210038_at
	NR	0.1317110	0.4768708
	R	0.8494560	0.7295487
tables$X210072_at
X210072_at
	NR	0.01156063	0.3737049
	R	0.57481931	0.4627490
tables$X210251_s_at
X210251_s_at
	NR	0.2240660	0.4879510
	R	−0.6597691	0.6547051
tables$X210260_s_at
X210260_s_at
	NR	−0.3640910	0.6337100
	R	0.4487179	0.3720418
tables$X210319_x_at
X210319_x_at
	NR	−0.08072798	0.5440481
	R	0.83296501	1.2085067
tables$X210375_at
X210375_at
	NR	−0.0859139	0.2736614
	R	0.9924649	1.0291749
tables$X210554_s_at
X210554_s_at
	NR	0.1522882	0.5489999
	R	−0.5083098	0.6130962
tables$X210835_s_at
X210835_s_at
	NR	0.2332468	0.5454729
	R	−0.4438314	0.6253821
tables$X210915_x_at
X210915_x_at
	NR	−0.2269420	0.466748
	R	0.5087007	0.360080
tables$X210972_x_at
X210972_x_at
	NR	−0.2866590	0.4272028
	R	0.5598691	0.4527992
tables$X210982_s_at
X210982_s_at
	NR	−0.3512586	0.5571462
	R	0.3419340	0.3732178
tables$X211066_x_at
X211066_x_at
	NR	0.2422814	0.6284310
	R	−0.5086901	0.7771297
tables$X211144_x_at
X211144_x_at
	NR	0.05087736	0.3119915
	R	0.70598903	0.4822038
tables$X211200_s_at
X211200_s_at
	NR	0.2580184	0.5530421
	R	−0.4922700	0.5506593
tables$X211339_s_at
X211339_s_at
	NR	−0.2296132	0.5247178
	R	0.5767409	0.5988969
tables$X211366_x_at
X211366_x_at
	NR	−0.3681938	0.6327750
	R	0.1432735	0.2631491
tables$X211367_s_at
X211367_s_at
	NR	−0.1751026	0.5723239
	R	0.3320629	0.2562800
tables$X211368_s_at
X211368_s_at
	NR	−0.51886132	0.7515452
	R	0.07358956	0.2643141
tables$X211654_x_at
X211654_x_at
	NR	−0.3850022	0.5573621
	R	0.3719847	0.3143733
tables$X211742_s_at
X211742_s_at
	NR	−0.2540869	0.6521022
	R	0.4880575	0.5506316
tables$X211796_s_at
X211796_s_at
	NR	−0.3093201	0.4536705
	R	0.4624019	0.3008702
tables$X211902_x_at
X211902_x_at
	NR	−0.2792212	0.5535743
	R	0.6836665	0.6034058
tables$X211990_at
X211990_at
	NR	−0.4590253	0.8582217
	R	0.4251869	0.4814630
tables$X211991_s_at
X211991_s_at
	NR	−0.2092869	0.6666829
	R	0.5537245	0.3967729
tables$X212067_s_at
X212067_s_at
	NR	−0.4803278	0.7242299
	R	0.3558230	0.6889846
tables$X212233_at
X212233_at
	NR	0.1442229	0.5131552
	R	−0.4879059	0.7214358
tables$X212538_at
X212538_at
	NR	−0.3849016	0.7522011
	R	0.6516464	0.6995619
tables$X212587_s_at
X212587_s_at
	NR	−0.3531934	0.5890246
	R	0.3718118	0.3431055
tables$X212588_at
X212588_at
	NR	−0.5662804	0.8162279
	R	0.4008046	0.4444447
tables$X212592_at
X212592_at
	NR	−0.3409693	0.4849486
	R	0.2387676	0.2127384
tables$X212657_s_at
X212657_s_at
	NR	−0.3419394	0.6083771
	R	0.2570024	0.4217927
tables$X212671_s_at
X212671_s_at
	NR	−0.5140866	0.8193929
	R	0.5074176	0.3776582
tables$X212713_at
X212713_at
	NR	0.03767197	0.3268940
	R	0.74731430	0.8347694
tables$X212763_at
X212763_at
	NR	0.2888164	0.8845972
	R	−0.6529463	0.9707572
tables$X212886_at
X212886_at
	NR	−0.3765371	0.7892555
	R	0.6201350	0.6611937
tables$X212977_at
X212977_at
	NR	−0.4688782	0.8767720
	R	0.5293928	0.6187406
tables$X212998_x_at
X212998_x_at
	NR	−0.2035514	0.6457962
	R	0.5296660	0.3118830
tables$X212999_x_at
X212999_x_at
	NR	−0.2290011	0.4910183
	R	0.4331640	0.3718106
tables$X213007_at
X213007_at
	NR	0.2632353	0.6401111
	R	−0.3996142	0.4037179
tables$X213008_at
X213008_at
	NR	0.4761995	0.7015473
	R	−0.4947303	0.8235263
tables$X213068_at
X213068_at
	NR	−0.1758656	0.4044001
	R	0.4193472	0.3911686
tables$X213095_x_at
X213095_x_at
	NR	−0.3502315	0.8054069
	R	0.3616843	0.3443190
tables$X213193_x_at
X213193_x_at
	NR	−0.2370856	0.4636341
	R	0.5058580	0.3505763
tables$X213475_s_at
X213475_s_at
	NR	−0.2137215	0.4617051
	R	0.4040370	0.4908631
tables$X213537_at
X213537_at
	NR	−0.3674984	0.5888660
	R	0.3219144	0.5336377
tables$X213539_at
X213539_at
	NR	−0.3813796	0.5040301
	R	0.3415072	0.2577433
tables$X213560_at
X213560_at
	NR	−0.5055000	0.7230271
	R	0.2766383	0.2303920
tables$X213566_at
X213566_at
	NR	−0.2311022	0.5691307
	R	0.3719339	0.4376776
tables$X213603_s_at
X213603_s_at
	NR	−0.3061774	0.6126919
	R	0.3508772	0.5262723
tables$X213618_at
X213618_at
	NR	−0.3695683	0.681454
	R	0.4212985	0.554157
tables$X213652_at
X213652_at
	NR	−0.2586966	0.4605599
	R	0.3270410	0.8177604
tables$X213819_s_at
X213819_s_at
	NR	0.00122895	0.3972336
	R	−0.64986825	0.9085849
tables$X213831_at
X213831_at
	NR	−0.3533186	0.4215363
	R	0.1563120	0.3886529
tables$X213888_s_at
X213888_s_at
	NR	−0.2086168	0.5349552
	R	0.4303498	0.4269851
tables$X213975_s_at
X213975_s_at
	NR	−0.4990363	0.6803409
	R	0.1878550	0.2710180
tables$X214023_x_at
X214023_x_at
	NR	0.1848739	0.7174998
	R	−0.4325008	0.4810479
tables$X214038_at
X214038_at
	NR	−0.3255701	0.6706608
	R	0.3599967	0.6048520
tables$X214181_x_at
X214181_x_at
	NR	−0.3415893	0.6522400
	R	0.2853699	0.2763122
tables$X214450_at
X214450_at
	NR	−0.1562932	0.2807857
	R	0.8434281	0.8613678
tables$X214470_at
X214470_at
	NR	−0.2839688	0.4885156
	R	0.4212807	0.3750679
tables$X214617_at
X214617_at
	NR	−0.3487562	0.4518071
	R	0.2125207	0.4242197
tables$X214669_x_at
X214669_x_at
	NR	−0.1915274	0.4981106
	R	0.3359622	0.4156267
tables$X214677_x_at
X214677_x_at
	NR	−0.2087490	0.4787112
	R	0.3128333	0.3867513
tables$X214719_at
X214719_at
	NR	−0.4511937	0.6070570
	R	0.2711287	0.3505487
tables$X215051_x_at
X215051_x_at
	NR	−0.3597073	0.8514825
	R	0.4054302	0.3092948
tables$X215121_x_at
X215121_x_at
	NR	−0.1634545	0.4642640
	R	0.3410072	0.4014670
tables$X215193_x_at
X215193_x_at
	NR	−0.2667421	0.7134086
	R	0.4777644	0.4030902
tables$X215223_s_at
X215223_s_at
	NR	−0.3883071	0.4910665
	R	0.2565276	0.4364856
tables$X215379_x_at
X215379_x_at
	NR	−0.09709331	0.4452099
	R	0.39542823	0.4092484
tables$X215561_s_at
X215561_s_at
	NR	−0.2711632	0.4077480
	R	0.7072055	0.9320206
tables$X215806_x_at
X215806_x_at
	NR	−0.007773052	0.3665788
	R	0.661454102	0.4785205
tables$X216155_at
X216155_at
	NR	0.5119447	0.6151164
	R	−0.1726881	0.3347342
tables$X216191_s_at
X216191_s_at
	NR	−0.01475148	0.4433394
	R	0.67109688	0.5079869
tables$X216194_s_at
X216194_s_at
	NR	0.1641682	0.3935104
	R	−0.3667475	0.4613841
tables$X216714_at
X216714_at
	NR	−0.1657215	0.6600958
	R	0.5669961	0.9931878
tables$X216841_s_at
X216841_s_at
	NR	−0.2378813	0.7063683
	R	0.5838156	0.5499012
tables$X216920_s_at
X216920_s_at
	NR	−0.3626922	0.5129860
	R	0.4424685	0.4026252
tables$X217028_at
X217028_at
	NR	−0.3936253	0.7242766
	R	0.2813510	0.3842826
tables$X217138_x_at
X217138_x_at
	NR	0.06341764	0.4690319
	R	0.61978484	0.5049407
tables$X217143_s_at
X217143_s_at
	NR	−0.1709594	0.6329777
	R	0.6395395	0.5675738
tables$X217147_s_at
X217147_s_at
	NR	−0.1919006	0.3907915
	R	0.4594408	0.3635919
tables$X217478_s_at
X217478_s_at
	NR	−0.3453566	0.7688595
	R	0.5037971	0.4475461
tables$X217525_at
X217525_at
	NR	−0.2639411	0.8866455
	R	0.6075298	0.5960824
tables$X217629_at
X217629_at
	NR	−0.1348654	0.671148
	R	0.8011176	1.134701
tables$X217767_at
X217767_at
	NR	−0.4316702	0.6383017
	R	0.3296425	0.3962954
tables$X217995_at
X217995_at
	NR	−0.6500190	1.0622844
	R	0.3656452	0.3596701
tables$X218002_s_at
X218002_s_at
	NR	−0.2371548	0.4549764
	R	0.3590465	0.5928193
tables$X218035_s_at
X218035_s_at
	NR	−0.3792486	0.6876336
	R	0.3685478	0.4296116
tables$X218145_at
X218145_at
	NR	0.5407030	0.7961511
	R	−0.5330237	0.7914334
tables$X218170_at
X218170_at
	NR	−0.2778944	0.5053423
	R	0.5047588	0.6555875
tables$X218322_s_at
X218322_s_at
	NR	−0.4368137	0.5136086
	R	0.3249243	0.2575257
tables$X218459_at
X218499_at
	NR	−0.2574311	0.6676495
	R	0.4022312	0.4066238
tables$X218736_s_at
X218736_s_at
	NR	−0.03615144	0.4561428
	R	1.08677338	1.1597104
tables$X218739_at
X218739_at
	NR	−0.02247695	0.4787563
	R	0.98329866	1.2407971
tables$X218764_at
X218764_at
	NR	−0.4099779	0.4830029
	R	0.3567869	0.4038910
tables$X218802_at
X218802_at
	NR	−0.3430126	0.4453773
	R	0.5970457	0.3951568
tables$X218805_at
X218805_at
	NR	−0.3671355	0.5708859
	R	0.4517210	0.2930704
tables$X218854_at
X218854_at
	NR	−0.3745559	0.7096822
	R	0.4739352	0.5603528
tables$X218899_s_at
X218899_s_at
	NR	0.3671446	0.5909345
	R	−0.5393210	0.4381099
tables$X218950_at
X218950_at
	NR	0.2691863	0.4573251
	R	−0.6111111	0.6474936
tables$X219054_at
X219054_at
	NR	0.01472793	0.584855
	R	2.49050475	2.683467
tables$X219093_at
X219093_at
	NR	−0.2971580	0.4688604
	R	0.5384298	0.6366817
tables$X219213_at
X219213_at
	NR	−0.1731958	0.4047427
	R	0.6423430	0.7730134
tables$X219243_at
X219243_at
	NR	−0.5195758	0.7578959
	R	0.4000750	0.3801539
tables$X219368_at
X219368_at
	NR	−0.1679820	0.3075502
	R	0.6324772	0.6637538
tables$X219440_at
X219440_at
	NR	0.08196161	0.2856868
	R	0.87878388	0.7545222
tables$X219454_at
X219454_at
	NR	−0.1553019	0.3324367
	R	0.6028235	0.7768835
tables$X219505_at
X219505_at
	NR	−0.335471	0.5884701
	R	0.331203	0.4762600
tables$X219519_s_at
X219519_s_at
	NR	−0.3029785	0.6574268
	R	0.4245899	0.6733826
tables$X219525_at
X219525_at
	NR	−0.4849566	0.6164310
	R	0.2295082	0.3984913
tables$X219528_s_at
X219528_s_at
	NR	−0.2597881	0.4319096
	R	0.4928448	0.5142826
tables$X219631_at
X219631_at
	NR	0.5705786	0.6831084
	R	−0.2784402	0.3830630
tables$X219666_at
X219666_at
	NR	−0.5430705	0.7930909
	R	0.2839697	0.3631652
tables$X219681_s_at
X219681_s_at
	NR	−0.417274	0.7733850
	R	0.376309	0.5736019
tables$X219710_at
X219710_at
	NR	0.2636804	0.4736957
	R	−0.3241903	0.5279440
tables$X219737_s_at
X219737_s_at
	NR	0.3596773	0.5146777
	R	−0.2409581	0.4405703
tables$X219777_at
X219777_at
	NR	−0.3965677	0.5974954
	R	0.5026195	0.4178151
tables$X219789_at
X219789_at
	NR	0.0625228	0.3929864
	R	1.5326986	1.6918348
tables$X219926_at
X219926_at
	NR	0.2428123	0.5989463
	R	−0.6869766	0.9798973
tables$X219938_s_at
X219938_s_at
	NR	−0.4681105	0.5841168
	R	0.3093149	0.2386032
tables$X220005_at
X220005_at
	NR	−0.09036238	0.5172305
	R	0.62083607	0.5403729
tables$X220066_at
X220066_at
	NR	−0.2813542	0.4958868
	R	0.2894245	0.2549095
tables$X220330_s_at
X220330_s_at
	NR	−0.1838030	0.5516329
	R	0.4155977	0.3566931
tables$X220485_s_at
X220485_s_at
	NR	−0.2516505	0.989380
	R	1.2092181	1.358517
tables$X221081_s_at
X221081_s_at
	NR	−0.3406222	0.5260212
	R	0.2204497	0.3080250
tables$X221087_s_at
X221087_s_at
	NR	−0.3965314	0.6050086
	R	0.2956204	0.3544964
tables$X221477_s_at
X221477_s_at
	NR	−0.3833003	0.7680959
	R	0.4128233	0.5675033
tables$X221651_x_at
X221651_x_at
	NR	−0.3022085	0.4778491
	R	0.2004842	0.2922928
tables$X221671_x_at
X221671_x_at
	NR	−0.3000931	0.4932356
	R	0.2268629	0.2801547
tables$X221698_s_at
X221698_s_at
	NR	−0.6376038	0.9130990
	R	0.3423824	0.3837021
tables$X221756_at
X221756_at
	NR	−0.1597059	0.4810294
	R	0.7144792	0.8100807
tables$X221760_at
X221760_at
	NR	−0.3895238	0.6667009
	R	0.2589523	0.4120362
tables$X222108_at
X222108_at
	NR	−0.3578270	0.4644883
	R	0.3207759	0.3326270
tables$X222142_at
X222142_at
	NR	−0.1876780	0.4933581
	R	0.3824561	0.4368395
tables$X222484_s_at
X222484_s_at
	NR	−0.4729730	0.6937840
	R	0.3761529	0.5801888
tables$X222496_s_at
X222496_s_at
	NR	−0.4144878	0.6266733
	R	0.2909259	0.2895369
tables$X222592_s_at
X222592_s_at
	NR	−0.2780972	0.5068942
	R	0.4106129	0.2951602
tables$X222725_s_at
X222725_s_at
	NR	−0.004398634	0.5694045
	R	1.150669643	1.2645302
tables$X222780_s_at
X222780_s_at
	NR	0.4139560	0.5398394
	R	−0.4224571	0.2983037
tables$X222838_at
X222838_at
	NR	−0.2978748	0.5457765
	R	0.2590990	0.2508078
tables$X222895_s_at
X222895_s_at
	NR	−0.4561043	0.5248071
	R	0.1985346	0.3539992
tables$X223044_at
X223044_at
	NR	−0.4249287	0.7273378
	R	0.3345815	0.5282742
tables$X223058_at
X223058_at
	NR	−0.5976291	0.7565737
	R	0.2836632	0.4557419
tables$X223059_s_at
X223059_s_at
	NR	−0.2707661	0.6996713
	R	0.5245500	0.4391394
tables$X223168_at
X223168_at
	NR	−0.3429218	0.5205996
	R	0.2543322	0.3823076
tables$X223235_s_at
X223235_s_at
	NR	−0.2858518	0.4718234
	R	0.6748075	0.7147878
tables$X223280_x_at
X223280_x_at
	NR	−0.5988057	0.8558921
	R	0.2763766	0.4726699
tables$X223322_at
X223322_at
	NR	−0.5307109	0.7623257
	R	0.4863893	0.5655322
tables$X223361_at
X223361_at
	NR	−0.2076597	0.5924435
	R	0.3858025	0.5723073
tables$X223395_at
X223395_at
	NR	−0.2616053	0.5452143
	R	0.4342364	0.5337485
tables$X223484_at
X223484_at
	NR	−0.2440592	0.3975480
	R	0.4224246	0.4741438
tables$X223809_at
X223809_at
	NR	−0.2342077	0.5645847
	R	0.3558237	0.3616038
tables$X223827_at
X223827_at
	NR	0.60366334	0.8225446
	R	−0.06966146	0.1454527
tables$X223922_x_at
X223922_x_at
	NR	−0.4981749	0.7014087
	R	0.2234232	0.3896602
tables$X223924_at
X223924_at
	NR	0.4849658	0.6301636
	R	−0.1459645	0.4704890
tables$X223952_x_at
X223952_x_at
	NR	0.1264371	0.4236437
	R	0.8628858	0.9031651
tables$X224356_x_at
X224356_x_at
	NR	−0.5122008	0.7621637
	R	0.2604697	0.4291461
tables$X224358_s_at
X224358_s_at
	NR	−0.4371837	0.8408400
	R	0.3218548	0.5126749
tables$X224451_x_at
X224451_x_at
	NR	−0.2604966	0.5285926
	R	0.4760714	0.4279992
tables$X224516_s_at
X224516_s_at
	NR	0.2968854	0.6541436
	R	−0.6889220	0.9012319
tables$X224710_at
X224710_at
	NR	0.2230392	0.3643719
	R	−0.7978563	0.9064005
tables$X224771_at
X224771_at
	NR	0.4329412	0.8903073
	R	−0.4421469	0.6725526
tables$X224772_at
X224772_at
	NR	0.1916542	0.4865887
	R	−0.5224768	0.4540955
tables$X224773_at
X224773_at
	NR	0.3157972	0.5857999
	R	−0.4979135	0.4238849
tables$X224774_s_at
X224774_s_at
	NR	0.5703417	0.6486541
	R	−0.5030708	0.5503160
tables$X224795_x_at
X224795_x_at
	NR	−0.3054091	0.4872416
	R	0.2135411	0.2854565
tables$X224859_at
X224859_at
	NR	0.4830222	0.7137397
	R	−0.3679703	0.6853105
tables$X224896_s_at
X224896_s_at
	NR	0.1816808	0.7977231
	R	−0.6408326	0.5850013
tables$X225502_at
X225502_at
	NR	−0.3910820	0.6073778
	R	0.4852237	0.4201402
tables$X225802_at
X225802_at
	NR	0.1344681	0.5702449
	R	−0.4950925	0.5294767
tables$X225895_at
X225895_at
	NR	−0.3277170	0.7566241
	R	0.6412089	0.7479682
tables$X226043_at
X226043_at
	NR	0.1973572	0.6004289
	R	−0.3655970	0.4868833
tables$X226068_at
X226068_at
	NR	−0.3490564	0.6019387
	R	0.4335378	0.4792696
tables$X226117_at
X226117_at
	NR	−0.2837194	0.5233255
	R	0.4253069	0.3317653
tables$X226218_at
X226218_at
	NR	−0.3859418	0.6090051
	R	0.4404194	0.3778062
tables$X226219_at
X226219_at
	NR	−0.2943873	0.5216637
	R	0.4004941	0.4131372
tables$X226303_at
X226303_at
	NR	−0.04068867	0.4037450
	R	0.73077236	0.8465357
tables$X226382_at
X226382_at
	NR	−0.3657410	0.4652645
	R	0.2469253	0.4366802
tables$X226459_at
X226459_at
	NR	−0.3680501	0.7660787
	R	0.5040254	0.5894990
tables$X226625_at
X226625_at
	NR	−0.3757333	0.7664846
	R	0.5166961	0.4684207
tables$X226659_at
X226659_at
	NR	−0.4911180	0.6832209
	R	0.2612643	0.5381065
tables$X226697_at
X226697_at
	NR	0.1958473	0.3711059
	R	−0.5652399	0.4049380
tables$X226818_at
X226818_at
	NR	−0.2318967	0.6119576
	R	0.4987669	0.3954684
tables$X226841_at
X226841_at
	NR	−0.2979441	0.7024396
	R	0.5392790	0.4413953
tables$X226865_at
X226865_at
	NR	−0.1559129	0.5471301
	R	0.5041605	0.5099762
tables$X227035_x_at
X227035_x_at
	NR	0.2005227	0.4921465
	R	−0.3809524	0.4152160
tables$X227231_at
X227231_at
	NR	0.2353572	0.7279505
	R	−0.6509830	0.8181286
tables$X227253_at
X227253_at
	NR	0.03671536	0.4958005
	R	1.03309945	1.0290932
tables$X227265_at
X227265_at
	NR	−0.3512747	0.6026026
	R	0.3283856	0.3401296
tables$X227346_at
X227346_at
	NR	−0.3365397	0.7439603
	R	0.6189716	0.5315020
tables$X227361_at
X227361_at
	NR	−0.2481734	0.4900125
	R	0.2745731	0.3724106
tables$X227458_at
X227458_at
	NR	−0.1210425	0.5832677
	R	0.5061539	0.5297024
tables$X227584_at
X227584_at
	NR	0.1614340	0.6512560
	R	−0.6792229	0.5867806
tables$X227609_at
X227609_at
	NR	−0.2162779	0.6215554
	R	0.4224651	0.4449701
tables$X227640_s_at
X227640_s_at
	NR	0.2476183	0.5414889
	R	−0.3764071	0.4938285
tables$X227780_s_at
X227780_s_at
	NR	−0.3434434	0.6237700
	R	0.4192693	0.6791114
tables$X227791_at
X227791_at
	NR	−0.2588648	0.5252067
	R	0.4328271	0.4393930
tables$X227983_at
X227983_at
	NR	−0.3232334	0.6182386
	R	0.3661930	0.5316841
tables$X227995_at
X227995_at
	NR	−0.1696409	0.3982272
	R	0.4873422	0.5629170
tables$X228054_at
X228054_at
	NR	0.1996287	0.5784055
	R	−0.4191671	0.4113732
tables$X228071_at
X228071_at
	NR	−0.5040346	0.7357555
	R	0.4529897	0.4488694
tables$X228094_at
X228094_at
	NR	−0.5037012	0.7256858
	R	0.5085461	0.4165603
tables$X228153_at
X228153_at
	NR	−0.3116782	0.6938566
	R	0.3443284	0.3237526
tables$X228339_at
X228339_at
	NR	−0.2039593	0.7344429
	R	0.5985043	0.7672987
tables$X228362_s_at
X228362_s_at
	NR	−0.3778104	0.5378346
	R	0.2342191	0.2730511
tables$X228372_at
X228372_at
	NR	−0.4350057	0.7819102
	R	0.4561920	0.3911495
tables$X228376_at
X228376_at
	NR	−0.3453361	0.7260925
	R	0.5292299	0.5379290
tables$X228427_at
X228427_at
	NR	0.1593717	0.7055373
	R	−0.6106282	0.8316641
tables$X228532_at
X228532_at
	NR	−0.3794859	0.6481241
	R	0.5000793	0.4684207
tables$X228552_s_at
X228552_s_at
	NR	0.1167790	0.4798513
	R	−0.5450925	0.7268180
tables$X228563_at
X228563_at
	NR	0.4236616	0.5619516
	R	−0.3316479	0.5347978
tables$X228660_x_at
X228660_x_at
	NR	0.5804684	0.7378901
	R	−0.1713584	0.4483440
tables$X228776_at
X228776_at
	NR	0.06752481	0.5251283
	R	−0.80628566	0.8423271
tables$X228812_at
X228812_at
	NR	−0.3127907	0.6313677
	R	0.5074128	0.6516242
tables$X228858_at
X228858_at
	NR	−0.2190644	0.7355751
	R	0.8241261	0.8754638
tables$X228869_at
X228869_at
	NR	−0.3255735	0.5223796
	R	0.3751149	0.4806706
tables$X228908_s_at
X228908_s_at
	NR	0.3383439	0.4459491
	R	−0.2935832	0.7121557
tables$X228964_at
X228964_at
	NR	−0.3612173	0.5362295
	R	0.2810782	0.4326503
tables$X229127_at
X229127_at
	NR	−0.4082796	0.5831644
	R	0.3339318	0.8204140
tables$X229163_at
X229163_at
	NR	0.4273831	0.7589842
	R	−0.2717283	0.5013583
tables$X229367_s_at
X229367_s_at
	NR	−0.05987742	0.3928434
	R	0.56349206	0.5126817
tables$X229390_at
X229390_at
	NR	−0.4894938	0.6210411
	R	0.1935497	0.2963602
tables$X229391_s_at
X229391_s_at
	NR	−0.4084651	0.5373347
	R	0.2172787	0.2684421
tables$X229543_at
X229543_at
	NR	−0.3788834	0.5874714
	R	0.2662277	0.2904183
tables$X229625_at
X229625_at
	NR	−0.3005955	0.6601697
	R	0.5530654	0.4811529
tables$X229723_at
X229723_at
	NR	−0.2920168	0.5053402
	R	0.4696342	0.4191172
tables$X230233_at
X230233_at
	NR	−0.4143786	0.5555824
	R	0.3424073	0.3923358
tables$X230391_at
X230391_at
	NR	−0.3501254	0.8265678
	R	0.4900276	0.4781532
tables$X230538_at
X230538_at
	NR	0.1276822	0.3932100
	R	−0.5735748	0.7224135
tables$X230728_at
X230728_at
	NR	0.3244249	0.4668566
	R	−0.2743950	0.5139070
tables$X231032_at
X231032_at
	NR	0.43019858	0.5207535
	R	−0.04588641	0.3560523
tables$X231262_at
X231262_at
	NR	0.05461486	0.2495836
	R	1.32806434	1.1081493
tables$X231577_s_at
X231577_s_at
	NR	−0.3279081	0.7462895
	R	0.4819051	0.4270797
tables$X231882_at
X231882_at
	NR	0.1390358	0.4492620
	R	−0.4280975	0.4211427
tables$X231929_at
X231929_at
	NR	−0.4149811	0.6028339
	R	0.3275499	0.4633949
tables$X232001_at
X232001_at
	NR	−0.4082551	0.5622408
	R	0.2120889	0.4452512
tables$X232024_at
X232024_at
	NR	−0.2767578	0.5975732
	R	0.4329087	0.3644723
tables$X232234_at
X232234_at
	NR	−0.2485230	0.5169943
	R	0.5378690	0.4919297
tables$X232311_at
X232311_at
	NR	−0.2207241	0.5017714
	R	0.4996502	0.4849287
tables$X232313_at
X232313_at
	NR	0.09690295	0.2976671
	R	0.96479280	0.7382041
tables$X232476_at
X232476_at
	NR	0.1978897	0.4874151
	R	−0.3000000	0.4272541
tables$X232543_x_at
X232543_x_at
	NR	−0.1276883	0.6158742
	R	0.6695534	0.5964269
tables$X232617_at
X232617_at
	NR	−0.2190263	0.6769132
	R	0.5988644	0.4031826
tables$X232746_at
X232746_at
	NR	−0.3742172	0.5931449
	R	0.3407643	0.5742058
tables$X232843_s_at
X232843_s_at
	NR	−0.3175189	0.5332408
	R	0.3950617	0.3666760
tables$X233123_at
X233123_at
	NR	−0.2015742	0.5531279
	R	0.4654343	0.7103440
tables$X233562_at
X233562_at
	NR	0.2792368	0.4159995
	R	−0.2877796	0.4229988
tables$X233955_x_at
X233955_x_at
	NR	0.3290657	0.6359343
	R	−0.3166667	0.5295163
tables$X235175_at
X235175_at
	NR	−0.1311223	0.4904278
	R	0.4533666	0.4676313
tables$X235238_at
X235238_at
	NR	0.1248063	0.3770484
	R	−0.5772758	0.7499223
tables$X235306_at
X235306_at
	NR	−0.5666624	1.047734
	R	0.4955309	0.534125
tables$X235391_at
X235391_at
	NR	0.3239007	0.6545010
	R	−0.5514259	0.6035657
tables$X235421_at
X235421_at
	NR	−0.2094653	0.4583538
	R	0.4672043	0.4014682
tables$X235639_at
X235639_at
	NR	0.3234035	0.5491068
	R	−0.3795961	0.6104110
tables$X235688_s_at
X235688_s_at
	NR	0.01982982	0.5208595
	R	−0.55915444	0.5353062
tables$X235804_at
X235804_at
	NR	0.2009344	0.5886169
	R	−0.4162556	0.4684402
tables$X235831_at
X235831_at
	NR	−0.08120476	0.4915252
	R	1.14904526	1.1198369
tables$X236203_at
X236203_at
	NR	0.005259016	0.3895193
	R	0.676842217	0.4524154
tables$X236280_at
X236280_at
	NR	−0.1220235	0.4998530
	R	0.5788924	0.4002499
tables$X236295_s_at
X236295_s_at
	NR	−0.1165942	0.5645452
	R	0.6163840	0.5662135
tables$X236583_at
X236583_at
	NR	0.02541689	0.5675783
	R	0.82576116	0.7584443
tables$X236908_at
X236908_at
	NR	0.5408046	0.8859905
	R	−0.3849473	0.3825884
tables$X238439_at
X238439_at
	NR	−0.08639162	0.4532391
	R	0.64076976	0.7133665
tables$X238488_at
X238488_at
	NR	−0.2588720	0.5056425
	R	0.4974834	0.7836170
tables$X238544_at
X238544_at
	NR	0.2824277	0.7145403
	R	−0.4079449	0.4677199
tables$X239196_at
X239196_at
	NR	0.04478165	0.456084
	R	0.92699218	0.784260
tables$X239237_at
X239237_at
	NR	−0.06887682	0.4538298
	R	0.56173192	0.5087772
tables$X239744_at
X239744_at
	NR	−0.1939947	0.4873477
	R	0.3861305	0.5051036
tables$X241671_x_at
X241671_x_at
	NR	0.3853780	0.6714183
	R	−0.2467927	0.4002054
tables$X241701_at
X241701_at
	NR	0.3603183	0.8440397
	R	−0.4068724	0.5295527
tables$X242458_at
X242458_at
	NR	−0.2312046	0.7607719
	R	0.5057350	0.7076187
tables$X242546_at
X242546_at
	NR	0.1097238	0.4715672
	R	−0.4309505	0.5259991
tables$X242874_at
X242874_at
	NR	−0.2219024	0.3807166
	R	0.5644292	0.7338815
tables$X242881_x_at
X242881_x_at
	NR	0.08543868	0.3930728
	R	−0.63018680	0.5655045
tables$X242986_at
X242986_at
	NR	0.2371634	0.5409865
	R	−0.6643602	0.7457416
tables$X243099_at
X243099_at
	NR	0.01903757	0.6357632
	R	0.80481642	0.8461258
tables$X244023_at
X244023_at
	NR	−0.3068381	0.6806949
	R	0.4666732	0.5605710
tables$X244061_at
X244061_at
	NR	−0.2379335	0.5919363
	R	0.5615362	0.6126814
tables$X32128_at
X32128_at
	NR	−0.04592188	0.6445335
	R	0.60003775	0.6856519
tables$X34210_at
X34210_at
	NR	−0.3404304	0.6066166
	R	0.4975685	0.2978426
tables$X38149_at
X38149_at
	NR	−0.4040241	0.6171240
	R	0.2427490	0.4577025
tables$X64064_at
X64064_at
	NR	−0.4613187	0.6447816
	R	0.4548881	0.3392856
	levels
	[1] “NR” “R”
	call
	naiveBayes.default(x = X, y = Y,
	laplace = laplace)

Claims

1-31. (canceled)

31. A method of designating a patient as having a responder or a non-responder gene profile to Mage cancer immunotherapy comprising the steps of: a) analyzing a patient derived tumor sample for upregulation of one or more of the following genes: CCL5, TRAT1, STAT4, PRKCQ, GPR171, UBD, CD52, CD3D, PRF1, CD8A, CXCL10, CD69, TRBV19, TRDV2, IL7R, GZMK, and CD45R; andb) characterizing the patient from which the sample was derived as a having a responder or a non-responder gene profile based on the results of step (a), wherein upregulation of at least one of said genes indicates the patient has a responder gene profile.

32. A kit comprising at least one component for performing an analysis on a patient derived sample to identify a responder according to the method of claim 31.

33. A method of inducing a responder gene profile in a patient characterised as a non-responder comprising the step of stimulating a systemic immune or inflammatory response in the patient by radiotherapy or administering effective amount of interferon.